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Abstract 
Background: Motor neurone disease (MND) is a fatal, progressive, neurodegenerative 
disease causing muscle weakness, spasticity and paralysis.  No small molecule drugs 
have translated from MND mouse models to MND patients, possibly because of MND 
mouse models being based on SOD1 mutations, representing only a small proportion of 
patients.  Nearly all non-SOD1 patients have TDP-43 pathology, whereas SOD1 patients 
do not, suggesting a mechanistic difference between non-SOD1 and SOD1-related MND.  
A TDP-43 model may be more representative of the patient population and lead to 
better translation of treatments.  There is also a need for translational biomarkers in 
MND to further improve translation. 
Methods: A colony of mice transgenic for mutant human TDP-43 (TDP-43Q331K) was 
established, alongside a control line (TDP-43WT).  The mice were characterised for motor 
function including rotarod, gait analysis, and neuroscoring.  Immunohistochemical, 
mRNA and protein level studies were also carried out.  Increased weight was noted in 
the TDP-43Q331K mice, leading to a study of voluntary activity and food intake.  A further 
study investigated electrophysiological parameters, apathy, and riluzole treatment.  
Preclinical 31P-MRS imaging was carried out in SOD1G93A mice in an attempt to find a 
translational biomarker. 
Results: TDP-43Q331K mice developed a progressive phenotype, whilst TDP-43WT mice 
showed none.  TDP-43Q331K mice showed signs of motor dysfunction, increased TDP-43 
in the nucleus and cytoplasm of motor neurons (supported by increased mRNA and 
protein levels), astrogliosis, and microgliosis in the spinal cord, apathy, overeating and 
electrophysiological findings suggestive of denervation.  Riluzole may have had a mild 
treatment effect in TDP-43Q331K mice, measured by electrophysiology.  No conclusions 
could be drawn from the preclinical 31P-MRS due to animal welfare issues. 
Conclusions: TDP-43Q331K mice have a progressive motor phenotype of low variability 
with reliable motor, pathological and cognitive readouts of disease and may provide a 
useful model for evaluating potential neuroprotective therapies.   
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1. Introduction 
1.1. Motor Neurone Disease (MND) 
Motor neurone disease (MND) is a progressive neurodegenerative disease causing 
muscle weakness, wasting, spasticity and eventual paralysis.  The lifetime risk of 
developing MND is approximately 1 in 400 (van Rheenen et al., 2016).  50% of patients 
die within 2 years of diagnosis (Hoppitt et al., 2011), most commonly from respiratory 
failure due to weakening of the diaphragm and intercostal muscles (Berlowitz et al., 
2016).   
 
1.1.1. Clinical Presentation 
The majority of patients present with the disease aged 55-75 years (Bergman et al., 
2015), however, the disease is frequently identified in patients of all ages, occasionally 
as young as in the third or fourth decade of life (Beghi et al., 2006).  Although 50% of 
patients die within 2 years of diagnosis (Hoppitt et al., 2011), 5-10% of patients live over 
a decade beyond diagnosis (Chio et al., 2009). 
MND has a tendency to affect a larger proportion of men than women, more so in the 
younger generations, with as many as 80% of patients under 40 being male (del Aguila 
et al., 2003). 
The majority of patients (66%) present with limb onset MND (Gordon, 2013) in which a 
particular limb is affected by weakness, fasciculations and/or spasticity, usually followed 
by symptoms in the contralateral limb or the other limb on the same side of the body.  
Approximately 30% of patients present with bulbar onset MND in which they experience 
dysarthria and/or dysphagia (Mitchell and Borasio, 2007).  The remaining patients 
(approximately 5%) present with respiratory onset MND in which they have difficulty 
breathing (Gautier et al., 2010). The disease will usually progress from the site of onset 
to eventually involve limb, bulbar, and respiratory symptoms. 
The majority of patients show signs of upper and lower motor neurone degeneration 
such as weakness, fasciculation, spasticity, stiffness, muscle wasting and hyperreflexia 
and are therefore diagnosed with amyotrophic lateral sclerosis (ALS).  However, the 
disease is occasionally confined to an upper or lower motor neurone variant.  Two 
percent of patients are diagnosed with the upper motor neurone variant, primary lateral 
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sclerosis (PLS), and experience spasticity, brisk reflexes, stiffness and weakness 
(Rowland and Shneider, 2001).  Approximately 20 percent of patients are diagnosed with 
the lower motor neurone variant, progressive muscular atrophy (PMA), and experience 
fasciculations, muscle wasting and weakness (Rowland and Shneider, 2001).  Patients 
are occasionally diagnosed with progressive bulbar palsy (PBP) in which their symptoms 
are initially confined to the bulbar area, however, these patients usually go on to 
develop ALS (Karam et al., 2010). 
It is now well recognised that MND is on a disease continuum with frontotemporal 
dementia (FTD) and current data suggest that at least 50% of MND patients demonstrate 
cognitive/behavioural changes (Ringholz et al., 2005).  10-15% of MND patients fulfil the 
criteria for ALSFTD, as diagnosed using a battery of psychological tests (Ringholz et al., 
2005).  The symptoms of FTD include behavioural changes including apathy, 
disinhibition, compulsive behaviour, changes in eating habits and loss of empathy (Chan 
et al., 2015). 
 
1.1.2. Diagnosis and Biomarkers of MND 
Diagnosis of MND requires the experience and knowledge of a specialist neurologist due 
to a lack of diagnostic tools/biomarkers.  There is no specific test for MND and diagnosis 
therefore requires elimination of other potential diseases or health problems which may 
have caused the patient’s symptoms.  Patients tend to present to a Neurologist 
approximately 12 months from symptom onset (Mitchell et al., 2010) and will usually 
undergo an MRI scan, blood tests and electrophysiological testing before a diagnosis can 
be given.   
There is an ongoing effort to find a suitable biomarker of MND and this is a rapidly 
evolving field which has shown progress over recent years (Turner et al., 2013).  A 
definitive biomarker is not only required for diagnosis but also to monitor disease 
progression and prognosis.  A biomarker of progression would be beneficial in 
therapeutic trials as it would enable a more accurate gauge of survival than the current 
measures of survival, such as ALS functional rating scale revised (ALS-FRS-R) (Brooks et 
al., 2000) and strength testing.  The identification of translational biomarkers (a 
biological measurement which can be reliably measured in MND models as well as 
patients) would be extremely useful for monitoring the effect of drugs in both preclinical 
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and clinical trials, allowing for easier determination of appropriate dosage by matching 
the change in biomarker levels found in models, to those found in patients. 
Potential biomarkers have been investigated in many areas including imaging, 
electrophysiology, blood sampling and cerebrospinal fluid (CSF) sampling (Turner et al., 
2013, Rosenfeld and Strong, 2015).   
 
1.1.3. Mechanisms of MND 
The principal mechanisms underlying the pathophysiology of MND have not been 
definitively identified.  However, many mechanisms have been implicated including 
oxidative stress (Cookson and Shaw, 1999), protein aggregation (Wood et al., 2003), 
axonal transport dysfunction (El-Kadi et al., 2007), neuroinflammation (Hooten et al., 
2015), microglial activation (Turner et al., 2004), defects of RNA processing 
(Polymenidou et al., 2012), excitotoxicity (Shaw, 1994) and energy metabolism 
dysfunction (Dupuis et al., 2011), including mitochondrial dysfunction (Beretta et al., 
2003).  It is unclear whether each of these mechanisms occurs simultaneously or as part 
of a sequential cascade.  It is also unclear whether particular disease mechanisms relate 
to specific phenotypes, subgroups or genetic mutations of the disease.  
 
1.1.4. Treatment of MND 
The lack of a well-defined mechanistic understanding of disease pathogenesis has 
hampered efforts to develop effective therapies.  Riluzole, a drug which reduces 
glutamate excitotoxicity, was first described as a therapeutic agent for MND in 1994 
(Bensimon et al., 1994) and has been shown to extend life by several months (Stewart 
et al., 2001, Miller et al., 2003).  However, in the SOD1G93A mouse model of MND (the 
most commonly used animal model of MND), riluzole appears to improve motor 
function but has little effect on lifespan (Gurney et al., 1998).  These findings fit with a 
common hypothesis that riluzole may be very beneficial for a subgroup of patients, but 
not necessarily effective for all patients (Georgoulopoulou et al., 2013).   
Patients experiencing respiratory failure are usually given non-invasive ventilation (NIV) 
to aid respiratory function.  NIV is commonly believed to improve quality of life, 
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particularly by improving quality of sleep (Bourke et al., 2006), and has also been shown 
to extend life by an estimated 13 months (Berlowitz et al., 2016). 
A recent study of diaphragm pacing has found this treatment to be detrimental as it was 
associated with decreased survival in comparison to treatment with NIV alone 
(McDermott et al., 2015a). 
Insertion of a feeding tube is a useful symptomatic treatment, enabling patients to 
maintain their body weight after losing the ability to swallow.  Maintenance of body 
weight is highly correlated with increased survival in MND patients (Desport et al., 2000) 
and it appears to be crucial that patients receive a feeding tube earlier on in disease to 
prevent major loss of body weight (McDermott et al., 2015b). 
 
1.2. Causes of MND 
Approximately 5-10% of MND cases are familial, leading to the identification of many 
causal mutations in several genes.  Currently, causal genetic mutations have been 
implicated in approximately two thirds of familial MND cases and 11% of sporadic cases 
(Renton et al., 2014). 
The first gene to be linked to MND was superoxide dismutase 1 (SOD1) (Rosen et al., 
1993).  Following this initial discovery, causal mutations were identified in many other 
genes including fused in sarcoma (FUS), transactivating response DNA binding protein 
43 (TARDBP) and a G4C2 repeat expansion was identified in C9ORF72 (DeJesus-
Hernandez et al., 2011), all of which have been found to cause MND and/or FTD (see 
table 1.1). 
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Table 1. 1: Causal genetic mutations in MND.  Table adapted from (Taylor et al., 2016). 
Locus Gene Protein Protein function Mutations Proportion of MND Reference 
          Familial Sporadic   
21q22.1 SOD1 Cu–Zn superoxide dismutase Superoxide dismutase >150 20% 2% (Rosen et al., 1993) 
2p13 DCTN1 Dynactin subunit 1 Component of dynein 
motor complex 
10 1% <1% (Puls et al., 2003) 
14q11 ANG Angiogenin Ribonuclease >10 <1% <1% (Greenway et al., 2006)  
1q36 TARDBP TDP-43 RNA-binding protein >40 4-5% <1% (Sreedharan et al., 
2008, Kabashi et al., 
2008) 
16p11.2 FUS FUS RNA-binding protein >40 5% <1% (Vance et al., 2009, 
Kwiatkowski et al., 
2009) 
9p13.3 VCP Transitional endoplasmic 
reticulum ATPase 
Ubiquitin segregase 5 1–2% <1% (Johnson et al., 2010) 
10p15-p14 OPTN Optineurin Autophagy adaptor 1 4% <1% (Maruyama et al., 2010)  
9p21-22 C9orf72 C9orf72 Possible guanine 
nucleotide exchange 
factor 
Intronic 
GGGGCC 
repeat 
25% 10% (DeJesus-Hernandez et 
al., 2011, Renton et al., 
2011) 
Xp11.23-
Xp13.1 
UBQLN2 Ubiquilin 2 Autophagy adaptor 5 <1% <1% (Deng et al., 2011) 
5q35 SQSTM1 Sequestosome 1 Autophagy adaptor 10 <1% unknown (Fecto et al., 2011, 
Teyssou et al., 2013) 
17p13.2 PFN1 Profilin-1 Actin-binding protein 5 <1% <1% (Wu et al., 2012a)  
12q13.1 HNRNPA1 hnRNP A1 RNA-binding protein 3 <1% <1% (Kim et al., 2013, Liu et 
al., 2016a)2013  
5q31.2 MATR3 Matrin 3 RNA-binding protein 4 <1% <1% (Johnson et al., 2014) 
2q36.1 TUBA4A Tubulin α-4A chain Microtubule subunit 7 <1% <1% (Smith et al., 2014) 
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22q11.23 CHCHD10 Coiled-coil-helix-coiled-coil-
helix domain-containing 
protein 10 
Mitochondrial protein 
of unknown function 
2 <1% <1% (Bannwarth et al., 2014) 
12q14.1 TBK1 Serine/threonine-protein 
kinase TBK1 
Regulates autophagy 
and inflammation 
10 unknown unknown (Freischmidt et al., 
2015) 
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1.2.1. SOD1 
SOD1 codes for copper/zinc superoxide dismutase and over 160 causal mutations have 
since been identified in SOD1, most of which are missense mutations with varying 
locations in the gene (Rosenfeld and Strong, 2015, Al-Chalabi et al., 2012).  Most SOD1 
cases show a dominant inheritance in families and dismutase activity has been found to 
be reduced in most, but not all cases, showing no correlation between dismutase activity 
and severity of disease (Brotherton et al., 2011, Andersen et al., 1995).  SOD1 mutations 
are associated with a wide range of heterogeneity and are rarely associated with 
cognitive deficits (Renton et al., 2014). 
The main function of SOD1 is to protect cells from oxidative stress (Rosen et al., 1993).  
However, when a mutation in SOD1 occurs, the SOD1 protein becomes misfolded in the 
motor neurons and glia of the spinal cord (Nagai et al., 2007).   
Causal mutations in SOD1 account for approximately 12% of familial MND cases, and 1-
2% of sporadic cases (Renton et al., 2014).  In recent years, SOD1-linked MND cases have 
been considered as distinct from other MND cases as SOD1 patient pathology lacks the 
TDP-43 proteinopathy found in almost all other cases (Mackenzie et al., 2007).  Post-
mortem SOD1 patient cord shows ubiquitin and p62-positive skeins or inclusions in the 
motor neurons without TDP-43 pathology (Mackenzie et al., 2007). 
 
1.2.2. TARDBP 
The TARDBP gene is located on chromosome 1 (Stover et al., 2001) and consists of 6 
exons.  TARDBP codes for TDP-43, a DNA-/RNA-binding protein (Ou et al., 1995, Buratti 
and Baralle, 2012).  Originally described as an HIV-1 protein (Ou et al., 1995), TDP-43 has 
more recently been uncovered as a key player in neurodegenerative disease, including 
MND and FTD (Neumann et al., 2006, Tollervey et al., 2011). 
 
1.2.2.1. TDP-43 Structure and Location 
The TDP-43 protein is 414 amino acids long and is a highly conserved heterogeneous 
ribonucleoprotein (hnRNP) (Krecic and Swanson, 1999).  As shown in figure 1.1 TDP-43 
contains two RNA recognition motifs (Neumann et al., 2006), a nuclear export signal 
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(NES) (Winton et al., 2008), a nuclear localisation signal (NLS) (Winton et al., 2008), and 
a glycine-rich C-terminal sequence (Wang et al., 2004). 
 
Figure 1. 1: TDP-43 structure (NLS = nuclear localisation signal, RRM = RNA recognition 
motif, NES = nuclear export signal). 
TDP-43 is predominantly nuclear,  but also shuttles between the nucleus and cytoplasm 
(Winton et al., 2008), in a transcription-dependent manner (Ayala et al., 2008).  Efflux of 
TDP-43 from the nucleus to the cytoplasm is associated with cellular stress (Barmada et 
al., 2010). 
The C-terminus of TDP-43 is critically involved in the cellular localisation, interactions 
with other proteins, and solubility of TDP-43 (Ayala et al., 2008, Budini et al., 2015, 
Chang et al., 2013).  Whereas, the N-terminus is involved in promoting oligomerisation 
and enhancing DNA-binding affinity (Chang et al., 2012).  The N-terminus is vital for the 
folded structure and splicing of TDP-43 (Zhang et al., 2013), and is integral to the 
function of the second RNA-recognition motif (Wang et al., 2013).   
 
1.2.2.2. TDP-43 Function 
TDP-43 is involved in multiple functions including DNA/RNA-binding, transcription, 
translational regulation, RNA splicing, transportation, mRNA stability, stress granule 
response, and microRNA biogenesis (Buratti and Baralle, 2010, Buratti and Baralle, 
2012).  TDP-43 can regulate its own mRNA levels via a negative feedback loop and 
therefore autoregulates TDP-43 protein levels (Ayala et al., 2011, Koyama et al., 2016) 
via the ubiquitin proteasome system and autophagy (Scotter et al., 2014, Wang et al., 
2010).  TDP-43 binds to the 3’ UTRs of over 1000 transcripts, regulating splicing and 
stability and therefore influencing many cellular processes (Tollervey et al., 2011, 
Polymenidou et al., 2011).    TDP-43 also has numerous binding sites on non-coding 
RNAs, which may be involved in many processes including transcription regulation and 
posttranscriptional processing (Tollervey et al., 2011). 
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TDP-43 is an important component of RNA transport granules and protein synthesis in 
dendrites, which are key facets of neuronal plasticity and development (Tollervey et al., 
2011).  A likely synaptic role for TDP-43 stems from observations that TDP-43 binds to 
many RNA targets which are involved in synaptic function, and deletion of TDP-43 in 
cultured neurons causes abnormal dendrite morphology.  It therefore appears likely that 
TDP-43 plays a key role in synaptic function (Fujii et al., 2005). 
Under cellular stress, TDP-43 forms cytoplasmic stress granules from protein complexes 
of redundant mRNA’s (Colombrita et al., 2009) and TDP-43 tends to relocate to the 
cytoplasm (Barmada et al., 2010). 
 
1.2.2.3. TDP-43 Pathology in MND-FTD 
Discovery of TDP-43 as a key part of ubiquitinated cytoplasmic neuronal inclusions in 
both MND and FTD (Neumann et al., 2006), was crucial in identifying these diseases as 
existing on a continuum.   
Approximately 97% of MND patients (including most non-SOD1 MND patients) have 
inclusions of ubiquitinated TDP-43 protein in motor neurons (Mackenzie et al., 2007).  In 
the hippocampus, neocortex and spinal cord of both MND and FTD patients, TDP-43 
mislocalises from the nucleus to the cytoplasm and forms detergent-resistant 
aggregates, containing hyper-phosphorylated, ubiquitinated, and C-terminal truncated, 
TDP-43 (Neumann et al., 2006, Tollervey et al., 2011).  The nuclear content of TDP-43 
becomes depleted. 
Neuronal aggregates and inclusions of TDP-43 in the cytoplasm of motor neurons have 
become a pathological hallmark of MND.  These aggregates and inclusions tend to be 
immunoreactive for ubiquitin and p62 (a marker of autophagy) but negative for tau and 
α-synuclein (Neumann et al., 2006, Arai et al., 2006).  These inclusions are also found in 
around 50% of FTD patients (Ling et al., 2013), regardless of whether they carry a 
mutation in the TARDBP gene.  TDP-43 pathology in non-primary motor areas appears 
highly correlated with cognitive functioning in MND-FTD (Prudlo et al., 2016). 
Aggregation of TDP-43 may not be necessary for neurodegeneration, or could be an 
occurrence at the very end stage of cell death, as several TDP-43 mouse models have 
shown neurodegeneration without aggregates (Arnold et al., 2013, Kraemer et al., 2010, 
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Ricketts et al., 2014).  A recent study of cultured cells and primary neurons showed that 
the extreme N-terminus of TDP-43 regulates the formation of TDP-43 aggregates and 
deletion of the N-terminus reduces aggregation (Sasaguri et al., 2016).  
Disruption of the NLS or NES causes cytoplasmic mislocalisation and aggregation of TDP-
43, regardless of whether a mutation is present in the C-terminus (Winton et al., 2008).  
Cleavage of TDP-43 results in C-terminal fragments moving out of the nucleus and in to 
the cytoplasm.  This occurrence is enhanced by the presence of C-terminal mutations 
(Sreedharan et al., 2008, Rutherford et al., 2008) and cellular stress (Dormann et al., 
2009).  Misfolded TDP-43 may cause further misfolding and aggregation of wild-type 
TDP-43, suggesting the pathology can spread throughout cells and intercellularly across 
axon terminals, in a prion-like manner (Zhu et al., 2014, Feiler et al., 2015). 
A recent study suggested that cytoplasmic TDP-43 of motor neurons may accumulate 
predominantly within the mitochondria, binding mRNAs and therefore, preventing 
translation, impairing aerobic energy metabolism by reducing complex I activity (Wang 
et al., 2016). 
 
1.2.2.4. MND-FTD Causal Mutations in TARDBP   
Following the discovery of TDP-43 pathology in MND, mutations in TARDBP were 
investigated.  Over 40 known mutations in TARDBP have been associated with MND 
(Renton et al., 2014), most of which have been identified in the C-terminal glycine rich 
domain of TARDBP (Gitcho et al., 2008, Sreedharan et al., 2008), which is associated with 
protein-protein interactions and cellular localisation (Ayala et al., 2008).   
Causal mutations in TARDBP account for approximately 4-5% of familial MND cases, and 
1% of sporadic cases (Renton et al., 2014, Millecamps et al., 2010).  Mutations in TARDBP 
are inherited in an autosomal dominant manner and have been found to cause both 
MND and FTD.  Within the one family, members with the same mutation may present 
with MND and no signs of FTD, whereas others present with FTD and no signs of MND 
(Sreedharan et al., 2008).    
Patients with causal mutations in TARDBP have a tendency to present with upper limb 
onset disease at a slightly earlier age when compared to sporadic cases, and show a 
moderately prolonged duration of disease (Corcia et al., 2012).  The pathology of 
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patients with TARDBP mutations is similar to that of sporadic patients (Yokoseki et al., 
2008) with neuronal loss, gliosis and TDP-43 positive cytoplasmic inclusions in both the 
upper and lower motor neurons. 
 
1.2.2.5. TDP-43 Loss and/or Gain of Function in MND-FTD 
Although it is well established that TDP-43 aggregates are a key pathological finding in 
MND, it is unclear whether they are a causal mechanism of neuronal death, or a 
consequence of upstream events.  It is possible that TDP-43 aggregates cause toxicity, 
either via a gain and/or loss of function of TDP-43. 
Several studies have suggested that a loss of nuclear TDP-43 causes disease via loss-of-
function.  In support of this splicing defects have been found in neuronal cell cultures 
(De Conti et al., 2015), post-mortem MND patient spinal cord and patient-derived cells 
(Highley et al., 2014), and mouse embryonic stem cells (Ling et al., 2015).  Additionally, 
knockout of TDP-43 in mice was shown to be embryonic lethal (Chiang et al., 2010, 
Kraemer et al., 2010, Sephton et al., 2010), highlighting the importance of TDP-43 in 
development.  Whereas partial or post-developmental knockout of TDP-43 produces 
progressive motor phenotypes and proteinopathy (Wu et al., 2012b, Iguchi et al., 2013, 
Yang et al., 2014). 
Conversely, the aggregation of TDP-43 in the cytoplasm may cause a toxic gain-of-
function.  Multiple TDP-43 models have shown that an increase in wild type TDP-43 
causes neurodegeneration and proteinopathy (Wils et al., 2010, Tsai et al., 2010, 
Stallings et al., 2010, Xu et al., 2010, Shan et al., 2010, Igaz et al., 2011, Swarup et al., 
2011), despite the fact that no overexpression has been found in MND patients.   The 
most logical explanation for this finding is a toxic gain of function in patients, replicated 
by an increased expression of TDP-43 in the models.  Furthermore, the cytoplasmic level 
of TDP-43 has been shown to be highly associated with neuronal death in primary rat 
cortical neurons (Barmada et al., 2010), also suggestive of toxic gain-of-function. 
However, other TDP-43 models have shown a role of loss and gain of splicing function 
(Arnold et al., 2013) and altered TDP-43 structure by misfolding (Zhu et al., 2014), which 
may indicate both loss and gain-of-function mechanisms being involved in the disease 
process.  
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1.2.3. FUS 
Causal mutations in FUS account for approximately 4% of familial MND cases, and 1% of 
sporadic cases (Renton et al., 2014). 
The FUS protein binds to RNA and has multiple functions including transcription, RNA 
splicing and transport (Vance et al., 2009).  The FUS protein is predominantly located in 
the nucleus, with a very similar role and location to TDP-43.  Mutations in FUS cause 
similar pathology to that of TDP-43 as the FUS protein aggregates in the cytoplasm of 
neurons without the presence of TDP-43 and ubiquitin (Kwiatkowski et al., 2009, Vance 
et al., 2009). 
 
1.2.4. C9ORF72 
The most commonly found causal mutations are in the chromosome 9 open reading 
frame 72 (C9ORF72) gene, which are responsible for 40-50% of familial MND cases and 
around 7% of apparently sporadic cases (Renton et al., 2014).   The genetic alterations 
consist of a hexanucleotide (GGGGCC) repeat expansion in intron 1 of the C9ORF72 
gene.  Many patients with these mutations also show signs of FTD (DeJesus-Hernandez 
et al., 2011, Renton et al., 2011).  Mutations in C9ORF72 have also been found in 25% of 
patients with FTD without signs of MND (Majounie et al., 2012). 
A higher proportion of patients with repeat expansions in C9ORF72 present with bulbar 
onset MND compared to other genetic subgroups and there appears to be an 
anticipation effect in families, meaning that subsequent generations carrying a C9ORF72 
expansion will develop MND-FTD progressively earlier (Cooper-Knock et al., 2014). 
The mechanisms linked to C9ORF72 pathogenesis include RNA toxicity, loss-of function, 
and accumulation of RNA-foci repeat associated non-ATG translated dipeptide repeat 
proteins (Haeusler et al., 2016, Hayes and Rothstein, 2016). 
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1.2.5. Genetic Risk Factors 
The investigation of genetic risk factors has been a broadening field in recent years, 
culminating with the onset of Project MinE, a large-scale worldwide project to identify 
genetic mutations involved in MND. 
Several studies have found genetic risk factors for both familial and sporadic MND.  It 
often appears that genetic susceptibility variants (e.g. ATXN2, SMN1 and UNC13A) are 
found in familial cases in which a causal mutation already exists (Dekker et al., 2016, 
Elden et al., 2010).  This may influence the age of onset of disease, explaining why 
members of the same family with the same causal mutation may present with MND at 
different ages and sites of onset. 
Genetic susceptibility variants are now being identified in sporadic patients, such as 
TUBA4A (Pensato et al., 2015) and UNC13A (Manuel Vidal-Taboada et al., 2015), 
suggesting that a genetic risk factor combined with environmental factors, may be a 
trigger for sporadic MND. 
 
1.2.6. Environmental Risk Factors 
Environmental risk factors are implicated not only in sporadic MND cases but also in 
familial cases, since family members who share causal genetic mutations will often 
develop disease at very difference ages, and show a propensity to develop FTD or MND.  
Therefore, it is likely that the occurrence, timing and severity of MND is dependent on a 
combination of genetic and environmental risk factors.  A wide variety of environmental 
factors have been proposed over time, mostly from epidemiological studies.   
Military service has been identified as a potential risk factor for MND in several studies 
(Haley, 2003, Weisskopf et al., 2005), which may be linked to exposure of BMAA and 
cyanobacteria (Cox et al., 2009).  A high proportion of MND in Italian football players 
was highlighted over a decade ago (Chio et al., 2005), adding to the debate over whether 
high levels of physical activity may be a risk factor for  MND (Harwood et al., 2009, 
Harwood et al., 2016, Longstreth et al., 1998, Armon, 2003, Sutedja et al., 2009).  Several 
studies and reviews have found smoking to be a risk factor for MND (Armon, 2003, 
Armon, 2009, Weisskopf et al., 2004), as well as exposure to toxins (Gunnarsson et al., 
1992) and exposure to magnetic fields (Sutedja et al., 2009). 
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1.3. Modelling of MND 
Modelling of MND is crucial to increase understanding of the disease and find potential 
therapies.  A wide variety of model types have been used to model MND, each with 
distinct advantages and limitations for use (see table 1.2). 
Table 1. 2: Features and limitations of modelling methods.  Table adapted from (Clerc 
et al., 2016). 
Methods Examples Features Limitations 
In vivo 
Caenorhabditis 
elegans 
Cellular focus without 
systemic complexity 
Lacks spinal cord and lower 
motor neurons affected by 
MND 
 
Drosophila More complexity than C. 
elegans, but less than 
vertebrates 
Wild-type human gene 
expression is toxic; 
relatively simple nervous 
system structure compared 
with human 
 
Zebrafish Cheap, quick, simple; 
vertebrate 
Not mammalian; relatively 
new models 
 
Mouse Many different models; 
short lifespan and disease 
length 
Overexpression artefacts; 
unique biological 
properties compared to 
humans (lifespan, 
metabolism,etc.) 
 
Rat Larger size; short lifespan 
and disease length 
Disease phenotype 
differences from mouse 
 
Dog Naturally occurring disease 
(Canine Degenerative 
Myelopathy) 
Disease similar to, but not 
same as MND 
 
Nonhuman 
primates 
Better disease mimic than 
other species 
Expensive, long lived, 
ethical issues 
In vitro 
cultures 
Yeast Simple, models protein 
aggregation well 
Not neuronal, or human 
 
Patient 
dissociated motor 
neurons 
Natural disease gene 
expression; easy, direct 
drug application 
Finite lifespan; difficult to 
transfect 
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Methods Examples Features Limitations 
 
NSC34 Immortal motor neuron-
like cell line; manipulable 
Induced disease 
phenotype; not true motor 
neuron line 
 
Stem cells Can transplant or 
differentiate for 
study/transplant 
Transplantation still 
experimental 
 
Induced 
pluripotent stem 
cells 
Can differentiate into 
motor neurons or glia 
Expensive; low neuronal 
yields; clonal issues. 
 
Tissue slice 
culture (animal) 
Easily manipulated; more 
systemic than cell cultures 
Same issues as whole 
animal in trying to find 
good model; distant 
connections severed 
 
 
1.3.1. Non-mouse in Vivo Models of MND 
Mice are often the model of choice for testing potential drug therapies once a drug has 
shown promise in vitro.   
At the less complex end of the spectrum Drosophila melangoster (fruit fly), 
Caenorhabditis elegans (nematode) and Danio rerio (zebrafish) models can be used for 
relatively fast, cheap and simple drug screening.  This is because development and 
breeding periods are very short and assays can be carried out very effectively using 
quantification of fluorescence, without dissecting the animals.  Nematode models have 
been produced carrying mutations in SOD1 (Wang et al., 2009) and FUS (Murakami et 
al., 2012).  Fly models of SOD1 (Watson et al., 2008), TARDBP (Diaper et al., 2013), FUS 
(Chen et al., 2011) and C9ORF72 (Mizielinska et al., 2014) have also shown the effects of 
these mutations on various mechanisms and pathways.  However, fruit flies and 
nematodes lack spinal cords and the structure of disease-related genes may differ from 
human genes, so findings in these models may not be well replicated in vertebrate 
models.   
In comparison, zebrafish have an orthologue for approximately 82% of genes which are 
associated with human diseases (Howe et al., 2013).  Several zebrafish models have 
been developed modelling a variety of causal genetic mutations including SOD1 
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(Lemmens et al., 2007, Ramesh et al., 2010), TARDBP (Kabashi et al., 2010), FUS (Acosta 
et al., 2014) and C9ORF72 (Ciura et al., 2013).  Zebrafish may be a more promising model 
for identifying potentially effective compounds, before moving on to the more costly 
and time consuming mammalian models.   
At the more complex, human-like end of the model spectrum we have non-human 
primates, which are very costly, time consuming and carry a heavy ethical burden.  
Despite this, a cynomolgus monkey overexpression model of TARDBP has been 
produced, showing many of the signs of human MND symptoms and pathology (Uchida 
et al., 2012). 
Several rat models have been created including models with SOD1 (Llado et al., 2006), 
TARDBP (Zhou et al., 2010) and FUS mutations (Huang et al., 2011).  Rat models can be 
very useful, especially because they are considerably larger than mice and this can be 
key for imaging studies and surgeries.  However, rats are more costly than mice and are 
less easy to use for genetic manipulation. 
Consequently, most MND in vivo studies use mouse models, particularly for testing 
potential drug therapies.   
 
1.3.2. Mouse Models of MND 
The first mouse proposed as a model of MND was the Wobbler mouse (Duchen and 
Strich, 1968), which arose by spontaneous mutation in 1955.  The Wobbler mouse 
carries a mutation in the Vps54 gene (Schmitt-John et al., 2005), which is not associated 
with MND.  This mouse has an MND-like phenotype including muscle atrophy, unsteady 
gait, reduced body weight, and tremor, however, it does not carry an MND-linked 
mutation and pathological studies have identified prominent vacuoles in the motor 
neurons, which is not a typical feature of MND (Moser et al., 2013).  Since the discovery 
of the Wobbler mouse, many models have been created, some of which model 
mutations found in only a small number of patients.  The following table provides a 
summary of MND models for the most commonly implicated genes SOD1, TARDBP, FUS 
and C9ORF72 (described previously). 
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Table 1. 3: Summary of mouse models of SOD1, TARDBP, FUS and C9ORF72. + 
demonstrates one or two features of MND (e.g. phenotype: muscle atrophy; pathology: 
neuronal loss), ++ demonstrates several features of MND (e.g. phenotype: muscle 
atrophy, weakness, anxiety; pathology: neuronal loss, astrogliosis, decreased brain 
volume), +++ demonstrates most features of MND (phenotype: muscle atrophy, 
weakness, progression to paralysis, anxiety, antisocial behaviour; pathology: neuronal 
loss, astrogliosis, microgliosis, cytoplasmic inclusions, poor NMJ morphology, decreased 
brain volume). 
Implicated 
gene 
Gene status  Phenotype Pathology 
 
Reference 
 
SOD1 
Human SOD1G93A 
transgenic 
+++ +++ (Gurney et al., 1994) 
Human SOD1G37R 
transgenic 
+++ +++ (Wong et al., 1995) 
Endogenous 
SOD1G85R mutation 
+++ +++ (Bruijn et al., 1997, 
Ripps et al., 1995) 
GFAP-SOD1G86R 
transgenic 
(astrocytes only) 
none + (Gong et al., 2000) 
Human 
SOD1H46R/H48Q 
transgenic  
++ +++ (Wang et al., 2002) 
Human SOD1WT 
transgenic  
+ none (Lino et al., 2002) 
Endogenous 
SOD1D83G mutation 
++ ++ (Joyce et al., 2015) 
TARDBP 
Human TDP-
43A315T transgenic 
++ +++ (Wegorzewska et al., 
2009)  
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Human TDP-43WT 
transgenic 
+++ +++ (Wils et al., 2010) 
Endogenous TDP-
43WT  
++ ++ (Tsai et al., 2010) 
Human TDP-43WT 
transgenic 
None + (Stallings et al., 2010) 
Human TDP-
43A315T transgenic 
+ ++ (Stallings et al., 2010) 
Human TDP-
43M337V transgenic  
++ ++ (Stallings et al., 2010) 
Human TDP-43WT 
transgenic 
+ ++ (Xu et al., 2010) 
Human TDP-43WT 
transgenic 
++ ++ (Shan et al., 2010) 
Conditional 
knockout 
unknown unknown (Chiang et al., 2010)  
Heterozygous 
knockout 
+ none (Kraemer et al., 2010) 
Human TDP-43WT 
transgenic 
+ ++ (Igaz et al., 2011) 
∆NLS partial 
knockout 
+ ++ (Igaz et al., 2011) 
Human TDP-
43M337V transgenic 
+++ ++ (Xu et al., 2011) 
Human TDP-43WT 
transgenic 
++ + (Swarup et al., 2011) 
Human TDP-
43A315T transgenic  
++ ++ (Swarup et al., 2011) 
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Human TDP-
43G348C transgenic 
++ +++ (Swarup et al., 2011) 
Conditional 
knockout  
+++ ++ (Wu et al., 2012b) 
Human TDP-
43M337V transgenic  
+++ +++ (Janssens et al., 2013) 
Human TDP-43WT 
transgenic 
++ ++ (Janssens et al., 2013) 
Partial knockout ++ ++ (Iguchi et al., 2013) 
Human TDP-
43Q331K transgenic  
++ ++ (Arnold et al., 2013) 
Human TDP-
43Q331K-low 
transgenic 
+ + (Arnold et al., 2013) 
Human TDP-
43M337V transgenic  
+ + (Arnold et al., 2013) 
Partial knockout +++ + (Yang et al., 2014) 
Endogenous TDP-
43Q10X mutation 
+ none (Ricketts et al., 2014) 
Conditional ∆NLS 
knockout 
+++ +++ (Walker et al., 2015) 
FUS 
Human FUSWT 
transgenic 
+++ ++ (Mitchell et al., 2013) 
Partial ∆NLS 
knockout 
+++ ++ (Shiihashi et al., 2016) 
C9ORF72 
Anti-sense 
oligonucleotide 
injection 
none + (Lagier-Tourenne et 
al., 2013) 
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Inducible human 
(G4C2)80 repeat 
expansion 
transgenic 
none ++ (Hukema et al., 2014) 
Human (G4C2)500 
repeat expansion 
transgenic 
none ++ (Peters et al., 2015) 
Human (G4C2)100-
1000 repeat 
expansion 
transgenic 
none ++ (O'Rourke et al., 2015) 
Endogenous 
(G4C2)66 repeat 
expansion 
++ +++ (Chew et al., 2015) 
Conditional 
knockout  
none none (Koppers et al., 2015) 
Human (G4C2)450 
repeat expansion 
transgenic 
++ ++ (Jiang et al., 2016) 
Heterozygous 
knockout 
+ none (Jiang et al., 2016) 
Homozygous 
knockout 
++ none (Atanasio et al., 2016) 
Homozygous 
knockout 
none none (O'Rourke et al., 2016) 
Human (G4C2)37-500 
repeat expansion 
transgenic 
+++ +++ (Liu et al., 2016b) 
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1.3.2.1. Lack of Translation from Mouse to Human 
The SOD1G93A mouse model is by far the most commonly used mouse model in 
therapeutic trials of MND (Benatar, 2007, Ludolph et al., 2007).  However, compounds 
found to be effective in the SOD1G93A mice may not then prove effective in human 
disease, as has been shown with several therapeutics including creatine (Klivenyi et al., 
1999, Groeneveld et al., 2003), vitamin E (Gurney et al., 1996, Desnuelle et al., 2001, 
Graf et al., 2005) and gabapentin (Gurney et al., 1996, Miller et al., 2001).  There are 
several potential reasons for this lack of translation including validity of the model, study 
design and a lack of translational biomarkers. 
 
1.3.2.1.1. Reliance on One Mouse Model 
A key reason for a lack of translation is that the SOD1G93A model is only representative 
of a very small proportion of familial MND (Ittner et al., 2015).  Therefore, a compound 
found to be effective in this model may also be effective in patients affected by SOD1.  
However, when given to a wide variety of patients (familial and sporadic), the potential 
effect on SOD1 patients is lost.   
As has been highlighted in recent years, SOD1-based MND appears to be rather distinct 
from non-SOD1 MND due to the lack of TDP-43 pathology (Mackenzie et al., 2007).  The 
treatment of SOD1 MND separate to non-SOD1 MND may therefore be key to finding 
effective compounds and the first SOD1-specific drug trial is currently underway. 
 
1.3.2.1.2. Poor Preclinical Study Design 
Another key reason for lack of translation is that many trials have used a SOD1G93A model 
on a mixed genetic background, increasing the variability of disease (Mead et al., 2011) 
and combined with poor study design this has led to a large number of false positive 
studies (Scott et al., 2008).   
Also, many preclinical trials are carried out without checking the pharmacokinetic (PK) 
properties of the drug in the model.  PK studies should be carried out to ensure the drug 
is penetrating the blood brain barrier (Ludolph et al., 2010) and accessing the drug target 
directly in neurons.  This PK data can later be used to match an effective dose in mice, 
to an effective dose in humans as plasma levels of the drug in patient trials can be tested 
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and compared to the mouse data.  One issue with this is that compound levels within 
the human brain and spinal cord will remain unknown.  However, matching the plasma 
drug levels may lead to more appropriate dosing. 
Furthermore, in most pre-clinical drug trials, the compound is administered prior to 
symptom onset (Benatar, 2007, Ittner et al., 2015, Ludolph et al., 2007) and therefore 
at a very early stage of the disease.  In comparison, patients will not be put on a drug 
trial until they are far beyond symptom onset and even diagnosis, at which point the 
disease may be too advanced for the drug to effectively rescue the target disease 
mechanism.  On this note, it can be argued that if a drug was found effective by pre-
symptomatic dosing, familial MND could be treated by administering the drug to 
unaffected family members to delay disease onset or reduce the pace of disease 
progression (Benatar, 2007).  However, no MND patient drug trials have been carried 
out in this manner and the study design for such an approach would require a prolonged 
follow-up phase. 
Preclinical trial outcomes are frequently assessed by survival of the mice (Benatar, 
2007), disregarding the effect of a drug on quality of life and symptom severity.  
However, patients would undoubtedly welcome a drug which improved their quality of 
life without an effect on survival.  Preclinical investigators are rarely blinded to which 
group is the treated group (Benatar, 2007) and this leads to a potential bias when 
collecting data.  Randomisation of mice to treatment groups is often neglected, creating 
potential for confounding factors to emerge (Benatar, 2007). 
A key example of these issues is in the case of minocycline, an inhibitor of microglial 
activation, which was found to extend survival of SOD1G93A mice when administered pre-
symptomatically (Kriz et al., 2002).  However, when a phase III human clinical trial was 
carried out, minocycline appeared to accelerate disease progression in patients (Gordon 
et al., 2007).  Subsequently, a preclinical trial was carried out in which SOD1G93A mice 
were administered minocycline post symptom onset and no effect on survival was found 
(Keller et al., 2011). 
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1.3.2.1.3. Lack of Translational Biomarkers 
As mentioned previously (1.1.2.), there is a lack of reliable biomarkers in MND, which 
are required not only for diagnosis but also disease monitoring.  This need extends to 
preclinical biomarkers which will translate from animal models to patients (Ludolph et 
al., 2010).  If biomarkers could be used in both preclinical and patient trials this could 
offer invaluable insights into the disease pathophysiology and, importantly, reduce the 
duration and cost of clinical trials.  A translatable biomarker would be incredibly valuable 
in translational studies to gauge the dose administered to patients if the effect of the 
drug on a biomarker could be matched between models and patients.   
Whilst the search for reliable biomarkers continues in patients, no previous reports of 
translational biomarker investigations could be found.   One area under constant 
investigation is imaging biomarkers, including magnetic resonance imaging (MRI), 
magnetic resonance spectroscopy (MRS) and diffusion tensor imaging (DTI) (Chio and 
Traynor, 2015).   
New research is currently underway at the institute, investigating 31P-MRS as a 
biomarker in MND patients.  31P-MRS measures phosphorous containing compounds, 
many of which are involved in energy metabolism, which is known to be dysregulated in 
MND (Dupuis et al., 2011).  Therefore, a minor part of this project was to investigate 
31P-MRS as a translational biomarker in a mouse model of MND. 
 
1.3.2.2. Identifying a Mouse Model More Likely to Translate 
A mouse model with a genetic mutation known to cause MND may only be 
representative of patients with mutations in the same gene, possibly even the same 
mutation in that gene.  However, if a mouse model was representative of sporadic MND, 
or at least a large proportion of MND, it would be far more likely to show translation of 
therapeutics to humans.   
As mentioned previously, familial cases represent approximately 5-10% of MND, hence 
modelling familial MND has limitations with translation.  Sporadic MND can have genetic 
elements (Renton et al., 2014) and may also be significantly influenced by the 
environment and therefore very hard to model as an entity.  However, 97% of patients 
can be ‘grouped’ in that they all show TDP-43 pathology (Mackenzie et al., 2007), so 
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although a variety of upstream causes may be present, they all share a common 
pathway/mechanism related to TDP-43 biology, resulting in this pathology.  If this TDP-
43 pathomechanism could be modelled, this may be an ideal way to target a mechanism 
affecting nearly all MND patients, creating a model with high translational potential. 
The overall aim of this PhD was to identify and characterise a TARDBP mouse model to 
increase the likelihood of successful therapeutic trials translating to patients. 
 
1.3.2.3. Choosing a TARDBP Mouse Model 
Many TARDBP models have been created over the past 7 years and several others are 
known to be under investigation at the moment.  A thorough review of TARDBP mouse 
models was made (see table 1.4), in order to choose the most appropriate model to set 
up in our institute. 
In general, a mouse model for disease research should be on a defined genetic 
background, have a reproducible phenotype, disease homogeneity, a mild-moderate 
disease severity, a moderate length of disease course and an appropriate control line.  
These qualities ensure that meaningful, statistically robust data can be collected whilst 
keeping the number of mice required in studies relatively low, reducing the time and 
cost of studies as well as suffering of the mice. 
A TARDBP mouse model should ideally have a degenerative phenotype due to loss of 
motor neurons and replicate MND pathology.  For our purposes the model also needed 
to be readily available and carry a mutated TARDBP gene.  Overexpression and knockout 
models were avoided as this is not seen in MND patients. 
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Table 1. 4: Summary of TARBP mouse models of MND. 
Reference Promoter, 
transgene, 
expression (Ax 
= A-fold 
expression) 
Genetic background Pathology Phenotype Symptom 
Onset 
Survival Reason(s) not to use 
as our chosen model 
(Wegorzews
ka et al., 
2009) 
mPrp, huTDP-
43 A315T, 3xflag 
tag 
 
B6.Cg-Tg(Prnp-
TARDBP*A315T) 
95Balo/J 
 
C57BL6/J x CBA, 
backcrossed to 
C57BL6/J for two 
generations 
Motor neuron and 
motor axon loss, 
astrogliosis, nuclear 
loss of TDP-43 
Muscular atrophy in 
hind legs, gait 
abnormality (3-4 
months), weight loss 
and ‘swimming gait’ at 
4.5 months 
91d 155d due to 
gastrointesti
nal 
problems 
(Hatzipetros 
et al., 2014) 
Concerns over 
gastrointestinal 
problems 
(Tsai et al., 
2010) 
CaMKII, mTDP-
43 cDNA WT 
2x 
FVB/N Some TDP-43-positive 
cytoplasmic inclusions, 
loss of cortical 
neurons, astrogliosis in 
cortex and 
hippocampus, reduced 
brain weight 
Impaired 
learning/memory, 
abnormal gait and 
reduced rotarod 
performance 
60d Normal Overexpression of 
wild type may not be 
representative of 
disease 
(Stallings et 
al., 2010) 
mPRP, 
TDP-43A315T 
4x 
STOCK Tg(Prnp-
TARDBP)4Jlel/J 
 
B6SJLF1 x CD1, 
backcrossed with 
CD1 or mixed 
background 
Astrogliosis in spinal 
cord, rare 
ubiquitinated, TDP-43+ 
inclusions 
Muscular atrophy, gait 
abnormality 
4 wks 14d-37.5 
wks 
 
Very short disease 
course, mixed 
background 
mPRP, 
TDP-43M337V 
>10x 
Neuronal 
morphological 
abnormalities, rare 
Reduced grip, 
weakness, spasticity 
Not 
recorded 
16-42d Very short disease 
course, mixed 
background 
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ubiquitinated TDP-43+ 
inclusions, astrogliosis 
mPRP, 
huTDP-43 WT 
3x 
Rare ubiquitinated 
inclusions, mild 
astrogliosis 
None None Normal No phenotype, 
overexpression of 
wild type may not be 
representative of 
disease 
(Xu et al., 
2010) 
mPRP, 
huTDP-43 
cDNA WT 
2.5x 
C57BL/6-Tg(Prnp-
TARDBP)3cPtrc/J 
 
 
Astrogliosis, rare 
cytoplasmic phospho-
TDP-43 aggregates, 
mitochondrial 
neuronal aggregates, 
rare nuclear clearance 
of TDP-43 and reduced 
brain weight 
Reduced body weight, 
gait abnormality and 
tremor 
2 wks 4.5-8.5 wks Very short disease 
course, 
overexpression of 
wild type may not be 
representative of 
disease 
(Wils et al., 
2010) 
Thy1.2, 
huTDP-43 
cDNA WT 
3.8-5.1x 
B6;SJL-Tg(Thy1-
TARDBP)4Singh/J 
 
C57BL/6 x SJL/J 
founders backcrossed 
to C57BL/6, n not 
stated 
Loss of motor neurons 
and motor axons, 
astrogliosis, nuclear 
loss of TDP-43 and rare 
ubiquitinated TDP-43+ 
aggregates 
Abnormal hind-limb 
reflex, reduced rotarod 
performance, gait 
abnormalities, 
paralysis, fasciculations 
and spasm of facial 
muscles  
 
2-8.5 wks 
(variation in 
phenotype 
proportional 
to TDP-43 
expression)  
4-29 wks 
(variation in 
phenotype 
proportional 
to TDP-43 
expression) 
High variability, 
overexpression of 
wild type may not be 
representative of 
disease 
(Shan et al., 
2010) 
Thy1.2, 
huTDP-43 
cDNA WT 
2.3-4.6x 
C57BL/6;SJL, 
backcrossed with 
C57BL/6. 
Cytoplasmic 
mitochondrial 
aggregation, 
intranuclear TDP-43, 
FUS inclusions, 
reduced large motor 
neurons, TDP-43+ 
Reduced body weight, 
gait abnormality, 
tremor, abnormal 
hindlimb reflex. 
M: 2-2.5 
wks 
F: 13 wks 
normal Overexpression of 
wild type may not be 
representative of 
disease 
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inclusions, abnormal 
NMJ morphology. 
(Chiang et 
al., 2010) 
Rosa26 
ubiquitous 
promoter, 
depletion of 
TDP-43 using 
Cre/lox 
knockout 
floxed 
TARDBP x Rosa26-
ErCre to generate 
inducible TARDBP-KO 
None reported Rapid weight loss and 
death 
Not 
recorded 
9 days post 
tamoxifen 
induction 
No pathology, very 
rapid disease 
progression 
(Kraemer et 
al., 2010) 
Knockout 
using gene 
trap insertion 
vector pGT1lxf 
TardbpGt(RB030)Byg  
chimeric mice were 
generated and 
backcrossed x5 on to 
C57Bl/6 
None Reduced grip strength Not 
recorded 
Normal No pathology, little 
phenotype 
(Swarup et 
al., 2011) 
Endogenous 
promoter, 
huTDP-43 A315T 
3x 
C3H x C57Bl/6 
backcrossed to 
C57Bl/6 
Cytoplasmic 
accumulation of TDP-
43, increase in small 
motor axons; decrease 
in larger axons. 
Astrogliosis and 
microgliosis in the 
brain and spinal cord 
(pathology milder than 
that of TDP-43G348C) 
Impaired learning, 
impaired memory, 
reduced rotarod 
function 
30 wks Normal 
 
Very late onset 
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Endogenous 
promoter, 
huTDP-43 G348C 
3x 
Cytoplasmic 
accumulation of TDP-
43, cytoplasmic 
ubiquitinated TDP-43-
positive aggregates, 
neurofilament 
disorganisation, 
increase in small motor 
axons; decrease in 
larger axons, 
astrogliosis and 
microgliosis in the 
brain and spinal cord 
Impaired learning, 
impaired memory, 
reduced rotarod 
performance 
30 wks Normal 
 
Very late onset 
Endogenous 
promoter, 
huTDP-43 WT 
3x 
Astrogliosis and 
microgliosis in the 
brain and spinal cord 
(similar to that found 
in TDP-43 A315T) 
Impaired learning, 
impaired memory, 
reduced rotarod 
performance 
30 wks Normal 
 
Overexpression of 
wild type may not be 
representative of 
disease 
(Igaz et al., 
2011) 
CaMKII TRE, 
∆NLS 
1.7x 
C57BL/6J x C3HeJ 
Crossed with tTa 
mice and tetO mice 
Time-dependent 
cerebral atrophy, 
astrogliosis, axon loss, 
nuclear loss of TDP-43 
and rare TDP-43+ 
aggregates 
Spasticity (more PLS-
like than ALS-like), 
abnormal hindlimb 
clasping 
7 d post 
induction  
Not 
recorded 
Lack of information 
on survival 
CaMKII TRE, 
huTDP-43 WT 
Cerebral atrophy, 
gliosis, nuclear loss of 
Spasticity (more PLS-
like than ALS-like), 
8-49 wks Not 
recorded 
Lack of information 
on survival 
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8-9x TDP-43 and rare TDP-
43+ aggregates 
abnormal hindlimb 
clasping 
(Xu et al., 
2011) 
mPRP, 
huTDP-43 M337V 
1-2x 
C57BL/6-Tg(Prnp-
TARDBP*M337V) 
4Ptrc/J 
 
C57BL/6 (B6) x B6 
Cytoplasmic 
phosphorylated TDP-
43 aggregates, reactive 
gliosis, widespread 
ubiquitination, 
cytoplasmic 
mitochondrial 
aggregates, abnormal 
phosphorylated tau, 
reduced brain weight 
Gait abnormalities, 
limb weakness, body 
tremors and difficulty 
recruiting hind-limbs 
3 wks 4 wks Very rapid disease 
course 
(Wu et al., 
2012b) 
HB9-
promoter, 
targeted 
knockout of 
TDP-43 using 
Cre/lox 
C57BL/6J x HB9:Cre Motor neuron loss, 
astrocytosis of the 
spinal cord, 
cytoplasmic 
ubiquitinated protein 
accumulations in TDP-
43 negative motor 
neurons 
Kyphosis, motor 
dysfunction, muscular 
atrophy, reduced body 
weight, weakness, 
abnormal hind limb 
clasping, reduced 
rotarod function 
20wks 10m Knockout may not be 
representative of 
disease 
(Janssens et 
al., 2013) 
Thy-1.2, 
huTDP-43M337V  
1.7x 
Bl6/SJL backcrossed 
to C57BL/6J 
Cytoplasmic, 
ubiquitinated TDP-43 
inclusions, 
phosphorylated TDP-
43, C-terminal 
fragments, gliosis, 
reduced brain weight 
Hindlimb clasping, 
muscular atrophy, 
paralysis, muscle 
twitches, reduced body 
weight 
11d 17-18d Very rapid disease 
course 
Thy-1.2, 
huTDP-43WT  
2x 
Cytoplasmic, 
ubiquitinated TDP-43 
inclusions, 
phosphorylated TDP-
Hindlimb clasping, 
muscular atrophy, 
paralysis 
14d 25-26d Very rapid disease 
course 
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43, C-terminal 
fragments, gliosis 
(Arnold et 
al., 2013) 
mPRP, huTDP-
43 Q331K cDNA, 
myc-tagged 
3x 
B6N.Cg-Tg(Prnp-
TARDBP*Q331K)103
Dwc/J 
 
B6N.Cg-Tg(Prnp-
TARDBP*Q331K)109
Dwc/J 
 
B6N.Cg-Tg(Prnp-
TARDBP)96Dwc/J 
 
C57Bl6/C3H 
backcrossed to 
C57Bl6 at least 4 
times 
LMN degeneration but 
no loss of UMNs, 
astrogliosis and 
microgliosis in the 
spinal cord, 
vacuolisation and 
myelin defects in 
motor axons, loss of 
motor axons, reduced 
neuromuscular 
junction endplates 
Tremor, hindlimb 
clasping, decreased 
hindlimb grip strength, 
decreased rotarod 
performance.  
3 months Normal Chosen model 
mPRP, huTDP-
43 Q331K-low 
cDNA, myc-
tagged 
lower than 
endogenous 
Age-dependent 
decrease in LMNs. 
Significant age-
dependent motor 
deficits (less so than 
TDP-43 Q331K) 
Not 
recorded 
Not 
recorded 
Lack of pathology 
and phenotype 
mPRP, huTDP-
43 M337V cDNA, 
myc-tagged 
similar to 
endogenous 
Age-dependent 
decrease in LMNs 
Significant age-
dependent motor 
deficits (less so than 
TDP-43 Q331K) 
Not 
recorded 
Not 
recorded 
Lack of pathology 
and phenotype 
(Iguchi et al., 
2013) 
Motor neuron 
specific 
knockout of 
TDP-43 using 
Cre/lox 
 
En1flox-neo x 
C57BL/6 backcrossed 
with C57BL/6 at least 
5 times, then crossed 
with CAChT-Cre 
Degeneration of large 
motor axons, 
denervation in the 
neuromuscular 
junction, autophagy-
related structures 
accumulated in cell 
Progressive weight loss 
and motor impairment, 
muscular atrophy, 
tremor, reduced 
rotarod performance 
and grip strength 
50 wks Normal Knockout may not be 
representative of 
disease 
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bodies of motor 
neurons 
(Yang et al., 
2014) 
Knockout 
using 
transgenic 
RNAi and 
Cre/lox 
amiR–TDP43u x 
CMV–Cre 
Progressive 
neurodegeneration, 
predominantly in 
cortical layer V and the 
spinal cord 
Hyperactivity, motor 
dysfunction, weakness, 
paralysis, reduced 
body weight 
5wks 44-100d Unpublished at the 
time 
(Ricketts et 
al., 2014) 
TARDBP-43Q10X 
from a N-
ethyl-N-
nitrosourea 
(ENU) mutant 
mouse archive 
endogenous 
(C3H/HeH.C57BL/6J) 
backcrossed on to 
C57BL/6J x 3-4 
None Limb clasping, lack of 
body tone 
32wks Normal Unpublished at the 
time 
(Walker et 
al., 2015) 
NEFH 
promoter 
doxycycline 
(Dox)-
suppressible 
expression of 
huTDP-43 with  
defective 
nuclear 
localization 
signal (∆NLS) 
50% reduction 
in expression  
Mixed 
C57BL/6J × C3HeJ F1 
Brain atrophy, 
insoluble cytoplasmic 
TDP-43 in the brain 
and spinal cord, muscle 
denervation, motor 
neuron loss 
Hindlimb clasping, 
tremor, reduced grip 
strength and rotarod 
performance, reduced 
body weight 
4 wks off 
dox 
10.3 wks off 
dox 
Unpublished at the 
time 
 32 
After careful consideration, the TDP-43Q331K mouse model (Arnold et al., 2013) was 
imported from Jackson laboratories (USA) along with the wild-type control line (huTDP-
43Q331K Jax #017933 and huTDP-43WT Jax #017907). 
This mouse model was chosen as it met most of the criteria described previously by 
having a degenerative phenotype due to motor neuron loss, a defined genetic 
background, a mild disease severity, a moderate length of disease course (10 months), 
and an appropriate control line (TDP-43WT) which lacked a phenotype.  In addition, 
unlike most other transgenic TDP-43 models, this model has been developed with the 
idea of creating a line with transgenic expression similar to the endogenous mouse gene, 
avoiding the issues seen in highly overexpressing models where both mutant and wild 
type TDP-43 overexpression cause neurodegeneration. 
The TDP-43WT mouse line is transgenic for human TARDBP and the TDP-43Q331K mouse 
line is transgenic for human TARDBP with a glutamine to lysine mutation at position 331 
(Q331K).  The Q331K mutation has been identified in exon 6 of the TARDBP gene in a 72 
year old male patient who developed limb-onset MND with a 3 year disease duration 
(Sreedharan et al., 2008).  In this mouse model, the human TARDBP gene is expressed 
under the murine prion promoter, which is mainly expressed in the astrocytes and 
motor neurons of the CNS (Wang et al., 2005) as well as the heart (Borchelt et al., 1996).  
The human TARDBP gene is also c-myc-tagged. 
Previous work with this mouse model showed widespread alterations in gene splicing, 
motor neuron and motor axon loss, reduced rotarod performance and grip strength, and 
a mild disease course which plateaus at 10 months of age (Arnold et al., 2013).   
The mice were backcrossed on to a C57BL/6NJ background before being deposited at 
Jackson laboratories.  Therefore, the mouse colonies established are on a slightly 
different genetic background compared to those in the original paper (C57BL/6NCrl), 
which may have a significant effect on disease severity (Heiman-Patterson et al., 2005). 
Subsequently, in 2015 a further study was published in which a different line of the TDP-
43Q331K mice was crossed with the TDP-43WT mice, causing a very rapid disease 
progression (Mitchell et al., 2015).  It is hypothesised that this cross pushed the level of 
TARDBP expression over a ‘threshold’, causing the disease to become far more 
aggressive.  However, the TDP-43Q331K mice used in this publication were a different line 
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compared to the mice in our colony as well as now being on a slightly different genetic 
background.  Therefore, comparison of data between this project and previous studies 
should be approached with caution. 
 
1.4. Aims of the project 
The overall aims of the project were to: 
1. Establish a breeding colony of a translationally relevant mouse model of MND.  
2. Identify quantitative readouts of disease progression with low variability, 
suitable for use in pre-clinical therapeutic trials. 
3. Carry out the first known drug trial of riluzole in the selected mouse model. 
4. Investigate 31P-MRS as a potential preclinical biomarker of MND. 
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2. Motor Phenotypic Characterisation of the TDP-43Q331K Mouse 
2.1. Introduction 
Upon receiving the TDP-43Q331K and TDP-43WT mice, colonies were established and a 
characterisation study was initiated.  This mouse model has been investigated previously 
on a C57BL/6NCrl background which had been backcrossed for a minimum of 4 
generations (Arnold et al., 2013) but has subsequently been backcrossed on to a 
different genetic background (C57BL/6NJ).  A difference in genetic background can have 
a large impact on disease severity, as found in the SOD1G93A mouse model (Heiman-
Patterson et al., 2005).  It was therefore of great importance to ensure the TDP-43Q331K 
colony we were establishing carried the described mutation and that there would be 
genetic homogeneity within the colonies. 
Previously, the TDP-43Q331K mouse model was described as developing a rotarod deficit 
and reduced grip strength with age, worsening over a period of 10 months (Arnold et 
al., 2013).  However, the difference in genetic background between the published model 
and the TDP-43Q331K model in use here, may cause a differing motor phenotype.  It is 
therefore appropriate to test for a motor phenotype in this TDP-43Q331K model. 
As discussed previously (chapter 1), homogeneity and reproducibility of disease is key in 
a disease model, especially when planning to carry out therapeutic trials, as minimal 
variability is crucial to identifying treatment effects with small group sizes (Mead et al., 
2011).  Carrying out a phenotypic study allowed for assessment of these parameters and 
for comparison of non-transgenic and TDP-43WT mice with TDP-43Q331K mice to identify 
mutant specific effects, as well as the effects of WT TDP-43 expression. 
Analysis of motor phenotype defines the disease severity and onset.  This is useful for 
therapeutic trials as users may wish to administer drugs from the onset of symptoms 
rather than from maturity (Benatar, 2007, Ittner et al., 2015).  Assessment of motor 
phenotype may also provide an indication of the degree of distress suffered by the mice, 
with the possibility of identifying humane disease endpoints, if relevant for the model.  
Motor function can be assessed in a variety of ways including grip strength, rotarod, the 
raised beam test, open field and gait analysis (Brooks and Dunnett, 2009).  Rotarod, grip 
strength, weight, gait analysis and neurological scoring are commonly used for the 
assessment of the motor phenotype in the SOD1G93A model (Weydt et al., 2003, Mead 
et al., 2011).  Practically, the accessibility of equipment must be considered when 
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designing a study and the readily available equipment for this study consisted of a 
rotarod and the Catwalk gait analysis system. Weight was also monitored and the overall 
neurological deficit was scored.  For the purposes of maintaining and managing colonies, 
it is always helpful to know the expected litter statistics for mouse models, and 
importantly, the breeding life of the mice.  In many models, including SOD1G93A, fertility 
is impaired.  Males have a short window of fertility from adulthood (50-60 days of age) 
to approximately 90 days of age (in-house data) and females are infertile.  Therefore, 
breeding statistics for TDP-43Q331K mice were also investigated, as these had not been 
reported previously. 
As described previously in chapter 1, approximately 97% of MND patients develop TDP-
43 pathology in motor neurons, including ubiquitinated inclusions and cytoplasmic 
mislocalisation (Mackenzie et al., 2007).  Ideally, the TDP-43Q331K mice would replicate 
this pathology, however, the previously published data showed small TDP-43 positive 
inclusions but no cytoplasmic mislocalisation (Arnold et al., 2013).  It is well established 
that inflammation is a key component of disease in humans, often reflected in the 
activation of astrocytes and microglia.  Both these cell types are activated in MND, as 
shown by microgliosis and astrocytosis, both in vitro and in vivo (Boillee et al., 2006, 
Ferraiuolo et al., 2011, Yamanaka et al., 2008b).  Previous investigation of the TDP-
43Q331K model found signs of astrogliosis with increased glial fibrillary acidic protein 
(GFAP) immunoreactivity, and microgliosis demonstrated by increased levels of IBA-1 
immunoreactivity (Arnold et al., 2013).  Therefore, it is important to establish whether 
these findings are also evident in the TDP-43Q331K model on a C57BL/6NJ background. 
 
2.2. Aims 
1. To assess the motor function of TDP-43Q331K and TDP-43WT mice over a period of 10 
months. 
2. To establish whether the TDP-43WT motor phenotype is similar/different to non-
transgenic mice of the same background strain. 
3. To assess the variability of the motor phenotype in TDP-43Q331K and TDP-43WT mice. 
4. To assess breeding and litter statistics in the TDP-43Q331K and TDP-43WT mice. 
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5. To investigate the TDP-43 pathology, astrogliosis and microgliosis in the spinal cord of 
TDP-43Q331K mice. 
 
2.3. Materials and Methods 
2.3.1. Ethics Statement 
All mouse experiments were carried out under the terms of the UK Animals (Scientific 
Procedures) Act 1986 and under a UK Home Office project license.  Mice were housed 
and cared for in accordance with the Home Office Code of Practice for Housing and Care 
of Animals Used in Scientific Procedures.  All procedures were carried out under an 
appropriate UK Project Licence by personal licence holders.  ARRIVE guidelines (Kilkenny 
et al., 2010) have been followed for the work described in this thesis. 
 
2.3.2. Transgenic C57BL/6NJ Mice 
TDP-43WT and TDP-43Q331K mice (Mus musculus) were originally generated on a 
C57BL/6NCrl background by insertion of c-myc-tagged human TARDBP cDNA constructs, 
injected in to the pronuclei of C57Bl6/C3H blastocysts and implanted in to 
pseudopregnant female mice (Arnold et al., 2013).  Offspring were subsequently 
backcrossed on to a C57BL/6NJ background before being deposited at the Jackson 
Laboratory (stock numbers 017907 and 017933, respectively).   
The basic characterisation tests were carried out with 5-7 males and 5-7 females per 
group (TDP-43WT and TDP-43Q331K), based on power calculations from rotarod data in 
SOD1G93A mice.  Non-transgenic littermates of each mouse were also tested, the data 
for which were pooled to create the non-transgenic (NTg) group.  Mice were recruited 
at 25 days of age and remained on the study until 300 days of age.   
Colonies were established using 3 male breeders and 6 female breeders in each colony.  
Transgenic males were mated with non-transgenic females from within the same 
colony.  All mice were fertile and remained as breeding stock up to 12 months of age. 
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2.3.3. Housing  
Mice were bred in a specified pathogen free (SPF) environment, and transferred to a 
conventional facility for the studies described here.  The facility uses a 12 h light/dark 
cycle, and room temperature set to 21˚C.  Cages were lined with fine sawdust (eco-pure 
flakes 6, Datesand, UK), which was changed weekly, and a plastic house was placed in 
each cage with paper wool (Datesand, UK) as bedding material.  Mice were fed 2018 
rodent diet (Harlan, UK) ad libitum.  Water was provided ad libitum and changed weekly.  
Fresh bottles were provided every four weeks. 
All mice were housed in same-sex littermate pairs or quadruplets.  However, some male 
pairs were separated at around six months of age due to fighting. 
 
2.3.4. Genotyping 
Mice were identified by ear clipping and the ear clip was then used for genotyping.  DNA 
was extracted by incubating ear clips at 65˚C for 15 minutes in a 20 µl volume of 
QuickExtract DNA Extraction Solution (Epicentre, Cambridge, UK), followed by a 2 
minute incubation at 98˚C.  1 µl of DNA was then placed in solution with 4 µl of Firepol 
(Solis Biodyne, Estonia), 11 µl of water, 0.5 µm of each huTDP-43 primer (forward 5’-
AGAGGTGTCCGGCTGGTAG-3’, reverse 5’-CCTGCACCATAAGAACTTCTCC-3’) and 0.5 µm 
of each interleukin-4 receptor control primer (forward 5’-
CTAGGCCACAGAATTGAAAGATCT-3’, reverse 5’-GTAGGTGGAAATTCTAGCATCATCC-3’), 
(Sigma-Aldrich, UK). 
This polymerase chain reaction (PCR) mix  was then run on a PCR machine (G-Storm, UK) 
with a 2 min incubation period at 94°C, followed by 10 cycles of 94°C for 20 seconds, 65-
50°C for 15 seconds and 68°C for 10 seconds.  This was followed by 28 cycles of 94°C for 
15 seconds, 50°C for 15 seconds, and 72°C for 10 seconds.  Following this was a 2 minute 
period at 72°C.  Samples were then held at 10°C. 
A 2% w/vol agarose/1xTAE solution was microwaved until the agarose was fully 
dissolved.  Once cooled, 1% ethidium bromide was added and the solution was poured 
into a gel mould.  Once set, the gel was placed in to a gel tank filled with 1xTAE.  4µl of 
100bp hyperladder (Bioline, UK) was loaded in the first well of each row and 8µl of PCR 
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product was then added to each subsequent well.  The gel was then run for 40 mins at 
120mV. 
Transgenic samples are represented by a predominant PCR product for the human TDP-
43 transgene at 228bp as well as the control IL4R PCR product at 324bp, whereas non-
transgenic samples are represented by a single band at 324bp. 
 
2.3.5. Sequence Analysis 
DNA was extracted by incubating ear clips at 65˚C for 15 minutes in a 20 µl volume of 
QuickExtract DNA Extraction Solution (Epicentre, Cambridge, UK), followed by a 2 
minute incubation at 98˚C. 
A 1 µl volume of DNA was then placed in solution with 4 µl of Firepol (Solis Biodyne, 
Estonia), 11 µl of water, 0.5 µm of each huTDP-43 primer (forward 5’-
AGAGGTGTCCGGCTGGTAG-3’, reverse 5’-CCTGCACCATAAGAACTTCTCC-3’) and 0.5 µm 
of each interleukin-4 receptor control primer (forward 5’-
CTAGGCCACAGAATTGAAAGATCT-3’, reverse 5’-GTAGGTGGAAATTCTAGCATCATCC-3’), 
(Sigma-Aldrich, UK). 
This solution was then run on a PCR machine (G-storm, UK) with a 2 min incubation 
period at 94°C, followed by 94°C for 20 seconds, 65-50°C for 15 seconds and 68°C for 10 
seconds, repeated for 10 cycles.  This was followed by 28 cycles of 94°C for 15 seconds, 
50°C for 15 seconds, and 72°C for 10 seconds.  Following this was a 2 minute period at 
72°C.  Samples were then held at 10°C. 
5µl of each PCR product was then placed in a 0.2ml Eppendorf with 0.05µl of 
exonuclease I (Thermo Fisher, UK), 1µl of shrimp alkaline phosphatase (Thermo Fisher, 
UK) and 4µl of nuclease-free water.  This solution was then incubated in a PCR machine 
(G-Storm, UK) at 37 oC for 45 mins, followed by 80 oC for 15 mins. 
These samples were then sent to the Core Genomic Facility, Medical School, University 
of Sheffield for sequencing using an Abi 3730 instrument (ThermoFisher Scientific, UK) 
and PTC-200 cyclers (ThermoFisher Scientific, UK) and a manufacturer-recommended 
BigDye Terminator kit (ThermoFisher Scientific, UK). 
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2.3.6. Copy Number Analysis 
Ear clips were taken from mice at 10 months of age (1 non-transgenic, 3 TDP-43WT, 12 
TDP-43Q331K) and sent to the Mary Lyon Centre, MRC Harwell, Didcot for analysis of 
human TARDBP copy number. 
A VIC-labelled reference assay (disruptor of telomeric silencing 1-like [Dot1l]) set at 2 
copies (CNV2) on the Bio-Rad QX200 droplet digital PCR (ddPCR) system (Bio-Rad, CA) 
was performed using a Taqman assay specific to human TARDBP cDNA to estimate the 
number of transgene integrations.  Reaction mixtures (20 μl) contained 1 μl crude DNA 
lysate, 1x ddPCR Supermix for probes (Bio-Rad, CA, USA), 225 nM of each primer (two 
primers/assay) and 50nM of each probe (one VIC-labelled probe for the reference gene 
assay and one FAM-labelled for the transgene target assay).  These reaction mixes were 
loaded into DG8 cartridges with 70 μl droplet oil per sample and droplets produced using 
the QX100 Droplet Generator, or alternatively were loaded in plate format into the Bio-
Rad QX200 AutoDG and droplets produced as per the manufacturer’s instructions.  After 
droplet generation, the oil/reagent emulsion was transferred to a 96 well semi-skirted 
plate (Eppendorf AG, Hamburg, Germany) and the samples were amplified on the Bio-
Rad C1000 Touch thermocycler (95°C for 10 min, then 40 cycles of 94°C for 30s and 58°C 
for 60s, followed by a final elongation step of 98°C for 10 min).  The plate was then 
loaded into the QX200 Droplet Reader (Bio-Rad, CA, USA).  Standard reagents and 
consumables supplied by Bio-Rad were used, including cartridges and gaskets, droplet 
generation oil and droplet reader oil.  
 
2.3.7. Neuroscoring and Weighing 
Neuroscores and weight were monitored weekly in the morning, measuring forelimb 
and hindlimb tremor on a subjective scale of 0-3 (normal-strong) adapted from the in-
house SOD1G93A neuroscoring system.  A ‘neuroscore’ scale was used to delineate motor 
dysfunction (0-normal, 1-significant hindlimb tremor, 2-abnormal gait, 3-severe waddle, 
4-dragging of one hindlimb).  Whenever possible, this scoring was carried out by the 
same investigator (JS).   
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Weight was monitored by placing the mice in a box on a set of scales (Kern, Germany) 
pre-set to zero.  These measurements were taken immediately prior to rotarod testing 
and in the same procedure room as the rotarod. 
 
2.3.8. Accelerating Rotarod Test 
Mice were placed on the accelerating rotarod (Jones & Roberts for mice 7650) for a 
period of 300 seconds.  In this time the rotarod accelerates from 4 to 40 rpm and latency 
to fall was recorded for each mouse.  All rotarod testing was carried out at a similar time 
of day (am) and all testing consisted of two trials, with the highest score being recorded 
for analysis.   
Mice were initially trained on the rotarod over 3 days (27-29 days of age) and underwent 
the first testing day at 30 days of age, being tested each week thereafter.  For each 
mouse at each time point the ratio of rotarod performance/weight was also plotted to 
account for the effect of weight. 
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2.3.9. Catwalk Gait Analysis 
The catwalk gait analysis system 7.1 (Noldus Information Technology B.V., Netherlands) 
was used to capture gait parameters at 1, 3, 6 and 10 months of age.  Mice were placed 
on the glass floor of the catwalk system in complete darkness and left to walk/run freely.  
Whenever possible, 6 straight continuous runs were recorded and the 3 best runs were 
selected for analysis.  Catwalk software 7.1 was used to label each paw print of each run 
(as shown in figure 2.1) and analyse the gait parameters of the mice.  Microsoft Excel 
was used to collate data within groups and select data which may be informative. 
As shown in the top panel (blue) each individual paw print was labelled and colour co-
ordinated for analysis.  Forepaws are bright; hindpaws are dull.  Left paws are red; right 
paws are green.  The bottom panel demonstrates the definition of stride length and base 
of support. 
 
Figure 2. 1: Demonstration of catwalk gait analysis software. 
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2.3.10. Litter Statistics 
Throughout maintenance of the TDP-43WT and TDP-43Q331K mouse colonies, data for 
each mouse was monitored and each litter was assessed for size, percentage of 
transgenic pups, and percentage of male pups.  Data for savaged pups was unavailable. 
 
2.3.11. qPCR 
Primer pairs were mixed and diluted to 5µM (see table 2.1 for primer sequences). 
Samples were plated in duplicate in non-skirted, frosted, thin-wall 0.2ml low profile 96 
well plates (P3-0402, Geneflow, UK) and covered with optical wide area 8-cap strips (P3-
0051, Geneflow, UK).  Each well contained 1µl cDNA, 1µl primer mix, 3µl water and 5µl 
brilliant III ultra-fast SYBR® green qPCR master mix (600882, Agilent Technologies, USA).  
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as the house-keeping 
gene.  A non-template control was plated for each primer pair. 
Samples were placed in the qPCR machine (Mx 3000P, Stratagene, USA) and run on the 
following protocol: 95˚C for 10 mins, 45 cycles (95˚C for 30s, 58˚C for 1 min, 72˚C for 1 
min), 95˚C for 1 min, 55˚C for 30s, 95˚C for 30s. 
Table 2. 1: Primer sequences. Forward and reverse primer sequences used for qPCR 
analysis. 
Primer pair Forward Reverse 
huTDP-43 TGGGATGAACTTTGGTGCGT TTTGGCTCCCTCTGCATGTT  
Mouse (total) TDP-43 TACCGGAATCCCGTGTCTCA GAGGAAGCATCTGTCTCATCCA 
GAPDH ATGGTGAAGGTCGGTGTGAA TGGCAACAATCTCCACTTTGC 
 
2.3.12. qPCR Analysis 
Cycle threshold (Ct) values were extracted using MxPro Mx3000P software version 4.10 
(Stratagene, USA).  Further analysis was carried out using Microsoft Excel 2013 
(Microsoft, USA) and GraphPad Prism 6 (GraphPad, USA). 
Mean Ct values were calculated for each sample from the duplicates.  Data were not 
used if duplicate Ct values differed by ≥1.  The relative concentration was calculated 
using the equation: 1/2(gene of interest Ct – GAPDH Ct).  Values were presented as a percentage 
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of the mean TDP-43WT value for each sample, or as a percentage of the mean non-
transgenic value wherever possible. 
 
2.3.13. Preparation of Lysates for Western Blotting 
Cortex samples (n = 3 male, 3 female/group, 10 months of age) were homogenised in 
700µl of RIPA buffer (150mM sodium chloride, 50mM Tris, 1% triton x-100, 0.5% SDS, 
0.5% sodium deoxycholate, pH 8.0), whilst spinal cord samples (n = 3 male, 3 
female/group, 10 months of age) were homogenised in 350µl of RIPA buffer.  Samples 
were homogenised using a plastic pestle in the Eppendorf, followed by passage through 
a syringe and needle at least 3 times.  Samples were then rolled at 4˚C for 30 mins and 
left on ice for a further hour. 
Samples were centrifuged at 18000 x g (14000rpm) for 10 mins at 4˚C and the 
supernatant was collected in aliquots and frozen at -80˚C.  Pellets were discarded. 
 
2.3.14. Western Blotting 
2.3.14.1. SDS-Polyacrylamide Gel Preparation 
Resolving gels were made at a concentration of 12% by mixing 3.5ml distilled water 
(dH20), 4ml acrylamide (30% w/v), 2.5ml resolving buffer (1.5M Trizma, 13.9mM SDS, 
pH 8.8), 50µl APS (10% w/v) and 20µL TEMED.  This solution was placed into 1mm spacer 
plates and short plates (Bio-Rad), assembled on the Mini-PROTEAN® Tetra Cell Casting 
Stand and clamps with gaskets (Bio-Rad).  A layer of isopropanol was left on the top of 
the gel whilst setting and poured/blotted off afterwards. 
Stacking gels were made at a concentration of 5% by mixing 5.8ml dH20, 1.7ml 
acrylamide (30% w/v), 2.5ml stacking buffer (0.5M Trizma, 13.9mM SDS, pH 6.8), 50µl 
APS (10% w/v) and 20µL TEMED.  This solution was then poured in to the gel cast to sit 
above the resolving gel.  A 1mm 10-well Mini-PROTEAN® comb (Bio-Rad) was inserted 
in to the top of the gel during setting (at least 10 mins).  
2µl of 4x Laemmli buffer (228mM Tris-HCl, 38% (v/v) glycerol, 277mM SDS, 0.038% (w/v) 
bromophenol blue, 5% (v/v) β-mercaptoethanol, pH 6.8) was added to 6µl of each 
sample and heated at 95˚C for 5 mins.  The protein gels were loaded in to a Mini-
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PROTEAN® Tetra Vertical Electrophoresis Cell (Bio-Rad), and the tank was filled with 
running buffer (25mM Tris, 3.5mM SDS, 20mM glycine).  2µl of pre-stained protein 
ladder was loaded in to one well of each gel and samples were then loaded in the 
remaining wells.  Electrophoresis was run at 50V for 30 mins, followed by 150V for 90 
mins.  
 
2.3.14.2. Transfer of SDS-Polyacrylamide Gel to Nitrocellulose Membrane 
Gels were removed from the electrophoresis apparatus and placed over a nitrocellulose 
membrane saturated in transfer buffer (47.9mM Tris, 38.6mM glycine, 1.38mM SDS, 
20% (v/v) methanol) and placed between 6 layers of Whatman paper, also saturated in 
transfer buffer.  These layers were then placed in the semi-dry apparatus (Biometra, 
Germany) and electrophoretic transfer was performed at 0.15A/gel for 1 hour. 
Membranes were then stained with Ponceau (0.1% (w/v) Ponceau S, 5% (v/v) acetic 
acid) to check for proteins, and then washed in TBST (20mM Tris, 137mM NaCl, 0.2% 
(v/v) Tween® 20, pH 7.6). 
 
2.3.14.3. Immunoblotting 
Membranes were blocked in 5% (w/v) milk/TBST for 20 mins at room temperature (RT) 
on a roller.  Membranes were then incubated with the rabbit anti-TDP-43 primary 
antibody (10782-2-AP, Proteintech, UK, 1/1000) in 5% (w/v) milk/TBST for 1 hour at RT 
on a roller followed by 3 x 5 min washes in TBST.  The horseradish peroxidase (HRP) anti-
rabbit secondary antibody (W401B, Promega, UK, 1/5000) in 5% (w/v) milk/TBST was 
then applied for 1 hour at RT on a roller followed by 3 x 5 min washes in TBST.  
Membranes were then incubated in enhanced chemiluminescence (ECL) for 1 min and 
imaged on the G:BOX (Syngene, UK). 
For the loading control, membranes were incubated with the mouse anti-β-actin 
primary antibody (ab6276, Abcam, UK, 1/1000) in 5% (w/v) milk/TBST for 1 hour at RT 
on a roller followed by 3 x 5 min washes in TBST.  The anti-mouse HRP conjugate 
secondary antibody (W402B, Promega, UK, 1/5000) in 5% (w/v) milk/TBST was then 
applied for 1 hour at RT on a roller followed by 3 x 5 min washes in TBST.  Membranes 
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were then incubated in ECL for 1 min and imaged on the G:BOX (Syngene, UK) using 
GeneSnap software (Syngene, UK). 
 
2.3.15. Western Blot Analysis 
GeneTools software (Syngene, UK) was used to quantify the signal of each band on the 
membrane.  Signal was quantified relative to the first band on the membrane and 
adjusting for the loading control (β-actin) and normalised to the mean non-transgenic 
total TDP-43 value for each gel. 
 
2.3.16. Tissue Collection for Immunohistochemical Staining 
Mice were sacrificed at 10 months of age by trans-cardiac perfusion following 
anaesthetic overdose using an intraperitoneal injection of pentobarbitone (2.5ml/kg).  
Under deep anaesthesia (checked by absence of pedal reflex) and prior to cessation of 
cardiac function, a thoracotomy was performed, in which the left ventricle was 
cannulated with a syringe containing phosphate buffered saline (PBS) and mild pressure 
applied to distend the right auricle, which was then cut.  The mouse was then perfused 
with PBS via the left ventricle of the heart, followed by perfusion with 4% 
paraformaldehyde (PFA)/PBS. 
Spinal columns were then extracted and placed in 4% PFA/PBS overnight.  The spinal 
cord was then extracted from the spinal column and cryoprotected by immersion 
through a gradient of 5, 10, 15 and 20% sucrose/PBS for 5 minutes in each concentration 
before incubation in 20% sucrose overnight.  The spinal cords were then dissected into 
cervical, thoracic, lumbar and sacral segments, and frozen in OCT embedding matrix 
(CellPath, UK) over dry ice, then stored at -80˚C. 
For sectioning of the lumbar spinal cord, samples were acclimatised at -20˚C for at least 
30 mins.  Lumbar sections were sliced at 14 μm using a cryostat and mounted on to 
uncoated, charged slides (CellPath, UK).  Sections were mounted serially over series’ of 
5 slides, with 5 sections per slide (total length of cord between sections on a slide being 
70 µm) for a total of 50 slides, then stored at -20˚C. 
 
 46 
2.3.17. Immunohistochemical Staining 
Slides were placed at 37˚C for 30 minutes and then washed three times in PBS at room 
temperature with shaking.  Sections were then permeabilised in 5% BSA, 0.5% triton X-
100/PBS for 90 minutes at 37˚C and subsequently placed in an antigen access unit (A. 
Menarini Diagnostics, UK) submerged in Access Revelation pH 6.5 (MP-607-x500, A. 
Menarini Diagnostics, UK) for a 30 minute cycle at 125˚C, with a pressure of 20 psi. 
After 3 x 5 min washes in PBS with shaking, slides were blocked with 5% BSA, 0.25% 
triton X-100/PBS for 10 minutes and then incubated with the primary antibodies (see 
table 2.2) diluted in 0.25% Triton X-100/PBS overnight at 4˚C. 
Following 6 quick washes and 3 x 5 min washes in PBS with shaking, slides were blocked 
in 5% BSA/PBS for 10 mins and then incubated with secondary antibodies (see table 2.2) 
at RT for 90 mins. 
Slides were then given 2 quick washes with PBS, 3 x 5 min washes in PBS and 1 x 5 min 
wash in filtered water, with shaking and in darkness.  Sections were mounted in 
Vectashield hard set aqueous mountant with 4',6-diamidino-2-phenylindole (DAPI) 
(Vector Laboratories, Peterborough, UK) and left to dry at 4˚C overnight in the dark. 
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Table 2. 2: Table of antibodies used for immunohistochemical analysis. 
Primary/ 
secondary 
Antibody To aid 
visualisation of 
Monoclonal/ 
polyclonal 
Animal raised in Supplier Supplier 
code 
Concentration 
primary anti-c-myc c-myc tagged 
huTDP-43 
polyclonal rabbit Sigma, UK C3956 1/1000 
primary anti-NeuN Neurons monoclonal mouse Merck Millipore, UK MAB377 1/1000 
primary anti-GFAP Astrocytes polyclonal chicken Abcam, UK Ab4674 1/1000 
primary anti-IBA-1 Microglia polyclonal rabbit Alpha Laboratories, UK 019-19741 1/500 
secondary Alexa fluor anti-
rabbit 488 
anti-rabbit 
primary 
polyclonal donkey Thermo Fisher Scientific, 
UK 
A21206 1/1000 
secondary Alexa fluor anti-
mouse 555 
anti-mouse 
primary 
polyclonal donkey Thermo Fisher Scientific, 
UK 
A31570 1/1000 
secondary Alexa fluor anti-
chicken 488 
anti-chicken 
primary 
polyclonal goat Thermo Fisher Scientific, 
UK 
A11039 
 
1/1000 
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2.3.18. Immunohistochemical Staining Image Analysis 
Images were captured using the IN Cell Analyzer 2000 (GE Healthcare, UK) and analysed 
using GE Developer Toolbox 1.9 (GE Healthcare, UK).   
NeuN and c-myc staining was captured at 20x magnification within each ventral horn of 
each spinal cord section.  NeuN staining was detected by object segmentation with 
kernel size 45 and sensitivity 23, followed by a sieve filter for an object size of over 
19.44µm2.  DAPI staining was filtered by intensity segmentation (grey level 55 - 4095) 
with a sieve filter for an object size of over 0.55µm2 to identify the nuclei of the motor 
neurons.  Staining intensity of c-myc was then recorded for the cytoplasm (in which 
there was NeuN and no DAPI staining), and the nucleus (in which there was DAPI 
staining).  TDP-43WT and TDP-43Q331K tissue was then compared for analysis. 
GFAP staining was captured at 60x magnification within each ventral horn of each spinal 
cord section.  GFAP staining was segmented by intensity level with a threshold of greater 
than 12500 grey levels and staining index ([unstained pixels-stained pixels]/2xSD) was 
recorded.  The mean staining index was calculated for each mouse.  Non-transgenic and 
TDP-43Q331K tissue was compared for analysis.  TDP-43WT tissue was of poor quality and 
appeared fragmented, the reason for which is unknown. 
IBA-1 staining was captured at 60x magnification within each ventral horn of each spinal 
cord section.  IBA-1 staining was detected by object segmentation with a kernel size of 
21 and sensitivity of 1, followed by a sieve filter for objects over 3µm2.  The mean 
staining area (μm2) for each mouse was then recorded.  Non-transgenic and TDP-43Q331K 
tissue was compared for analysis.  Image montage figures were contrast adjusted and 
produced using ImageJ.   
 
2.3.19. Statistics 
GraphPad Prism 6 was used for all statistical analyses (GraphPad, San Diego, CA, USA).  
Two-way ANOVA with Tukey’s post-test was used unless otherwise stated.  All data are 
represented as a mean and standard deviation, unless otherwise stated. 
Power analysis was carried out using G*Power Version 3.1.9.2. (Faul et al., 2009) using 
a student’s t-test, two-tailed, α = 0.05, β = 0.8. 
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2.4. Results 
2.4.1. Confirmation of the Q331K Mutation 
DNA sequencing was carried out to ensure that TDP-43WT and TDP-43Q331K mice carried 
the correct gene sequence. 
DNA sequencing of the TARDBP gene in a TDP-43Q331K mouse (figure 2.2B) shows 
cytosine (C) replaced by adenine (A) at codon position 331 of the sequenced PCR product 
(highlighted in blue) when compared to the sequence of a TDP-43WT mouse (figure 2.2A). 
The triplet CAG in the TDP-43WT sequence encodes glutamine (Q), whereas the triplet 
AAG in the TDP-43Q331K sequence encodes lysine (K) at amino acid position 331. 
 
 
 
 
 
 
 
 
Raw chromatographs show sequences from the human TARDBP gene in the TDP43WT 
transgenic mice, in which the nucleotides CAG form glutamine (A); and the sequence of 
the TDP43Q331K mice, in which nucleotides AAG form lysine (B). 
 
2.4.2. Human TARDBP Copy Number Estimation 
Human TARDBP copy number was investigated in each mouse line.  The non-transgenic 
mouse showed no sign of human TARDBP (table 2.3).  All TDP-43WT mice appear to carry 
one copy of the human TARDBP gene.  TDP-43Q331K mice appear to express a range of 
copy numbers between one and five.  Samples for which the copy number estimation is 
non-specific (e.g. 4/5) indicate an uncertainty in the prediction of copy number. 
 
B 
A 
Figure 2. 2: DNA sequence of TDP43WT and TDP43Q331K transgenic mice. 
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Table 2. 3: Human TARDBP copy number estimation. Estimated copy number of human 
TARDBP in 1 non-transgenic mouse, 3 TDP-43WTmice and 12 TDP-43Q331Kmice.  Mouse 
numbers 11 and 12 presented with a typical weight and rotarod for TDP-43Q331K mice, 
despite apparently having only one copy of the mutated gene. 
Mouse number Genotype Copy number M/F 
1 Non-transgenic 0 M 
2 TDP-43WT 1 F 
3 TDP-43WT 1 F 
4 TDP-43WT 1 M 
5 TDP-43Q331K 4/5 F 
6 TDP-43Q331K 2/3 F 
7 TDP-43Q331K 3 F 
8 TDP-43Q331K 3 F 
9 TDP-43Q331K 4 F 
10 TDP-43Q331K 3 F 
11 TDP-43Q331K 1 F 
12 TDP-43Q331K 1 M 
13 TDP-43Q331K 4 M 
14 TDP-43Q331K 5 M 
15 TDP-43Q331K 5 M 
16 TDP-43Q331K 4 M 
 
2.4.3. Abnormal Gait Evident at 27 Weeks of Age in TDP-43Q331K Mice 
Male and female TDP-43Q331K mice develop a neuroscore of 2 (abnormal gait) around 27 
weeks of age and progress to develop a waddling gait.  Female TDP-43Q331K mice produce 
more consistent neuroscores with less variation amongst mice compared to male TDP-
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43Q331K mice.  Conversely, TDP-43WT and non-transgenic mice show no significant sign of 
tremor or an abnormal gait (figure 2.3).   
 
Figure 2. 3: Neuroscores. 
Median neuroscores (± interquartile range) for male (A) and female (B) TDP-43Q331K mice 
(n = 6/7) compared to TDP-43WT (n = 6) and non-transgenic (NTg, n = 12) mice.  0 = 
normal, 1 = significant hindlimb tremor, 2 = abnormal gait, 3 = severe waddle, 4 = 
dragging of one hindlimb.   
 
2.4.4. TDP-43Q331K Mice are Heavier than TDP-43WT Mice 
TDP-43Q331K mice are significantly heavier than the TDP-43WT and non-transgenic mice 
(see figure 2.4) from 10 weeks of age in males (n = 6/7 TDP-43Q331K; 6 TDP-43WT; 12 NTg, 
29±3.3g TDP-43Q331K vs 24.4±0.7g TDP-43WT, p<0.05) and 9 weeks of age in females (n = 
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5-12, 21.5±2g TDP-43Q331K vs 17.4±1.3g TDP-43WT, p<0.05).  On a two-way ANOVA with 
repeated measures and Tukey’s post-test, all groups get significantly heavier with age 
(p<0.0001) and TDP-43Q331K mice were significantly heavier than TDP-43WT and non-
transgenic mice in males (p<0.001) and females (p<0.0001). 
 
Figure 2. 4: Body weight of the TDP-43Q331K, TDP-43WT and non-transgenic mice. 
Mean weight (± SD) for male (A) and female (B) TDP-43Q331K mice (n = 6/7) compared to 
TDP-43WT (n = 6) and non-transgenic (NTg, n = 12) mice.  TDP-43Q331K mice were 
significantly heavier than the other groups.  *p<0.05 vs all other groups, ****p<0.0001 
vs all other groups, two-way ANOVA with repeated measures and Tukey's post-tests. 
 
0 5 1 0 1 5 2 0 2 5 3 0 3 5 4 0 4 5
0
1 0
2 0
3 0
4 0
5 0
6 0
M a le s
A g e  (w e e k s )
W
e
ig
h
t 
(g
)
T D P -4 3
Q 3 3 1 K
N Tg
T D P -4 3
W T
* - * * * *
0 5 1 0 1 5 2 0 2 5 3 0 3 5 4 0 4 5
0
1 0
2 0
3 0
4 0
5 0
6 0
F e m a le s
A g e  (w e e k s )
W
e
ig
h
t 
(g
)
* - * * * *
T D P -4 3
Q 3 3 1 K
N Tg
T D P -4 3
W T
A
B
 53 
 
2.4.5. Rotarod Performance Decreases with Age in the TDP-43Q331K Mice 
TDP-43Q331K mice show a significantly decreased latency to fall compared to the TDP-
43WT and non-transgenic mice (see figure 2.5) by 7 weeks of age in males (n = 5-12, 
147.8±34.6s TDP-43Q331K vs 261±49.4s TDP-43WT, p<0.01) and 10 weeks of age in females 
(n = 5-12, 201.6±36.9s TDP-43Q331K vs 264.8±40.8 TDP-43WT, p<0.01) (figure 2.5).  On a 
two-way ANOVA with repeated measures and Tukey’s post-test rotarod performance 
reduced significantly with age in all groups (p<0.0001) and TDP-43Q331K mice had a 
significantly decreased latency to fall compared to non-transgenic and TDP-43WT mice 
(p<0.0001). 
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Figure 2. 5: Rotarod performance. 
Mean latency to fall (± SD) for male and female TDP-43Q331K mice compared to TDP-43WT 
and non-transgenic (NTg) mice.  TDP-43Q331K mice had a significantly decreased latency 
to fall compared to the other groups.  *p<0.05 vs all other groups, **p<0.01 vs all other 
groups, ****p<0.0001 vs all other groups, two-way ANOVA with repeated measures and 
Tukey's post-test. 
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2.4.6. Rotarod Performance Decreases Despite Weight 
Weight may have a significant influence on rotarod performance, so a correlation of 
mean rotarod performance and mean weight (n = 5-12) was therefore calculated for 
each group (figure 2.6).  In the TDP-43Q331K male and female mice, the correlation 
between weight and rotarod was highly significant (males r = -0.9507, p<0.0001; females 
r = -0.9799, p<0.0001).  There was also a strong correlation between weight and rotarod 
in the non-transgenic male and female mice (males r = -0.2875, p>0.05; females r = 
0.09947, p>0.05) but interestingly, no correlation was found in the male and female 
TDP-43WT data (males r = -0.8483, p<0.0001; females r = -0.5919, p<0.0001). This may 
suggest that if weight alone influenced rotarod performance then some correlation with 
rotarod performance for TDP-43WT mice may have been observed but was not. However, 
it may still be the case that weight influences rotarod performance, as suggested by the 
TDP-43Q331K and non-transgenic correlations. 
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Figure 2. 6: Spearman correlation of weight vs rotarod. 
Spearman correlation of mean weight vs mean rotarod for male TDP-43Q331K mice (A, r = 
-0.9507, p<0.0001), male TDP-43WT mice (C, r = -0.2875, p>0.05), male non-transgenic 
mice (E, r = -0.8483, p<0.0001), female TDP-43Q331K mice (B, r = -0.9799, p<0.0001), 
female TDP-43WT mice (D, r = 0.09947, p>0.05), and female non-transgenic mice (F, r = -
0.5919, p<0.0001). 
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After consultation with several statisticians to devise a method which would account for 
the influence of weight on the rotarod, several methods of analysis were considered 
including a regression analysis, a general linear model, a mixed model, and an analysis 
of covariance.  After much deliberation, the simple method of normalising the rotarod 
to weight through division was used. 
To eliminate the influence of weight, rotarod performance was normalised for weight 
by generating a ratio of rotarod performance/weight as shown in figure 2.7. A two-way 
ANOVA with repeated measures and Tukey’s post-test revealed that the TDP-43Q331K 
mice performed considerably worse than the TDP-43WT and non-transgenic mice.  The 
ratio of rotarod performance/weight decreases over time in all groups, in both males 
and females (p<0.0001) and the TDP-43Q331K mice show a significant reduction in 
rotarod/weight compared to the other groups (p<0.0001) on a two-way ANOVA with 
Tukey’s post-tests.  The non-transgenic and TDP-43WT mice show a similar starting point 
with a similar decline, whereas the TDP-43Q331K mice have a lower rotarod/weight value 
from the beginning and throughout the disease course, in both male and female mice 
(figure 2.7A).   
The female rotarod/weight values are higher compared to the male data in both TDP-
43WT and non-transgenic mice.  The female decline in rotarod/weight in TDP-43Q331K 
mice is more pronounced than in males and more significantly different when compared 
to the other groups (figure 2.7B). 
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Figure 2. 7: Rotarod performance/weight. 
Mean latency to fall/weight (± SD) for male and female TDP-43Q331K mice compared to 
TDP-43WT and non-transgenic (NTg) mice.  TDP-43Q331K mice show a significantly lower 
rotarod/weight ratio compared to all other groups.  *p<0.05 vs all other groups, 
**p<0.01 vs all other groups, ***p<0.001 vs all other groups, ****p<0.0001 vs all other 
groups, two way ANOVA with Tukey's post-tests. 
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2.4.7. huTARDBP Copy Number vs Rotarod Performance 
Plotting of the rotarod performance for each mouse with a known huTARDBP copy 
number estimation shows no clear difference between the rotarod performances of 
mice with a higher or lower huTARDBP copy number estimation (figure 2.8). 
 
Figure 2. 8: Rotarod performance and huTARDBP copy number estimation. 
Latency to fall on the rotarod is plotted for each of the mice with a known copy number 
estimation for males (A) and females (B).  Copy number estimation is shown in the 
legend.  All mice are TDP-43Q331K. 
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Rotarod performance of the male mouse with an estimated human TARDBP copy 
number of one shows a slightly increased rotarod performance compared to the mean 
TDP-43Q331K rotarod data (figure 2.9A).  The female mouse with an estimated human 
TARDBP copy number of one shows no obvious difference in rotarod performance when 
compared to the mean TDP-43Q331K rotarod data (figure 2.9B). 
 
Figure 2. 9: Rotarod performance of all TDP-43Q331K mice compared to those with an 
estimated copy number of one. 
Latency to fall on the rotarod is plotted for each of the TDP-43Q331K mice with the low 
copy number mouse data plotted as a separate line in males (A) and females (B). 
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2.4.8. Gait Analysis 
Gait parameters were analysed at 1, 3, 6, and 10 months of age in the TDP-43Q331K, TDP-
43WT and non-transgenic mice.  Pawprint images display a wider gait with larger 
pawprints in the TDP-43Q331K mice (figure 2.10C), compared to the gait of non-transgenic 
(figure 2.10A) and TDP-43WT mice (figure 2.10B). 
Footprint traces of non-transgenic (A), TDP-43WT (B) and TDP-43Q331K (C) mice, as seen by 
the camera from below.  Red prints = left hand limbs, green prints = right hand limbs, 
bright prints = forelimbs, darker prints = hindlimbs.  
 
All statistics for significant findings are reported in table 2.4. 
Forelimb intensity (figure 2.11A & B) is a measure of weight support in the forepaws.  
Forelimb intensity is increased at 10 months of age compared to 1, 3 and 6 months of 
age in all groups of male mice (figure 2.11A).  However, there is no significant difference 
between groups at any age in males.  The female data show a significantly increased 
forelimb intensity at 3 months of age in the TDP-43Q331K mice compared to the TDP-43WT 
and non-transgenic mice (figure 2.11B).  This increase is not evident at 6 months of age 
but is shown again at 10 months of age. 
C 
B 
A 
Figure 2. 10: Catwalk gait analysis. 
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Print length (figure 2.11C & D) is a measure of the paw print length.  The forelimb print 
length does not appear to change significantly over time, nor does it show any 
differences between groups in males or females. 
Stride length (figure 2.11E & F) is a measure of the distance covered by each stride, or 
the distance between paw prints of the same paw.  In male mice, the forelimb stride 
length data do not show any significant changes over time and no differences between 
groups of mice.  However, in female mice, the forelimb stride length increases with age 
in the TDP-43WT and non-transgenic mice, whilst remaining the same in the TDP-43Q331K 
mice, presenting as a non-significantly shorter stride length at 6 months of age, and a 
significantly shorter stride length at 10 months of age. 
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Figure 2. 11: Catwalk gait analysis of male and female forelimb intensity (A, B), print 
length (C, D) and stride length (E, F). 
Intensity is a measure of weight support in the paws.  Print length is a measure of the 
paw print length.  Stride length is a measure of the distance covered by each stride.  
Numbers are presented as a mean of the right and left side for each mouse, mean (±SD), 
n = 4-12, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 TDP-43Q331K vs all other groups, 
two way ANOVA with Tukey's post-tests. 
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Duty cycle (figure 2.12A & B) is the length of time a paw is on the floor, expressed as a 
percentage of the total time taken for each stride.  The forelimb duty cycle does not 
appear to change significantly over time, nor does it show any differences between 
groups in males.  However, in females the forelimb duty cycle is decreased at 6 months 
of age in all groups compared to all other time points.  At 6 months of age the female 
TDP-43Q331K mice have a significantly increased forelimb duty cycle, and this is more 
significantly increased at 10 months of age. 
Swing time (figure 2.12C & D) is the length of time between placements of each 
individual paw.  In both males and females the forelimb swing time appears to increase 
at 6 months of age in all groups compared to all other time points.  Male forelimb swing 
time is significantly increased at 3 months of age in the TDP-43Q331K mice.  This increase 
is more significant at 6 and 10 months of age.  Similarly, female forelimb swing time is 
significantly increased at 3 months of age in the TDP-43Q331K mice.  This increase is more 
significant at 6 and 10 months of age.  
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Figure 2. 12: Catwalk gait analysis of male and female forelimb duty cycle (A, B) and 
swing time (C, D). 
Duty cycle is the length of time a paw is on the floor, expressed as a percentage of the 
total time taken for each stride.  Swing time is the length of time between placements of 
each paw.  Numbers are presented as a mean of the right and left side for each mouse, 
mean (±SD), n = 6/7 TDP-43Q331K; 6 TDP-43WT; 12 NTg, *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001 TDP-43Q331K vs all other groups, two way ANOVA with Tukey's post-tests. 
 
Hindlimb intensity (figure 2.13A & B) is a measure of weight support in the hindpaws.  
The hindlimb intensity is decreased at 6 months of age and increased at 10 months of 
age compared to 1 and 3 months of age in all groups, in both male and female mice.  The 
male data show a decreased hindlimb intensity throughout in the TDP-43Q331K mice and 
this is significant at 10 months of age. However, there is no significant difference 
between groups at any age in the female hindlimb intensity. 
Print length (figure 2.13C & D) is a measure of the paw print length.  The hindlimb print 
length does not appear to change significantly over time, nor does it show any 
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differences between groups in males.  However, in females, the hindlimb print length is 
significantly increased in the TDP-43Q331K hindlimb at 10 months of age. 
Stride length (figure 2.13E & F) is a measure of the distance covered by each stride, 
meaning the distance between paw prints of the same paw.  In male mice, the hindlimb 
stride length data do not show any significant changes over time and no differences 
between groups of mice.  However, in female mice, the hindlimb stride length increases 
with age in the TDP-43WT and non-transgenic mice, whilst remaining the same in the 
TDP-43Q331K mice, presenting as a non-significantly shorter hindlimb stride length at 6 
months of age, and a significantly shorter stride length at 10 months of age. 
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Figure 2. 13: Catwalk gait analysis of male and female hindlimb intensity (A, B), print 
length (C, D) and stride length (E, F). 
Intensity is a measure of weight support in the paws.  Print length is a measure of the 
paw print length.  Stride length is a measure of the distance covered by each stride.  
Numbers are presented as a mean of the right and left side for each mouse, mean (±SD), 
n = 4-12, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 TDP-43Q331K vs all other groups, 
two way ANOVA with Tukey's post-tests. 
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Duty cycle (figure 2.14A & B) is the length of time a paw is on the floor, expressed as a 
percentage of the total time taken for each stride.  The hindlimb duty cycle shows a 
slight increase at 10 months of age in males compared to 1, 3 and 6 months.  The male 
data show no differences between groups other than a decreased duty cycle in TDP-
43Q331K mice at 3 months of age.  However, in females the hindlimb duty cycle is 
decreased at 6 months of age in all groups compared to all other time points and at 10 
months of age the female TDP-43Q331K mice have a significantly increased hindlimb duty 
cycle. 
Swing time (figure 2.14C & D) is the length of time between placements of each 
individual paw.  In both males and females the hindlimb swing time appears to increase 
at 6 months of age in all groups compared to all other time points.  Male hindlimb swing 
time is significantly increased at 6 and 10 months of age in the TDP-43Q331K.  Similarly, 
female hindlimb swing time is significantly increased at 6 months of age in the TDP-
43Q331K mice.  However, there is no significant difference in hindlimb swing time 
between female groups at 10 months of age. 
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Figure 2. 14: Catwalk gait analysis of male and female hindlimb duty cycle (A, B) and 
swing time (C, D). 
Duty cycle is the length of time a paw is on the floor, expressed as a percentage of the 
total time taken for each stride. Swing time is the length of time between placements of 
each foot.  Numbers are presented as a mean of the right and left side for each mouse, 
mean (±SD), n = 4-12, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 TDP-43Q331K vs all 
other groups, two way ANOVA with Tukey's post-tests. 
 
Base of support (BOS) is the distance between the two paws.  The forelimb BOS (figure 
2.15A & B) has a tendency to increase with age in both males and females.  However, 
there are no significant differences between groups at any age in the male mice.  Female 
TDP-43Q331K mice show a significantly larger forelimb BOS at 10 months of age. 
Hindlimb BOS (figure 2.15C & D) is increased at 6 and 10 months in all groups compared 
to 1 and 3 months in both males and females.  In males, the hindlimb BOS is significantly 
larger in the TDP-43Q331K mice at 6 and 10 months.  In females, the hindlimb BOS is 
significantly larger in the TDP-43Q331K mice at 6 and 10 months.  This appears to be the 
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most consistent and useful measure of gait abnormalities in these mice and reflects well 
the ‘waddling gait’ observed. 
 
Figure 2. 15: Catwalk gait analysis of male and female hindlimb base of support in the 
forelimb (A, B) and hindlimb (C, D). 
Base of support (BOS) is the distance between the two paws.  Mean (±SD), n = 4-12, *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001 TDP-43Q331K vs all other groups, two way ANOVA 
with Tukey's post-tests. 
 
Walking duration (figure 2.16A & B) is the time taken to cross the length of the recording 
area (43.8cm).  Walking remains similar in TDP-43WT and non-transgenic mice at 1, 3, 6 
and 10 months of age, in both males and females.  However, walking duration is 
increased by 3 months of age in males, significantly so by 6 months of age and more so 
by 10 months of age.  In female mice, the walking duration is significantly increased at 3 
months of age, 6 months of age and 10 months of age. 
The percentage of time spent walking with a diagonal step pattern is shown in figure 
2.16C & D (left forepaw placed down in time with right hindpaw; right forepaw placed 
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down in time with left hindpaw).  In males and females the percentage of diagonal 
stepping pattern shows no obvious trends with age in the TDP-43WT and non-transgenic 
mice.  However, the percentage of diagonal stepping is decreased in the TDP-43Q331K 
male mice at 6 and 10 months of age.  In females, the percentage of diagonal stepping 
is significantly decreased in the TDP-43Q331K mice at 10 months of age. 
The percentage of time spent walking with three paws on the ground at any one time is 
also shown in figure 2.16E & F.  In males and females the percentage of three paw step 
pattern shows no obvious trends with age in the TDP-43WT and non-transgenic mice.  
However, the percentage of three paw stepping is non-significantly decreased in the 
TDP-43Q331K mice at 6 and 10 months of age.  In females, the percentage of three paw 
stepping is significantly decreased in the TDP-43Q331K mice at 10 months of age. 
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Figure 2. 16: Catwalk gait analysis of male and female duration (A, B), percentage of 
time on diagonal paws (C, D) and percentage of time on three paws (E, F). 
Duration is the time it takes the mice to walk the distance of the catwalk (43.8cm).  For 
the percentage of time spent walking with a diagonal step pattern and the percentage 
of time spent on 3 paws, statistics are also based on logit transformation.  Mean (±SD), 
n=4-12, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 TDP-43Q331K vs all other groups, 
two way ANOVA with Tukey's post-tests. 
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Table 2. 4: Table of significant statistics for catwalk gait analysis. *=p<0.05, **=p<0.01, ***=p<0.001, ****=p<0.0001, IU=intensity units.  All 
differences are between the TDP-43Q331K and control groups, there were no significant differences between the non-transgenic and TDP-43WT groups. 
Catwalk 
parameter 
Age 
(months) 
Gender TDP-43Q331K  TDP-43WT Non-transgenic Significance of the 
difference between 
the TDP-43Q331K and 
control groups 
Forelimb 
intensity 
3 Females 105.2±7.9IU 89.1±4.9IU 90.9±4.6IU ** 
10 Females 139±7.1IU 95.8±10.1IU 111.1±17.8IU **** 
Forelimb stride 
length 
10 Females 47.2±8.5mm 57.6±5.8mm 62.5±9.5mm * 
Forelimb duty 
cycle 
6 Females 53.7±7.6% 46.6±8.2% 44.3±6% * 
10 Females 70.5±4.8% 53.1±4.5% 58.1±4.4% **** 
Forelimb swing 
time 
3 Males 0.122±0.02s 0.088±0.011s 0.09±0.017s ** 
6 Males 0.16±0.013s 0.103±0.008s 0.111±0.007s **** 
10 Males 0.125±0.03s 0.095±0.009s 0.087±0.01s **** 
3 Females 0.108±0.008s 0.084±0.011s 0.086±0.009s ** 
6 Females 0.154±0.015s 0.108±0.008s 0.11±0.018s **** 
10 Females 0.126±0.01s 0.095±0.015s 0.081±0.11s *** 
Hindlimb 
intensity 
10 Males 113.2±19.2IU 131.9±9IU 130.4±12.6IU * 
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Hindlimb print 
length 
10 Females 10.7±1.6mm 6.7±0.8mm 7.1±1.1mm **** 
Hindlimb stride 
length 
10 Females 47.6±6.2mm 58.4±5.6mm 61.9±7.6mm * 
Hindlimb duty 
cycle 
3 Males 55.9±2.6% 65.3±1.5% 62.9±8.1% * 
10 Females 47.6±6.2% 58.4±5.6% 61.9±7.6% **** 
Hindlimb swing 
time 
6 Males 0.133±0.025s 0.088±0.004s 0.086±0.009s **** 
10 Males 0.105±0.03s 0.075±0.008s 0.069±0.01s *** 
6 Females 0.141±0.017s 0.093±0.018s 0.093±0.015s **** 
Forelimb BOS 10 Females 15.4±1.2mm 12.8±1.5mm 13.6±1.4mm * 
Hindlimb BOS 
6 Males 34.3±5.1mm 28.1±2.5mm 27.6±2mm ** 
10 Males 36.6±7.1mm 28.6±3mm 28.5±2.5mm **** 
6 Females 32.7±3mm 25.5±2.2mm 27.5±1.8mm *** 
10 Females 35.8±5.1mm 26.4±3.1mm 28.3±2.8mm **** 
Duration 
6 Males 3.4±0.9s 1.8±0.2s 2.0±0.4s **** 
10 Males 3.6±1.6s 2.1±0.3s 1.9±0.4s **** 
3 Females 2.8±0.7s 1.9±0.6s 1.7±0.4s * 
6 Females 3.0±0.8s 1.7±0.5s 1.4±0.3s *** 
10 Females 4.7±1.5s 1.6±0.2s 1.5±0.3s **** 
Diagonal walking 
6 Males 54.9±11.7% 70.7±4.4% 65.6±8.2% * 
10 Males 41.6±14.9% 56.1±5.9% 52.7±8.4% * 
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10 Females 30.7±15.9% 69.1±9.1% 65.3±11% **** 
Three paw 
walking 
10 Females 35±8.4% 20.5±7.7% 20.3±5.7% * 
 
2.4.9. Variability of Parameters 
In order to determine the group sizes required for therapeutic testing, statistical power analysis was conducted on all of the readouts using G*Power 
3.1.9.2. (Faul et al., 2009) (table 2.4). Coefficients of variation are relatively low (<16%) for the majority of parameters measured.  Power analysis 
(student’s t-test, two-tailed, α = 0.05, β = 0.8) was conducted on data at 6 and 10 months of age for most parameters and the N number required to 
detect a 10, 15 and 20% difference from TDP-43Q331K mice calculated.  For rotarod data we have previously found in SOD1G93A mice that the time taken 
to reach a 20% decline in performance is the least variable measure, and so this was used again here. The analysis suggests an N of 14 per group would 
be sufficient to detect a difference of at least 15% for all parameters. Overall, the data suggest that a study length of 10 months does not offer many 
advantages over a study length of 6 months with most of the effect sizes relatively unchanged between 6 and 10 months of age.  Overall a study length 
of 6 months with group sizes of 14 is sufficient for the investigation of therapeutic agents in preclinical studies in this model. 
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Table 2. 5: Coefficient of variation and power analysis.  Coefficient of variation and 
power analysis for all measured parameters at 6 and 10 months of age in female mice.  
Power = 80%. 
Parameter Age 
(months) 
Mean values 
in TDP-43Q331K 
mice (±s.d.) 
Coefficient 
of 
Variation 
Mean 
difference 
TDP-43WT vs 
TDDP-43Q331K 
N required to 
detect an x% 
improvement 
Time to reach a 
neuroscore of 2 
(severe waddle) 
N/A 26.43 weeks ± 
0.535 
2.02% N/A 10% = 3 
15% = 2 
20% = 2 
Weight 6 35.27g ± 3.651 10.4% +55% 10% = 14 
15% = 7 
20% = 5 
10 43.8g ± 4.418 10.09% +54% 10% = 14 
15% = 7 
20% = 5 
Increase by 2 
weeks in time to 
reach a 20% 
decline in 
rotarod 
performance 
from maximum 
N/A 11.43 weeks ± 
1.813 
15.86% N/A 11 
Catwalk 
hindlimb base 
of support 
6 32.651 ± 3.006 9.2% +28% 10% = 12 
15% = 6 
20% = 4 
10 35.843 ± 5.143 14.3% +36% 10% = 27 
15% = 13 
20% = 8 
 
2.4.10. Litter Statistics 
Litter size, percentage of transgenic pups, and percentage of male pups were compared 
between the two colonies TDP-43WT and TDP-43Q331K (figure 2.17).  The litter size of the 
TDP-43Q331K colony was significantly higher than the TDP-43WT colony (6±2.61 in TDP-
43WT vs 7±2.12 in TDP-43Q331K).  The percentage of transgenic (49.91±22.37% in TDP-
43WT vs 47.91±22.68%) and male (48.06±24.84% in TDP-43WT vs 53.32±20.26%) pups 
within each litter were equal between the two colonies.  Breeding consistently uses 
transgenic males with non-transgenic females.  The males appear to be fertile until at 
least 10 months of age in both colonies. 
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Figure 2. 17: Litter statistics for TDP-43WT and TDP-43Q331K colonies. 
Comparisons between colonies for litter size (A), percentage of transgenic pups (B), and 
percentage of male pups (C).  Litter size was compared using a Mann Whitney U test as 
the data were not normally distributed.  Percentage of transgenic and male pups were 
compared using a student’s t-test. 
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2.4.11. huTARDBP Gene Expression 
The same cDNA samples were used to measure gene expression of huTDP-43 in the 
cDNA of cortex, spinal cord and hindlimb muscles of TDP-43WT and TDP-43Q331K mice at 
10 months of age (figure 2.18) to assess the levels of expression compared with 
previously reported levels on a C57BL/6NCrl background (Arnold et al., 2013).  For all 
tissues, TDP-43Q331K values were expressed as a percentage of the TDP-43WT values. 
Expression of huTDP-43 was over 3-fold higher in the TDP-43Q331K cortex compared to 
the TDP-43WT cortex (100±17.3% in TDP-43WT vs 308.4±36.4% in TDP-43Q331K, p<0.0001).  
Expression of huTDP-43 was over 2-fold higher in the TDP-43Q331K spinal cord compared 
to the TDP-43WT spinal cord (100±13.3% in TDP-43WT vs 213.3±65.8% in TDP-43Q331K, 
p<0.0001).  Expression of huTDP-43 was over 4-fold higher in the TDP-43Q331K hindlimb 
muscle compared to the TDP-43WT hindlimb muscle (100±19.8% in TDP-43WT vs 
407.6±111.9% in TDP-43Q331K, p<0.0001).  Relative huTDP-43 expression was therefore 
highest in the TDP-43Q331K muscle, followed by cortex, and spinal cord. 
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Figure 2. 18: huTDP-43 gene expression ± SD at 10 months of age. 
Gene expression of huTDP-43 as a percentage of the mean TDP-43WT levels, as measured 
in cDNA of cortex (A), spinal cord (B) and hindlimb muscles (C) of TDP-43WT and TDP-
43Q331K mice (n=9-12). ****p<0.0001, student’s t-test. 
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2.4.12. Total (mouse + human) TARDBP Gene Expression 
Gene expression of total (mouse + human) TDP-43 was measured in the cDNA of cortex 
and spinal cord of non-transgenic, TDP-43WT and TDP-43Q331K mice at 10 months of age 
(figure 2.19), and expressed as a percentage of the mean non-transgenic value.  Gene 
expression of total (mouse + human) TDP-43 was also measured in the hindlimb muscles 
of TDP-43WT and TDP-43Q331K mice, and expressed a percentage of the mean TDP-43WT 
value. 
Expression of TDP-43 was significantly lower in both TDP-43WT and TDP-43Q331K cortex 
compared to the non-transgenic cortex (100±28% in non-transgenic vs 77.8±23.9 in TDP-
43WT vs 67±18.6% in TDP-43Q331K, p<0.01).  Expression of TDP-43 was significantly lower 
in both TDP-43WT and TDP-43Q331K spinal cord compared to the non-transgenic spinal 
cord (100±15.7% in non-transgenic vs 69.6±8.2% in TDP-43WT vs 67.6±15.2% in TDP-
43Q331K, p<0.0001).  Expression of TDP-43 was significantly higher in the TDP-43Q331K 
hindlimb muscle compared to the TDP-43WT hindlimb muscle (100±19.7% in TDP-43WT 
vs 139±51.5% in TDP-43Q331K, p<0.05). 
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Figure 2. 19: Mouse (total) TDP-43 gene expression at 10 months of age. 
Gene expression as a percentage of the mean non-transgenic levels, measured in cDNA 
of cortex (A) and spinal cord (B) of non-transgenic, TDP-43WT and TDP-43Q331K mice (n=9-
12).  **<0.01, ****p<0.0001, one-way ANOVA.  Gene expression as a percentage of the 
mean TDP-43WT levels, as measured in cDNA of hindlimb muscles (C) of TDP-43WT and 
TDP-43Q331K mice (n=9-12). *p<0.05, student’s t-test. 
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2.4.13. TDP-43 Protein Quantification 
Western blotting with an anti-TDP-43 antibody allowed for quantification of both human 
and mouse TDP-43 protein as separate bands due to the c-myc tag on the human protein 
increasing the molecular weight, as shown in figure 2.20.  All samples used for protein 
quantification were the same as those used in section 2.4.11 and 2.4.12 for protein 
expression quantification. 
 
Figure 2. 20: Example of a Western blot for TDP-43. 
The Western blot showed two separate bands for human (44.2kD) and mouse TDP-43 
(43kD) between protein ladder markers for 35 and 48.  This example shows non-
transgenic, TDP-43WT and TDP-43Q331K 10m male cortex samples respectively (n=3). 
 
As expected, Western blot analysis shows no human TDP-43 protein in the non-
transgenic mice, and moderate levels in the TDP-43WT mice (66.6±8.6% in cortex, 
126.1±67.1 in cord), whilst levels in the TDP-43Q331K mice were relatively high 
(151±23.1% in cortex, 213.9±154.1 in cord).  Conversely, mouse TDP-43 was highest in 
the non-transgenic mice, reduced in the TDP-43WT mice (47.5±16.2% in cortex, 
65.5±16.3 in cord) and further reduced in the TDP-43Q331K mice (13.6±2.3% in cortex, 
70.7±29.6 in cord).  Total TDP-43 levels are highest in the TDP-43Q331K mice (164.6±23.1% 
 83 
in cortex, 191.6±78.5 in cord), and moderate in the TDP-43WT mice (114.1±22.8% in 
cortex, 284.5±173.3 in cord) (see figure 2.21). 
 
Figure 2. 21: Western blot quantification of TDP-43. 
Relative human, mouse and total TDP-43 protein levels in 10m non-transgenic, TDP-43WT 
and TDP-43Q331K mice for cortex (A), and spinal cord (B), n=5-6.  All samples are 
normalised to the non-transgenic total TDP-43 value for each Western blot.  In all tissues, 
human TDP-43 is undetected in the non-transgenic mice, moderately detected in the 
TDP-43WT mice and highly detected in the TDP-43Q331K mice.  Conversely, mouse TDP-43 
is highest in the non-transgenic mice, moderate in the TDP-43WT mice and low in the TDP-
43Q331K mice.  Total TDP-43 levels are highest in the TDP-43Q331K mice, and lowest in the 
non-transgenic. 
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2.4.14. Immunohistochemical Analysis of huTDP-43 Localisation 
Lumbar spinal cord sections from 10 month old TDP-43WT and TDP-43Q331K mice show 
clear nuclear staining for c-myc-tagged huTDP-43 (green), representative of c-myc 
tagged huTDP-43 protein.  C-myc-tagged huTDP-43 can also be seen in the cytoplasm of 
the motor neurons, which are identified by anti-NeuN staining and their large size and 
location (red) (figure 2.22).  Image analysis enabled staining intensities (average grey 
level) of nuclear and cytoplasmic regions of motor neurons (large ventral horn neurons 
with size > 19.44µm²) to be determined. 
Nuclear staining intensity of c-myc-tagged huTDP-43 was significantly higher (average 
grey level 10119±1285 in TDP-43WT vs 14982±1985 in TDP-43Q331K, student’s t-test, 
p<0.01) in the lumbar cord motor neurons of the TDP-43Q331K mice compared to the TDP-
43WT mice (figure 2.23).  However, there was no significant difference between 
cytoplasmic staining intensity of c-myc-tagged huTDP-43 (5124±842.7 in TDP-43WT vs 
6102±638.9 in TDP-43Q331K, student’s t-test, p>0.05) in the lumbar cord of the TDP-43WT 
and TDP-43Q331K mice (figure 2.23).  The ratio of nuclear/cytoplasmic staining intensity 
of c-myc-tagged huTDP-43 was significantly higher (1.99±0.13 in TDP-43WT vs 2.479±0.24 
in TDP-43Q331K, student’s t-test, p<0.01) in the lumbar spinal cord of TDP-43Q331K mice 
compared to TDP-43WT mice (figure 2.23). 
 85 
 
Figure 2. 22: Immunohistochemical staining of huTDP-43. 
Staining of spinal cord ventral horn in 10m old mice.  Nuclei are stained by DAPI in blue, 
motor neurons are stained by anti-NeuN in red, huTDP-43 is stained by anti-c-myc in 
green. 
 
Quantification of c-myc in the nuclei and cytoplasm of spinal cord motor neurons shows 
the quantity of c-myc (and therefore huTDP-43) is higher in the nucleus of the motor 
W
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W
T 
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neurons of TDP-43Q331K mice compared to the TDP-43WT mice.  The ratio of 
nuclear/cytoplasmic c-myc is also higher in the TDP-43Q331K mice, suggestive of a higher 
proportion of c-myc in the nucleus and no cytoplasmic mislocalisation of huTDP-43 
(figure 2.23). 
Figure 2. 23: Immunohistochemical staining localisation of huTDP-43. 
Quantification of the amount of huTDP-43 in the nuclei (A), cytoplasm (B) and 
nuclear/cytoplasmic ratio (C) of spinal cord motor neurons in 10m TDP-43WT and TDP-
43Q331K mice (n=5-6).  **p<0.01 vs all other groups. 
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2.4.15. Immunohistochemical Analysis of Astrogliosis 
Spinal cord sections from 10 month old mice were stained for GFAP immunoreactivity, 
for which higher staining levels (both area and intensity) are suggestive of astrogliosis.  
Immunohistochemical staining of GFAP showed a higher staining index of GFAP in the 
TDP-43Q331K 10 month spinal cord, compared to the non-transgenic (8.11x107±3.347x107 
in TDP-43Q331K vs 5.356x107±2.827x107 in non-transgenic), suggestive of astrogliosis. 
  
Figure 2. 24: GFAP staining and staining index. 
Quantification of GFAP staining in the spinal cord of 10m TDP-43Q331K and non-transgenic 
mice (n = 5).  Non-significant on a student’s t-test. 
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2.4.16. Immunohistochemical Analysis of Microgliosis 
10 month spinal cord sections were stained for IBA-1 immunoreactivity, for which 
increased area of staining is suggestive of microgliosis (staining intensity is unaffected 
by microgliosis).  Immunohistochemical staining of IBA-1 showed a significantly higher 
staining area of IBA-1 in the TDP-43Q331K 10 month spinal cord, compared to the non-
transgenic (2992±571µm2 in TDP-43Q331K vs 2213±474µm2 in non-transgenic), suggestive 
of microgliosis. 
  
Figure 2. 25: IBA-1 staining and quantification of staining area. 
Quantification of IBA-1 staining in the spinal cord of 10m TDP-43Q331K and non-transgenic 
mice (n = 5-6).  *p<0.05 vs all other groups. 
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2.5. Discussion 
There is a clear need for additional mouse models of MND, not only for evaluation of 
potential therapeutic agents, but also to probe mechanisms of neurodegeneration.  No 
therapies have translated to humans from the most commonly tested model, the 
SOD1G93A mouse (Gurney et al., 1994), and no consistent effect of organic small molecule 
drugs have been found in this model (Ittner et al., 2015).  Given the heterogeneity of 
MND in terms of both genotype and phenotype, trials of novel therapeutic agents 
would, ideally, be performed across several disease models.  For the maximum efficiency 
of such studies, new models must be carefully characterised prior to integration into 
drug testing paradigms. 
TDP-43 models may play an important role in testing therapeutics, given the almost 
ubiquitous nature of TDP-43 pathology in human MND (Gitcho et al., 2008, Mackenzie 
et al., 2007).  Therefore, characterisation of this novel TDP-43Q331K model is key in 
assessing its validity and reliability for therapeutic trials. 
 
2.5.1. huTARDBP Sequencing and Copy Number 
Sequence analysis found the TDP-43Q331K transgene to have an adenine to cytosine 
nucleotide mutation, causing a glutamine to lysine amino acid change at position 331 of 
the human TARDBP gene, confirming the Q331K mutation, which was not found in the 
TDP-43WT mice.  The TDP-43Q331K mice therefore carry a mutation which has previously 
been identified in an MND patient (Sreedharan et al., 2008). 
TARDBP copy number analysis showed that although TDP-43WT mice appear to 
consistently have just one copy of the human TARDBP gene, the TDP-43Q331K mice 
potentially vary in copy number.  Gene copy number has been directly correlated with 
disease severity in the SOD1G93A mouse model (Alexander et al., 2004).  However, as the 
subsequent data shows, there is low variance in the measured parameters in the present 
study.  Plotting of the rotarod performance of each of the TDP-43Q331K mice with a known 
copy number variation showed no obvious differences in rotarod performance between 
those mice with a low copy number and those with a high copy number. It is also worth 
bearing in mind that the variability seen may be due to technical issues with sample 
preparation or digital PCR itself. Digital PCR is very sensitive to small changes in copy 
number and for some samples a precise copy number estimation could not be 
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determined.  It would appear that in general the TDP-43Q331K mice have more copies and 
this allows for greater variation in copy number estimation, whereas TDP-43WT have a 
single copy and so estimation of copy number is more precise. Despite this, digital PCR 
is more reliable than previous methods (qPCR) (Whale et al., 2012), which have been 
used and which in general, only identify large changes in copy number. 
A comparison of mean TDP-43Q331K rotarod performance and the rotarod performance 
of mice with an estimated copy number of one shows a slightly increased performance 
in the low copy number mice.  However, as copy number was not estimated for all mice 
on the study, it is possible that there are other low copy number mice in the mean data. 
It can therefore be concluded that in this model, copy number variation may have a 
slight impact on motor phenotype, but this requires further investigation and 
monitoring. 
 
2.5.2. Variability of Parameters 
As shown in table 2.3, the coefficient of variation (the standard deviation as a 
percentage of the mean) was relatively low for all the parameters measured, providing 
reassurance that the model has low phenotypic variability.  The data shown in the table 
were for females, as they had a lower variance than the males and any therapeutic trials 
will therefore use females only, in order to reduce the number of mice required per 
group. 
Power analysis suggests group sizes of 14 would be sufficient to detect a 10% difference 
in neuroscores, weight, rotarod and a 15% difference in hindlimb base of support on the 
catwalk.  This would be an ideal group size for therapeutic trials as it would allow for a 
therapeutic effect size of 15% to be detected using the described parameters.  This 
group size of 14 is relatively low compared to the suggested group size for SOD1G93A 
mice of 24 animals per group (Scott et al., 2008).  
 
2.5.3. The Effect of huTARDBP Copy Number on Phenotype 
TDP-43WT mice showed no significant differences in neuroscores, weight, rotarod 
performance or catwalk gait analysis when compared to the non-transgenic mice.  It 
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would appear that for these parameters, carrying a huTARDBP had no effect on motor 
phenotype. 
The TDP-43WT mice are therefore an ideal control line and the findings in TDP-43Q331K 
mice are specific to the mutation, rather than due to the expression of huTARDBP. 
 
2.5.4. Disease Severity and Onset 
As found previously (Arnold et al., 2013), the disease phenotype in the TDP-43Q331K mice 
is mild.  There were no signs of distress in the animals and no mice reached a humane 
endpoint, as defined within our Home Office License.  Differences in phenotype are 
evident by 6 months in all the parameters measured, and rate of progression is slow 
beyond 6 months of age.   
A significant tremor is detectable by 10 weeks of age in the TDP-43Q331K mice, as was 
found previously at 3 months of age (Arnold et al., 2013), and a significant reduction in 
rotarod performance can be detected by 12 weeks of age.  This indicates that onset of 
visible signs of disease in the TDP-43Q331K mice is around 10-12 weeks of age. 
 
2.5.5. Weight 
Unexpectedly the TDP-43Q331K mice became overweight with age, as reflected in the 
weight data.  Dissection of the mice for tissue confirmed that the weight gain was due 
to increased white fat, particularly in the abdominal area.  This was not reported 
previously but has been found in another TDP-43 mouse model carrying an A315T 
mutation (Stallings et al., 2013).  Conversely, knockout of TDP-43 in another mouse 
model found that a lack of fat deposition led to early death (Chiang et al., 2010).  Both 
studies related fat metabolism to expression of the gene TBC1D1, which was tightly 
coupled with TDP-43 levels.  This weight gain will therefore be a focus of further study, 
as reported in chapter 3. 
 
2.5.6. Rotarod Deficit vs Weight 
It is possible that rotarod findings are partially influenced by the weight of the mice, as 
a study in 3xTg-AD mice found a correlation between increased weight and decreased 
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rotarod performance (Stover et al., 2015).  However, clinical signs of disease including 
tremor and muscular atrophy are already present at the onset of rotarod decline in TDP-
43Q331K mice and a significant difference was found in rotarod performance before a 
significant difference in weight became evident (compare figures 2.4 and 2.5).   
When weight is taken into account by plotting rotarod performance/weight , the decline 
in performance is still evident in the TDP-43Q331K mice compared to the other groups, 
suggesting that the decline in rotarod performance is indicative of motor dysfunction, 
despite the influence of weight. 
 
2.5.7. Correlation of Neuroscore with Other Measures 
Decreased rotarod performance is evident in both male and female TDP-43Q331K mice by 
10 weeks of age and many differences are found in catwalk gait analysis at both 3 and 6 
months of age.  However, differences in neuroscores did not become apparent until 27 
weeks (post the 3 and 6 month time points), suggesting that neuroscoring is not 
sensitive to onset of disease, as measured by motor function.  This is also seen in the 
SOD1G93A model where a significant rotarod deficit is obvious before the onset of visible 
signs of disease (Mead et al., 2011), and running wheel performance declines before 
symptom onset (Bruestle et al., 2009).  Indeed, it is often noted by MND patients that 
they felt different long before onset of their first clinical sign of MND.  A classic example 
of this is Lou Gehrig, the famous American baseball player, whose home-run average 
declined dramatically before symptom onset and diagnosis of MND (Kasarskis and 
Winslow, 1989). 
Previously published work found significant hindlimb clasping in the TDP-43Q331K mice 
from 3 months of age (Arnold et al., 2013) and initially hindlimb clasping was measured 
in this study.  However, hindlimb clasping was highly variable within each mouse, so it 
was deemed unreliable in this model and measurement was stopped. 
It must be considered that at the time of neuroscoring in this study, a model-specific 
neuroscoring protocol had not been developed and therefore, a more specific 
neuroscoring protocol was subsequently developed for future studies (see chapter 4).  
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2.5.8. Catwalk Gait Analysis 
Gait analysis has been used to detect early signs of disease in the SOD1G93A mouse 
model, consistently finding increased stand time in the SOD1G93A mice compared to 
controls (Wooley et al., 2005, Mead et al., 2011), increased base of support (BOS) 
(Mancuso et al., 2011a, Guillot et al., 2008), and decreased stride length (Mead et al., 
2011, Wooley et al., 2005), to the extent of being used as a therapeutic trial readout 
(Lee et al., 2013, Sun et al., 2014).  
 
2.5.8.1. Differences in Forelimb Gait 
Forelimb paw intensity shows a tendency to increase in all groups of males at 10 months 
of age, possibly due to the increase in weight of all males.  This increase is more 
exaggerated in the TDP-43Q331K females, possibly due to the larger difference in weight 
between the TDP-43Q331K and other groups.  However, weight is significantly increased 
in TDP-43Q331K males and females by 10 weeks of age, yet no difference in forelimb 
intensity is found at 3 or 6 months of age.  Therefore, although weight may be a 
contributing factor, it is possible that the forelimb intensity is affected by the 
unsteadiness of the mice and greater reliance on forepaws.   
No differences were found with age, group or gender in forelimb print length, which is 
to be expected as the size of the paws would not be expected to change post maturity. 
Forelimb stride length showed no differences in males with age or group.  However, in 
females, the stride length appeared to increase slightly in the TDP-43WT and non-
transgenic groups, whilst reducing slightly in the TDP-43Q331K mice (no findings were 
significant), as found in SOD1G93A mice (Mead et al., 2011).  The forelimbs of SOD1G93A 
mice tend to be relatively unaffected, whereas there is potentially an effect in the 
forelimbs of the TDP-43Q331K mice.  The reason for an increase in stride length of the 
TDP-43WT and non-transgenic mice is unknown.  It is possible that the decrease in stride 
length of the TDP-43Q331K mice is due to weakness of the forelimbs, limiting the amount 
of lift given to each paw, and therefore the amount of distance covered. 
An increase in duty cycle may represent a decreased ability to initiate movement of the 
limb off the ground, as found in TDP-43Q331K males at 10 months of age, and TDP-43Q331K 
females at 6 and 10 months of age.  A decrease in duty cycle of all groups was found in 
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females at 6 months of age, possibly due to an increased swing time, affectively 
decreasing the proportion of time spent with the paws on the surface and in turn, 
decreasing the duty cycle. 
Forelimb swing time is increased in the TDP-43Q331K male and female mice at 3, 6 and 10 
months.  This is suggestive of a generalised slowing of movement, likely due to weakness 
of the forelimbs.  Forelimb swing time shows a slight increase in all groups at 6 months 
compared to all other time points.  The reason for this is unknown. 
Forelimb BOS increases in all groups with age in both males and females, possibly due 
to an increase in size of the mice with age, increasing the distance between the paws.  
Forelimb BOS is significantly higher in the female TDP-43Q331K mice at 10 months of age.  
In the forepaws, a swimming gait was not observed and cannot therefore explain this 
finding.  It is possible that an increased weight has caused a wider stance.  However, this 
is not evident at 6 months of age, despite a significantly increased weight at this 
timepoint.   
 
2.5.8.2. Differences in Hindlimb Gait 
Hindlimb paw intensity shows a decrease in all groups of both males and females at 6 
months of age for an unknown reason.  Hindlimb intensity is significantly lower in the 
TDP-43Q331K mice compared to all other groups at 10 months of age, suggesting that less 
weight is being placed on the hind paws, despite an increase in the weight of the animal.  
This is consistent with a slight increase in forelimb paw intensity at 10 months of age, 
suggesting that the mice are placing more weight on to the forelimbs, possibly because 
the hindlimbs are weaker than the forelimbs, increasing reliance on forelimb strength.  
However, this finding is not seen in female mice, despite an increase in forelimb 
intensity. 
Hindlimb print length showed no differences with age, group or sex, other than an 
increase in the TDP-43Q331K females at 10 months of age, the reason for which is 
unknown as it is not expected that paw size would change post maturity. 
Hindlimb stride length showed no differences in males with age or group.  However, in 
females, the stride length appeared to increase slightly in the TDP-43WT and non-
transgenic groups, whilst reducing slightly in the TDP-43Q331K mice.  As with the forelimb 
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findings, this is in keeping with findings in SOD1G93A mice (Mead et al., 2011).  The reason 
for an increase in stride length of the TDP-43WT and non-transgenic mice is unknown.  It 
is possible that the decrease in stride length of the TDP-43Q331K mice is due to weakness 
of the hindlimbs, limiting the amount of lift given to each paw, and therefore the amount 
of distance covered. 
Hindlimb duty cycle expresses the hindlimb stance time as a percentage of the step cycle 
duration and is as such representative of the amount of time a paw remains on the 
surface within each stride.  A decreased duty cycle was found in TDP-43Q331K males at 3 
months of age, the reason for which is unknown.  An increase in duty cycle may 
represent a decreased ability to initiate movement of the limb off the ground, as found 
in both TDP-43Q331K males at 10 months of age, and females at 6 and 10 months of age.  
A decrease in duty cycle of all groups was found in females at 6 months of age, possibly 
due to an increased swing time, effectively decreasing the percentage of duty cycle. 
Hindlimb swing time is increased in the TDP-43Q331K male and female mice at 6 and 10 
months of age.  This is suggestive of a generalised slowing of movement, likely due to 
weakness of the muscles, as found in the forelimbs. 
Hindlimb BOS increases in all groups with age in both males and females, possibly due 
to an increase in size of the mice, increasing the distance between the hindpaws.  At 6 
and 10 months the TDP-43Q331K male and female mice show a larger hindlimb BOS 
compared to other groups, likely due to their increased weight, which is mainly evident 
in the lower torso, resulting in an increased distance between the hindlimbs.  The 
waddling gait of the mice will also increase the distance between hindpaw placements, 
increasing hindlimb BOS further. 
 
2.5.8.3. Differences in Overall Gait Pattern and Duration 
Walking duration, indicative of walking speed, remains similar with age in the TDP-43WT 
and non-transgenic mice.  However, in the TDP-43Q331K mice, walking duration increases 
with age in both males and females, indicating a slowing down of the mice, consistent 
with the decrease in swing time.  This general slowing in walking pace is suggestive of 
limb weakness and/or a lack of motivation to move. 
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Ordinarily, mice will spend most of their time walking in a diagonal stepping pattern, 
meaning they will step with the left forepaw whilst stepping with the right hindpaw; 
then step with the right forepaw whilst stepping with the left hindpaw.  When a mouse 
becomes less stable, they may become more reliant on a three paw stepping pattern, 
spending more time with three paws on the ground.  A tendency towards three paw 
stepping was found in both male and female TDP-43Q331K mice.  A decrease in diagonal 
stepping coincided with an increase in three paw stepping in males at 6 and 10 months, 
and in females at 10 months of age.   
These results indicate that the TDP-43Q331K mice become slower and more unsteady with 
age. 
 
2.5.9. Litter Statistics 
No records could be found for litter size, percentage of transgenic pups and percentage 
of male pups for the C57BL/6NJ genetic background or for the TDP-43Q331K mouse 
model.   Our own data in SOD1G93A mice indicates a reduction in the percentage of 
transgenic pups from the expected 50% to approximately 40%. 
The TDP-43WT colony have an average litter size of 6 with 50% of pups being transgenic 
and 48% of pups being male.  The TDP-43Q331K colony have an average litter size of 7 
with 48% of pups being transgenic and 53% of pups being male.  This suggests that there 
is no particular biological preference specific to gender or genotype.  The reason for an 
increased litter size in the TDP-43Q331K colony is unknown, but may be due to bias in the 
original breeding trios, which has subsequently been inherited by the following 
generations. 
 
2.5.10. huTARDBP Gene Expression 
Previously published data described the huTARDBP expression levels in TDP-43Q331K mice 
as being 1-1.5 fold compared to the levels of endogenous expression in non-transgenic 
mice (Arnold et al., 2013).  The non-transgenic mice do not carry any huTDP-43 so 
ideally, total levels of TDP-43 (both human and mouse) would be compared.  However, 
primer pairs with an equal affinity for both human and mouse TDP-43 could not be 
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designed (see section 3.5.11. below).  Hence, huTDP-43 expression was compared 
between the TDP-43WT and TDP-43Q331K mice.   
The huTDP-43 gene is expressed under a murine prion promotor, which is primarily 
expressed in the CNS, hence huTDP-43 expression levels were measured in the cortex 
and spinal cord.  Expression levels were also measured in the hindlimb muscle, as this is 
a potential target tissue for the induction of pathology by the TDP-43Q331K mutation. 
In comparison to the TDP-43WT tissue, expression of huTDP-43 in the TDP-43Q331K mice 
was found to be approximately 2-fold in the spinal cord, 3-fold in the cortex, and 4-fold 
in the hindlimb muscles.  It seems that there is a significantly increased expression of 
huTDP-43 in the TDP-43Q331K mice as compared to the TDP-43WT mice, which may 
translate to an increased protein level which could lead to toxicity independent of 
mutation status. 
It is surprising that the highest expression was found in the hindlimb muscle, despite the 
murine prion promotor being primarily expressed in the CNS (Arnold et al., 2013), and 
the previously published data suggested that levels of huTDP-43 were relatively low in 
muscle (Arnold et al., 2013).  The reason for the difference in these findings is unclear. 
 
2.5.11. Total (mouse + human) TDP-43 Gene Expression 
Due to the self-regulatory nature of the TARDBP gene, the presence of huTDP-43 may 
result in a decrease in endogenous TDP-43 (Ayala et al., 2011).  In the previously 
published data, total TDP-43 mRNA and protein levels in the spinal cord were found to 
be approximately 2-fold in the TDP-43WT and 3-fold in the TDP-43Q331K mice, when 
compared to endogenous levels in the non-transgenic (Arnold et al., 2013).  It was then 
expected that the total TDP-43 cDNA would be highest in the TDP-43Q331K mice, and 
lowest in the non-transgenic mice.  However, the total TDP-43 cDNA was shown to be 
highest in the non-transgenic mice. 
In-house data showed that the TDP-43 primers used were complimentary to human and 
mouse TDP-43, with R-squared values of 0.98 and 0.97 respectively when tested against 
a human or mouse cDNA template dilution in a qPCR reaction to test specificity.  
However, upon closer inspection of the sequences, the primer pair has 3 mismatches 
with the human cDNA sequence, whereas they are fully complimentary to the mouse 
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cDNA sequence (see table 2.5).  It is assumed that the primers may preferentially bind 
to mouse TDP-43 when both mouse and human TDP-43 are present.  The data therefore, 
are mostly representative of endogenous mouse TDP-43 expression but it cannot be 
assumed that the data is solely representative of mouse TDP-43 expression alone.  The 
specificity of these primers must be checked before a conclusion is drawn.   
Table 2. 6: Primer sequences vs complimentary cDNA.  Mismatches between the 
primers and huTDP-43 are highlighted in blue. 
 Forward primer sequence/ 
complimentary cDNA sequence 
(Reverse primer sequence)/ 
complimentary cDNA sequence 
Mouse cDNA TACCGGAATCCCGTGTCTCA TGGATGAGACAGATGCTTCCTC 
Human cDNA TACAGGAATCCAGTGTCTCA TGGATGAGACAGATGCTTCATC 
Primer pair TACCGGAATCCCGTGTCTCA (GAGGAAGCATCTGTCTCATCCA) 
TGGATGAGACAGATGCTTCCTC 
 
2.5.12. TDP-43 Protein Levels 
In both cord and cortex, total TDP-43 levels were highest in the TDP-43Q331K mice at 
approximately 1.5-3 fold that of non-transgenic mice, and TDP-43WT mice had 1.1-1.9-
fold that of non-transgenic mice, similar to levels found in a previous study of the mice 
on a different genetic background (Arnold et al., 2013).  As found in the gene expression 
data, endogenous mouse TDP-43 levels decreased as human TDP-43 protein levels 
increased, due to the self-regulatory nature of TDP-43 (Ayala et al., 2011). 
Protein levels of human TDP-43 were found to be 1.5-2.1-fold that of the non-transgenic 
in TDP-43Q331K mice, considerably more than the 1-1.5-fold increase found previously 
(Arnold et al., 2013).   
Overall, protein levels were in keeping with the data recorded for gene expression, and 
showed similar results to those published previously.  The TDP-43WT mice do carry a 
slight overexpression of TDP-43, and the TDP-43Q331K mice more so but the levels 
recorded are not excessively high compared to many other TDP-43 mouse models (see 
table 1.4). 
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It must be considered that the TDP-43 antibody affinity to mouse and human TDP-43 
was assumed to be equal.  It is important to check the antibody affinity if further study 
of protein levels are carried out. 
 
2.5.13. Immunohistochemical Analysis 
Unfortunately the quality of tissue used in this analysis was poor, which reduced the 
number of spinal cords which could be used for analysis.  Future tissue collection will 
use different methods of tissue collection for better quality of immunostaining. 
 
2.5.13.1. Immunohistochemical Analysis of huTDP-43 Localisation 
Localisation of huTDP-43 was carried out using immunohistochemical staining of the c-
myc tag.  Previous investigations of TDP-43Q331K mice on a C57BL/6NCrl background 
found small cytoplasmic inclusions of TDP-43 in the lumbar spinal cord but no evidence 
of nuclear clearing (Arnold et al., 2013).  Another study, in which the TDP-43Q331K mice 
were crossed with TDP-43WT mice found cytoplasmic mislocalisation of TDP-43, 
alongside cytoplasmic inclusions in the TDP-43Q331K/WT spinal cord (Mitchell et al., 2015).  
Interestingly this study suggested that nuclear clearance of TDP-43 may accelerate 
disease, but is not a necessary feature, seeing as the TDP-43Q331K mice have no nuclear 
clearance of TDP-43 and a slow progression of disease; whereas the TDP-43Q331K/WT mice 
had nuclear clearance of TDP-43 and a rapid disease progression. 
Increased cytoplasmic huTDP-43 was not found in this study in the TDP-43Q331K mice 
compared to the TDP-43WT mice at 10 months of age.  Increased nuclear huTDP-43 was 
reported in the TDP-43Q331K mice compared to the TDP-43WT mice, which has not been 
described previously.  This confirms that nuclear clearance of TDP-43 is not critical for a 
neurodegenerative phenotype, although found in several other TDP-43 mouse models 
(Wegorzewska et al., 2009, Xu et al., 2010, Wils et al., 2010, Igaz et al., 2011).   
It must be noted that in this study quantification of TDP-43 was the aim of this 
immunohistochemical investigation and no search was carried out for cytoplasmic 
inclusions of TDP-43.  There may therefore have been inclusions in the tissue, as found 
previously (Arnold et al., 2013), and in most other mouse models of TDP-43 (see table 
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1.4 for details) (Tsai et al., 2010, Stallings et al., 2010, Xu et al., 2010, Wils et al., 2010, 
Shan et al., 2010, Swarup et al., 2011, Igaz et al., 2011, Xu et al., 2011, Wu et al., 2012b). 
 
2.5.13.2. Immunohistochemical Analysis of GFAP 
GFAP has long been used as a marker of astrocytes, which increases in reactivity with 
astrogliosis (Eng and Ghirnikar, 1994), as found in other models of MND (Ferraiuolo et 
al., 2011, Yamanaka et al., 2008a) and most TDP-43 mouse models (see table 1.4 for 
more details) (Wegorzewska et al., 2009, Tsai et al., 2010, Stallings et al., 2010, Xu et al., 
2010, Wils et al., 2010, Swarup et al., 2011, Igaz et al., 2011, Xu et al., 2011, Wu et al., 
2012b).  Therefore, immunohistochemical GFAP quantification requires a measurement 
of intensity and area of staining, for which a staining index was used.   
GFAP immunoreactivity was found to be non-significantly higher in the ventral horn of 
10 month TDP-43Q331K mice compared to non-transgenic mice, as found in the spinal 
cord of young TDP-43Q331K mice on a C57BL/6NCrl background (Arnold et al., 2013).  It is 
therefore likely that astrogliosis may be evident from an early stage in the TDP-43Q331K 
mice. 
 
2.5.13.3. Immunohistochemical Analysis of IBA-1 
IBA-1 is recognised as a marker of microglia (Ahmed et al., 2007), and microgliosis is 
evident in several models of MND (Boillee et al., 2006), including a TDP-43 mouse model 
(Swarup et al., 2011).  The intensity of IBA-1 immunoreactivity does not increase with 
microgliosis.  The area of IBA-1 immunoreactivity was measured and found to be higher 
in the spinal cord of 10 month old TDP-43Q331K mice compared to non-transgenic mice, 
suggestive of microgliosis. 
These findings are consistent with those of young TDP-43Q331K mice on a C57BL/6NCrl 
background (Arnold et al., 2013), indicating likelihood that microgliosis is present from 
an early stage of disease in the TDP-43Q331K mice. 
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2.6. Conclusion 
In conclusion, this study showed that the TDP-43Q331K mice have a progressive mild 
motor phenotype in both the forelimbs and hindlimbs, with low variability, especially in 
female mice.  There appears to be no significant difference between the motor 
phenotype of TDP-43WT and non-transgenic mice, suggesting the presence of huTARDBP 
is not responsible for the motor phenotype found in TDP-43Q331K mice. 
Expression of huTDP-43 cDNA is increased in TDP-43Q331K cortex, spinal cord and muscle, 
and this is correlated with TDP-43 protein levels.   
Astrogliosis and microgliosis is evident in the spinal cords of TDP-43Q331K mice by 10 
months of age along with increased nucleic TDP-43 levels, but there is no discernible 
cytoplasmic mislocalisation. 
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3. Running Wheel Activity and Food Intake 
3.1. Introduction 
Although unreported in previous papers, the initial characterisation study in these mice 
found a striking weight gain in the TDP-43Q331K mice compared to the TDP-43WT and non-
transgenic mice (see chapter 2).   
Previously, the level of huTARDBP protein in TDP-43Q331K mice has been described as 
being slightly higher than the endogenous expression, with similar levels of total TDP-43 
as the control line TDP-43WT (Arnold et al., 2013).  A link between TARDBP and fat 
metabolism has been identified in previous studies, which have reported that a 
conditional knockout of TARDBP in mice causes a lethal decrease in fat metabolism due 
to downregulation of TBC1 domain family member 1 (TBC1D1) (Chiang et al., 2010).  
Conversely, another mouse model which showed an overexpression of TARDBP with an 
A315T mutation had increased fat deposition, correlated with increased TBC1D1 
expression, increased food intake (although the increase was relative to body weight), 
and decreased activity levels (Stallings et al., 2013).   
TBC1D1 is an obesity candidate gene (Taylor et al., 2008, Stone et al., 2006) involved in 
regulating the translocation of the glucose transporter type 4 (GLUT4) (Sakamoto and 
Holman, 2008, Taylor et al., 2008).  Expression of TBC1D1 is predominantly in muscle 
(Chadt et al., 2008, Taylor et al., 2008) and its activity is increased in the presence of 
insulin and muscle contraction (An et al., 2010, Taylor et al., 2008, Sakamoto and 
Holman, 2008).   
It appears to be well established that knockout of TBC1D1 increases fatty acid uptake 
and oxidation, causing weight loss (Chadt et al., 2008, Chiang et al., 2010); whereas 
overexpression decreases fatty acid uptake and oxidation, causing weight gain (Chadt et 
al., 2008, Stallings et al., 2013).  Therefore, as expression of TBC1D1 appears to be linked 
with TDP-43 expression (Stallings et al., 2013), an investigation of TBC1D1 gene 
expression, food intake and activity levels in the TDP-43Q331K mouse model could provide 
insights into the mechanisms causing increased weight.   
Motor function tests such as rotarod provide an indication of forced activity capabilities.  
However, voluntary activity provides an indicator of the more natural, habitual activity 
levels of the mice.  An ideal way to investigate this is by using home cage running wheels, 
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which the mice can use at their will (De Bono et al., 2006).  An increase in activity levels 
due to running wheel access may decrease weight in the mice (Bennett et al., 2014), 
especially in males (De Bono et al., 2006).  However, not all studies have found a 
difference in weight between mice that have access to wheels and those that do not 
(Allen et al., 2001). 
Earlier studies of running wheel activity in C57BL/6 mice have shown that the mice will 
run considerable distances, almost exclusively during the night (Lapvetelainen et al., 
1997). Mice usually run in short bouts, and have a tendency to maintain a regular 
cruising speed (De Bono et al., 2006).  In one study, female mice ran consistently 
throughout the night and ran on average 40% further than male mice, whilst male mice 
ran mostly during the first half of the night.  However, running activity was more varied 
in female mice, possibly due to the oestrous cycle (De Bono et al., 2006), as supported 
by in-house data for specific strains. 
A running wheel study in SOD1G93A mice showed low variability and a reliable decline in 
running time and distance with disease progression, consistent with a decline in rotarod 
performance (Bennett et al., 2014).  Previous studies have consistently shown a steady 
increase in running time and distance at the beginning of a running wheel study, 
suggestive of a training period (Bennett et al., 2014, De Bono et al., 2006, Allen et al., 
2001).  However, it must be considered that the mouse model under investigation here 
is on a different genetic background to the mice used in previous running wheel studies 
and the mouse strain may have a large impact on voluntary running activity (Massett 
and Berk, 2005, Turner et al., 2005). 
It is expected that running wheel activity in the TDP-43Q331K and TDP-43WT mice will 
increase with time at the beginning of the study, with females showing higher levels of 
activity compared to males. Running activity and evaluation of food intake may provide 
an indicator of the mechanisms involved in the increased weight of TDP-43Q331K mice 
compared to their counterparts. 
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3.2. Aims 
1. To assess activity levels of male and female TDP-43Q331K mice in comparison to TDP-
43WT mice. 
2. To assess the food intake of male and female TDP-43Q331K mice in comparison to 
TDP-43WT mice. 
3. To assess TBC1D1 expression in the cortex, spinal cord and muscle of TDP-43WT and 
TDP-43Q331K mice. 
 
3.3. Materials and methods 
3.3.1. Ethics Statement 
All mouse experiments were carried out under the terms of the UK Animals (Scientific 
Procedures) Act 1986 and under a UK Home Office project license.  Mice were housed 
and cared for in accordance with the Home Office Code of Practice for Housing and Care 
of Animals Used in Scientific Procedures.  All procedures were carried out under under 
an appropriate UK Project Licence by personal licence holders.  ARRIVE guidelines 
(Kilkenny et al., 2010) were adhered to during this report. 
 
3.3.2. Transgenic C57BL/6NJ Mice 
TDP-43WT and TDP-43Q331K mice (Mus musculus) were originally generated on a 
C57BL/6NCrl background by insertion of c-myc-tagged human TARDBP (Arnold et al., 
2013) and were subsequently backcrossed on to a C57BL/6NJ background before being 
deposited at the Jackson Laboratory (stock numbers 017907 and 017933, respectively).   
The running wheel study was carried out with 6 males and 6 females per group (TDP-
43WT and TDP-43Q331K).  Mice were recruited at 30 days of age and remained under 
evaluation until 300 days of age.   
For genotyping methods see section 2.3.4. 
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3.3.3. Housing  
Mice were bred in a SPF environment, and transferred to a conventional facility for the 
studies described here.  The facility uses a 12 h light/dark cycle, and room temperature 
is set to 21˚C.  Cages (L36 x W21 x H18.5cm) were lined with fine sawdust (eco-pure 
flakes 6, Datesand, UK), which was changed every 2 weeks, a plastic house was placed 
in each cage and paper wool (Datesand, UK) was used as bedding material.   
Each cage contained a 37.8cm circumference Fast Trac running wheel (LBS Biotech, UK) 
mounted at 25˚ below horizontal on a 4cm fixed post.  The wheel was placed in the 
corner of each cage where the circumference was 5-10mm from the edge of two 
perpendicular sides of the cage.  A 5 x 10mm neodymium magnet was glued to the 
underside of each Fast Trac wheel and a bicycle computer (Cateye Velo, Japan) with reed 
switch was fixed to the side of the cage (see figure 3.1).  Time spent running, distance 
run and average running speed were recorded daily.  This set up was based on the in-
house protocol used in a previous study (Bennett et al., 2014). 
All mice were housed separately due to the use of running wheels in the home cage. 
Mice were fed 2018 rodent diet (Harlan, UK) ad libitum.  Water was provided ad libitum 
and changed weekly.  Fresh bottles were provided every four weeks. 
 
Figure 3. 1: Running wheel cage set-up (Bennett et al., 2014). 
The Fast Trac running wheel is fixed in the corner of the cage, with a magnet attached 
to the underside, detected by a reed switch on the side of the cage which is connected to 
a cycle computer. 
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3.3.4. Weight and Food Intake Monitoring 
Weight was monitored weekly by placing the mice in a box on a set of scales (Kern, 
Germany) pre-set to zero.  Food intake was monitored fortnightly by weighing the food 
on a set of scales (Kern, Germany), and re-weighing the food approximately 72 hours 
later.  During the 72 hour period, the sawdust in the cage was replaced with paper 
towelling, to ensure that any small pieces of food which may have dropped from the top 
of the hopper could be included for weighing. 
 
3.3.5. Tissue Collection 
Mice were sacrificed at 10 months of age by overdose using an intraperitoneal injection 
of pentobarbitone (2.5ml/kg) and exsanguination via cardiac puncture using a 25 gauge 
0.5 x 16mm needle (BD Microlance, Ireland) and a 1ml syringe (Terumo Europe, 
Belgium,) after cessation of the pedal reflex.  The head was decapitated and the brain 
removed and placed on a plastic square, wrapped in wet paper towel.  The blunt edge 
of a steel back industrial single edge blade (Fisher Scientific, UK) was used to peel off the 
cortex from the remaining brain.  An incision was made over the spine at the level of the 
hips and PBS was pushed in to the spinal cavity using a 20ml syringe (BD Plastipak, UK) 
fixed with a pipette tip (Fisherbrand, UK), ejecting the spinal cord from the rostral end 
of the spinal column. 
Triceps surae muscles were removed by dissection.  Cortex, spinal cord and muscles 
were immediately snap frozen in liquid nitrogen and then stored at -80˚C.  Cortex and 
spinal cord from non-transgenic mice had been prepared using these methods from a 
previous cohort.  Unfortunately non-transgenic snap frozen muscle tissue was 
unavailable, as non-transgenic mice were not used in this study. 
 
3.3.6. RNA Extraction 
RNA was extracted using an RNeasy® lipid tissue mini kit (74804, Qiagen, UK) as per the 
manufacturer’s instructions.  Firstly, tissues were homogenised using a pellet pestle 
motor (Fisher Scientific, UK) in 1ml of QIAzol lysis reagent and incubated at room 
temperature (RT) for 5 mins.  200µl of chloroform was added to each sample and the 
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samples were shaken for 15 seconds before incubating at RT for 2 mins, followed by 
centrifugation at 12000 x g for 15 mins at 4˚C.  The supernatant was then transferred 
and mixed with one volume of 70% ethanol.  This solution was centrifuged through an 
RNeasy® spin column at 8000 x g for 15 seconds at RT.  Buffer RW1 was then centrifuged 
through the spin column at 8000 x g for 15 seconds at RT, followed by buffer RPE at 8000 
x g for 15 seconds at RT and again at 8000 x g for 2 mins at RT.  In a fresh tube, 50µl of 
RNase-free water was then centrifuged through the spin column at 8000 x g for 1 min at 
RT, the product of which was the RNA, which was stored at -80˚C. 
 
3.3.7. cDNA Extraction 
Sample RNA concentrations were estimated using the nanodrop spectrophotometer 
ND-1000 (Labtech International, UK).  cDNA was extracted from RNA using a high 
capacity RNA-to-cDNA kit (4387406, Applied Biosystems, USA).  Solutions were made of 
10µl of RT buffer mix 20x (Applied Biosystems, USA), 1µl of RT enzyme mix 2x (Applied 
Biosystems, USA) and a 9µl dilution of 2µg of sample in water.  Samples were placed in 
the PCR machine (G-storm, UK) for 1 hour at 37˚C, followed by 5 mins at 95˚C.  60µl of 
water was added to each sample and then stored at -20˚C. 
 
3.3.8. qPCR 
Primer pairs were mixed and diluted to 5µM (see table 3.1 for primer sequences). 
Samples were plated in duplicate in non-skirted, frosted, thin-wall 0.2ml low profile 96 
well plates (P3-0402, Geneflow, UK) and covered with optical wide area 8-cap strips (P3-
0051, Geneflow, UK).  Each well contained 1µl cDNA, 1µl primer mix, 3µl water and 5µl 
brilliant III ultra-fast SYBR® green QPCR master mix (600882, Agilent Technologies, USA).  
GAPDH was used as the house-keeping gene.  A non-template control was plated for 
each primer pair. 
Samples were placed in the qPCR machine (Mx 3000P, Stratagene, USA) and run on the 
following protocol: 95˚C for 10 mins, 45 cycles (95˚C for 30 seconds, 58˚C for 1 min, 72˚C 
for 1 min), 95˚C for 1 min, 55˚C for 30 seconds, 95˚C for 30 seconds. 
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Table 3. 1: Primer sequences.  Forward and reverse primer sequences used for qPCR 
analysis. 
Primer pair Forward Reverse 
TBC1D1 GTGAGGAAGAGGCGTTCAAG AGGTCTCGGTGGTAATCGTG 
GAPDH ATGGTGAAGGTCGGTGTGAA TGGCAACAATCTCCACTTTGC 
 
3.3.9. qPCR Analysis 
Cycle threshold (Ct) values were extracted using MxPro Mx3000P software version 4.10 
(Stratagene, USA).  Further analysis was carried out using Microsoft Excel 2013 
(Microsoft, USA) and GraphPad Prism 6 (GraphPad, USA). 
Mean Ct values were calculated for each sample from the duplicates.  Data were not 
used if duplicate Ct values differed by ≥1.  The relative concentration was calculated 
using the equation: 1/2(gene of interest Ct – GAPDH Ct).  Values were presented as a percentage 
of the mean TDP-43WT value for each sample, or as a percentage of the mean non-
transgenic value wherever possible. 
 
3.3.10. Statistical Analysis 
Running activity was variable across days, consequently the maximum running time, 
distance and speed run each week was used as a representation of running activity.  Age 
to a 20% decline in running time, distance and speed were calculated by determining 
the age at which a consistent 20% decline from the initial readout (week 5) was 
detected. 
The relative concentration of each sample was calculated for gene expression in cortex, 
spinal cord and muscles from non-transgenic, TDP-43Q331K and TDP-43WT mice (n = 6-
12/group). 
GraphPad Prism 6 was used for all statistical analyses (GraphPad, USA).  Two-way 
ANOVA with repeated measures and a Sidak post-test was used for all data with multiple 
time points; Students’s t-test was used for all data with a  normal distribution in which 
there were 2 groups at one timepoint; the Mann-Whitney U test was used for all data 
with non-normal distribution in which there were 2 groups at one timepoint.  All data 
are represented as mean and standard deviation. 
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3.4. Results 
3.4.1. Running Time 
In both TDP-43Q331K and TDP-43WT males and females, mean running time declined with 
age (figure 3.2A & B).  The male data showed a slight increase in running time at the 
beginning of the study, suggestive of a training period; whereas the females showed an 
age-dependent decline from the beginning of the study.  There was no significant 
difference in running time between TDP-43Q331K and TDP-43WT mice in males or females 
on a two-way ANOVA with repeated measures (Sidak post-test). 
Male TDP-43Q331K mice reached a mean maximum running time at 6 weeks of age (162 
± 79.2 minutes) followed by a steady decline to a minimum mean running time at 30 
weeks of age (5.3 ± 7.3 minutes).  In contrast, male TDP-43WT mice had an increase in 
running time from 5 weeks of age until reaching a maximum mean running time at 10 
weeks of age (243 ± 106.1 minutes), then gradually declining to a minimum mean 
running time at 41 weeks of age (37.3 ± 25.3 minutes).   
Female TDP-43Q331K mice reached a mean maximum running time at 5 weeks of age (338 
± 78.7 minutes) followed by a steady decline to a minimum mean running time at 43 
weeks of age (6.1 ± 3.6 minutes).  In contrast, female TDP-43WT mice reached a mean 
maximum running time at 6 weeks of age (269 ± 107.6 minutes) followed by a steady 
decline to a minimum mean running time at 43 weeks of age (28.8 ± 21.5 minutes). 
Age to reach a 20% decline in running time (figure 3.2C & D) was higher in TDP-43WT 
mice compared to TDP-43Q331K mice but also showed much more variability in both 
males (9.8 ± 2.2 weeks in TDP-43Q331K vs 20.5 ± 12.9 weeks in TDP-43WT, p<0.05) and 
females (12.2 ± 4.1 weeks in TDP-43Q331K vs 18.9 ± 13.9 weeks in TDP-43WT). 
When comparing male and female mice (figure 3.2E & F), female mice ran for longer 
than male mice in the TDP-43Q331K group, however, this was not significant on a two-way 
ANOVA with repeated measures (Sidak post-test).  In the TDP-43WT mice, there was no 
difference between males and females on a two-way ANOVA with repeated measures 
(Sidak post-test).  
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Figure 3. 2: Maximum running time/night within each week ± SD. 
Maximum time spent running per night within each week (n=6) of male and female TDP-
43WT and TDP-43Q331K mice.  A & B: there was no significant difference in running time 
between TDP-43Q331K and TDP-43WT mice on a two-way ANOVA with repeated measures 
and Sidak post-test but there was a decline in running time with age in all groups 
(p<0.0001).  C & D: there was a significant difference in age to reach a 20% decline in 
running time between TDP-43Q331K and TDP-43WT male mice (p<0.05) but not in female 
mice on a Mann-Whitney U test.  E & F:  there was no significant difference in running 
time between males and females in the TDP-43Q331K or TDP-43WT groups on a two-way 
ANOVA with repeated measures and Sidak post-test, multiple comparisons showed 
increased running time in the TDP-43Q331K females compared to males, *p<0.05 vs all 
other groups, **p<0.01 vs all other groups, ***p<0.001 vs all other groups, 
****p<0.0001 vs all other groups. 
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3.4.2. Running Distance 
In both TDP-43Q331K and TDP-43WT males and females, mean running distance declined 
significantly with age (figure 3.3A & B, p<0.0001).  The male data showed a slight 
increase in running distance at the beginning of the study, suggestive of a training 
period; whereas the females showed an age-dependent decline from the beginning of 
the study.  There was no significant difference in running distance between TDP-43Q331K 
and TDP-43WT mice in males or females on a two-way ANOVA with repeated measures 
(Sidak post-test). 
Male TDP-43Q331K mice reached a mean maximum running distance at 6 weeks of age 
(4.25 ± 2.7km) followed by a steady decline to a minimum mean running distance at 38 
weeks of age (0.03 ± 0.02km).  In contrast, male TDP-43WT mice had an increase in 
running distance from 5 weeks of age until reaching a maximum mean running distance 
at 10 weeks of age (7.85 ± 7.5km), then gradually declining to a minimum mean running 
distance at 41 weeks of age (0.82 ± 1km).   
Female TDP-43Q331K mice reached a mean maximum running distance at 5 weeks of age 
(11.58 ± 5.8km) followed by a steady decline to a minimum mean running distance at 42 
weeks of age (0.07 ± 0.06km).  In contrast, female TDP-43WT mice reached a mean 
maximum running distance at 5 weeks of age (8.11 ± 5.5km) followed by a steady decline 
to a minimum mean running distance at 42 weeks of age (0.77 ± 1.1km). 
Age to reach a 20% decline in running distance (figure 3.3C & D) showed no difference 
between TDP-43WT mice and TDP-43Q331K mice in males (19.5 ± 13 weeks in TDP-43Q331K 
vs 9.6 ± 2.9 weeks in TDP-43WT) or females (19.5 ± 13 weeks in TDP-43Q331K vs 18.7 ± 12.3 
weeks in TDP-43WT). 
When comparing male and female mice (figure 3.3E & F), female mice ran further than 
male mice in the TDP-43Q331K group, however this was not significant on a two-way 
ANOVA with repeated measures (Sidak post-test).  In the TDP-43WT mice, there was no 
difference between males and females on a two-way ANOVA with repeated measures 
(Sidak post-test). 
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Figure 3. 3: Maximum distance/night within each week ± SD. 
Maximum distance run per night within each week (n=6) of male and female TDP-43WT 
and TDP-43Q331K mice.  A & B: there was no significant difference in running distance 
between TDP-43Q331K and TDP-43WT mice on a two-way ANOVA with repeated measures 
and Sidak post-test but there was a decline in running time with age in all groups 
(p<0.0001).  C & D: there was no significant difference in age to reach a 20% decline in 
running distance between TDP-43Q331K and TDP-43WT mice on a Mann-Whitney U test.  E 
& F:  there was no significant difference in running time between males and females in 
the TDP-43Q331K or TDP-43WT groups on a two-way ANOVA with repeated measures and 
Sidak post-test. 
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3.4.3. Running Speed 
In both TDP-43Q331K and TDP-43WT males and females, the mean running speed 
significantly declined with age after a short period of increasing speed at the beginning 
of the study, suggestive of a training period (figure 3.4A & B, p<0.0001).  The decline in 
speed with age appeared steeper in females when compared to males, but there was 
no significant difference in average running speed between TDP-43Q331K and TDP-43WT 
mice in males or females on a two-way ANOVA with repeated measures (Sidak post-
test). 
Male TDP-43Q331K mice reached a mean maximum running speed at 7 weeks of age (1.61 
± 0.5km/hr) followed by a steady decline to a minimum mean running speed at 30 weeks 
of age (0.29 ± 0.3km/hr).  In contrast, male TDP-43WT mice had an increase in running 
speed from 5 weeks of age until reaching a maximum mean running speed at 13 weeks 
of age (1.78 ± 0.8km/hr), then gradually declining to a minimum mean running speed at 
38 weeks of age (0.88 ± 0.7km/hr).   
Female TDP-43Q331K mice reached a mean maximum running speed at 7 weeks of age 
(2.02 ± 0.7km/hr) followed by a steady decline to a minimum mean running speed at 43 
weeks of age (0.18 ± 0.2km/hr).  In contrast, female TDP-43WT mice reached a mean 
maximum running speed at 11 weeks of age (1.89 ± 0.5km/hr) followed by a steady 
decline to a minimum mean running speed at 37 and 40 weeks of age (0.69 ± 
0.6/0.7km/hr). 
Age to reach a 20% decline in average running speed (figure 3.4C & D) showed no 
difference between TDP-43WT and TDP-43Q331K mice in males (12.8 ± 2.8 weeks in TDP-
43Q331K vs 23.7 ± 17.1 weeks in TDP-43WT) or females (17.3 ± 3.4 weeks in TDP-43Q331K vs 
31 ± 15 weeks in TDP-43WT). 
When comparing male and female mice (figure 3.4E & F), female mice ran faster than 
male mice in the TDP-43Q331K group, however, this was not significant on a two-way 
ANOVA with repeated measures (Sidak post-test).  In the TDP-43WT mice, there was no 
difference between males and females on a two-way ANOVA with repeated measures 
(Sidak post-test). 
 114 
 
Figure 3. 4: Maximum average speed/night within each week ± SD. 
A & B: there was no significant difference in average running speed between TDP-43Q331K 
and TDP-43WT mice on a two-way ANOVA with repeated measures and Sidak post-test 
but there was a decline in running time with age in all groups (p<0.0001).  C & D: there 
was no significant difference in age to reach a 20% decline in average running speed 
between TDP-43Q331K and TDP-43WT mice on a Mann-Whitney U test.  E & F:  there was 
no significant difference in average running speed between males and females in the 
TDP-43Q331K or TDP-43WT groups on a two-way ANOVA with repeated measures and 
Sidak post-test. 
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3.4.4. TDP-43Q331K Mice are Heavier than TDP-43WT Mice 
Male and female TDP-43Q331K and TDP-43WT mice showed a significant increase in weight 
with age (figure 3.5).  In both male and female mice, the TDP-43Q331K mice are heavier 
than the TDP-43WT mice.  In the male mice, the weight difference between the two 
groups begins to disappear at around 36 weeks of age when the TDP-43Q331K weight 
plateaus, whilst the TDP-43WT weight continues to increase, closing the gap between the 
weights of the two groups.  Conversely, the female TDP-43Q331K mice increase in weight 
throughout the study at a much steeper incline than the TDP-43WT mice, making the 
difference significant from 18 weeks of age (26 ± 1.7g TDP-43Q331K vs 21.2 ± 1.6g TDP-
43WT, p<0.05). 
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Figure 3. 5: Whole body weight ± SD. 
Body weight, as measured each week (n=6) in male and female TDP-43WT and TDP-
43Q331K mice.  In males (A), the data were significantly different on a two-way ANOVA 
with repeated measures and Sidak post-test for the effects of group (p<0.05) and age 
(p<0.0001).  In females (B), the data were significantly different on a two-way ANOVA 
with repeated measures and Sidak post-test for the effects of group (p<0.001) and age 
(p<0.0001).  *p<0.05 vs all other groups, **p<0.01 vs all other groups, ***p<0.001 vs all 
other groups, ****p<0.0001 vs all other groups, two-way ANOVA with repeated 
measures (Sidak post-test). 
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3.4.5. Food Intake 
Male and female TDP-43Q331K mice showed a significantly increased food intake 
compared to the TDP-43WT mice on a two-way ANOVA with repeated measures and 
Sidak post-test (figure 3.6).  All male mice, and the female TDP-43Q331K mice show an 
upwards trend in food intake at the beginning of the study from 7 weeks, plateauing at 
11 weeks of age.  Towards the end of the study, food intake appears to increase in the 
TDP-43WT mice. 
 
Figure 3. 6: Food intake ± SD. 
Food intake over a 72 hour period, as measured every 2 weeks (n=6) in male and female 
TDP-43WT and TDP-43Q331K mice.  In both males (A) and females (B), the data were 
significantly different on a two-way ANOVA with repeated measures (Sidak post-test) for 
the effect of group (p<0.01).  *p<0.05 vs all other groups, **p<0.01 vs all other groups, 
***p<0.001 vs all other groups, two-way ANOVA with repeated measures (Sidak post-
test). 
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3.4.6. Weight of Running vs Non-running Mice 
Comparison of weight from the running wheel study and the previous characterisation 
study (see chapter 2) shows mice on the running wheels appeared to be heavier than 
those which did not have wheels in the characterisation study (figure 3.7).  Wheel mice 
appeared heavier in males and females of both TDP-43Q331K and TDP-43WT mice.  These 
data suggest that running wheel use does not decrease weight in these mice. Statistical 
analysis could not be performed as the data were not collected as part of the same 
study.  A separate study would be needed to confirm the effect of wheel use on weight 
in these mice. 
 
Figure 3. 7: Whole body weight of running wheel mice vs non-running mice (from 
previous study). 
Body weight, as measured each week in male (A) and female (B) TDP-43WT and TDP-
43Q331K mice in both the running wheel study and the previous characterisation study 
(described in chapter 2).  Statistical analysis could not be performed as data were not 
collected as part of the same study. 
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3.4.7. TBC1D1 Gene Expression 
Gene expression of TBC1D1 was measured in the cDNA of cortex and spinal cord from 
non-transgenic, TDP-43WT and TDP-43Q331K mice at 10 months of age (figure 3.8), 
expressed as a percentage of the non-transgenic values.  Gene expression of TBC1D1 
was also measured in the cDNA of hindlimb muscles of TDP-43WT and TDP-43Q331K mice, 
expressed as a percentage of the TDP-43WT values. 
Expression of TBC1D1 was not significantly different in the TDP-43WT or TDP-43Q331K 
cortex compared to the non-transgenic cortex (100 ± 23.1% in non-transgenic vs 97.9 ± 
13.4% in TDP-43WT vs 100 ± 8.9% in TDP-43Q331K) or TDP-43WT and TDP-43Q331K spinal cord 
compared to the non-transgenic spinal cord (100 ± 12.5% in non-transgenic vs 95.5 ± 
11.5% in TDP-43WT vs 91.2 ± 8.2% in TDP-43Q331K).  Expression of TBC1D1 was not 
significantly different in the TDP-43Q331K hindlimb muscle compared to the TDP-43WT 
hindlimb muscle (100 ± 24.2% in TDP-43WT vs 108.4 ± 34.1% in TDP-43Q331K). 
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Figure 3. 8: TBC1D1 gene expression ± SD at 10 months of age. 
Gene expression as a percentage of the mean non-transgenic levels, as measured in 
cDNA of cortex (A) and spinal cord (B) of TDP-43WT and TDP-43Q331K mice (n=9-12) 
showed no differences on a one-way ANOVA.  Gene expression as a percentage of the 
mean TDP-43WT levels, as measured in cDNA of hindlimb muscles (C) of TDP-43WT and 
TDP-43Q331K mice (n=9-12) showed no differences on a Student’s t-test. 
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3.5. Discussion 
3.5.1. Running Activity Over Time 
As found in a previous running wheel study in SOD1G93A mice (Bennett et al., 2014), 
running time and distance declined with age and disease severity  in both the TDP-43WT 
and TDP-43Q331K mice.   
Several running wheel studies have described an initial training period in which the 
running activity gradually increases when the mice are first housed with a running wheel 
(De Bono et al., 2006, Bennett et al., 2014, Allen et al., 2001).  In the study conducted 
here, a slight training period was seen in both the TDP-43WT and TDP-43Q331K male mice 
for time, distance and average speed.  However, a training period was not seen in the 
TDP-43WT and TDP-43Q331K female mice, other than for average speed in the TDP-43Q331K 
mice.  It is unclear why there would be a difference between male and female training 
as the previous studies showed a training period in both male and female mice. 
 
3.5.2. Gender Effects on Running Activity  
A previous study which compared male and female running wheel activity found that 
female mice ran considerably further than male mice (De Bono et al., 2006).  This was 
also found in the study described here in the TDP-43Q331K mice, as females ran for a 
longer time and distance compared to males and had a higher maximum distance during 
the disease course, but no differences were found in the TDP-43WT group.   
The oestrous cycle of female mice has been suggested to influence running wheel 
activity (De Bono et al., 2006) and to increase the variability in this activity measure.  In 
this study the female running wheel activity showed no more variability than the male 
running wheel activity.  However, any variance due to the oestrous cycle may have been 
eliminated by the use of a weekly maximum time, distance and speed reached. 
 
3.5.3. Running Activity and Disease 
Running time, distance and average speed were all non-significantly lower in both male 
and female TDP-43Q331K mice compared to the TDP-43WT mice, suggesting that voluntary 
activity levels were slightly reduced in the TDP-43Q331K mice due to disease.  Lower 
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activity levels have also been found in another overweight mutant TDP-43 mouse model 
(Stallings et al., 2013).  The decreased activity levels are likely to be a contributing factor 
to the increased weight of TDP-43Q331K mice. 
As suggested in the SOD1G93A mice (Bennett et al., 2014), reduced activity could also be 
due to motor dysfunction.  However, the disease phenotype is very mild in this model 
so unlikely to be the cause of reduced activity.  It is well documented that normal mice 
are highly motivated to run on a wheel (Sherwin, 1998), and it is therefore also possible 
that reduced running in the TDP-43Q331K mice is due to a cognitive aspect of their disease 
such as lack of motivation. 
The overall running wheel activity of both TDP-43WT and TDP-43Q331K mice was 
considerably lower than that found in other studies, in which mice ran for a time period 
of 4-6 hours per night (Bennett et al., 2014), compared to a matter of 0-4 hours in the 
study discussed here.  This is likely to be due to the background strain of the model as it 
has been shown that genetic background has a large influence on running wheel activity 
in mice (Turner et al., 2005, Massett and Berk, 2005).  No record could be found of 
running wheel activity in C57BL/6N mice and this study shows it to be relatively low 
compared to other strains. 
 
3.5.4. Weight 
As found in a previous study (chapter 2), the mice gained weight with age, significantly 
more so in the TDP-43Q331K mice compared to the TDP-43WT mice. 
Surprisingly, when comparing the weight of the mice on running wheels in this study, 
with the mice which were not on running wheels in the previous study (chapter 2), it 
appears that the mice on running wheels were heavier than those which were not in 
males and females of both TDP-43Q331K and TDP-43WT mice.  The wheel running activity 
therefore, did not appear to cause any relative weight loss.  Conversely, most previous 
studies have found the mice on running wheels to be lighter than those which were not 
on running wheels (Bennett et al., 2014), especially in male mice (De Bono et al., 2006).  
However, another study found no difference in weight between the mice on wheels and 
the mice which were not (Allen et al., 2001).  No records could be found of mice being 
heavier when on running wheels.  It is possible that the mice were heavier due to 
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increased muscle mass, but the activity levels were so minimal, especially towards the 
end of the study, that this seems unlikely. 
 
3.5.5. Food Intake 
Food intake increased with age during the first few weeks of the study, at which time 
the mice were still maturing and were therefore increasing their food intake as they 
grew.  Food intake was higher in both male and female TDP-43Q331K mice compared to 
TDP-43WT mice, as reported in another overweight mutant TDP-43 mouse model 
(Stallings et al., 2013).  Further experiments to assess appetite and metabolic pathways 
could elucidate the reason for this increased food intake.  The increased food intake is 
likely to be a contributing factor to the increased weight of TDP-43Q331K mice and may 
be a sign of hyperphagia, a symptom which can occur in FTD in humans (Ahmed et al., 
2016a). 
A very interesting future study would be to restrict food intake in these mice, providing 
further indication of how much increased food intake is influencing the weight of the 
mice. 
 
3.5.6. TBC1D1 Gene Expression 
As described previously, several mouse models have identified a link between TDP-43 
and TBC1D1 expression with conditional deletion decreasing TBC1D1 expression and 
TDP-43 overexpression increasing TBC1D1 expression, which may explain the lethal 
leaness and obesity seen in these two model systems respectively (Chiang et al., 2010, 
Stallings et al., 2013).  This TDP-43Q331K model shows increased weight gain and 
increased expression of huTDP-43 compared to the TDP-43WT expression and so TBC1D1 
gene expression was evaluated by qPCR, with an increase in expression anticipated. 
The data (figure 3.8) indicated that levels of TBC1D1 expression were no different in the 
cortex, spinal cord and hindlimb muscles of TDP-43Q331K mice when compared to TDP-
43WT and non-transgenic mice.   There appears to be no direct link in this case between 
levels of huTDP-43, TBC1D1, and the observed weight gain.  This leaves open the 
question of why these mice show increased weight gain.  Certainly the reduced activity 
as evidenced by the poor running wheel performance and increased food intake may 
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explain the weight gain observed in these mice but the underlying cause of this is 
unknown.  
 
3.6. Conclusion 
In conclusion, the TDP-43Q331K mice have increased food intake and reduced activity 
levels compared to TDP-43WT mice.  Expression of huTDP-43 cDNA is increased in TDP-
43Q331K but this increase in expression is not correlated with expression levels of TBC1D1.  
As a result, the underlying reason for increased fat deposition in the TDP-43Q331K mouse 
model remains uncertain. 
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4. Riluzole and Electrophysiology Study 
4.1. Introduction 
4.1.1. Riluzole 
As discussed previously (chapter 1), riluzole is the only drug licenced for treatment of 
MND, and extends life by several months (Stewart et al., 2001, Miller et al., 2003), 
potentially as long as 12 months (Georgoulopoulou et al., 2013).  Riluzole was first 
published as an effective treatment for MND in 1994 (Bensimon et al., 1994) and 
approved by the Food and Drug Administration in 1995. The most likely mechanism of 
action is to reduce glutamate toxicity and modulate sodium channels, thereby reducing 
cortical and axonal hyperexcitability (Geevasinga et al., 2016). 
The general consensus is that 100mg/day of riluzole can extend median survival and has 
a small beneficial effect on bulbar and limb function but not muscle strength (Miller et 
al., 2012).  However, other studies have suggested that riluzole has little or no effect on 
MND (Stewart et al., 2001) and this may be related to the concept of MND consisting of 
multiple clinical subgroups, with riluzole only being effective in a subset of patients, 
limiting its overall effect on the MND populations investigated (Georgoulopoulou et al., 
2013). 
Some investigators test therapeutic compounds in SOD1G93A mice in combination with 
riluzole (Waibel et al., 2004, Snow et al., 2003), arguing that it is more clinically relevant 
as patients will remain on riluzole during clinical trials. 
Studies in SOD1G93A mice found that riluzole has a slight effect on survival and motor 
function at 24 and 44mg/kg/day, dosed from 42-43 days of age, mixed into feeding 
pellets, prior to disease onset (Gurney et al., 1998).  The improvement in motor function, 
measured by running wheel activity, was larger during the earlier stages of disease.   
A more recent study showed dosing of riluzole at 8mg/kg/day in SOD1G93A mice had no 
effect on disease onset or survival (Li et al., 2013), as has been suggested in several other 
studies at varying doses (Scott et al., 2008).   
Riluzole has a short half-life which can be affected by age (Le Liboux et al., 1999) and in 
humans the mean half-life after multiple doses is 12 hours (Bryson et al., 1996), hence 
patients take riluzole twice a day.  Mice have a much faster metabolism than humans 
and clear drugs more rapidly.  For this reason, previous studies have administered 
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riluzole to mice in the drinking water, ensuring continual dosage.  In-house studies have 
treated SOD1G93A mice with riluzole at doses ranging from 120 to 2000µg/ml of riluzole 
in the drinking water (equating to doses of 36 to 100mg/kg).  The higher doses showed 
some sedative effect.  A dose of 240µg/ml significantly reduced the decline in motor 
function in SOD1G93A mice in two separate studies. 
It has been shown in patients that the plasma concentrations of riluzole are strongly 
correlated with therapeutic effect (Le Liboux et al., 1999).  Plasma levels should 
therefore be considered when designing a preclinical study. 
Such mixed results in the SOD1G93A mouse model may indicate that SOD1 patients are a 
subgroup of MND which may or may not benefit from taking riluzole.  A preclinical trial 
of riluzole in TDP-43Q331K mice may provide insight in to whether riluzole is effective in 
patients with TDP-43 mutations and/or TDP-43 pathology.  To date, no riluzole studies 
have been recorded in a TARDBP mouse model.   
 
4.1.2. Electrophysiology 
Biomarkers are measurable indicators of biological processes, either of normal function, 
pathological processes or responses to therapeutic intervention (Turner et al., 2009).  In 
the case of MND, the latter two processes are of interest in order to facilitate diagnosis 
and disease monitoring, and measure the effect of therapeutic trials. 
There is currently no single diagnostic test for MND.  Diagnosis relies on a history of 
progressive motor symptoms , supported by examination findings and the elimination 
of other diseases (Turner et al., 2009) through MRI, blood tests and electromyography 
(EMG).  Due to the gradual onset of symptoms, the extensive range of tests and the level 
of expertise required, diagnosis of MND takes an average of one year from symptom 
onset (Zoccolella et al., 2006).  A biomarker which could be used to make an earlier, 
more concrete diagnosis would help patients in future planning and allow earlier access 
to relevant healthcare services and symptomatic therapies. 
Monitoring of the disease is key for healthcare professionals and carers to plan ahead 
and put in place the necessary care and practicalities needed at end of life.  Disease 
monitoring usually consists of symptom assessment, measurement of one or more 
functional rating scales, respiratory function tests, and assessments of muscle strength 
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and patient quality of life (Costa et al., 2010).  Currently, prognosis can only be inferred 
by observing clinical disease presentation and speed of progression (Chio et al., 2009), 
whereas a reliable biomarker could enable more accurate predictions.  
A biomarker to carry through from trials of animal models to patients could offer 
invaluable insights into disease pathophysiology and enable monitoring of the response 
to therapeutic agents from the laboratory to the clinic.  This translational approach is 
invaluable in increasing confidence when moving into clinical studies and has the 
potential to offer new insights into disease pathophysiology and, importantly, reduce 
the duration and cost of clinical trials in patients, allowing more potential new 
treatments to be tested. 
Nerve conduction studies and EMG are currently one of the main diagnostic tests 
undertaken when patients are being investigated for suspected MND (Benatar et al., 
2016). One of their key aims is to exclude other diseases which may mimic MND such as 
cervical myeloradiculopathy, hereditary spastic paraparesis or inclusion body myositis 
(Turner and Talbot, 2013).  Nerve conduction studies are undertaken in both the arms 
and legs.  Receiving electrodes are placed on the muscle and stimulating electrode 
needles are placed on to the nerve.  A supramaximal stimulation is applied to the nerve 
and a compound muscle action potential (CMAP) is measured.  CMAP is a standard test 
in nerve conduction studies, which quantifies the depolarisation of muscle fibres 
following supramaximal stimulation of the nerve innervating that muscle, as detected 
by the electrodes.  Reduced CMAP amplitude usually correlates with a loss in functional 
motor axons and/or the fibre they innervate. In MND patients (Benatar et al., 2016), 
CMAP amplitudes may be reduced due to degeneration of the motor axons which in 
turn leads to a reduction in muscle strength and function.   
Motor unit number estimation (MUNE) is an electrophysiological method which has 
been used for decades (McComas et al., 1971), and can be calculated in several ways.  
One method estimates the action potential of the whole muscle using a supramaximal 
stimulation, and divides this by the estimated action potential of a single motor unit, as 
calculated using minimal stimulation.  Alternatively, the stimulus is gradually increased 
and with each increase in response, another motor unit is assumed to have been 
recruited, allowing for counting of the number of motor units.  A more recently 
developed but similar method is motor unit number index (MUNIX) (Nandedkar et al., 
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2010), in which CMAP is divided by an average motor unit size derived from surface 
interference patterns obtained as the patient voluntarily contracts the muscle being 
examined.   In both MUNE and MUNIX, lower numbers of motor units are found in MND 
patients compared to control subjects (Neuwirth et al., 2015, Baumann et al., 2012).   
A further test carried out in diagnostic investigations, most commonly when 
investigating neuromuscular junction (NMJ) disorders such as myasthenia gravis, is 
repetitive stimulation.  In this, repeated stimulation is applied to the nerve. During 
normal activation of the NMJ, increased pre-synaptic calcium causes an increase in 
acetylcholine (ACh) release.  As post-synaptic ACh receptors are activated, an influx of 
sodium occurs into the myocyte, causing an endplate potential (EPP).  If the EPP is above 
threshold, an action potential will occur in the muscle fibre, resulting in contraction.  The 
safety factor is defined as the difference between the EPP and the threshold potential 
required to produce an action potential, or the amount of excess neurotransmitter 
beyond the point of producing an action potential (Wood and Slater, 2001). 
During repetitive stimulation, the primary store of ACh is depleted, reducing the EPP.  
However, so long as the EPP remains above threshold, an action potential will still occur.  
After approximately 1 second, a secondary store of ACh will be available for release and 
the EPP will rise back to normal levels.  Therefore, during a slow repetitive stimulation 
(3Hz), a temporary reduction in EPP may be seen around the fourth stimulus.  However, 
the CMAP amplitude will usually remain unaffected as the EPPs will always remain above 
threshold.   
During fast repetitive stimulation or exercise (30-50Hz), the primary store of ACh is 
depleted very rapidly and the secondary store is activated faster, combined with an 
increase in calcium concentration, further increasing release of ACh; EPPs (and CMAP 
amplitude) remain the same throughout in healthy subjects. 
In MND patients a decremental response to repetitive nerve stimulation has been 
reported (Iwanami et al., 2011, Wang et al., 2001). While this is incompletely 
understood, it is thought to reflect an underlying reduction in the safety factor, perhaps 
due to axons being in the process of degenerating. As the train of stimuli proceed the 
threshold for successful transmission is not achieved for a proportion of neuromuscular 
junctions. This results in fewer muscle fibres being activated and so a drop in the 
amplitude of the CMAP. 
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EMG is also utilised in the diagnostic process. In this a needle electrode is inserted in to 
a muscle of interest. The recording activities during both rest and voluntary muscle 
activation (if possible) are then recorded and analysed.   When the muscle is at rest no 
electrical activity should be recorded by the needle electrode.  If any activity is recorded 
this is generally held to be abnormal and a sign of denervation.  Fibrillation 
potentials/positive sharp waves are signs of spontaneous EPPs in which an individual 
muscle fibre is spontaneously activated (Whittaker, 2012) and fasciculation potentials 
are indicators of spontaneous motor unit action potentials, both of which can be signs 
of the denervation that occurs in MND (Costa et al., 2012).  The Awaji criteria allow for 
EMG data to be equated to clinical examination and historical evidence of lower motor 
neuron pathology (de Carvalho et al., 2008).  
Motor evoked potentials (MEPs) are another useful electrophysiological measurement 
in mice as they give an indication of motor connectivity involving stimulation of the 
motor cortex and measurement of the electrical current at the spine or the muscle.  
However, MEPs can be invasive and require a wider range of equipment and are 
therefore, not as frequently used in diagnosis as other methods.  In patients, transcranial 
magnetic stimulation can be used to evoke MEPs, reducing its invasive nature and 
providing useful indicators of upper motor neuron dysfunction (Menon et al., 2015).   
CMAP amplitude, MUNE and fibrillation potential measurements have been reported in 
mouse models of neurological disease and suggested as translational biomarkers, 
showing similarities to measurements in human studies (Arnold et al., 2015, Arnold et 
al., 2014).  A decremental response in repetitive stimulation has also been shown in a 
mouse model of spinal muscular atrophy, showing promise as a translational 
electrophysiological biomarker (Bogdanik et al., 2015). 
Many electrophysiological studies have been carried out on MND mouse models, mostly 
on the SOD1G93A mice.  Studies have found a reduction in CMAP amplitude (Mancuso et 
al., 2014, Alves et al., 2011, Li et al., 2013, Mancuso et al., 2011b), MUNE (Li et al., 2013, 
Shefner et al., 2002, Mancuso et al., 2011b) and MEPs (Mancuso et al., 2011b). 
Furthermore, EMG has demonstrated spontaneous fibrillations in the hindlimb muscles 
(Azzouz et al., 1997, Miana-Mena et al., 2005).   
The published data on the TDP-43Q331K model used electrophysiological studies to 
investigate the loss of upper/lower motor neurons (Arnold et al., 2013).  Muscle MEPs 
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were reduced in the TDP-43Q331K mice compared to control mice, demonstrating a loss 
of connectivity in the motor system.  However, spinal MEPs were not reduced in the 
TDP-43Q331K mice, indicating that there was no loss of upper motor neurons, only lower 
motor neurons. Consistent with this, EMG demonstrated spontaneous activity 
suggestive of fibrillations. 
In summary, electrophysiological measures may provide a translational biomarker of 
MND, whilst concurrently providing additional insight in to the TDP-43Q331K mouse 
model under investigation.  Neurophysiological measures have been used in this study 
to further characterise the phenotype of the model and investigate the potential 
therapeutic effect of riluzole in the TDP-43Q331K mouse model. 
 
4.1.3. Marble Burying 
Marble burying assays are tests in which mice are placed in a cage of deep bedding with 
marbles placed on the surface and the number of marbles buried in a set time are 
counted (Deacon, 2006).  The true meaning of marble burying activity has long been 
debated and marble burying activity widely varies with genetic background (Deacon, 
2006, Thomas et al., 2009).   
Marble burying was traditionally thought of as a test of anxiety seeing as anxiolytic drugs 
reduce marble burying behaviour (Ichimaru et al., 1995, Nicolas et al., 2006).  However, 
several studies propose that the marbles do not induce fear/anxiety, as mice will dig in 
the new environment regardless of whether marbles are present (Gyertyan, 1995, 
Thomas et al., 2009), repetitive exposure to the marbles does not reduce the burying 
response (Londei et al., 1998, Thomas et al., 2009, Njunge and Handley, 1991), mice did 
not avoid marbles when given the choice (Njunge and Handley, 1991), and marble 
burying activity does not correlate with other anxiety measures (Thomas et al., 2009). 
Marble burying has frequently been used as a measure of repetitive behaviour, 
especially in mouse models of obsessive compulsive disorder (Angoa-Perez et al., 2013, 
Londei et al., 1998, Ichimaru et al., 1995, Egashira et al., 2008).  Glutamate-related drugs 
used to treat obsessive behaviour have been shown to reduce marble burying behaviour 
without reducing locomotor activity, although riluzole had no effect on marble burying 
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behaviour (Egashira et al., 2008).  Anti-psychotic drugs have also been shown to reduce 
marble burying behaviour (Nicolas et al., 2006). 
It is now a common belief that marble burying is simply a measure of digging behaviour 
(Deacon, 2006, Gyertyan, 1995) and one study showed that marble burying correlated 
with digging behaviour and digging behaviour was unaffected by the presence of 
marbles (Thomas et al., 2009).  It could therefore be concluded that marble burying is a 
measure of normal behaviour, as digging is a habitual behaviour in mice, by which they 
explore their environment (Deacon, 2006).   
As described previously, an estimated 50% of MND patients will experience 
cognitive/behavioural changes (Ringholz et al., 2005), and 10-15% of MND patients will 
be diagnosed with MND-FTD, the symptoms of which may include repetitive behaviours 
and apathy (Chan et al., 2015).  Symptoms of FTD may be measured in mice by using 
measures of normal behaviour such as mothering, nest construction and self-grooming 
(Cathomas et al., 2015), in which apathy is presented by a lack of normal behaviour.   
No cognitive investigations have been carried out in the TDP-43Q331K mice, as yet.  We 
propose therefore, that marble burying could be considered as a measure of habitual 
behaviour, which could be increased by the presence of FTD in the TDP-43Q331K mice, as 
found in FTD patients (Chan et al., 2015).  Conversely, the presence of FTD may cause 
apathy in the mice, reducing normal digging behaviour, and consequently marble 
burying activity.  Current data from the running wheel study (chapter 3) suggests that 
the mice may show signs of apathy as they demonstrate reduced running activity, again 
a normal behaviour in mice, although this may be complicated by any pure motor deficit 
which is also present.  
Marble burying has been used recently in mouse models of C9ORF72, in which mice with 
a (G4C2)450 repeat expansion showed increased marble burying behaviour compared to 
wild type mice, interpreted as increased levels of anxiety (Jiang et al., 2016). 
 
4.2. Aims 
 1. To assess whether riluzole is an effective treatment in TDP-43Q331K mice. 
2. To use electrophysiology to characterise the hindlimb denervation of TDP-43Q331K 
mice. 
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3. To assess marble burying behaviour in TDP-43Q331K mice as a measure of normal 
behaviour. 
 
4.3. Materials and Methods 
4.3.1. Ethics Statement 
All mouse experiments were carried out under the terms of the UK Animals (Scientific 
Procedures) Act 1986 and under a UK Home Office project license.  Mice were housed 
and cared for in accord with the Home Office Code of Practice for Housing and Care of 
Animals Used in Scientific Procedures.   
All procedures were carried out under an appropriate UK Project Licence by personal 
licence holders. 
ARRIVE guidelines (Kilkenny et al., 2010) were adhered to during this report. 
 
4.3.2. Transgenic C57BL/6N Mice 
TDP-43WT and TDP-43Q331K mice (Mus musculus) were originally generated on a 
C57BL/6NCrl background by insertion of c-myc-tagged human TARDBP (Arnold et al., 
2013) and were subsequently backcrossed on to a C57BL/6NJ background before being 
deposited at the Jackson Laboratory (stock numbers 017907 and 017933, respectively).   
Power analysis (see table 2.4) was used to calculate minimum group sizes to detect 
differences in latency to fall on the rotarod.  Required group sizes were lower in females 
and therefore only female mice were used in this study.  14 TDP-43Q331K mice were 
recruited to the riluzole and vehicle groups, 7 of which were also assessed by 
electrophysiological investigations.  A group of 7 TDP-43WT and 7 non-transgenic mice 
were also recruited as controls for the electrophysiological investigations.  The number 
of mice recruited to each group eventually differed slightly from that planned as one 
mouse was culled due to encephalitis and the replacement was accidentally recruited to 
a different group.  Mice were recruited at 25 days of age and remained on the study 
until 6 months of age.   
For genotyping methods see section 2.3.4. 
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4.3.3. Housing  
Mice were bred in a SPF environment, and transferred to a conventional facility for the 
studies described here.  The facility uses a 12 h light/dark cycle, and room temperature 
is set to 21˚C.  Cages were lined with fine sawdust (eco-pure flakes 6, Datesand, UK), 
which was changed weekly, a plastic house was in each cage and paper wool (Datesand, 
UK) was used as bedding material.  Mice were fed 2018 rodent diet (Harlan, UK) ad 
libitum.   
All mice were housed in littermate pairs or trios whenever possible. 
 
4.3.4. Mass Spectrometry of Riluzole Compounds 
Mass spectrometry of two riluzole batches was carried out at the University of Sheffield 
Mass Spectrometry facility.   
Liquid chromatography-mass spectrometry was carried out on 0.4mg/ml samples of 
riluzole (Apollo Scientific, UK).  Liquid chromatography was carried out on an Agilent 
1260 Infinity instrument (Agilent, UK).  Mass spectrometry was carried out on an Agilent 
6530 Q-ToF instrument (Agilent, UK) with an injection volume of 1µl and a flow rate of 
0.4ml/min. 
 
4.3.5. Administration of Riluzole/Vehicle 
Riluzole (Apollo Scientific, UK) was administered in the drinking water at 240ug/ml 
(approximately 70mg/kg) in 0.1% dimethyl sulfoxide (DMSO, Sigma-Aldrich, UK).  All 
non-transgenic, TDP-43WT and vehicle mice were administered 0.1% DMSO in the 
drinking water. 
Mice were dosed from 30 days of age.  Drinking water was changed every 2/3 days and 
drinking bottles changed weekly. 
The primary investigator (JS) was blinded to the treatment group throughout the study. 
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4.3.6. Riluzole PK Study 
An initial pharmacokinetic (PK) study was carried out in a cohort of 6 female non-
transgenic mice, all of which were administered riluzole (as described in 4.3.4.) for 7 
days.  On the eighth day, half of the cohort were culled at 6am; half at 6pm (anticipated 
to represent peak and trough exposure respectively due to lighting hours). 
Mice were culled with an overdose of pentobarbitone.  Blood samples were taken by 
cardiac puncture.  Spinal cords were removed and snap frozen in liquid nitrogen.  
Samples were sent for riluzole quantification using ultra-high performance liquid 
chromatography time of flight - TOF mass spectrometry using electrospray ionisation 
(Pharmidex, UK). 
 
4.3.7. Neuroscoring and Weighing 
Neuroscores and weight were monitored weekly in the morning.  A modified 
neuroscoring system was devised in which forelimb tremor was measured by holding 
the mouse by the tail and scoring the forelimbs on a subjective scale of 0-3 (normal-
strong).  Resting tremor was measured by placing the mouse in the hand (0-no tremor, 
1-intermittent tremor, 2-continuous tremor, 3-continuous tremor with large, whole 
body convulsions).  A ‘neuroscore’ scale was used to delineate motor dysfunction (0-
normal, 1-significant resting tremor, 2-abnormal gait, 3-severe waddle).  Whenever 
possible, this scoring was carried out by the same investigator (JS).   
Weight was monitored by placing the mice in a box on a set of scales (Kern, Germany) 
pre-set to zero. 
These measurements were taken immediately prior to rotarod testing and in the same 
procedure room as the rotarod. 
 
4.3.8. Accelerating Rotarod Test 
Mice were placed on the accelerating rotarod (Jones & Roberts for mice 7650) for a 
period of 300 seconds.  In this time the rotarod accelerates from 4 to 40 rpm and latency 
to fall was recorded for each mouse.  All rotarod testing was carried out at a similar time 
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of day (am) and all testing consisted of two trials, with the highest score being recorded 
for analysis.   
Mice were initially trained on the rotarod over 3 days (27-29 days of age) and underwent 
the first testing day at 30 days of age, being tested each week thereafter.   
 
4.3.9. Catwalk Gait Analysis 
The catwalk gait analysis system 7.1 (Noldus Information Technology B.V., Netherlands) 
was used to capture gait parameters at 1, 3, 6 and 10 months of age.  Mice were placed 
on the glass floor of the catwalk system in complete darkness and left to walk/run freely.  
Whenever possible, 6 straight continuous runs were recorded and the 3 straightest, 
most continuous runs were selected for analysis.  Catwalk software 7.1 was used to 
analyse the gait parameters of the mice.  Microsoft excel was used to collate data within 
groups.  Walking duration is the time taken to cross the length of the recording window 
(43.8 cm).  Base of support is the distance between the paws whilst walking.  For more 
details see section 2.3.9. 
 
4.3.10. Electrophysiology 
Electrophysiology was carried out at 1, 3 and 6 months of age in all non-transgenic, TDP-
43WT, TDP-43Q331K riluzole/electrophysiology, and TDP-43Q331K vehicle 
/electrophysiology groups (n = 7-8 per group).  Mice were placed under gaseous 
anaesthesia (1–2% isoflurane, flow rate 1.0 L/min oxygen and nitrous oxide continuous 
inhalation through a nose cone).  Body temperature was maintained using an electric 
heat pad (CWE, USA).  The fur of the left hindlimb and lower back was shaved and 
depilatory cream used to remove any remaining fur.
All recordings were made using a Dantec Keypoint Focus EMG System (Optima, UK).  For 
CMAP and repetitive stimulation, supramaximal stimuli were applied subcutaneously at 
the sciatic notch using twisted pair subdermal electrodes (Ambu Neuroline, UK).  A 
grounding electrode was placed in the base of the tail (Ambu Neuroline, UK), and ring 
recording electrodes were placed circumferentially around the distal hindlimb muscles 
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(Alpine Biomed, Denmark), layered with Ten20 nerve conductive paste (Pulse Medical 
Ltd, UK), see figure 4.1. 
The mouse was maintained under gaseous anaesthesia with stimulating electrodes over 
the sciatic notch, a grounding electrode in the base of the tail and ring electrodes around 
the hindlimb. 
 
CMAPs were acquired by applying a single, square wave electrical impulse of 0.1ms 
duration to the sciatic notch. The position of the subcutaneous stimulating electrodes 
was trialled to ensure that a response was obtained using a stimulating current of 
around 1-2mA. The stimulation intensity was then increased until no further increase in 
amplitude was seen and hence a supramaximal response elicited.   
The electrodes were then held in the same place whilst repetitive stimulation was 
carried out. This involved ten pulses, applied at 3Hz, 10Hz and 50Hz.  The area and 
amplitude of the response decrement were recorded. Analyses were undertaken using 
the change in amplitude/area seen on the 10th response relative to the first response 
(as typically employed in the clinical investigation of neuromuscular junction disorders) 
and also the relative change seen on the final response.  
Ring 
electrodes 
Stimulating 
electrodes 
Grounding 
electrode 
Nose cone 
(anaesthesia) 
Figure 4. 1: Electrophysiology set-up. 
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At 6 months of age, in mice for which electrophysiology was non-recovery, EMG 
recordings were taken using a 30 gauge concentric cable electrode (Ambu Neuroline, 
UK).  Recordings were taken in the gastrocnemius and tibialis anterior muscles. 
Electrophysiology training and analysis was carried out with the help of Dr James Alix. 
 
4.3.11. Marble Burying 
Mice were placed in a semi-light room in cages 19cm deep x 33cm long x 21cm wide, 
filled with sawdust approximately 8cm deep.  24 marbles were placed in 4 x 6 grid 
pattern on the surface of the sawdust (see figure 4.2A).  Mice were left undisturbed for 
1 hour and then returned to their home cage.  Marbles were counted as buried when 
2/3 covered by sawdust (see figure 4.2B). 
As shown in A, marbles are placed in a 4 x 6 grid pattern.  Post marble burying (B), 
marbles are counted as buried if 2/3 covered by sawdust (green arrow), marbles are not 
counted as buried if they are <2/3 covered by sawdust (purple arrow). 
 
A B 
A 
Figure 4. 2: Marble burying cage layout (A) and cage after marble burying (B). 
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4.3.15. Statistics 
GraphPad Prism 6 was used for all statistical analyses (GraphPad, San Diego, CA, USA).  
Two-way ANOVA with Tukey’s post-test was used unless otherwise stated.  All data are 
presented as a mean and standard deviation. 
 
4.4. Results 
4.4.1. Mass Spectrometry of Riluzole 
Before administering riluzole to the mice, it was noted that the colour of the substance 
was different to that used in a simultaneous study within the department.  Therefore, a 
sample of each riluzole batch was sent for mass spectrometry analysis to ensure they 
were suitably pure. 
The total ion current (TIC) intensities of two riluzole samples are shown in figure 4.3.  
Both samples show a peak in the spectra at approximately 6.5 and 7.9 mins.   
In both spectra the 6.5 min peak is much larger than the 7.9 min peak at approximately 
4.6x107, this is representative of the riluzole compound.  The 7.9 min peak is larger in 
sample 2 at 0.4x107, compared to sample 1 where it is 0.2x107, this is representative of 
an impurity which is still within acceptable limits.  These data confirm identity and purity 
of the riluzole batch used. 
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Mass spectrometry shows both batches contain a single major peak although the 
impurity peak is slightly larger in batch 2 they are both >95% pure.   
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Figure 4. 3: Total ion current (TIC) intensity spectra of riluzole samples. 
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4.4.2. Riluzole PK Study 
A PK study was carried out to ensure that the riluzole was penetrating the blood brain 
barrier at therapeutic levels which match those found in humans. 
Riluzole levels in blood and spinal cord were detected at anticipated peak and trough 
exposures at the end and the beginning of the night cycle respectively (table 4.1).  Peak 
levels were higher than trough in both blood (116.2 ±54.4nM peak vs 78.7 ± 8.3nM 
trough) and spinal cord (307.4 ±173.6nM peak vs 220.8 ±43.8nM trough), with a similar 
spinal cord/blood ratio in both groups (2.5 ±0.6nM peak and 2.8 ±0.4nM trough).   
Therefore, as expected, riluzole penetrated the blood brain barrier and more riluzole 
was consumed during the dark hours of the light-dark cycle. 
Table 4. 1: Riluzole concentrations (uHPLC/TOF Mass spec).  Mean riluzole 
concentrations in the blood and spinal cord for 7-day dosed mice at peak and trough 
dosage (n = 3, mean +/- SD). 
 Blood (nM) Spinal cord (nM) Spinal cord/blood ratio 
Peak 116.2 (±54.4) 307.4 (±173.6) 2.5 (±0.6) 
Trough 78.7 (± 8.3) 220.8 (±43.8) 2.8 (±0.4) 
 
4.4.3. Neuroscoring 
Neuroscoring was carried out weekly in all TDP-43Q331K mice, both riluzole and vehicle 
groups. 
Neuroscoring consisted of 3 measurements, forelimb tremor, hindlimb tremor and an 
overall neuroscore, all measured on a scale of 0-3.  No difference was evident between 
the riluzole and vehicle groups in any measurement on a two-way ANOVA. 
Both groups presented with a median forelimb tremor score of 1 (mild tremor when 
lifted by the tail base) from the beginning of data collection (5 weeks of age) and this 
remained at 1 throughout the study.  Some mice developed to a score of 2 (moderate 
tremor) but most mice maintained a forelimb tremor score of 1 throughout. 
Both groups presented mostly with a hindlimb tremor score of 0, with a few mice 
presenting with a score of 1 at 5 weeks of age.  Hindlimb tremor progressed to a median 
score of 3 in both groups by 25 weeks of age.  Most mice progressed to a hindlimb 
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tremor score of 3 (continuous resting tremor with whole-body convulsions), whilst 
several mice progressed to a hindlimb tremor score of 2 (continuous resting tremor). 
A median overall neuroscore of 0 was found in both groups at 5 weeks of age, 
progressing to a median neuroscore of 3 by 25 weeks of age, suggesting that most mice 
developed to a neuroscore of 3 (severe waddle), whilst some mice progressed to a 
neuroscore of 2 (abnormal gait). 
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Figure 4. 4: Median neuroscores over time. 
Graphs showing median (± interquartile range) forelimb tremor, hindlimb tremor and 
neuroscores based on a scale of 0-3 from 5-25 weeks of age in riluzole and vehicle female 
TDP-43Q331K mice (n = 13-15). 
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4.4.4. Body Weight 
Body weight was measured weekly in the riluzole and vehicle groups from 5-23 weeks 
of age (female TDP-43Q331K).  As found previously, weight increased with age.  In the 
riluzole group (n = 15), weight increased from 15.4 ± 1.4g at 5 weeks, to 33.6 ± 6.8g at 
23 weeks of age.  In the vehicle group (n = 13), weight increased from 15.5 ± 1.2g at 5 
weeks of age to 30.1 ± 5.1g at 23 weeks of age.  There was no significant difference in 
weight between each group on a two-way ANOVA with repeated measures.  Riluzole, 
therefore, had no effect on the weight of TDP-43Q331K mice. 
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Figure 4. 5: Mean body weight (±SD) in vehicle and riluzole TDP-43Q331K mice. 
Body weight increased from 5-23 weeks of age in the riluzole and vehicle groups (female, 
TDP-43Q331K, n = 13-15).  There is no significant difference in weight between the two 
groups (two-way ANOVA with repeated measures). 
 
4.4.5. Rotarod Performance 
Rotarod performance was measured weekly in the riluzole and vehicle groups from 5-
23 weeks of age (female TDP-43Q331K).  As found previously, rotarod performance 
decreased with age.  In the riluzole group (n = 15), rotarod performance declined from 
257.2 ± 54.3s at 5 weeks, to 168.7 ± 49.5s at 23 weeks of age.  In the vehicle group (n = 
13), rotarod performance declined from 264.5 ± 49.6s at 5 weeks of age to 182.5 ± 63.3s 
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at 23 weeks of age.  There was no significant difference in rotarod performance between 
each group on a two-way ANOVA with repeated measures.  Riluzole, therefore, showed 
no treatment effect on rotarod performance. 
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Figure 4. 6: Mean rotarod performance (±SD) in vehicle and riluzole TDP-43Q331K mice. 
Rotarod performance decreased from 5-23 weeks of age in the riluzole and vehicle 
groups (female, TDP-43Q331K, n = 13-15).  There is no significant difference in latency to 
fall between between the two groups (two-way ANOVA with repeated measures). 
 
4.4.6. Catwalk Gait Analysis 
Gait analysis was carried out in all groups at 3 and 6 months of age.  All numbers for 
significant findings are recorded in table 4.2. 
Duration (the time taken to cross the recording area of the catwalk equipment) showed 
no differences between the riluzole and vehicle dosed TDP-43Q331K groups or between 
the non-transgenic and TDP-43WT groups at 3 or 6 months of age.  However, both TDP-
43Q331K groups had a significantly longer duration compared to the non-transgenic and 
TDP-43WT groups at 3 and 6 months. 
Forelimb base of support (the distance between the forepaws during walking) showed 
no differences between any of the groups at 3 or 6 months. 
Hindlimb base of support (the distance between the hindpaws during walking) showed 
no differences between the riluzole and vehicle TDP-43Q331K groups or between the non-
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transgenic and TDP-43WT groups at 3 or 6 months of age.  However, the TDP-43Q331K 
groups had a significantly increased hindlimb BOS compared to the control groups at 3 
and 6 months of age. 
Diagonal stepping (the percentage of time spent walking in a diagonal stepping pattern: 
left forepaw placed at the same time as right hindpaw; right forepaw placed at the same 
time as left hindpaw) showed no differences between the riluzole and vehicle TDP-
43Q331K groups or between the non-transgenic and TDP-43WT groups at 3 or 6 months of 
age.  However, both TDP-43Q331K groups had significantly less diagonal stepping 
compared to the control groups at 3 and 6 months. 
Three paw stepping (the percentage of time spent walking with three paws on the 
surface) showed no significant differences between any groups. 
Four paw stepping (the percentage of time spent walking with four paws on the surface) 
showed no differences between the riluzole and vehicle TDP-43Q331K groups or between 
the non-transgenic and TDP-43WT groups at 3 or 6 months of age.  However, both TDP-
43Q331K groups had significantly more four paw stepping compared to the control groups 
at 3 and 6 months. 
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Figure 4. 7: Catwalk gait analysis: mean (±SD) duration (A), diagonal stepping (B), 
forelimb BOS (C), three paw stepping (D), hindlimb BOS (E) and four paw stepping (F). 
Mean duration (A), forelimb BOS (C) and hindlimb BOS (E) for all groups at 3 and 6 
months of age (n = 7-14) showing significantly longer walking duration in both TDP-
43Q331K groups at 3 and 6 months of age compared to the control groups (p<0.001, 
p<0.0001 respectively) and significantly increased hindlimb BOS at in both TDP-43Q331K 
groups at 6 months of age compared to the control groups (p<0.001).  Percentage of 
time spent stepping in a diagonal (B), three paw (D) and four paw (F) pattern for all 
groups at 3 and 6 months of age (n = 7-14).  Diagonal stepping was significantly lower in 
the TDP-43Q331K groups compared to the control groups at 3 and 6 months of age 
(p<0.05) and four paw stepping was significantly increased in the TDP-43Q331K groups 
compared to the control groups at 3 and 6 months of age (p<0.0001, p<0.01 
respectively). 
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Forelimb swing time (the mean time between lifting a forepaw and placing it back down) 
showed no significant differences between any groups at 3 months of age.  However, 
both TDP-43Q331K groups had a significantly increased forelimb swing compared to the 
control groups at 6 months of age. 
Forelimb stride length (the mean distance between forepaw prints) showed no 
significant differences between any groups at 3 or 6 months of age. 
Forelimb duty cycle (the length of time a paw is on the surface, expressed as a 
percentage of the total time taken for each stride) showed no differences between the 
riluzole and vehicle TDP-43Q331K groups or between the non-transgenic and TDP-43Q331K 
groups at 3 or 6 months of age.  However, both TDP-43Q331K groups had a significantly 
higher duty cycle compared to the control groups at 3 and 6 months. 
Hindlimb swing time (the mean time between lifting a hindpaw and placing it back 
down) showed no significant differences between any groups at 3 months of age.  
However, both TDP-43Q331K groups had a significantly increased hindlimb swing 
compared to the control groups at 6 months of age. 
Hindlimb stride length (the mean distance between hindpaw prints) showed no 
significant differences between any groups at 3 or 6 months of age. 
Hindlimb duty cycle (the length of time a paw is on the surface, expressed as a 
percentage of the total time taken for each stride) showed no differences between the 
riluzole and vehicle TDP-43Q331K groups or between the control groups at 3 or 6 months 
of age.  However, both TDP-43Q331K groups had a significantly higher duty cycle 
compared to the control groups at 3 and 6 months. 
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Figure 4. 8: Mean (±SD) catwalk gait analysis: forelimb swing time (A), stride length 
(B) and duty cycle (C), hindlimb swing time (D), stride length (E) and duty cycle (F). 
Forelimb swing time (A), stride length (B) and duty cycle (C) for all groups at 3 and 6 
months of age (n = 7-14).  Forelimb swing time was significantly increased in the TDP-
43Q331K groups compared to the control groups at 6 months of age (p<0.01) and forelimb 
duty cycle was significantly increased in the TDP-43Q331K groups compared to the control 
groups at both 3 and 6 months of age (p<0.0001, p<0.01 respectively). Hindlimb swing 
time (D), stride length (E) and duty cycle (F) for all groups at 3 and 6 months of age (n = 
7-14).  Hindlimb swing time was significantly increased in the TDP-43Q331K groups 
compared to the control groups at 6 months of age (p<0.01) and hindlimb duty cycle was 
significantly increased in the TDP-43Q331K groups compared to the control groups at both 
3 and 6 months of age (p<0.01).
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Table 4. 2: Table of significant catwalk gait analysis findings.  * = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001. 
Catwalk parameter Age TDP-43Q331K 
riluzole 
TDP-43Q331K 
vehicle 
TDP-43WT Non-transgenic Significance of 
the difference 
between the TDP-
43Q331K and 
control groups 
Duration 3 3±0.3s 3.1±0.4 2±0.3s 2.2±0.4s *** 
 6 3.4±0.6s 3.4±0.5s 1.8±0.4s 1.8±0.4s **** 
Hindlimb BOS 6 31.6±4.5mm 30.8±2.9mm 22.9±2.5mm 24.4±1.8mm *** 
Diagonal stepping 3 38.5±12.2% 41.8±9.9% 57±11.4% 56.7±11% * 
 6 41.4±12% 40.7±8.4% 56.4±8.3% 57.6±13.8% * 
Four paw stepping 3 26.3±7.7% 23.5±4.9% 8.9±3.4% 9.1±3.9% **** 
 6 24.5±5.5% 22.7±6.5% 13.8±4.6% 11.9±6.1% ** 
Forelimb swing time 6 0.12±0.02s 0.13±0.04s 0.09±0.01s 0.09±0.01s ** 
Forelimb duty cycle 3 67.6±5.9% 65.8±4% 56.8±2.9% 56.8±2.6% **** 
 6 65.4±3.8% 65.7±3.8% 59.9±3.6% 60.1±2.1% * 
Hindlimb swing time 6 0.1±0.01s 0.1±0.02s 0.07±0.01s 0.08±0.02s ** 
Hindlimb duty cycle 3 73.2±3.2% 72.6±2.9% 64.6±4.4% 65.1±5.4% ** 
 6 74±4.4% 73.3±1.7% 65.8±4.7% 64.6±8.4% ** 
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4.4.7. CMAP 
CMAP amplitude, representative of the amount of functional motor axons and muscle 
fibres, was measured in the hindlimb of mice in all groups at 1, 3 and 6 months of age.  
CMAP amplitude showed no differences between the riluzole and vehicle TDP-43Q331K 
groups or between the non-transgenic and TDP-43Q331K groups at 1, 3 or 6 months of 
age.  However, both TDP-43Q331K groups had a significantly lower CMAP amplitude 
compared to the non-transgenic and TDP-43WT groups at 1 month (22.6±6.4mV TDP-
43Q331K riluzole vs 24.7±6.7mV TDP-43Q331K vehicle vs 34.6±2.7mV non-transgenic vs 
32.9±2.4mV TDP-43WT, p<0.05, two-way ANOVA), 3 months (26.9±4.5mV TDP-43Q331K 
riluzole vs 26.3±6.7mV TDP-43Q331K vehicle vs 49.2±8.9mV non-transgenic vs 
50.1±5.1mV TDP-43WT, p<0.0001, two-way ANOVA) and 6 months (24.6±7mV TDP-
43Q331K riluzole vs 25.3±5.9mV TDP-43Q331K vehicle vs 46.2±5.7mV non-transgenic vs 
45.7±5.2mV TDP-43WT, p<0.0001, two-way ANOVA), suggestive of a lower number of 
functional motor axons in the TDP-43Q331K mice throughout. 
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Figure 4. 9: CMAP amplitude (±SD) at 1, 3 and 6 months of age. 
CMAP amplitude was recorded in the hindlimb of all mice (n = 7-8) at 1, 3 and 6 months 
of age.  CMAP was significantly lower in TDP-43Q331K groups compared to the control 
groups at 1 (p<0.05), 3 (p<0.0001) and 6 months (p<0.0001). 
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4.4.8. Repetitive Stimulation Total Decrement 
Repetitive stimulation was carried out at 1, 3 and 6 months of age to investigate the 
functionality of the NMJs.  In healthy subjects, the response to repetitive stimulation 
would be expected to remain at a steady state; a reduction in response could be 
suggestive of disease. 
 
4.4.8.1. Differences with Age 
Repetitive stimulation was carried out at 3Hz in all groups at 1, 3 and 6 months of age.  
The decrement between stimuli 1 and 10 showed no significant differences at any age 
between the non-transgenic and TDP-43WT mice.  Although non-significant, the riluzole 
group did show a consistently smaller decrement compared to the vehicle group 
throughout, indicative of a potential treatment effect.  Differences between the TDP-
43Q331K groups and the control groups were evident throughout but not consistently 
significant (see figure 4.12).  However, the TDP-43Q331K groups had a larger decrement 
than the control groups at 1 month (-4.3±3.5% TDP-43Q331K riluzole vs -3.1±3.1% TDP-
43Q331K vehicle vs -0.5±3.4% non-transgenic vs -0.6±5.3% TDP-43WT), 3 months (-
6.4±2.1% TDP-43Q331K riluzole vs -4.2±2.7% TDP-43Q331K vehicle vs -1.4±0.9% non-
transgenic vs 0.1±2.7% TDP-43WT) and 6 months (-3.2±0.4% TDP-43Q331K riluzole vs -
5±3.5% TDP-43Q331K vehicle vs -0.7±0.9% non-transgenic vs -0.8±1.9% TDP-43WT). 
The data for 3Hz was very variable, and therefore difficult to assess changes over time 
within groups.  At 10Hz, a trend can be seen in the TDP-43Q331K riluzole group in which 
repetitive stimulation response decreases over time.  However, there are no obvious 
trends in any other groups over time.  50Hz was only measured at 6 months and so there 
are no data over time for this parameter. 
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Figure 4. 10: Repetitive stimulation – total decrement from first to last stimulus. 
The decrement between stimuli 1 and 10 were recorded at 3 and 10Hz in the hindlimb of 
all groups (n = 7-8) at 1, 3 and 6 months of age.  50Hz was carried out in the same mice 
at 6 months of age.  Repetitive stimulation at 3Hz was significantly different for the effect 
of group (p<0.001), but not for the effect of age on a two-way ANOVA with repeated 
measures and Tukey’s post-tests.  Repetitive stimulation at 10Hz was significantly 
different for the effect of group (p<0.0001), but not for the effect of age on a two-way 
ANOVA with repeated measures and Tukey’s post-tests.  Repetitive stimulation at 50Hz 
was significantly different on a one-way ANOVA with Tukey’s post-tests (p<0.01).  
Multiple comparisons were also made (* = p<0.05, ** = p<0.01, *** = p<0.001, **** = 
p<0.0001). 
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4.4.8.2. Analysis of Individual Stimuli at 1 Month 
Analysis of each individual stimulus response was plotted to enable further 
interpretation and to ensure that stimulus responses were not decreasing and returning 
to baseline between stimuli 1 and 10.   
With a stimulus of 3Hz at 1 month of age (figure 4.13), a slight decrement in response is 
shown over time in all groups in response to repeated stimuli.  Overall, there is no 
significant difference between groups on a two-way ANOVA with repeated measures, 
and multiple comparisons show no differences between groups for any stimuli. 
With a stimulus of 10Hz (figure 4.13), a decrement in response is shown over time in 
both TDP-43Q331K groups, whereas the TDP-43WT and non-transgenic groups show no 
decrease in response to repeated stimuli.  Overall, there is a significant difference 
between groups on a two-way ANOVA with repeated measures (p<0.001), and multiple 
comparisons show no differences between the TDP-43Q331K riluzole and vehicle groups, 
no differences between the TDP-43WT and non-transgenic groups.  Some differences 
were found between TDP-43Q331K groups and control groups but these were inconsistent 
across stimuli. 
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Figure 4. 11: Repetitive stimulation showing individual stimuli at 1 month. 
The response (±SD) for each stimuli normalised to the first stimulus at 3, 10, and 50Hz in 
the hindlimb of all groups (n = 7-8) at 1 month of age.  At 3Hz, no significant difference 
was found between groups on a two-way ANOVA with repeated measures and Tukey’s 
post-tests.  At 10Hz, there was a significant difference (p<0.001) between groups on a 
two-way ANOVA with repeated measures and Tukey’s post-tests. 
 
4.4.8.3. Analysis of Individual Stimuli at 3 Months 
With a stimulus of 3Hz at 3 months of age (figure 4.14), a slight decrement in response 
is shown over time in both TDP-43Q331K groups, whereas the TDP-43WT and non-
transgenic groups show little or no decrease in response to repeated stimuli.  Overall, 
there is a significant difference between groups on a two-way ANOVA with repeated 
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measures (p<0.0001), and multiple comparisons show no differences between the TDP-
43Q331K riluzole and vehicle groups, no differences between the TDP-43WT and non-
transgenic groups, and significant differences between the TDP-43Q331K riluzole group 
and the control groups from stimulus 3 (p<0.01), a consistent significant difference 
between the TDP-43Q331K vehicle group and TDP-43WT from stimulus 6 (p<0.01), and a 
significant difference between the TDP-43Q331K vehicle group and non-transgenic group 
at stimulus 10 (p<0.05). 
With a stimulus frequency of 10Hz (figure 4.14), a decrement in response is shown over 
time in both TDP-43Q331K groups, whereas the TDP-43WT and non-transgenic groups 
show no decrease in response to repeated stimuli.  Overall, there is a significant 
difference between groups on a two-way ANOVA with repeated measures (p<0.001). 
Multiple comparisons show no differences between the TDP-43Q331K riluzole and vehicle 
groups, no differences between the TDP-43WT and non-transgenic groups, and no 
differences between the TDP-43Q331K riluzole group and the control groups.   Significant 
differences were found between the TDP-43Q331K riluzole group and the control groups 
from stimulus 3 (p<0.01), a significant difference between the TDP-43Q331K vehicle group 
and non-transgenic from stimulus 5 (p<0.01), and a significant difference between the 
TDP-43Q331K vehicle group and TDP-43WT non-transgenic group at stimulus 6 (p<0.01). 
It should be noted that, although non-significant, the riluzole group show a consistently 
reduced decrement compared to the vehicle group throughout both the 3Hz and 10Hz 
stimulations, showing a potential treatment effect. 
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Figure 4. 12: Repetitive stimulation showing individual stimuli at 3 months. 
The response (±SD) for each stimuli normalised to the first stimulus at 3, 10, and 50Hz in 
the hindlimb of all groups (n = 7-8) at 3 months of age.  At 3Hz, there was a significant 
difference (p<0.0001) between groups on a two-way ANOVA with repeated measures 
and Tukey’s post-tests.  At 10Hz, there was a significant difference (p<0.001) between 
groups on a two-way ANOVA with repeated measures and Tukey’s post-tests. 
 
4.4.8.4. Analysis of Individual Stimuli at 6 Months 
With a stimulus of 3Hz at 6 months of age (figure 4.15), a decrement in response is 
shown over time in both TDP-43Q331K groups, whereas the TDP-43WT and non-transgenic 
groups show no decrease in response to repeated stimuli.  Overall, there is a significant 
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difference between groups on a two-way ANOVA with repeated measures (p<0.001).  
Multiple comparisons show no differences between the TDP-43Q331K riluzole and vehicle 
groups, no differences between the TDP-43WT and non-transgenic groups but significant 
differences between the TDP-43Q331K groups and the control groups from stimulus 7 
(p<0.05). 
With a stimulus of 10Hz (figure 4.15), a decrement in response is shown over time in 
both TDP-43Q331K groups, whereas the TDP-43WT and non-transgenic groups show no 
decrease in response to repeated stimuli.  Overall, there is a significant difference 
between groups on a two-way ANOVA with repeated measures (p<0.001), and multiple 
comparisons show no differences between the TDP-43Q331K riluzole and vehicle groups, 
no differences between the TDP-43WT and non-transgenic groups and no differences 
between the TDP-43Q331K riluzole group and the control groups.  However, there are 
significant differences between the TDP-43Q331K vehicle group and the control groups 
from stimulus 6 (p<0.05).  This shows that there is potentially a slight rescue effect in 
the riluzole group, given that the repetitive stimulation responses are not significantly 
lower compared to the control groups, whereas the vehicle group are. 
With a stimulus of 50Hz (figure 4.15), a decrement in response is shown over time in all 
groups in response to repeated stimuli.  Overall, there is a significant difference between 
groups on a two-way ANOVA with repeated measures (p<0.01), and multiple 
comparisons show no differences between the TDP-43Q331K riluzole and vehicle groups, 
no differences between the TDP-43WT and non-transgenic groups, no differences 
between the TDP-43Q331K riluzole group and the control groups, and significant 
differences between the TDP-43Q331K vehicle group and the control groups from stimulus 
4 (p<0.05), again, suggestive of a slight treatment effect in the riluzole group. 
As with the 3 month data, it should be noted that the riluzole group shows a significantly 
reduced decrement compared to the vehicle group at 3, 10 and 50Hz, showing a possible 
treatment effect. 
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Figure 4. 13: Repetitive stimulation showing individual stimuli at 6 months. 
The response (±SD) for each stimulus normalised to the first stimulus at 3, 10, and 50Hz 
in the hindlimb of all groups (n = 7-8) at 6 months of age.  At 3Hz, there was a significant 
difference (p<0.001) between groups on a two-way ANOVA with repeated measures and 
Tukey’s post-tests.  At 10Hz, there was a significant difference (p<0.001) between groups 
on a two-way ANOVA with repeated measures and Tukey’s post-tests. At 50Hz, there 
was a significant difference (p<0.01) between groups on a two-way ANOVA with 
repeated measures and Tukey’s post-tests. 
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4.4.9. EMG 
Spontaneous activity was investigated as its presence is usually considered indicative of 
denervation. 
Spontaneous EMG activity was not identified in every TDP-43Q331K mouse but was found 
in the hindlimb of seven out of the eight mice investigated and there was no obvious 
difference in the frequency of spontaneous activity between the riluzole and vehicle 
groups.  Spontaneous activity included fasciculations (figure 4.16A & B), heightened 
insertional activity (figure 4.16C), and positive sharp waves (figure 4.16D). Some possible 
motor unit action potentials were also seen to fire briefly (see figure 4.16E). 
Examples of spontaneous activity recorded in the TDP-43Q331K mice include fasciculations 
(A & B), heightened insertional activity in response to the EMG needle (C), positive sharp 
waves (D), and possible motor unit action potentials (E). 
A 
E 
D C 
B 
Figure 4. 14: Electrophysiological traces of spontaneous activity recorded in TDP-
43Q331K female mice at 6 months of age. 
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Although far less frequent, some positive sharp waves were also found in one or two of 
the seven TDP-43WT and seven non-transgenic mice investigated.  As with the TDP-
43Q331K mice, possible motor unit action potentials were found (see figure 4.17).  No 
signs of fasciculations, fibrillations, or heightened insertional activity were found. 
Examples of spontaneous activity recorded in the TDP-43WT mice possible motor unit 
action potentials (A), and positive sharp waves (B). 
 
4.4.10. Marble Burying 
At 6 months of age mice were placed in new cages containing 24 evenly spaced marbles 
and the number of marbles buried in 1 hour was recorded.  As discussed in section 4.1.3, 
the main purpose of the marble burying paradigm was to identify apathy as an indicator 
of FTD in the TDP-43Q331K model.   
The data show a much higher proportion of marbles being buried by the non-transgenic 
and TDP-43WT mice compared to the TDP-43Q331K riluzole and vehicle mice (4.7±5.1 TDP-
43Q331K riluzole vs 9.2±7.4 TDP-43Q331K vehicle vs 13.7±8 non-transgenic vs 17.3±4.8 TDP-
43WT).  There was a significant difference between the TDP-43WT and TDP-43Q331K riluzole 
group (p<0.001, one-way ANOVA), the TDP-43WT and TDP-43Q331K vehicle group (p<0.05, 
one-way ANOVA), and the non-transgenic and TDP-43Q331K riluzole group (p<0.05, one-
way ANOVA). 
The decreased marble burying activity in TDP-43Q331K groups may be indicative of 
apathetic behaviour or could be due to motor dysfunction. 
B A 
Figure 4. 15: Electrophysiological traces of spontaneous activity recorded in TDP-43WT 
female mice at 6 months of age. 
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Figure 4. 16: Marble burying. 
Number of marbles buried (out of 24) at 6 months of age in all groups (n = 7-15) within 
1 hour.  The TDP-43Q331K vehicle group buried significantly fewer marbles than the TDP-
43WT group, and the TDP-43Q331K riluzole group buried significantly less marbles than 
both the TDP-43WTand non-transgenic group. 
 
4.4.11. End of Study Riluzole Concentrations 
Riluzole levels in blood and brain were analysed at the end of the riluzole study in mice 
from the dosed group (table 4.2).  Riluzole levels in blood were found to be very similar 
to the earlier PK study (116.2 ± 54.4nM peak in the PK study vs 123.9 ± 54.4nM at the 
end of the study) and the brain concentrations recorded here were at similar levels to 
those found in the PK study trough spinal cord reported in section 5.4.2. (220.8 ± 43.8nM 
PK trough spinal cord vs 194.7 ± 115.3nM in brain).  These results indicate that the CNS 
riluzole levels were maintained throughout the study. 
Table 4. 3: Riluzole concentrations (uHPLC/TOF Mass spec).  Mean riluzole 
concentrations in the blood and spinal cord of TDP-43Q331K mice dosed with 240µg/ml in 
drinking water from 1-6 months of age (blood n = 2, brain n = 5). 
Blood (nM) Brain (nM) Brain/Blood ratio 
123.9 (±54.4) 194.7 (±115.3) 2.05 (±0.5) 
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4.5. Discussion 
4.5.1. Mass Spectrometry of Riluzole 
As seen in figure 4.3, riluzole batch 2 (from a previous study) was found to have a higher 
peak of impurity at 7.9mins retention time, when compared to batch 1.  The expert 
opinion of the mass spectrometer was that both samples were at least 95% riluzole 
which correlated with the data sheets provided by the supplier.  However, batch 1 had 
higher purity and was therefore used for this study. 
 
4.5.2. Riluzole PK Study 
The purpose of the PK study was to assess the CNS penetrance of the riluzole and ensure 
that the drug exposure was comparable to that in MND patients. 
In patients, riluzole levels within the CNS have not been measured as far as we are aware 
(for example in cerebrospinal fluid).  However, plasma levels have been measured in 
several studies.  Steady state plasma concentrations are reached within 5 days of dosing 
in patients (Bryson et al., 1996), with highly variable serum concentrations (which 
correlate highly with plasma levels) among individuals (Groeneveld et al., 2008). 
In healthy volunteers, mean peak serum concentrations of riluzole were reported as 
0.173-0.269mg/L (0.73-1.15µM) (Le Liboux et al., 1999).  In MND patients, mean trough 
to peak serum levels of riluzole were 0.11-0.432mg/L (0.47-1.84µM) and minimum 
trough to peak serum levels of riluzole were 0.013-0.034mg/L (0.056-0.145µM) 
(Groeneveld et al., 2001). 
In the PK study carried out here, whole blood levels of riluzole were measured in the 
mice, which are assumed to be comparable to serum and plasma levels, as is found with 
many drugs (Flanagan et al., 2003).  The mean trough-peak range of riluzole 
concentrations in the blood was 78.7-116.2nM (0.0787-0.1162µM).  Therefore, 
although relatively low, the blood concentrations found in this study were within the 
minimum peak and trough range found in patients (0.056-0.145µM) (Groeneveld et al., 
2001), as was the end of study mean blood concentration of riluzole (0.123µM). 
Peak levels were higher than trough levels in the spinal cord and blood, showing that 
the mice consume more of their drinking water, and therefore more riluzole, during the 
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night.  The high spinal cord/blood ratio in the PK study and brain/blood ratio in the end 
of study riluzole concentrations indicate that riluzole is highly CNS penetrant.   
Overall, the PK study data suggest that an optimal riluzole concentration may require a 
higher dose in the TDP-43Q331K mice.  However, this must be approached with caution as 
a high dose in SOD1G93A mice has been shown to have a sedative effect (in-house data). 
 
4.5.3. Neuroscoring 
In chapter 2, neuroscoring was assessed using criteria based on the SOD1G93A mouse 
model.  However, differences between TDP-43Q331K, TDP-43WT and non-transgenic mice 
were not found by this neuroscoring method until after differences were evident on 
both rotarod and catwalk measures, suggesting that an adjusted neuroscoring system 
may be required. 
A new assessment protocol was created for this study and the data show consistent 
findings with low variability, signifying an effective system. 
No differences were identified between the riluzole and vehicle TDP-43Q331K groups, 
however, a clear phenotypic progression can now be identified through neuroscoring, 
in which forelimb tremor is evident from early on in the model but does not appear to 
progress, whilst hindlimb resting tremor progresses rapidly to a consistent continuous 
resting tremor at 6 months of age, and walking progresses from normal to a severe 
waddling gait in most mice by 6 months of age. 
Since forelimb tremor shows little change with disease, measurement of hindlimb 
resting tremor and walking (overall neuroscore) would be sufficient in measuring 
disease progression in the TDP-43Q331K model. 
 
4.5.4. Body Weight and Rotarod 
Body weight and rotarod data showed no significant differences between the TDP-
43Q331K riluzole and vehicle groups but there was a very slight trend for increased weight 
and decreased rotarod performance in the riluzole group.     
Riluzole has been shown to reduce glutamate release and facilitate glial uptake of 
glutamate (Banasr et al., 2010, Chowdhury et al., 2008), in turn increasing glucose 
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oxidative metabolism and glutamate/glutamine cycling (Chowdhury et al., 2008), and 
therefore affecting metabolism.  A study in rats showed a 2mg/kg dose of riluzole 
decreased baseline metabolic rate and motor activity (Faustino and Donnelly, 2006).  
One or both of these may be occurring in the TDP-43Q331K riluzole group, and resulting 
in their slightly increased weight. 
In comparison to the data presented in chapter 2 (see sections 2.4.4. and 2.4.5.), the 
weight and rotarod data showed a considerably lower mean weight and increased 
rotarod performance from the beginning of the study at 5 weeks of age (weight: 
17.7±1.3 in TDP-43Q331K  vs 15.5±1.2 in TDP-43Q331K vehicle; rotarod: 230.1±50.8 in TDP-
43Q331K vs 264.5±49.6 in TDP-43Q331K vehicle), to the end of the study at 23 weeks of age 
(weight: 34.9±3.7 in TDP-43Q331K vs 30.1±5.1 in TDP-43Q331K vehicle; rotarod: 105±30.7 in 
TDP-43Q331K vs 182.5±63.3 in TDP-43Q331K vehicle).  The reason for differences in weight 
and rotarod between the two studies is unknown but could relate to the intake of DMSO 
in the drinking water, the absence of male mice in the room or genetic drift within the 
colony.  It will be important to monitor inter-study variability between control groups 
over time as has been reported for the SOD1G93A mouse model (Mead et al., 2011).  
 
4.5.5. Catwalk Gait Analysis 
No differences were found between the TDP-43Q331K riluzole and vehicle groups, at any 
time point.  Differences were found between the TDP-43Q331K groups and control groups.  
Catwalk gait analysis has not been reported previously in the TDP-43Q331K mice, but was 
described in chapter 2 (section 2.4.8.) of this thesis.   
Duration (time taken to cross the catwalk) is significantly increased in the TDP-43Q331K 
groups compared to control groups at 3 and 6 months of age, as found in chapter 2.  
Forelimb BOS showed no significant differences but a tendency towards increased BOS 
in the TDP-43Q331K mice compared to controls, as supported by findings in chapter 2, in 
which forelimb BOS increased with age in the TDP-43Q331K mice, with the difference 
becoming significant at 10 months of age.  Hindlimb BOS increased in the TDP-43Q331K 
compared to the control groups, becoming significantly larger by 6 months of age, as 
was also found in chapter 2.  These findings signify a considerably slower walking speed 
in the TDP-43Q331K, with a wider stance. 
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Diagonal walking (stepping using diagonal paws) is the most commonly used stepping 
pattern in mice, used approximately 80% of the time (Gruntman et al., 2007).  In the 
TDP-43Q331K mice, they use diagonal stepping significantly less compared to the control 
groups at 3 and 6 months of age, using significantly more three and four-paw stepping 
at the same ages.  Interestingly, these findings appeared earlier than in the cohort of 
mice described in chapter 2, in which these parameters were not significantly different 
until 10 months of age, possibly due to smaller group sizes.  It appears that the TDP-
43Q331K mice are becoming more unsteady and reliant on support from a third or even 
fourth paw whilst walking and this was more evident in this study, compared to the 
previous characterisation study. 
Forelimb and hindlimb swing time were significantly increased in the TDP-43Q331K groups 
compared to controls at 6 months of age, as was found in chapter 2.  Tendencies towards 
an increased forelimb and hindlimb stride length were found in the control groups over 
time, whilst stride length in the TDP-43Q331K groups remained the same, however, 
differences were significant at these time points in the earlier study (figures 2.11 and 
2.13).  Forelimb and hindlimb duty cycle were increased in the TDP-43Q331K groups 
compared to controls at 3 and 6 months of age but were only significant at 6 months of 
age in chapter 2.   
Overall, the catwalk gait analysis findings were very similar to those found previously 
(chapter 2), showing consistency in findings between studies in these mice.  It appears 
that dosing of riluzole did not have any therapeutic effects detectable by gait analysis. 
 
4.5.6. Electrophysiology 
CMAP amplitude, repetitive stimulation and EMG were measured in all groups at 1, 3 
and 6 months of age. 
 
4.5.6.1. CMAP  
CMAP amplitude quantifies the depolarisation of stimulated muscle fibres and a 
reduction in CMAP correlates with loss of functional motor axons or muscle fibres. A 
reduction in CMAP amplitude is often seen in MND patients following degeneration of 
motor axons (Benatar et al., 2016).  
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No difference was found in CMAP amplitude between the TDP-43Q331K riluzole and 
vehicle groups.  CMAP amplitude was significantly lower in both TDP-43Q331K groups 
compared to the control group at 1, 3 and 6 months, suggestive of a loss of functional 
motor axons/fibres, as has been demonstrated previously in the SOD1G93A mouse model 
(Mancuso et al., 2011b, Alves et al., 2011). 
CMAP amplitude increased with age initially, and then plateaued.  This initial increase 
may be due to an increase in muscle fibre size as the mice develop and a similar pattern 
with age has been documented in another mouse model (Verhamme et al., 2011). 
 
4.5.6.2. Repetitive Stimulation 
Repetitive stimulation provides a measure of the fidelity of neuromuscular transmission. 
In healthy subjects, no decrement in response will be seen across stimuli; in MND a 
decrement is seen in most patients (Wang et al., 2001, Iwanami et al., 2011, Killian et 
al., 1994).  The exact aetiology behind this observation remains unclear but is usually 
interpreted as representing the presence of immature neuromuscular junctions 
(Iwanami et al., 2011). 
A previous study using a mouse model of SMA found that repetitive stimulation at 10Hz 
showed a decremental response (Bogdanik et al., 2015) but no records of repetitive 
stimulation in a mouse model of MND could be found.  In this study there was no obvious 
change in response to repetitive stimulation with age in any of the control groups, and 
no obvious decrement across stimuli was evident in the control groups at 3 or 10Hz.  It 
is probable that the decrement seen at 50Hz in the control groups at 6 months was 
related to a change in confirmation of the muscle due the tetanic stimulus response. 
In comparison, the TDP-43Q331K mice showed a significant decrement in response at all 
frequencies and ages, as is consistent with findings in MND patients.  This is suggestive 
of a reduction in the safety factor at the neuromuscular junction, potentially a sign of 
recent reinnervation in which endplates have a lower safety factor (Wang et al., 2001, 
Iwanami et al., 2011) or a lack of acetylcholine replacement after depletion (Iwanami et 
al., 2011).   
It appears that the decremental response was less severe in the TDP-43Q331K riluzole 
group, compared to the vehicle group at 3 and 6 months of age, indicative of a treatment 
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effect.  It is possible that this treatment effect could have been clarified by putting more 
stress on the neuromuscular junction (i.e. a higher frequency of repetitive stimulation).  
When this was attempted at 50Hz, it is believed that the frequency was too high, 
affecting the confirmation of the limb.  A compromise of 20 or 30Hz may have been a 
more appropriate frequency to investigate. 
If these findings do demonstrate a treatment effect, it is interesting that no effect was 
found in any motor function tests such as the catwalk or rotarod.  However, it has been 
found in MND patients that although riluzole extends survival, it does not improve 
functional outcome measures including motor function, lung function, fasciculations, 
muscle strength and motor symptoms (as stated in the Summary of Product 
Characteristics for riluzole).  It is possible therefore that any treatment effect at the 
neuromuscular junction was too subtle to detect using motor function tests.  
It is likely that the repetitive stimulation decrement is reduced in the riluzole group 
because less NMJs are unstable due to a reduction in denervation/reinnervation events, 
in which the safety factor for action potential conduction is impaired.  Unfortunately 
there is no NMJ immunostaining to support this theory but it is an interesting topic for 
further research. 
There are a number of ways in which riluzole may reduce NMJ instability.  Riluzole 
affects many neural mechanisms and the mechanisms by which it extends life in MND 
patients remain unclear.  The mechanisms of action include: reduced glutamate release 
from the pre-synaptic terminal, inhibition of voltage-gated calcium currents, 
potentiation of calcium-dependent potassium currents, inhibition of voltage-gated 
potassium current, inhibition of sodium currents (both persistent and fast) (Bellingham, 
2011) and blocking of muscle ACh receptors in vitro (Deflorio et al., 2012). 
MND patients are recorded as having increased levels of persistent sodium and a 
decreased potassium conductance (Vucic and Kiernan, 2006).  Riluzole reduces 
hyperexcitability, which increases the threshold voltage, requiring further 
depolarization in order to produce an action potential (Kuo et al., 2006, Del Negro et al., 
2002).  This reduction in hyperexcitability is as a result of decreased sodium influx and 
potassium efflux, reducing the occurrence of over-activation of the neurons and in turn, 
reducing neurodegeneration, preventing NMJ instability (Stys et al., 1992).  Hence, 
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riluzole has a neuroprotective effect, which reduces the number of unstable NMJs, 
increasing the muscle’s ability to maintain a response to repetitive stimulation. 
A second factor is whether the dose of riluzole is high enough. As shown in table 4.1 we 
have achieved reasonable levels of riluzole in the CNS, but the levels of riluzole may be 
much higher in the CNS of patients judging by the levels in the systemic circulation in 
the two species (blood in mice, serum in patients).  This raises the question of whether 
a higher dose of riluzole may show a more profound difference.  However, in-house 
studies have found that high doses of riluzole have a sedative effect in SOD1G93A mice so 
higher doses must be approached with caution.  It is also possible that an alternative 
method of dosing may be more effective and should be considered. 
 
4.5.6.3. EMG 
Spontaneous EMG activity is not specific to motor neuron loss and may be seen in a 
range of pathologies such as neuropathies and myopathies (although fasciculation 
potentials are not seen in myopathic conditions).   
Positive sharp waves have been found in the SOD1G93A (Miana-Mena et al., 2005) and 
wild type SOD1 (PeledKamar et al., 1997) mouse models. However it must be considered 
that normal healthy mice may have some nerve injury from normal everyday life, as 
found in healthy people (Falck and Alaranta, 1983). 
Insertional activity occurs due to discharge potentials as the cell membrane is disrupted 
by the EMG needle.  Heightened insertional activity is considered a sign of denervation 
(Shi et al., 2014) and was not found in the non-transgenic or TDP-43WT mice, but was 
identified in the TDP-43Q331K mice.  Heightened insertional activity has also been 
identified previously in a wild type SOD1 mouse model (PeledKamar et al., 1997) and a 
knockout SOD1 mouse model (Shi et al., 2014).   
Fibrillations and fasciculations are a classic electrophysiological finding in MND and 
indeed in mouse models of MND (Costa et al., 2012, Azzouz et al., 1997, Miana-Mena et 
al., 2005). The previous study of TDP-43Q331K mice reported fibrillation potentials (Arnold 
et al., 2013) and we also found both fasciculation and fibrillation potentials in TDP-
43Q331K mice in this study.  While it is a little surprising to observe spontaneous activity 
in the wild type and non-transgenic groups, including positive sharp waves, fasciculation 
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and fibrillations have been recorded in healthy people (Falck and Alaranta, 1983).  It is 
possible that this activity related to age related changes or minor injuries sustained over 
time in cages with other mice.  It is difficult to quantify the amount of spontaneous 
activity as it can be subjective and also liable to sampling error, given the small recording 
area of the EMG needle.  As a result we did not attempt quantification of spontaneous 
activity.  However, we did not observe increased insertional activity or fasciculation 
potentials in the TDP-43WT mice.  
Overall, the spontaneous activity was evident but was not consistently found in all mice 
tested.  This may be due to some reinnervation, as the phenotype does not progress 
rapidly.  Carrying out EMG at earlier time points would have allowed us to investigate 
this further but the EMG needle is relatively large (30 gauge) and so it was deemed safest 
to only carry out EMG during terminal procedures (at 6 months of age). 
Ultimately, the increased spontaneous activity in the TDP-43Q331K group is in keeping 
with the MND phenotype. 
 
4.5.7. Marble Burying 
As described previously, marble burying is believed to be a surrogate marker of normal 
digging behaviour in mice (Deacon, 2006).   
As was found in a previous study of non-transgenic mice (Egashira et al., 2008), riluzole 
had no impact on marble burying behaviour, as demonstrated by no difference in marble 
burying activity between the TDP-43Q331K riluzole and vehicle groups. 
The TDP-43Q331K groups buried fewer marbles than the TDP-43WT and non-transgenic 
groups, suggesting a decrease in normal digging behaviour.  This was evident in the mice 
during the task, as the TDP-43Q331K mice would often sit motionless and show no signs 
of exploration.  It is possible that this lack of digging could be due to motor dysfunction, 
however, the motor phenotype in this model is mild so that appears unlikely, and little 
attempt at digging was observed in the TDP-43Q331K mice.  The lack of digging behaviour 
is more likely to signify a cognitive phenotype, namely apathy, or a lack of interest in 
digging.  10-15% of MND patients will develop a diagnosis of MND-FTD, exhibiting as 
signs such as inappropriate behaviour, repetitive behaviour, and/or apathy (Chan et al., 
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2015).  Overall, the lack of marble burying activity in the TDP-43Q331K mice may be 
indicative of an FTD phenotype. 
 
4.6. Conclusion 
This study has allowed further characterisation of the TDP-43Q331K mice and highlighted 
a potential FTD phenotype.  The study has also allowed us to define a more reliable 
neuroscoring system for the TDP-43Q331K and TDP-43WT colonies.  Riluzole appeared to 
have no significant effect on gross motor phenotype in the TDP-43Q331K mice, but did 
seem to improve the NMJ safety factor, reducing the repetitive stimulation decrement 
and posing interesting ideas for future studies.  Further investigation using 
immunohistochemistry is needed to determine whether riluzole treatment influences 
the disease pathology.  
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5. 31P-MRS Imaging 
5.1. Introduction 
5.1.1. Energy Metabolism in MND Patients 
Most MND patients lose weight during their disease course, partially due to muscle loss 
and lowered food intake (Kasarskis et al., 1996, Slowie et al., 1983); but also, at least in 
some patients, due to an increased basal metabolic rate (hypermetabolism) (Dupuis et 
al., 2011).  Hypermetabolism, along with dysphagia, can make it very hard for MND 
patients to maintain weight, however, maintenance of weight is crucial, as weight loss 
correlates with morbidity and mortality (Kasarskis et al., 1996, Koerner et al., 2013) in 
MND patients. 
It is widely accepted that many MND patients become hypermetabolic, but it appears 
that it is not ubiquitous, and it is unclear which subgroups of patients are at risk.  
Estimates of the proportion of patients who are hypermetabolic range widely from 50% 
(Bouteloup et al., 2009), 62% (Desport et al., 2005), and 52% in purely sporadic cases; to 
100% in familial cases (Funalot et al., 2009). 
The underlying cause of hypermetabolism in MND is unknown and it appears that 
several metabolic pathways/elements may be implicated, including insulin signalling, 
glycolysis, and fatty acid oxidation (Raman et al., 2015).  Many investigations have 
identified mitochondrial dysfunction as a key contributor to hypermetabolism in MND.  
In muscle biopsy samples from MND patients, mitochondria have been found to have 
increased volume and poor morphology (Siklos et al., 1996) with a tendency to 
pathological grouping in the lumbar spinal cord (Sasaki and Iwata, 1996) and 
sarcolemma of skeletal muscle (Afifi et al., 1966).  Mutations and deletions in 
mitochondrial DNA have been found in patients (Comi et al., 1998, Dhaliwal and Grewal, 
2000, Wiedemann et al., 2002) and axonal transport of mitochondria is often disrupted 
(De Vos et al., 2008). 
It is also possible that the phosphocreatine (PCr) pathway is affected in MND.  It has 
been regularly suggested that patients have increased levels of phosphocreatine kinase, 
suggestive of increased PCr pathway activity or muscle damage (Williams and Bruford, 
1970, Felice and North, 1998, Rafiq et al., 2016).  This has led to pre-clinical trials of 
creatine supplementation for the treatment of MND (Snow et al., 2003, Andreassen et 
 171 
al., 2001), however, these results have not translated through to beneficial effects in 
human clinical trials (Groeneveld et al., 2003, Shefner et al., 2004). 
It is likely that, whilst some energy pathways are disrupted in MND, such as glycolysis 
and fatty acid oxidation, activity of other components such as the PCr pathway may be 
upregulated in a compensatory manner, in order to provide the energy required for life. 
 
5.1.2. 31P-MRS  
Magnetic resonance spectroscopy (MRS) is an imaging method which can assess the 
molecular content of living tissue based on magnetic resonance signal characteristics.  
Some phosphorous-containing compounds can be measured using 31P-MRS, providing 
comparative levels of several compounds including PCr, inorganic phosphate (Pi), α-
adenosine triphosphate (α-ATP), β-ATP, and γ-ATP at the positions stated in table 5.1.  
Table 5. 1: Spectral position for each of the main 31P-MRS metabolites. 
Metabolite Spectral position (ppm) 
PCr 0 
Pi 5.14 
γ-ATP -2.389 
α-ATP -7.529 
β-ATP -16.072 
The phosphocreatine pathway is a key source of rapidly available ATP (the energy 
currency of the cell).  The enzyme phosphocreatine kinase is the catalyst for the 
reversible conversion of PCr + ATP  Pi + creatine + adenosine diphosphate (ADP).  A 
calculation based on the distance between peaks of Pi and PCr can be used to calculate 
intracellular pH (Ren et al., 2015, Petroff et al., 1985). 
 
5.1.3. 31P-MRS in MND Patients 
A number of studies using 31P-MRS of muscle have been carried out in MND patients, 
one of which applied the imaging after aerobic and ischaemic muscle contraction in 10 
patients vs 38 controls (Grehl et al., 2007).  The study showed that consumption of PCr 
during both exercise conditions was significantly lower in MND patients compared to 
controls, and hypothesised several alternate mechanisms for this observation including: 
a decrease in substrate availability; a decreased energy demand; or defective energy 
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metabolism.  The ratio of PCr/ATP was significantly higher in patients than in controls.  
The authors stated that it was unclear whether this was due to increased PCr, decreased 
ATP levels, or both.  They concluded that they could not confirm mitochondrial 
dysfunction using this method.  Another study of 31P-MRS in MND patients using an 
exercise protocol showed pH and PCr to be lower; and Pi to be higher in patients 
compared to controls during the exercise phase but not during the recovery phase. 
However, none of these metabolic responses to exercise showed  statistically significant 
differences (Sharma et al., 1995).   
Another study was carried out in patients at rest, in which the triceps surae was studied 
and no differences in metabolites were found between patients and controls (Ryan et 
al., 2014).  However, the groups were small (6 patients, 7 controls) and unmatched.   
 
5.1.4. Energy Metabolism in Mouse Models of MND 
Studies of various mouse models of MND have demonstrated evidence of 
hypermetabolism with increased oxygen consumption (Dupuis et al., 2004) and reduced 
body mass (Dupuis et al., 2004, Wong et al., 1995), despite equal or increased calorie 
intake compared to control animals (Dupuis et al., 2004).   
At the muscle level, oxygen consumption has been shown to be increased in SOD1G93A 
mice using a Clark electrode in an oxygraphic cell containing muscle fibre bundles 
(Leclerc et al., 2001) but unchanged at the spinal cord level, as measured by a 
respirometer (Wendt et al., 2002).  The SOD1G93A mouse model has also demonstrated 
reduced ATP synthesis in the brain and spinal cord measured using a luciferase/luciferin-
based system (Mattiazzi et al., 2002) and muscle using an enzymatic assay (Derave et 
al., 2003).  However, in the SOD1G86R mouse model, ATP synthesis in the spinal cord was 
not significantly different from control mice (Mattiazzi et al., 2002).  In another study, 
energy use in muscle appeared to be derived preferentially from lipids rather than 
glucose at the presymptomatic stage (Palamiuc et al., 2015).  These contrasting results 
could support the hypothesis that patterns of energy metabolism dysfunction may differ 
with genotype.  
From an environmental perspective, diet has been shown to affect survival and disease 
in mouse models, with a high energy diet increasing mean survival by 20% and reducing 
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loss of motor neurons (Dupuis et al., 2004).  Meanwhile, long term calorie restriction 
appears to cause earlier disease onset and hasten disease progression (Hamadeh et al., 
2005), as does short term calorie restriction, when compared to an ad libitum diet 
(Hamadeh and Tarnopolsky, 2006). 
As shown in patients, many mouse models of MND appear to show changes in 
morphology of mitochondria.  In brainstem, cerebellum and forebrain of mice with high 
expression of human SOD1, mitochondria were swollen, with dilation of the 
intermembrane space and swollen cristae, from 30 weeks of age compared to controls.  
Axons showed vacuolated mitochondria and older mice had aggregates of degenerating 
mitochondria at symptomatic stages of disease (Jaarsma et al., 2000). 
Motor neuronal mitochondria in the spinal cords of many mouse models of MND at 
onset/symptomatic stages have been found to be aggregated (Xu et al., 2010), swollen 
(Jaarsma et al., 2001, Bendotti et al., 2001, Wong et al., 1995) and vacuolated (Xu et al., 
2010, Bendotti et al., 2001, Higgins et al., 2003, Kong and Xu, 1998) with fewer, 
disorganised cristae (Xu et al., 2010, Bendotti et al., 2001, Wong et al., 1995, Dalcanto 
and Gurney, 1995, Kong and Xu, 1998) and extended, leaking and even unravelled outer 
membranes (Higgins et al., 2003, Wong et al., 1995, Dalcanto and Gurney, 1995, Kong 
and Xu, 1998). 
The morphology of mitochondria in muscle of mouse models of MND has been less 
extensively investigated.  A SOD1G93A mouse model showed abnormalities in 
mitochondria at the neuromuscular junction and not in muscle (Gould et al., 2006), 
whereas another SOD1G93A mouse model showed clustered, swollen and vacuolated 
mitochondria with abnormal cristae at the end stage of disease (Dobrowolny et al., 
2008).  These defects in mitochondrial morphology and functionality increase 
generation of free radicals, causing increased oxidative stress, and impairing function of 
the electron transport chain, as measured histochemically in SOD1G93A mice (Bendotti et 
al., 2001, Shaw, 2005). 
31P-magnetic resonance spectroscopy has not yet been investigated in mouse models 
of MND.  However, a study which measured PCr in SOD1G93A mice by enzymatic analysis 
with standard fluorometric assays, found significantly reduced PCr in SOD1G93A mice 
compared to controls (Derave et al., 2003). 
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One study using enzymatic analysis found that creatine levels in muscle were higher in 
SOD1G93A mice compared to control mice (Derave et al., 2003).  However, in spinal cord, 
creatine kinase levels were significantly decreased (Wendt et al., 2002).  In contrast to 
findings in patients, creatine supplementation in mouse models of MND was shown to 
improve survival and disease progression (Klivenyi et al., 1999, Ikeda et al., 2000). 
Overall, it appears that SOD1 mouse models of MND exhibit deficits in energy 
metabolism which may be partially ameliorated by increased availability of energy 
substrates and many studies suggest this is partly due to mitochondrial dysfunction.  
Clearly, there is energy dysfunction in both MND patients and SOD1 mouse models, and 
a large proportion of studies have focused on mitochondrial function.  As demonstrated 
with the lack of translation of creatine as a therapeutic intervention, it must be 
considered that findings may not always translate between mouse models and patients, 
but may give an indication of subgroup pathologies.  Little focus has been made on the 
PCr pathway in mouse models of MND and investigation of 31P-MRS in the SOD1G93A 
mouse model would provide the opportunity to fill this gap in knowledge and compare 
findings in the mice with those from patients. 
 
5.2. Aims 
1. To establish a safe protocol for 31P-MRS in mice. 
2. To optimise the MR sequence for 31P-MRS. 
2. To investigate differences in energy metabolism of SOD1G93A mice compared with 
controls using 31P-MRS. 
 
5.3. Materials and methods 
5.3.1. Mice 
5.3.1.1. Ethics Statement 
All mouse experiments were carried out in accordance with the Animals (Scientific 
Procedures) Act 1986 under an appropriate UK Project Licence.  Animals were housed 
and cared for in-house at the University of Sheffield, adhering to the Home Office Code 
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of Practice for the Housing and Care of Animals Used in Scientific Procedures Act (ASPA 
1986) in-house at the University of Sheffield. 
 
5.3.1.2. Transgenic SOD1G93A Mice 
Mice were from a well-established in-house colony of C57BL/6J Ola Hsd SOD1G93A mice 
bred by crossing C57BL/6J Ola Hsd females (Harlan, UK) with males which are 
hemizygous for the SOD1G93A transgene.  Non-transgenic littermates were used as 
control mice.  All mice used for imaging were male. 
 
5.3.1.3. Study Sizes 
For the initial preliminary experiment, one non-transgenic mouse was scanned at 106 
days of age.  For the second preliminary experiment, one 113 day old non-transgenic, 
and one 110 day old SOD1G93A mouse were scanned. 
For the main pilot study, 6 SOD1G93A mice were scanned together with 6 non-transgenic 
littermates for the 36 day time point.  However, all 12 mice were culled due to welfare 
issues (see section 5.4.4).  Therefore, a new cohort was established for the 73 day scan 
of 6 SOD1G93A mice and 6 non-transgenic mice.  By the 115 day time point 3 SOD1G93A 
mice remained and 3 non-transgenic mice.  The details for the changes in sample size 
are given below. 
For the follow up experiment (using a narrower spectral width and a cotton blanket with 
heat pad), 2 SOD1G93A mice were scanned together with 2 non-transgenic mice at 49-50 
days of age.  
 
5.3.2. Anaesthesia and Physiological Monitoring of Mice 
5.3.2.1. Original Method using Heat Pad 
Animals were placed on a sponge bed in a custom built Perspex magnet capsule and 
imaged under gaseous anaesthesia (1–2%, flow rate 1.0 L/min oxygen and nitrous oxide 
continuous inhalation through a nose cone). Anaesthetic level was controlled on the 
basis of respiratory parameters using a pressure sensitive pad under the subject’s chest 
(SAII Model 1025 monitoring and gating system, SAII, USA).  
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Inside the capsule, a non-magnetic ceramic heated hot air system (SAII - MR-compatible 
Heater System for Small Animals, SAII, USA) and rectal temperature probe (SAII - MR-
compatible Heater System for Small Animals, SAII, USA), integrated into the 
physiological monitoring system maintained and monitored the temperature of the 
animal.   
Post-scanning, animals were placed in an incubator at 31-32˚C for 10-30 minutes whilst 
they recovered from the anaesthesia. 
 
5.3.2.2. Modified Heat Pad Protocol Covering Tails  
After some of the animals developed tail necrosis issues thought to relate to thermal 
injury (see section 5.4.4.), wet gauze was placed over the tail of the mice to reduce the 
temperature and increase humidity.  All other aspects of the protocol remained the 
same. 
 
5.3.2.3. Modified Heat Pad Protocol Placing Pad Underneath 
After further issues with tail necrosis, the procedure was abandoned as unsafe and an 
alternative heating method was used, in which a heat pad (CWE, PA, USA) was placed 
under the sponge bed of the mouse within the scanner, and a rectal temperature probe 
(Harvard, UK) was used to supply feedback to the monitoring system (CWE, PA, USA). 
 
5.3.2.4. Warm Water System  
Due to further problems with overheating, a warm water system was trialled.  The 
custom built Perspex magnet capsule had an incorporated hollowed-out area to allow 
passage of a water tube under the mouse.  This system was plugged in to a water bath 
(Heating Circulator SC150-S5P, ThermoFisher Scientific, UK), warming the water to 60˚C, 
which then passed under the mouse to maintain body temperature.  The rectal probe 
and pressure pad were used to detect body temperature and respiratory rate 
respectively.  However, this method was insufficient. 
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5.3.2.5. Heat Pad Method with Cotton Blanket 
A cotton blanket was wrapped around the mouse with the pressure pad to the chest.  
The heat pad was then placed over the back of the mice (with the cotton blanket 
protecting the fur of the mice from the heat pad).  The rectal probe provided 
temperature feedback (CWE, PA, USA). 
 
5.3.3. Scanning Parameters 
The animals were scanned on a 7 Tesla MRI system (Bruker BioSpecAVANCEII, 310mm bore, 
B/C 70/30), with pre-installed 12 channel RT-shim system (B-S30) and fitted with an 
actively shielded, 116mm inner diameter, water cooled, 3 coil gradient system (Bruker 
BioSpin MRI GmbH B-GA12S. 660 mT/m maximum strength per axis with 80µs ramps). 
 
5.3.3.1. Long TR Method 
A 31P single pulse sequence utilising a block excitation pulse was used, with centre 
frequency 121.57MHz, and an acquisition time of 102ms, with repetition time (TR) of 4s.  
The spectral width was 164ppm/20000Hz with 2048 points and 450 averages, giving a 
spectral resolution of 4.88Hz/pt. 
The whole brain of each mouse was scanned using a 2cm diameter surface coil.  
Saturation slices were used to suppress signal from surrounding muscle.  The total 
scanning time was 30 minutes. 
 
5.3.3.2. Short TR Method 
Short TR scans were carried out using the same parameters, except with a shorter 
repetition time of 400ms, meaning we could increase averaging to 4500 in an effort to 
improve signal to noise ratio. 
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5.3.3.3. Narrower Spectral Width Method 
A 31P sinc3 pulse sequence was used with an acquisition time of 500ms, flip angle 45˚, 
TR 5s, spectral width 41.13ppm/20000Hz with 2500 points and 128 averages, giving a 
spectral resolution of 1Hz/pt.  The total scanning time was 10 minutes. 
 
5.3.4. Data Processing 
Firstly, a manually identified phase shift was applied to all spectra using Matlab 7 
(Mathworks Inc, USA).  Spectra using the same scanning parameters had the same phase 
shift applied.  31P-MRS spectra were normalised along the X-axis to align the PCr peaks 
of each trace.  Peak values were then extracted for PCr, Pi, γ-ATP, α-ATP and β-ATP (see 
table 5.1).  The three ATP-peaks represent each of the phosphates bound to adenosine. 
For visual comparison of the average spectra, the PCr peak was normalised to 1 because 
some scans produce spectra in which all peak values are high/low, so normalising to the 
PCr peak height compensates for this.  Conventionally, in 31P-MRS, the PCr peak is used 
for this purpose. 
ATP was measured using the β-ATP peak. 
Integrals of peak values, ratios of peak values, and comparisons of ratios and integrals 
were calculated and plotted using Graphpad Prism 6.0.  Ratios and integrals for the 
transgenic and non-transgenic groups were compared using unpaired t-tests.  When 
multiple t-tests were carried out, a Bonferroni correction was applied. 
 
5.4. Results 
5.4.1. First Preliminary Scan 
Firstly, a single mouse was scanned using the 31P-MRS surface coil.  Whole brain 
acquisition was performed for 30 minutes to ensure a spectrum could be obtained.  No 
adverse events occurred. 
Figure 5.1 shows the first spectrum obtained, with no post-processing of the data.  Peaks 
are identifiable for phosphomonoesters (PME), Pi, PCr, γ-ATP, α-ATP and β-ATP.  The x-
axis was not aligned to the correct position and is approximately 8ppm shifted to the 
right due to field drift in the MR system. 
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Figure 5. 1: Raw 31P-MRS spectrum from whole brain of a 106 day old non-transgenic 
mouse (TR = 4s). 
 
5.4.2. Second Preliminary Scans 
To ensure the scans could be replicated and the protocol ran smoothly, a second set of 
31P-MRS scanning was carried out on whole brain for 30 minutes on a pair of mice, one 
transgenic; one non-transgenic.  No adverse events occurred. 
Figure 5.2 shows the non-transgenic spectrum obtained, with no post-processing of the 
data.  Peaks are identifiable for PME, Pi, PCr, γ-ATP, α-ATP and β-ATP.  The x-axis was 
not aligned to the correct position and is approximately 3ppm shifted to the right due 
to drift in the MR system. 
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Figure 5. 2: Raw 31P-MRS spectrum from whole brain of a 113 day old non-transgenic 
mouse (TR = 4s). 
Figure 5.3 shows the SOD1G93A spectrum obtained, with no post-processing of the data.  
As with the non-transgenic spectrum, peaks are identifiable for PME, Pi, PCr, γ-ATP, α-
ATP and β-ATP and the x-axis was not aligned to the correct position and is 
approximately 3ppm shifted to the right. 
 
 
Figure 5. 3: Raw 31P-MRS spectrum from whole brain of a 110 day old SOD1G93A mouse 
(TR = 4s). 
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The spectra collected were similar in height, shape and noise, providing confidence in 
the reproducibility of the scans, and the protocol had produced no adverse events so 
appeared sufficient to begin a pilot study, comparing whole brain spectroscopy in 
SOD1G93A and non-transgenic mice. 
 
5.4.3. Pilot Study 36-Day Scanning 
Six pairs of mice were scanned using a 31P-MRS surface coil placed to provide coverage 
of the whole brain.  It was noted that, over time, noise in the spectra increased.  This 
was thought to represent a physical effect due to the increase in temperature of the 
coil, caused by the hot air flow used to maintain the body temperature of the mice.  
Therefore, an ice pack was applied between scans to reduce the temperature of the coil.  
However, it is unknown what effect this warming of the coil may have had on the 
average spectra. 
When normalised to the PCr peak height, the spectra of the transgenic brain appeared 
to show higher Pi, higher γ-ATP and lower α-ATP compared to the non-transgenic brain 
(figure 5.4).
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However, no obvious differences could be extrapolated from the PME, PDE and β-ATP peaks.   
PME: phosphomonoesters; Pi: inorganic phosphate; PDE: phosphodiesters; PCr: phosphocreatine; gATP: γ-ATP; aATP: α-ATP; bATP: β-ATP.  Peak height 
of PCr normalised to 1.  
To compare peaks quantitatively, peak height ratios and integrals for PCr, Pi and ATP (β-ATP) were derived. 
Peak height ratios (figure 5.5) showed no significant differences between the spectra of SOD1G93A and non-transgenic mice for any of the ratios Pi/PCr 
(non-transgenic 0.71±0.10 vs SOD1G93A 0.71±0.09), ATP/Pi (non-transgenic 0.65±0.11 vs SOD1G93A 0.63±0.09) and ATP/PCr (non-transgenic 0.45±0.06 
vs SOD1G93A 0.44±0.07).  No obvious trends were present. 
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Figure 5. 4: Average 31P-MRS spectra of whole mouse brain at 36 days of age (n = 6), TR 4s. 
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Figure 5. 5: Scatter plot graphs illustrating metabolite peak height ratios in the 
transgenic (Tg) and non-transgenic (NTg) (n = 6) mice groups at 36 days of age. 
Unpaired t-tests showed no significant difference between groups with any of the 
comparisons. 
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Alternatively, integrals of the peaks can be investigated, as this provides a figure for the 
whole peak, taking width of the peak in to consideration rather than just the height.  Due 
to slight magnetic field inhomogeneity some molecules will resonate around an 
approximate frequency, rather than at an exact frequency, and this method accounts 
for molecules resonating slightly above or below the estimated frequency.   
Interestingly, each of the integral graphs (figure 5.6) demonstrates a higher mean 
integral for the SOD1G93A compared to the non-transgenic spectra for PCr (non-
transgenic 1.9x107±4.1x106 vs SOD1G93A 2.2x107±4.6x106), Pi (non-transgenic 
1.6x107±3.3x106 vs SOD1G93A 1.8x107±3.8x106), and ATP (non-transgenic 
5.3x107±1.2x107 vs SOD1G93A 6.5x107±1.2x107).  This appears most marked for ATP.  
However, these differences were not statistically significant. 
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Figure 5. 6: Scatter plot graphs illustrating metabolite integrals for PCr, Pi and ATP in 
the SOD1G93A and non-transgenic (NTg) (n = 6) mice at 36 days of age. 
Unpaired t-tests showed no significant difference between groups with any of the 
metabolites. 
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5.4.4. Adverse Events 
During the week after scanning, several mice developed a necrotic-like appearance to 
the tail. These mice were immediately humanely sacrificed. To determine whether this 
might be caused by air flow in the scanner we scanned a single mouse with its tail 
covered by a wet gauze. This modification to the technique prevented the adverse event 
from occurring, and was used for subsequent scans. 
 
5.4.5. Pilot Study 73-Day Scanning 
Six pairs of mice were scanned at 73 days of age using the 31P-MRS surface coil to obtain 
whole brain coverage.  An ice pack was applied between scans to reduce the 
temperature of the coil.  The tails of the mice were covered with wet gauze in an attempt 
to avoid tail necrosis.  Two mice died during scanning under anaesthesia, reducing the 
number of mice in the non-transgenic group to 4.   
When normalised to the PCr peak, the brain spectra from the transgenic mice appeared 
to show higher PME, Pi, γ-ATP, α-ATP and β-ATP compared to the non-transgenic mice 
(figure 5.7).  There was no difference in PDE.  However, it appears likely that these 
differences in spectra are due to a lower PCr peak in the transgenic spectra, 
consequentially increasing the other peaks when the PCr peaks are normalised to 1.  To 
compare peaks more easily, ratios of peaks heights and integrals of peaks were 
compared. 
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PME: phosphomonoesters; Pi: inorganic phosphate; PDE: phosphodiesters; PCr: phosphocreatine; gATP: γ-ATP; aATP: α-ATP; bATP: β-ATP. Peak height 
of PCr normalised to 1. 
The main pattern evident in the ratios of peak heights at 73 days of age (figure 5.8) is that ATP/PCr (non-transgenic 0.66±0.19 vs SOD1G93A 0.79±0.09) 
appears higher in the SOD1G93A group than in the non-transgenic group.  In contrast, ATP/Pi ratios (non-transgenic 0.61±0.11 vs SOD1G93A 0.61±0.08) 
appear lower in the transgenic group and Pi/PCr (non-transgenic 0.39±0.06 vs SOD1G93A 0.47±0.05) is slightly higher in the SOD1G93A group compared 
to the non-transgenic.   
Although the ATP/PCr ratio initially appears significantly higher in SOD1G93A mice compared to the non-transgenic mice on a student’s t-test (p<0.05), 
the significant difference between the peak height ratio ATP/PCr is no longer significant when calculations are adjusted using a bonferroni correction. 
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Figure 5. 7: Average 31P-MRS spectra of whole mouse brain at 73 days of age (6 SOD1G93A, 4 NTg), TR = 4s. 
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Figure 5. 8: Scatter plot graphs illustrating metabolite peak height ratios in the 
SOD1G93A (n = 6) and non-transgenic (NTg) (n = 4) mice groups at 73 days of age. 
Unpaired t-tests showed no significant difference between Tg and NTg spectra for any 
ratios. 
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Interestingly, each of the integral graphs for 73 days of age (figure 5.9) show a slightly 
higher mean integral for the non-transgenic spectra compared to the SOD1G93A spectra 
for PCr (non-transgenic 2.2x107±1x107 vs SOD1G93A 1.9x107±8.1x106), Pi (non-transgenic 
1.7x107±8.2x106 vs SOD1G93A 1.6x107±6.8x106), and ATP (non-transgenic 6x107±3x107 vs 
SOD1G93A 5.7x107±2.5x107), showing the opposite trend to the 36-day integral values.  
However, these differences are non-significant. 
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Figure 5.9: Scatter plot graphs illustrating metabolite integrals for PCr, Pi and ATP in 
the SOD1G93A (n = 6) and non-transgenic (NTg) (n = 4) mice at 73 days of age. 
Unpaired t-tests showed no significant difference between groups with any of the 
metabolites. 
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5.4.6. Adverse Events 
During the week after scanning, despite use of the wet gauze, several mice developed a 
necrotic-like appearance to the tail. These mice were immediately humanely sacrificed.  
 
5.4.7. Pilot Study 115-Day Scanning 
Three pairs of mice were scanned at 115 days of age using the 31P-MRS surface coil to 
achieve whole brain coverage.  The core temperature of the mice was maintained using 
a heat pad rather than the hot air system.  One mouse died during scanning as it did not 
survive the anaesthesia and one mouse was scanned using a shorter TR so could not be 
grouped with other scans.  Therefore, data were collected from 4 mice only. 
When normalised to the PCr peak, the spectra of the SOD1G93A brain appeared to show 
lower PME, PDE and Pi compared to the non-transgenic brain (figure 5.10).  However, 
no obvious differences can be observed between the γ-ATP, α-ATP and β-ATP peaks.  To 
compare peaks more quantitatively, ratios of peak heights and integrals of peaks were 
compared. 
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PME: phosphomonoesters; Pi: inorganic phosphate; PDE: phosphodiesters; PCr: phosphocreatine; gATP: γ-ATP; aATP: α-ATP; bATP: β-ATP. Peak height 
of PCr normalised to 1.  
The peak heights data for 115 days of age are shown in figure 5.11 for comparison with previous time points.  However, there are insufficient data to 
draw any conclusions or conduct statistical analysis between groups. 
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Figure 5. 70: Average 31P-MRS spectra of whole mouse brain at 115 days of age (1 SOD1G93A, 3 NTg), TR = 4s. 
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Figure 5. 81: Scatter plot graphs illustrating metabolite peak height ratios in the 
SOD1G93A (n = 1) and non-transgenic (NTg) (n = 3) mice groups at 115 days of age. 
There were insufficient numbers to perform formal statistical testing. 
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The peak integral graphs at 115 days of age are shown in figure 5.12 below.  Again, there 
are no obvious differences between groups and insufficient data to draw conclusions.   
There were insufficient numbers to perform formal statistical testing. 
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Figure 5. 92: Scatter plot graphs illustrating metabolite integrals for PCr, Pi and ATP in 
the SOD1G93A (n = 1) and non-transgenic (NTg) (n = 3) mice at 115 days of age. 
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5.4.8. Adverse Events 
During the week after scanning, several mice developed a necrotic-like appearance to 
the tail and feet. These mice were immediately humanely sacrificed. 
 
5.4.9. Changes in 31P-MRS Over Time 
The changes in 31P-MRS peak height ratios over time show no statistically significant 
changes between 36 and 73 days of age using a two-way ANOVA (figure 5.13).  115 day 
data was not plotted as there was only one mouse in the SOD1G93A group. 
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Figure 5. 103: Changes in 31P-MRS peak height ratios from 36 days of age (SOD1G93A n 
= 6, NTg n = 6) to 73 days of age (Tg n = 6, NTg n = 4).  TR = 4s. 
The changes in 31P-MRS integrals over time also show no statistically significant changes 
between 36 and 73 days of age on a two-way ANOVA (figure 5.14). 
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Figure 5. 114: Changes in 31P-MRS peak integrals from 36 days of age (SOD1G93A n = 6, 
NTg n = 6) to 73 days of age (Tg n = 6, NTg n = 4).  TR = 4s. 
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5.4.10. Water Bath Method 
The water bath tubing within the mouse scanning bed did not cover the whole area in 
which the mouse lays.  Therefore, an attempt was made to maintain body temperature 
of the mouse using this method outside of the magnet, prior to any attempts within the 
magnet, where the temperature is lower.   
Unfortunately, the mouse could not maintain body temperature using this method and 
had to be removed from the bed and placed in the incubator.  This heating method was 
therefore deemed unsafe for use. 
 
5.4.11. 31P-MRS Findings from Final Experiment 
At a much later time point and after several discussions with the vet, project licence 
holder, and head of Biological Services, a final attempt was made to collect 31P-MRS 
data from 2 pairs of mice at 49-50 days of age.  In this experiment the mice were 
wrapped in a cotton blanket before the heat pad was placed over the back of the mouse. 
The mean spectra suggest decreased Pi concentrations in the SOD1G93A mice compared 
to the non-transgenic but no obvious differences in any other peaks.  However, due to 
normalisation to the PCr peak, it is more informative to look at peak ratio values. 
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Spectra are normalised to PCr peaks.  Peaks are identified for Pi, PCr, γ-ATP, α-ATP, and 
β-ATP. 
The ratio values (figure 5.16) show a lower Pi/PCr for the SOD1G93A mice compared to 
the non-transgenic, and a higher ATP/Pi, whilst ATP/PCr looks to be similar.  Considering 
the small numbers of mice in each group (n = 2), statistical differences were not 
calculated. 
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Figure 5. 15: Mean 31P-MRS spectra for 49-50 day old SOD1G93A and non-transgenic 
mice (n = 2). 
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Figure 5. 16: Ratio values for mean spectra of the final set of scanning (n = 2). 
There were insufficient data to calculate statistical differences. 
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5.4.12. Final Heat Pad Method 
With this method, the mouse was wrapped in a cotton blanket before application of the 
heat pad to the back. It was ensured that the heat pad was kept well away from the tail 
of the mouse. Despite this, within 24 hours, damage to the tail was evident.   
jbkj 
After the mouse was culled, the tail was removed and sent to Central Diagnostic Services 
at the University of Cambridge for histological analysis.  The report stated a diagnosis of 
severe extensive coagulation necrosis oedema and perivascular inflammation consistent 
with thermal injury.  From this, it can be concluded that overheating is a problem, but 
no solution has been found thus far. 
 
5.4.13. Comparison of Scanning Parameters 
One of the major limitations of this technique in mice is the lack of signal from such a 
small volume of tissue, requiring long sequences with multiple scans averaged to 
improve signal to noise ratio.  During discussions with colleagues at the nuclear magnetic 
resonance (NMR) facility at the University of Sheffield it was suggested that a shorter TR 
would allow for more data points to be collected within the same time frame, possibly 
increasing the signal to noise ratio and eliminating the ‘phospholipid bump’ seen in 
figure 5.17 (black spectra).   
Subsequently, a shorter TR of 0.4s, collecting 4000 data points, was used.  The main 
limitation of this method is that a short TR may prevent the molecules relaxing back to 
their original state between scanning points, so may not represent the number of 
phosphates present in the tissue, making the data less quantitative.  As shown by the 
red spectra in figure 5.17, this method eliminates the ‘phospholipid bump’, reducing the 
amount of post-processing required for analysis. 
During the final period of scanning, a third set of parameters were used, with a narrower 
spectral width (figure 5.17, green spectra), allowing for higher resolution.  This method 
acquired a similar resolution of scanning with a much shorter scanning time, when 
compared to the previous scanning parameters.   
The purpose of this comparison was to investigate whether the larger number of 
averages in the 0.4s TR scan would improve the signal-to-noise ratio of the spectra whilst 
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maintaining a spectrum which is representative of the tissue phosphates and therefore, 
similar to the scans which used a 4s TR.  
 
 203 
Figure 5.17: Raw spectra from each set of scanning parameters. 
Chemical Shift (ppm) 
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The original scanning parameters (long TR) shown in black, short TR shown in red, and a 
shorter spectral width shown in green.  All spectra are from whole brain, male non-
transgenic mice. 
 
5.5. Discussion 
5.5.1. Feasibility of 31P-MRS 
This pilot study investigating 31P-MRS scanning in mice demonstrated technical 
feasibility as spectra were reproducible, with similar profiles and peak locations to 
previously published work in mice (Renema et al., 2003, Tracey et al., 1996).  However, 
the experiment was limited by significant and recurrent problems relating to mouse 
welfare, which are discussed below.   
When attempting to work up a 31P-MRS protocol, it may have been more appropriate 
to use mouse models of metabolic disease, in which the differences in metabolite levels 
between non-transgenic and disease groups would have been far greater and 
predictions of differences could have been made.  31P-MRS findings would then have 
been further validated.  This may be worthy of consideration for any further studies in 
to 31P-MRS in mice, prior to looking for subtle differences in metabolites. 
 
5.5.2. Adverse Events 
No studies could be found which reported necrosis of rodents caused by MRS, 
anaesthesia, or by use of any similar heating systems.  Other groups conducting MRI in 
mice at other academic centres have used circulating warmed water, so this technique 
was attempted.  However, our water system proved insufficient to maintain body 
temperature in the mice.   
Previous experience from our group using the same mouse model applying MRI to 
detect muscle volume changes at 30, 60, 90 and 120 days, had not identified any issues 
(Mead et al., 2011), so this problem was not foreseen.  However, since these studies 
were performed, a new magnet was purchased which ran at a colder temperature and 
we hypothesise that this made the heating system insufficient and during the initial 
equilibrium phase, additional demands on the system may have led to higher local 
temperatures.  This decreased temperature of the magnet system was adjusted by the 
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manufacturers after our initial issues.  However, we continued to have serious problems 
despite switching to a water system and then a heat pad with cotton blanket.  Therefore, 
it appears that despite the temperature of the magnet bore being as warm as possible, 
the heating systems were still having to work very hard, causing necrosis with the heat 
pad and cotton blanket protocol, as confirmed by a diagnostic report. 
The reasons for necrotic-like appearance to the tail in MRS studies remains a mystery. 
Several attempts were made to resolve this issue, but none were successful. We 
therefore conclude that this approach is not suitable for further investigation in our 
models. 
 
5.5.3. Comparison of 31P-MRS in SOD1G93A and Non-Transgenic Mice 
Due to the issues described above, the conclusions drawn from our experiments are 
limited.  No ratios of peak heights were found to have significant differences between 
the transgenic and non-transgenic groups, at 36, 73 or 115 days of age.  No significant 
findings were found in the differences between transgenic and non-transgenic peak 
integrals at 36, 73 or 115 days of age.  The limitations of small sample size reached their 
peak at 115 days of age, at which time only one mouse was in the transgenic group, 
precluding statistical analysis.  The last set of scanning was also carried out with too few 
mice to analyse the data statistically but no recurrent trends were found in the data as 
a whole.   
In a previous study using this mouse model, ATP was found to be lower in the brain at 
end stage (17 weeks of age) using a luciferase/luciferin based assay (Mattiazzi et al., 
2002).  Therefore, with larger group sizes, it would be hypothesised that a decrease in 
ATP-values may be found at the end stage of disease.  We can neither confirm nor refute 
this hypothesis with the data acquired in this study.  Overall, no conclusions can be made 
with regard to differences in 31P-MRS spectra between transgenic and non-transgenic 
mice, without testing larger group sizes.  It must also be considered that these scans 
were of whole brain, whereas MND affects some, but not all brain areas.  Therefore, 
scans of specific brain regions, such as the forebrain, may represent an alternative 
approach. 
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5.5.4. Changes in 31P-MRS over Time 
The 115 day scan results could not be included in the comparison of 31P-MRS over time 
due to attrition of the sample size.  Comparison of peak heights and peak integrals 
between 36 and 73 days of age in the pilot study showed no significant differences.  
However, as mentioned previously, increased group sizes would be necessary to find out 
whether there are any differences in peaks over time.  
This is a novel area of investigation in MND mouse models and in the human disease.  
No reports could be found in the literature for 31P-MRS in mouse or human brains with 
age, therefore, it is unknown what may be expected if 31P-MRS was investigated further 
in SOD1G93A mice. 
 
5.5.5. Comparison of 31P-MRS Scanning Parameters 
Throughout the study, scanning parameters were adjusted to improve the quality of the 
spectra by firstly shortening the TR, then shortening the spectral width. 
It is possible that the long TR scanning provides more quantitative peaks, as the 
phosphorus molecules can fully relax between scans, providing a similar signal with each 
scan.  Whereas, with the short TR, phosphorus molecules may not have time to fully 
relax between scans, resulting in peak heights which do not represent the absolute 
number of phosphorus molecules in a particular environment but are relative to the 
number of phosphorus molecules.  However, the long TR results in a large bump under 
the spectra, deemed to be a ‘phospholipid bump’, and shortening the TR eliminates this 
bump. 
Shortening of the spectral width prevents the scans recording activity from areas of the 
spectra which are not of interest and subsequently, shortens the scanning time.  In the 
interests of welfare, a shorter scanning time is always preferable as it reduces the 
chance of the mice failing to recover from the anaesthesia.  In future studies, a shorter 
scanning time would therefore be recommended. 
 
5.6. Conclusions 
This study revealed a problem with the methods used to maintain mouse body 
temperature during MRS imaging that proved to be intractable. 
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The best scanning parameters were the final set in which the spectral width was 
reduced, producing a good quality spectra whilst decreasing the amount time the mice 
spend in the scanner. These parameters would be preferable for future studies. 
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6. Discussion 
6.1. Was the TDP-43Q331K Mouse Model an Appropriate Choice? 
As discussed in chapter 1, the main reason for choosing this TDP-43Q331K mouse model 
(Arnold et al., 2013) was to avoid a knockout or a high overexpression of TDP-43, 
ensuring that the genotype of the mice was as close to the human MND genotype as 
possible (i.e. a mutation in the endogenous gene).  Since the acquisition of this model, 
CRISPR/Cas9 technology has been developed for use in mouse models, enabling the 
knock-in of specific mutations in the endogenous mouse gene with relative ease (Wu et 
al., 2013, Platt et al., 2014).  This technology provides a fast method of creating mouse 
models without the overexpression caused by most other techniques, and could provide 
the ideal disease model genotype.  However, at the time of choosing a TDP-43 mouse 
model, this technique was not available and no other knock-in TDP-43 mouse models 
had been created. 
Investigations made here have found that the overexpression of TDP-43 in this model 
was slightly higher than expected from previous findings (Arnold et al., 2013).  However, 
this overexpression is still moderately low compared to the overexpression levels in 
other models (see table 1.4). 
The main qualities required in a TDP-43 model were defined in chapter 1 as: being on a 
defined genetic background, having a reproducible phenotype with low variability in 
readouts, disease homogeneity, a mild-moderate disease severity, a moderate disease 
length, having an appropriate control line, having a degenerative phenotype due to loss 
of motor neurons, and signs of MND pathology.   
Many of these criteria were already met by choosing the TDP-43Q331K mouse model over 
other models, including the defined genetic background (due to backcrossing at Jackson 
laboratories), which in turn increases disease homogeneity, and an appropriate control 
line was also available; the TDP-43WT line.  During this project, three in vivo studies were 
carried out to investigate the remaining characteristics.  The low variability was evident 
in the coefficients of variation for most of the phenotypic readouts, including rotarod 
performance, catwalk gait analysis, running wheel performance and marble burying, as 
well as by the relatively low numbers of animals required to achieve good statistical 
power for detecting changes of 10-20% from the baseline.   
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The data were similar between studies, particularly for catwalk gait analysis.  However, 
there was a noticeable drift in weight and rotarod data across studies, by which the 
increase in weight and decline in rotarod performance were not as large in the later 
studies of TDP-43Q331K mice.  There is a need here for replication studies to establish the 
reason for these shifts in data and to assess the influence of these on preclinical trial 
data.  It is also important to replicate studies at different centres to ensure the model is 
robust. 
Copy number showed some variability in the TDP-43Q331K line and it is known that copy 
number can cause wide variability in phenotype in mutant SOD1 transgenic mice 
(Alexander et al., 2004).    Tissue was not available to investigate the TDP-43 expression 
levels and pathological differences between the mice tested for TDP-43 copy number, 
hence only rotarod differences were investigated, which were not suggestive of a 
difference in phenotype.  This, coupled with the low variability found in all three in vivo 
studies, indicates that the low copy number observed in two TDP-43Q331K mice was likely 
due to a technical error.  Ideally, further investigation would be made by sending a larger 
number of samples for gene copy number estimation. 
As expected from previous studies (Arnold et al., 2013, Mitchell et al., 2015), the disease 
phenotype of TDP-43Q331K mice was relatively mild and did not progress to a state of 
paralysis or a humane end point, ensuring minimal distress.  Our studies suggested that 
the disease progression beyond 6 months of age was minimal, and that a 6 month study, 
as opposed to 10 months, provided a big enough window in phenotype to measure 
neuroprotective agents or to investigate the mechanisms of pathogenesis.  This greatly 
reduces the cost and time required for studies in this model, and also reduces the total 
distress experienced by the mice under study, satisfying the refinement aspect of in vivo 
studies. 
A degenerative phenotype was evident in the TDP-43Q331K mice which showed reduced 
rotarod performance, reduced muscle mass, reduced CMAP, reduced repetitive 
stimulation response, and spontaneous EMG activity.  However, this cannot be 
supported by a reduced number of motor neurons as, although this investigation was 
planned, it was not completed due to issues with tissue quality and time constraints.  A 
reduced number of motor neurons is to be expected as a 35% reduction in motor 
neurons at 12 months of age was recorded previously in this model when on a 
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C57BL/6NCrl background (Arnold et al., 2013).  Furthermore, a reduction in CMAP 
amplitude (as reported in chapter 4) is suggestive of motor axon loss.  Despite this, the 
counting of motor neurons is a key investigation for further study as it would confirm 
whether the cell body of the motor neurons are also lost.  Investigation of NMJ integrity 
(suggested by the reduced response to repetitive stimulation shown in chapter 4) is also 
of importance, as it could confirm the presence of a ‘dying back’ axonopathy, as found 
in both MND patients and the SOD1G93A mouse model (Dadon-Nachum et al., 2011, 
Fischer et al., 2004). 
Pathological investigations confirmed the presence of astrogliosis and microgliosis in the 
spinal cord of TDP-43Q331K mice, as found previously (Arnold et al., 2013, Mitchell et al., 
2015).  Although nuclear clearing of TDP-43 with increased cytoplasmic levels are found 
in motor neurons in MND (Neumann et al., 2006), we identified elevated TDP-43 levels 
in the nucleus of spinal motor neurons in the TDP-43Q331K mice, which is the converse of 
findings in MND patient motor neurons (Neumann et al., 2006, Tollervey et al., 2011).  
It is interesting that a degenerative phenotype is present in such a scenario and may 
suggest the absolute level of TDP-43 in either compartment (nucleus or cytoplasm), or 
overall, is the critical factor.   
The absolute level of TDP-43 expression, as described in the introduction, has been 
clearly linked to neurodegeneration and in models with significant wild type 
overexpression, a very severe phenotype is found.  This was the reason why one the 
main criteria for choosing this model was that the total TDP-43 gene expression and 
protein levels were deemed to be similar to those in the wild type and non-transgenic 
mice (Arnold et al., 2013).  However, upon investigation we found that total TDP-43 
levels in the wild-type mice were approximately 2-fold that of the non-transgenic mice, 
and 3-fold in the TDP-43Q331K mice, differing depending on tissue type and considerably 
higher than the levels reported previously.  This poses potential for an influence of the 
overexpression on the TDP-43Q331K mice which is independent of the mutation, however 
this is expected to be of little relevance as these overexpression levels are still relatively 
low compared to wild type overexpression models (Wils et al., 2010, Shan et al., 2010).  
The importance of total TDP-43 expression levels is perhaps best emphasised by the 
report in which TDP-43Q331K mice were crossed with TDP-43WT, creating a TDP-43Q331K/WT 
mouse with a severe phenotype, resulting in a total TDP-43 expression in the brain of 
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over 4-fold that of non-transgenic mice, and death by 8-10 weeks of age (Mitchell et al., 
2015).  Although this overexpression is not dramatically higher than seen here in the 
TDP-43Q331K mice, the effect on the phenotype is dramatic.  It appears that a 4-fold total 
TDP-43 expression level pushes the TDP-43 levels beyond a threshold, which accelerates 
the disease course and causes severe motor dysfunction with a striking TDP-43 
pathology. 
Further investigation for TDP-43 pathology is required in the TDP-43Q331K model as 
aggregates and inclusions were not identified in this project, although cytoplasmic 
ubiquitin and p62-positive inclusions of TDP-43 have been identified in TDP-43Q331K/WT 
motor cortex and spinal cord at 8 weeks of age (Mitchell et al., 2015).  Immunostaining 
for phospho-TDP-43, p62 and ubiquitin should be conducted in the brain and spinal cord 
of TDP-43Q331K mice, all of which have been identified in motor neurons of MND patients 
(Neumann et al., 2006, Arai et al., 2006). 
All-in-all, this model met most of the requirements expected of a TDP-43 mouse model 
and presented as the best available model at the time of choosing.  However, more 
investigation is required to confirm the pathology and pattern of motor neuron death in 
this model, as well the potential for genetic drift within the colonies. 
 
6.2. Utility of the TDP-43Q331K Mouse Model for Pre-clinical Trials 
As described in table 2.4, many readouts measured in this model have provided data 
with low variability, which is ideal when looking for a treatment effect in preclinical 
trials.  Based on this, power analysis has suggested group sizes of 14 females, which is a 
relatively low number of animals per group for pre-clinical trials, when compared to the 
SOD1G93A model (Scott et al., 2008).   
Treatment effects in therapeutic preclinical trials of TDP-43Q331K mice can be identified 
by measuring motor phenotype, which can be easily and reliably measured using 
rotarod (Hamm et al., 1994, Gilli et al., 2016).  These findings can also be supported using 
more time consuming measurements such as neuroscoring, Catwalk gait analysis and 
electrophysiological studies.  Pathologically, a treatment effect may be identified by a 
reduction in astrogliosis, microgliosis or cytoplasmic TDP-43 levels.  Added to this, 
further pathological studies of spinal cord, brain and muscle in this model may add to 
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the pathological readouts which may identify treatment effects.  Electrophysiological 
studies may be of particular relevance for preclinical trials as this is a measurement 
which can also be monitored in patients, increasing the translational aspects of the 
transition from preclinical to patient trials. 
The TDP-43Q331K mouse model was characterised in this project in the hope that it may 
be representative of a larger population of MND patients compared to the SOD1G93A 
mouse model, increasing translation from MND models to patients.  We showed here 
that the TDP-43Q331K mice have increased cytoplasmic TDP-43 in spinal cord motor 
neurons, as found in MND patients (Neumann et al., 2006, Arai et al., 2006), and clear 
signs of a neurodegenerative phenotype, coupled with a potential FTD phenotype, all of 
which can be reliably monitored.  The TDP-43Q331K mouse model is therefore well suited 
to pre-clinical trials due to the low variability, moderate length disease course and 
reliability of readouts. 
However, it is key to replicate studies within the centre and across centres to establish 
the robustness of the model, prior to its use in preclinical trials. 
 
6.3. How Problematic is the Increased Weight of TDP-43Q331K Mice? 
An unexpected finding in this project was the increased weight of TDP-43Q331K mice 
compared to their TDP-43WT counterparts, the reason for which remains unknown.  
Slightly decreased voluntary activity levels and increased food intake were found, which 
may be indicative of FTD (see chapter 3) and in part, explain the increased weight.   
The increased weight was a concern as it may confound other findings such as the 
rotarod (Stover et al., 2015) and catwalk gait analysis (Deumens et al., 2007).  However, 
after a number of methods were considered, the rotarod data were normalised for 
weight, and a decline in rotarod performance was still evident.  Also, weight is unlikely 
to impact on electrophysiological and pathological investigations, providing reliable 
measures of neurodegeneration, regardless of weight.  Furthermore, reduced muscle 
mass was identified in the hindlimb, which is certainly not linked with the increased body 
weight.   
We therefore suggest that motor function testing should always be supported by 
electrophysiological and/or pathological studies in therapeutic trials using the TDP-
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43Q331K mouse model and weight should always be monitored so it can be taken in to 
account for rotarod measurements. 
 
6.4. Does the TDP-43Q331K Mouse Model the MND-FTD Continuum? 
Signs of apathy, reduced activity levels and over-eating are found in FTD patients 
(Ahmed et al., 2016b, Chan et al., 2015), and led to an investigation of cognitive function 
in the TDP-43Q331K mice.  Marble burying was chosen as a simple, yet effective 
measurement of normal exploratory behaviour (digging).  As hypothesised, TDP-43Q331K 
mice buried significantly less marbles than TDP-43WT mice, suggesting reduced digging 
behaviour, which may be interpreted as a sign of apathy.   
Apathy combined with over-eating is highly suggestive of FTD in the TDP-43Q331K mice.  
However, other measurements of FTD such as a lack of social interaction, anxiety, 
repetitive behaviour, and a lack of fear response must be carried out in these mice 
before an assumption of FTD can be made.  Further studies could include a three 
chamber social approach test (Gascon et al., 2014, Yin et al., 2010), which may confirm 
or refute the hypothesis that reduced marble burying may be interpreted as a sign of 
FTD. 
 
6.5. The Implications of Riluzole Having no Treatment Effect on Motor Function in TDP-
43Q331K Mice 
Riluzole is the only drug which has been licenced for treatment of MND and has been 
predicted to extend life by as long as 12 months (Georgoulopoulou et al., 2013, Miller 
et al., 2012).  However, other studies have suggested riluzole has little or no effect on 
MND (Stewart et al., 2001) and this may be related to the concept of subgroups, limiting 
its overall effect on the MND population (Georgoulopoulou et al., 2013). 
Studies on the effect of riluzole in SOD1G93A mice have reported mixed findings (Gurney 
et al., 1998, Li et al., 2013, Scott et al., 2008), so it is debatable whether riluzole is an 
effective treatment in this model.  It is interesting therefore, that riluzole appeared to 
have no significant effect on motor function in TDP-43Q331K mice.  However, as discussed 
in the Summary of Product Characteristics for riluzole, no effect has been found on 
motor function in MND patients, only on survival.  A potential treatment effect was 
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identified here in the repetitive stimulation results for TDP-43Q331K mice, suggestive of a 
subtle rescue effect at the NMJ,  but this finding requires further investigation, including 
NMJ histology.   
It could be that a higher dose of riluzole is required to see a more definite treatment 
effect in the TDP-43Q331K mouse model but such an effect may never appear as a clear 
rescue of motor function.  The possibility of using a higher dose is highlighted by 
comparing the riluzole PK concentrations to studies in SOD1G93A mice (in-house data), 
for which the TDP-43Q331K data is within the trough range for both blood and brain.  
Future studies should include the administration of riluzole at a higher dose, in which 
the blood levels of riluzole reach the mid-high levels of those found in patients and 
equate more to the levels found in SOD1G93A mice.   
 
6.6. 31P-MRS as a Pre-clinical Biomarker 
This study was the first known attempt at measuring 31P-MRS in a mouse model of MND 
(chapter 5) which could be a useful translational biomarker, indicative of underlying 
metabolic changes during disease (Grehl et al., 2007, Sharma et al., 1995, Ryan et al., 
2014).  SOD1G93A mice were used for this investigation as the TDP-43Q331K and TDP-43WT 
mice were not available at that point and they have a more profound phenotype with 
well described metabolic changes (Leclerc et al., 2001, Derave et al., 2003, Mattiazzi et 
al., 2002).   
Issues with animal welfare resulted in low numbers of mice at later time points, limiting 
the conclusions which could be drawn.  Furthermore, the scanning parameters were 
frequently changed to improve the quality of scanning, reducing consistency between 
scans.  Now that scanning parameters have been optimised, repeated scanning of a 
cohort of mice at different time points is required, to assess the utility of 31P-MRS as a 
translational biomarker.   
In order to scan a cohort of mice, the animal welfare issues must be addressed by 
installing a safe and suitable heating system.  The hot water system (see section 4.3.2.4.) 
which was used in one of the scanning sessions was unsuitable as the warm water 
beneath the mouse only covered half of the body area, and the mouse lost temperature 
very quickly.  We suggest a modification to this method in which the water flows under 
the whole of the mouse by adjusting the layout of the scanning bed.  This modification 
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has already been made but has not been tested.  This would be a logical technique to 
test in the first instance. 
 
6.7. Future Work 
This project had limitations which could be overcome with future work, primarily by a 
thorough investigation of the brain, spinal cord and muscle of the TDP-43Q331K mice.  
Pathological investigations should include NMJ staining, motor neuron counts and 
motor neuron staining for p62, ubiquitin and phospho-TDP-43, as well as careful 
examination for TDP-43 inclusions and aggregates.  These investigations could further 
elucidate the underlying mechanisms involved in neurodegeneration in the TDP-43Q331K 
model, and potentially provide insights in to the development of TDP-43 pathology in 
MND patients. 
Further investigations of gene copy number are required by sending a large number of 
samples for quantification.  Studies in to the potential FTD phenotype of TDP-43Q331K 
mice using a variety of tests could be very informative, as well as another riluzole study 
using a higher dose.  Further testing of a heating system is required for future 31P-MRS 
imaging. 
 
6.8. Overall Conclusions 
Overall, this project has provided new insights into the TDP-43Q331K mouse model and 
showed potential benefits of using this model in future pre-clinical trials.  Detailed 
phenotypic characterisation has provided a number of novel readouts of disease in this 
model and shown that an increase of nuclear TDP-43 may be sufficient to cause 
neurodegeneration.  The EMG readouts provide a useful measure which can be 
implemented in an identical manner to human studies, facilitating the translation of 
therapeutic effects from one species to another.  The fact that riluzole was able to 
improve the reduction in CMAP amplitude on repetitive stimulation may indicate that 
this is a useful translational readout for riluzole mimics or other compounds that can act 
on this pathway.  There is also room for the identification of therapeutics which modify 
the motor phenotype (as riluzole did not, similar to the human disease).  Finally the 
identification of a phenotype which may mimic MND-FTD to an extent is intriguing and 
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worthy of further investigation and again, may make this model particularly valuable for 
investigation of therapeutics and mechanisms across the MND-FTD disease spectrum.  
The TDP-43Q331K model has a reliable and reproducible motor phenotype, signs of 
pathology, and a potential FTD-like phenotype.  Further studies of pathology and signs 
of FTD in this model could be very beneficial to increase the number of readouts 
available for monitoring in pre-clinical therapeutic trials. 
  
 217 
7. References 
ACOSTA, J. R., GOLDSBURY, C., WINNICK, C., BADROCK, A. P., FRASER, S. T., LAIRD, A. S., HALL, T. 
E., DON, E. K., FIFITA, J. A., BLAIR, I. P., NICHOLSON, G. A. & COLE, N. J. 2014. Mutant 
human FUS is ubiquitously mislocalized and generates persistent stress granules in 
primary cultured transgenic zebrafish cells. Plos One, 9.6. 
AFIFI, A. K., ALEU, F. P., GOODGOLD, J. & MACKAY, B. 1966. Ultrastructure of atrophic muscle in 
amyotrophic lateral sclerosis. Neurology, 16, 475-475. 
AHMED, R. M., IRISH, M., PIGUET, O., HALLIDAY, G. M., ITTNER, L. M., FAROOQI, S., HODGES, J. 
R. & KIERNAN, M. C. 2016. Amyotrophic lateral sclerosis and frontotemporal dementia: 
distinct and overlapping changes in eating behaviour and metabolism. Lancet Neurol, 
15, 332-42. 
AHMED, Z., SHAW, G., SHARMA, V. P., YANG, C., MCGOWAN, E. & DICKSON, D. W. 2007. Actin-
binding proteins coronin-1a and IBA-1 are effective microglial markers for 
immunohistochemistry. Journal of Histochemistry & Cytochemistry, 55, 687-700. 
AL-CHALABI, A., JONES, A., TROAKES, C., KING, A., AL-SARRAJ, S. & VAN DEN BERG, L. H. 2012. 
The genetics and neuropathology of amyotrophic lateral sclerosis. Acta 
Neuropathologica, 124, 339-352. 
ALEXANDER, G. M., ERWIN, K. L., BYERS, N., DEITCH, J. S., AUGELLI, B. J., BLANKENHORN, E. P. & 
HEIMAN-PATTERSON, T. D. 2004. Effect of transgene copy number on survival in the 
G93A SOD1 transgenic mouse model of ALS. Molecular Brain Research, 130, 7-15. 
ALLEN, D. L., HARRISON, B. C., MAASS, A. H., BELL, M. L., BYRNES, W. C. & LEINWAND, L. A. 2001. 
Cardiac and skeletal muscle adaptations to voluntary wheel running in the mouse. 
Journal of Applied Physiology, 90, 1900-1908. 
ALVES, C. J., DE SANTANA, L. P., DIAS DOS SANTOS, A. J., DE OLIVEIRA, G. P., DUOBLES, T., 
SCORISA, J. M., MARTINS, R. S., MAXIMINO, J. R. & CHADI, G. 2011. Early motor and 
electrophysiological changes in transgenic mouse model of amyotrophic lateral sclerosis 
and gender differences on clinical outcome. Brain Research, 1394, 90-104. 
AN, D., TOYODA, T., TAYLOR, E. B., YU, H., FUJII, N., HIRSHMAN, M. F. & GOODYEAR, L. J. 2010. 
TBC1D1 regulates insulin- and contraction-induced glucose transport in mouse skeletal 
muscle. Diabetes, 59, 1358-1365. 
ANDERSEN, P. M., NILSSON, P., ALAHURULA, V., KERANEN, M. L., TARVAINEN, I., HALTIA, T., 
NILSSON, L., BINZER, M., FORSGREN, L. & MARKLUND, S. L. 1995. Amyotrophic lateral 
sclerosis associated with homozygosity for an ASP90ALA mutation in CuZn-superoxide 
dismutase. Nature Genetics, 10, 61-66. 
ANDREASSEN, O. A., JENKINS, B. G., DEDEOGLU, A., FERRANTE, K. L., BOGDANOV, M. B., 
KADDURAH-DAOUK, R. & BEAL, M. F. 2001. Increases in cortical glutamate 
concentrations in transgenic amyotrophic lateral sclerosis mice are attenuated by 
creatine supplementation. Journal of Neurochemistry, 77, 383-390. 
ANGOA-PEREZ, M., KANE, M. J., BRIGGS, D. I., FRANCESCUTTI, D. M. & KUHN, D. M. 2013. Marble 
burying and nestlet shredding as tests of repetitive, compulsive-like behaviors in mice. 
Jove-Journal of Visualized Experiments, 82, e50978-e50978. 
ARAI, T., HASEGAWA, M., AKIYAMA, H., IKEDA, K., NONAKA, T., MORI, H., MANN, D., TSUCHIYA, 
K., YOSHIDA, M., HASHIZUME, Y. & ODA, T. 2006. TDP-43 is a component of ubiquitin-
positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic 
lateral sclerosis. Biochemical and Biophysical Research Communications, 351, 602-611. 
ARMON, C. 2003. An evidence-based medicine approach to the evaluation of the role of 
exogenous risk factors in sporadic amyotrophic lateral sclerosis. Neuroepidemiology, 22, 
217-228. 
ARMON, C. 2009. Smoking may be considered an established risk factor for sporadic ALS. 
Neurology, 73, 1693-1698. 
ARNOLD, E. S., LING, S.-C., HUELGA, S. C., LAGIER-TOURENNE, C., POLYMENIDOU, M., 
DITSWORTH, D., KORDASIEWICZ, H. B., MCALONIS-DOWNES, M., PLATOSHYN, O., 
PARONE, P. A., DA CRUZ, S., CLUTARIO, K. M., SWING, D., TESSAROLLO, L., MARSALA, 
 218 
M., SHAW, C. E., YEO, G. W. & CLEVELAND, D. W. 2013. ALS-linked TDP-43 mutations 
produce aberrant RNA splicing and adult-onset motor neuron disease without 
aggregation or loss of nuclear TDP-43. Proceedings of the National Academy of Sciences 
of the United States of America, 110, E736-E745. 
ARNOLD, W. D., PORENSKY, P. N., MCGOVERN, V. L., IYER, C. C., DUQUE, S., LI, X., MEYER, K., 
SCHMELZER, L., KASPAR, B. K., KOLB, S. J., KISSEL, J. T. & BURGHES, A. H. 2014. 
Electrophysiological biomarkers in spinal muscular atrophy: preclinical proof of concept. 
Ann Clin Transl Neurol., 1, 34-44. 
ARNOLD, W. D., SHETH, K. A., WIER, C. G., KISSEL, J. T., BURGHES, A. H. & KOLB, S. J. 2015. 
Electrophysiological motor unit number estimation (MUNE) measuring compound 
muscle action potential (CMAP) in mouse hindlimb muscles. Journal of visualized 
experiments : JoVE, 103, e52899-e52899. 
ATANASIO, A., DECMAN, V., WHITE, D., RAMOS, M., IKIZ, B., LEE, H.-C., SIAO, C.-J., BRYDGES, S., 
LAROSA, E., BAI, Y., FURY, W., BURFEIND, P., ZAMFIROVA, R., WARSHAW, G., ORENGO, 
J., OYEJIDE, A., FRALISH, M., AUERBACH, W., POUEYMIROU, W., FREUDENBERG, J., 
GONG, G., ZAMBROWICZ, B., VALENZUELA, D., YANCOPOULOS, G., MURPHY, A., 
THURSTON, G. & LAI, K.-M. V. 2016. C9orf72 ablation causes immune dysregulation 
characterized by leukocyte expansion, autoantibody production, and 
glomerulonephropathy in mice. Scientific Reports, 6, 23204-23204. 
AYALA, Y. M., DE CONTI, L., AVENDANO-VAZQUEZ, S. E., DHIR, A., ROMANO, M., D'AMBROGIO, 
A., TOLLERVEY, J., ULE, J., BARALLE, M., BURATTI, E. & BARALLE, F. E. 2011. TDP-43 
regulates its mRNA levels through a negative feedback loop. Embo Journal, 30, 277-288. 
AYALA, Y. M., ZAGO, P., D'AMBROGIO, A., XU, Y.-F., PETRUCELLI, L., BURATTI, E. & BARALLE, F. E. 
2008. Structural determinants of the cellular localization and shuttling of TDP-43. 
Journal of Cell Science, 121, 3778-3785. 
AZZOUZ, M., LECLERC, N., GURNEY, M., WARTER, J. M., POINDRON, P. & BORG, J. 1997. 
Progressive motor neuron impairment in an animal model of familial amyotrophic 
lateral sclerosis. Muscle & Nerve, 20, 45-51. 
BANASR, M., CHOWDHURY, G. M. I., TERWILLIGER, R., NEWTON, S. S., DUMAN, R. S., BEHAR, K. 
L. & SANACORA, G. 2010. Glial pathology in an animal model of depression: reversal of 
stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating 
drug riluzole. Molecular Psychiatry, 15, 501-511. 
BANNWARTH, S., AIT-EL-MKADEM, S., CHAUSSENOT, A., GENIN, E. C., LACAS-GERVAIS, S., 
FRAGAKI, K., BERG-ALONSO, L., KAGEYAMA, Y., SERRE, V., MOORE, D. G., VERSCHUEREN, 
A., ROUZIER, C., LE BER, I., AUGE, G., COCHAUD, C., LESPINASSE, F., N'GUYEN, K., DE 
SEPTENVILLE, A., BRICE, A., YU-WAI-MAN, P., SESAKI, H., POUGET, J. & PAQUIS-
FLUCKLINGER, V. 2014. A mitochondrial origin for frontotemporal dementia and 
amyotrophic lateral sclerosis through CHCHD10 involvement. Brain, 137, 2329-2345. 
BARMADA, S. J., SKIBINSKI, G., KORB, E., RAO, E. J., WU, J. Y. & FINKBEINER, S. 2010. Cytoplasmic 
mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated 
with familial amyotrophic lateral sclerosis. Journal of Neuroscience, 30, 639-649. 
BAUMANN, F., HENDERSON, R. D., RIDALL, P. G., PETTITT, A. N. & MCCOMBE, P. A. 2012. Use of 
Bayesian MUNE to show differing rate of loss of motor units in subgroups of ALS. Clinical 
Neurophysiology, 123, 2446-2453. 
BEGHI, E., LOGROSCINO, G., CHIO, A., HARDIMAN, O., MITCHELL, D., SWINGLER, R., TRAYNOR, 
B. J. & CONSORTIUM, E. 2006. The epidemiology of ALS and the role of population-based 
registries. Biochimica Et Biophysica Acta-Molecular Basis of Disease, 1762, 1150-1157. 
BELLINGHAM, M. C. 2011. A review of the neural mechanisms of action and clinical efficiency of 
riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last 
decade? Cns Neuroscience & Therapeutics, 17, 4-31. 
BENATAR, M. 2007. Lost in translation: Treatment trials in the SOD1 mouse and in human ALS. 
Neurobiology of Disease, 26, 1-13. 
 219 
BENATAR, M., BOYLAN, K., JEROMIN, A., RUTKOVE, S. B., BERRY, J., ATASSI, N. & BRUIJN, L. 2016. 
ALS Biomarkers for therapy development: state of the field and future directions. 
Muscle & Nerve, 53, 169-182. 
BENDOTTI, C., CALVARESI, N., CHIVERI, L., PRELLE, A., MOGGIO, M., BRAGA, M., SILANI, V. & DE 
BIASI, S. 2001. Early vacuolization and mitochondrial damage in motor neurons of FALS 
mice are not associated with apoptosis or with changes in cytochrome oxidase 
histochemical reactivity. Journal of the Neurological Sciences, 191, 25-33. 
BENNETT, E. J., MEAD, R. J., AZZOUZ, M., SHAW, P. J. & GRIERSON, A. J. 2014. Early detection of 
motor dysfunction in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis 
(ALS) using home cage running wheels. Plos One, 9.9, e107918. 
BENSIMON, G., LACOMBLEZ, L., MEININGER, V., BOUCHE, P., DELWAIDE, C., COURATIER, P., 
BLIN, O., VIADER, F., PEYROSTPAUL, H., DAVID, J., MALOTEAUX, J. M., HUGON, J., 
LATERRE, E. C., RASCOL, A., CLANET, M., VALLAT, J. M., DUMAS, A., SERRATRICE, G., 
LECHEVALLIER, B., PEUCH, A. J., NGUYEN, T., SHU, C., BASTIEN, P., PAPILLON, C., 
DURRLEMAN, S., LOUVEL, E., GUILLET, P., LEDOUX, L., ORVOENFRIJA, E. & DIB, M. 1994. 
A controlled trial of riluzole in amyotrophic lateral sclerosis. New England Journal of 
Medicine, 330, 585-591. 
BERETTA, S., SALA, G., MATTAVELLI, L., CERESA, C., CASCIATI, A., FERRI, A., CARRI, M. T. & 
FERRARESE, C. 2003. Mitochondrial dysfunction due to mutant copper/zinc superoxide 
dismutase associated with amyotrophic lateral sclerosis is reversed by N-acetylcysteine. 
Neurobiology of Disease, 13, 213-221. 
BERGMAN, B. P., MACKAY, D. F. & PELL, J. P. 2015. Motor neurone disease and military service: 
evidence from the Scottish Veterans Health Study. Occupational and Environmental 
Medicine, 72, 877-879. 
BERLOWITZ, D. J., HOWARD, M. E., FIORE, J. F., JR., HOORN, S. V., O'DONOGHUE, F. J., WESTLAKE, 
J., SMITH, A., BEER, F., MATHERS, S. & TALMAN, P. 2016. Identifying who will benefit 
from non-invasive ventilation in amyotrophic lateral sclerosis/motor neurone disease in 
a clinical cohort. Journal of Neurology Neurosurgery and Psychiatry, 87, 280-286. 
BOGDANIK, L. P., OSBORNE, M. A., DAVIS, C., MARTIN, W. P., AUSTIN, A., RIGO, F., BENNETT, C. 
F. & LUTZ, C. M. 2015. Systemic, postsymptomatic antisense oligonucleotide rescues 
motor unit maturation delay in a new mouse model for type II/III spinal muscular 
atrophy. Proceedings of the National Academy of Sciences of the United States of 
America, 112, E5863-E5872. 
BOILLEE, S., YAMANAKA, K., LOBSIGER, C. S., COPELAND, N. G., JENKINS, N. A., KASSIOTIS, G., 
KOLLIAS, G. & CLEVELAND, D. W. 2006. Onset and progression in inherited ALS 
determined by motor neurons and microglia. Science, 312, 1389-1392. 
BORCHELT, D. R., DAVIS, J., FISCHER, M., LEE, M. K., SLUNT, H. H., RATOVITSKY, T., REGARD, J., 
COPELAND, N. G., JENKINS, N. A., SISODIA, S. S. & PRICE, D. L. 1996. A vector for 
expressing foreign genes in the brains and hearts of transgenic mice. Genetic Analysis-
Biomolecular Engineering, 13, 159-163. 
BOURKE, S. C., TOMLINSON, M., WILLIAMS, T. L., BULLOCK, R. E., SHAW, P. J. & GIBSON, G. J. 
2006. Effects of non-invasive ventilation on survival and quality of life in patients with 
amyotrophic lateral sclerosis. Lancet Neurology, 5, 140-147. 
BOUTELOUP, C., DESPORT, J. C., CLAVELOU, P., GUY, N., DERUMEAUX-BUREL, H., FERRIER, A. & 
COURATIER, P. 2009. Hypermetabolism in ALS patients: an early and persistent 
phenomenon. Journal of Neurology, 256, 1236-1242. 
BROOKS, B. R., MILLER, R. G., SWASH, M., MUNSAT, T. L. & WORLD FEDERATION NEUROLOGY 
RES, G. 2000. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic 
lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 1, 
293-299. 
BROOKS, S. P. & DUNNETT, S. B. 2009. Tests to assess motor phenotype in mice: a user's guide. 
Nature Reviews Neuroscience, 10, 519-529. 
 220 
BROTHERTON, T., POLAK, M., KELLY, C., BIRVE, A., ANDERSEN, P., MARKLUND, S. L. & GLASS, J. 
D. 2011. A novel ALS SOD1 C6S mutation with implications for aggregation related 
toxicity and genetic counseling. Amyotrophic Lateral Sclerosis, 12, 215-219. 
BRUESTLE, D. A., CUTLER, R. G., TELLJOHANN, R. S. & MATTSON, M. P. 2009. Decline in daily 
running distance presages disease onset in a mouse model of ALS. Neuromolecular 
Medicine, 11, 58-62. 
BRUIJN, L. I., BECHER, M. W., LEE, M. K., ANDERSON, K. L., JENKINS, N. A., COPELAND, N. G., 
SISODIA, S. S., ROTHSTEIN, J. D., BORCHELT, D. R., PRICE, D. L. & CLEVELAND, D. W. 1997. 
ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly 
progressive disease with SOD1-containing inclusions. Neuron, 18, 327-338. 
BRYSON, H. M., FULTON, B. & BENFIELD, P. 1996. Riluzole - A review of its pharmacodynamic 
and pharmacokinetic properties and therapeutic potential in amyotrophic lateral 
sclerosis. Drugs, 52, 549-563. 
BUDINI, M., ROMANO, V., QUADRI, Z., BURATTI, E. & BARALLE, F. E. 2015. TDP-43 loss of cellular 
function through aggregation requires additional structural determinants beyond its C-
terminal Q/N prion-like domain. Human Molecular Genetics, 24, 9-20. 
BURATTI, E. & BARALLE, F. E. 2010. The multiple roles of TDP-43 in pre-mRNA processing and 
gene expression regulation. Rna Biology, 7, 420-429. 
BURATTI, E. & BARALLE, F. E. 2012. TDP-43: gumming up neurons through protein-protein and 
protein-RNA interactions. Trends in Biochemical Sciences, 37, 237-247. 
CATHOMAS, F., HARTMANN, M. N., SEIFRITZ, E., PRYCE, C. R. & KAISER, S. 2015. The translational 
study of apathy-an ecological approach. Frontiers in Behavioral Neuroscience, 9, 241-
241. 
CHADT, A., LEICHT, K., DESHMUKH, A., JIANG, L. Q., SCHERNECK, S., BERNHARDT, U., DREJA, T., 
VOGEL, H., SCHMOLZ, K., KLUGE, R., ZIERATH, J. R., HULTSCHIG, C., HOEBEN, R. C., 
SCHUERMANN, A., JOOST, H.-G. & AL-HASANI, H. 2008. Tbc1d1 mutation in lean mouse 
strain confers leanness and protects from diet-induced obesity. Nature Genetics, 40, 
1354-1359. 
CHAN, H.-M., STOLWYK, R., NEATH, J., KELSO, W., WALTERFANG, M., MOCELLIN, R., PANTELIS, 
C. & VELAKOULIS, D. 2015. Neurocognitive similarities between severe chronic 
schizophrenia and behavioural variant frontotemporal dementia. Psychiatry Research, 
225, 658-666. 
CHANG, C.-K., WU, T.-H., WU, C.-Y., CHIANG, M.-H., TOH, E. K.-W., HSU, Y.-C., LIN, K.-F., LIAO, Y.-
H., HUANG, T.-H. & HUANG, J. J.-T. 2012. The N-terminus of TDP-43 promotes its 
oligomerization and enhances DNA binding affinity. Biochemical and Biophysical 
Research Communications, 425, 219-224. 
CHANG, H.-Y., HOU, S.-C., WAY, T.-D., WONG, C.-H. & WANG, I. F. 2013. Heat-shock protein 
dysregulation is associated with functional and pathological TDP-43 aggregation. Nature 
Communications, 4, 2757-2757. 
CHEN, Y., YANG, M., DENG, J., CHEN, X., YE, Y., ZHU, L., LIU, J., YE, H., SHEN, Y., LI, Y., RAO, E. J., 
FUSHIMI, K., ZHOU, X., BIGIO, E. H., MESULAM, M., XU, Q. & WU, J. Y. 2011. Expression 
of human FUS protein in Drosophila leads to progressive neurodegeneration. Protein & 
Cell, 2, 477-486. 
CHEW, J., GENDRON, T. F., PRUDENCIO, M., SASAGURI, H., ZHANG, Y.-J., CASTANEDES-CASEY, 
M., LEE, C., JANSEN-WEST, K., KURTI, A., MURRAY, M. E., BIENIEK, K. F., BAUER, P. O., 
WHITELAW, E. C., ROUSSEAU, L., STANKOWSKI, J. N., STETLER, C., DAUGHRITY, L. M., 
PERKERSON, E. A., DESARO, P., JOHNSTON, A., OVERSTREET, K., EDBAUER, D., 
RADEMAKERS, R., BOYLAN, K. B., DICKSON, D. W., FRYER, J. D. & PETRUCELLI, L. 2015. 
C9ORF72 repeat expansions in mice cause TDP-43 pathology, neuronal loss, and 
behavioral deficits. Science, 348, 1151-1154. 
CHIANG, P.-M., LING, J., JEONG, Y. H., PRICE, D. L., AJA, S. M. & WONG, P. C. 2010. Deletion of 
TDP-43 down-regulates Tbc1d1, a gene linked to obesity, and alters body fat 
metabolism. Proceedings of the National Academy of Sciences of the United States of 
America, 107, 16320-16324. 
 221 
CHIO, A., BENZI, G., DOSSENA, M., MUTANI, R. & MORA, G. 2005. Severely increased risk of 
amyotrophic lateral sclerosis among Italian professional football players. Brain, 128, 
472-476. 
CHIO, A., LOGROSCINO, G., HARDIMAN, O., SWINGLER, R., MITCHELL, D., BEGHI, E., TRAYNOR, 
B. G. & EURALS, C. 2009. Prognostic factors in ALS: A critical review. Amyotrophic Lateral 
Sclerosis, 10, 310-323. 
CHIO, A. & TRAYNOR, B. J. 2015. Biomarkers for ALS-in search of the Promised Land. Nature 
Reviews Neurology, 11.2, 72-74. 
CHOWDHURY, G. M. I., BANASR, M., DE GRAAF, R. A., ROTHMAN, D. L., BEHAR, K. L. & 
SANACORA, G. 2008. Chronic riluzole treatment increases glucose metabolism in rat 
prefrontal cortex and hippocampus. Journal of Cerebral Blood Flow and Metabolism, 28, 
1892-1897. 
CIURA, S., LATTANTE, S., LE BER, I., LATOUCHE, M., TOSTIVINT, H., BRICE, A. & KABASHI, E. 2013. 
Loss of function of C9orf72 causes motor deficits in a zebrafish model of amyotrophic 
lateral sclerosis. Annals of Neurology, 74, 180-187. 
COLOMBRITA, C., ZENNARO, E., FALLINI, C., WEBER, M., SOMMACAL, A., BURATTI, E., SILANI, V. 
& RATTI, A. 2009. TDP-43 is recruited to stress granules in conditions of oxidative insult. 
Journal of Neurochemistry, 111, 1051-1061. 
COMI, G. P., BORDONI, A., SALANI, S., FRANCESCHINA, L., SCIACCO, M., PRELLE, A., FORTUNATO, 
F., ZEVIANI, M., NAPOLI, L., BRESOLIN, N., MOGGIO, M., AUSENDA, C. D., TAANMAN, J. 
W. & SCARLATO, G. 1998. Cytochrome c oxidase subunit I microdeletion in a patient 
with motor neuron disease. Annals of Neurology, 43, 110-116. 
COOKSON, M. R. & SHAW, P. J. 1999. Oxidative stress and motor neurone disease. Brain 
Pathology, 9, 165-186. 
COOPER-KNOCK, J., SHAW, P. J. & KIRBY, J. 2014. The widening spectrum of C9ORF72-related 
disease; genotype/phenotype correlations and potential modifiers of clinical 
phenotype. Acta Neuropathologica, 127, 333-345. 
CORCIA, P., VALDMANIS, P., MILLECAMPS, S., LIONNET, C., BLASCO, H., MOUZAT, K., DAOUD, H., 
BELZIL, V., MORALES, R., PAGEOT, N., DANEL-BRUNAUD, V., VANDENBERGHE, N., 
PRADAT, P. F., COURATIER, P., SALACHAS, F., LUMBROSO, S., ROULEAU, G. A., 
MEININGER, V. & CAMU, W. 2012. Phenotype and genotype analysis in amyotrophic 
lateral sclerosis with TARDBP gene mutations. Neurology, 78, 1519-1526. 
COSTA, J., GOMES, C. & DE CARVALHO, M. 2010. Diagnosis, pathogenesis and therapeutic 
targets in amyotrophic lateral sclerosis. Cns & Neurological Disorders-Drug Targets, 9, 
764-778. 
COSTA, J., SWASH, M. & DE CARVALHO, M. 2012. Awaji criteria for the diagnosis of amyotrophic 
lateral sclerosis a systematic review. Archives of Neurology, 69, 1410-1416. 
COX, P. A., RICHER, R., METCALF, J. S., BANACK, S. A., CODD, G. A. & BRADLEY, W. G. 2009. 
Cyanobacteria and BMAA exposure from desert dust: A possible link to sporadic ALS 
among Gulf War veterans. Amyotrophic Lateral Sclerosis, 10, 109-117. 
DADON-NACHUM, M., MELAMED, E. & OFFEN, D. 2011. The "dying-back" phenomenon of motor 
neurons in ALS. Journal of Molecular Neuroscience, 43, 470-477. 
DALCANTO, M. C. & GURNEY, M. E. 1995. Neuropathological changes in 2 lines of mice carrying 
a transgene for mutant human Cu,Zn SOD and in mice overexpressing wild-type human 
SOD - a model of familial amyotrophic lateral sclerosis (FALS). Brain Research, 676, 25-
40. 
DE BONO, J. P., ADLAM, D., PATERSON, D. J. & CHANNON, K. M. 2006. Novel quantitative 
phenotypes of exercise training in mouse models. American Journal of Physiology-
Regulatory Integrative and Comparative Physiology, 290, R926-R934. 
DE CARVALHO, M., DENGLER, R., EISEN, A., ENGLAND, J. D., KAJI, R., KIMURA, J., MILLS, K., 
MITSUMOTO, H., NODERA, H., SHEFNER, J. & SWASH, M. 2008. Electrodiagnostic criteria 
for diagnosis of ALS. Clinical Neurophysiology, 119, 497-503. 
DE CONTI, L., AKINYI, M. V., MENDOZA-MALDONADO, R., ROMANO, M., BARALLE, M. & 
BURATTI, E. 2015. TDP-43 affects splicing profiles and isoform production of genes 
 222 
involved in the apoptotic and mitotic cellular pathways. Nucleic Acids Research, 43, 
8990-9005. 
DE VOS, K. J., GRIERSON, A. J., ACKERLEY, S. & MILLER, C. C. J. 2008. Role of axonal transport in 
neurodegenerative diseases. Annual Review of Neuroscience, 31, 151-173. 
DEACON, R. M. J. 2006. Digging and marble burying in mice: simple methods for in vivo 
identification of biological impacts. Nature Protocols, 1, 122-124. 
DEFLORIO, C., PALMA, E., CONTI, L., ROSETI, C., MANTECA, A., GIACOMELLI, E., CATALANO, M., 
LIMATOLA, C., INGHILLERI, M. & GRASSI, F. 2012. Riluzole blocks human muscle 
acetylcholine receptors. Journal of Physiology-London, 590, 2519-2528. 
DEJESUS-HERNANDEZ, M., MACKENZIE, I. R., BOEVE, B. F., BOXER, A. L., BAKER, M., 
RUTHERFORD, N. J., NICHOLSON, A. M., FINCH, N. A., FLYNN, H., ADAMSON, J., KOURI, 
N., WOJTAS, A., SENGDY, P., HSIUNG, G.-Y. R., KARYDAS, A., SEELEY, W. W., JOSEPHS, K. 
A., COPPOLA, G., GESCHWIND, D. H., WSZOLEK, Z. K., FELDMAN, H., KNOPMAN, D. S., 
PETERSEN, R. C., MILLER, B. L., DICKSON, D. W., BOYLAN, K. B., GRAFF-RADFORD, N. R. 
& RADEMAKERS, R. 2011. Expanded GGGGCC Hexanucleotide repeat in noncoding 
region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron, 72.2, 245-256. 
DEKKER, A. M., SEELEN, M., VAN DOORMAAL, P. T. C., VAN RHEENEN, W., BOTHOF, R. J. P., VAN 
RIESSEN, T., BRANDS, W. J., VAN DER KOOI, A. J., DE VISSER, M., VOERMANS, N. C., 
PASTERKAMP, R. J., VELDINK, J. H., VAN DEN BERG, L. H. & VAN ES, M. A. 2016. Large-
scale screening in sporadic amyotrophic lateral sclerosis identifies genetic modifiers in 
C9orf72 repeat carriers. Neurobiology of Aging, 39, 220-e9. 
DEL AGUILA, M. A., LONGSTRETH, W. T., MCGUIRE, V., KOEPSELL, T. D. & VAN BELLE, G. 2003. 
Prognosis in amyotrophic lateral sclerosis - A population-based study. Neurology, 60, 
813-819. 
DEL NEGRO, C. A., MORGADO-VALLE, C. & FELDMAN, J. L. 2002. Respiratory rhythm: An 
emergent network property? Neuron, 34, 821-830. 
DENG, H.-X., CHEN, W., HONG, S.-T., BOYCOTT, K. M., GORRIE, G. H., SIDDIQUE, N., YANG, Y., 
FECTO, F., SHI, Y., ZHAI, H., JIANG, H., HIRANO, M., RAMPERSAUD, E., JANSEN, G. H., 
DONKERVOORT, S., BIGIO, E. H., BROOKS, B. R., AJROUD, K., SUFIT, R. L., HAINES, J. L., 
MUGNAINI, E., PERICAK-VANCE, M. A. & SIDDIQUE, T. 2011. Mutations in UBQLN2 cause 
dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature, 477, 211-
U113. 
DERAVE, W., VAN DEN BOSCH, L., LEMMENS, G., EIJNDE, B. O., ROBBERECHT, W. & HESPEL, P. 
2003. Skeletal muscle properties in a transgenic mouse model for amyotrophic lateral 
sclerosis: effects of creatine treatment. Neurobiology of Disease, 13, 264-272. 
DESNUELLE, C., DIB, M., GARREL, C., FAVIER, A. & GRP, A. L. S. R.-T. S. 2001. A double-blind, 
placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the 
treatment of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other 
Motor Neuron Disorders, 2, 9-18. 
DESPORT, J.-C., TORNY, F., LACOSTE, M., PREUX, P.-M. & COURATIER, P. 2005. Hypermetabolism 
in ALS: correlations with clinical and paraclinical parameters. Neurodegenerative 
Diseases, 2, 202-207. 
DESPORT, J. C., PREUX, P. M., TRUONG, C. T., COURAT, L., VALLAT, J. M. & COURATIER, P. 2000. 
Nutritional assessment and survival in ALS patients. Amyotrophic Lateral Sclerosis and 
Other Motor Neuron Disorders, 1, 91-96. 
DEUMENS, R., JAKEN, R. J. P., MARCUS, M. A. E. & JOOSTEN, E. A. J. 2007. The CatWalk gait 
analysis in assessment of both dynamic and static gait changes after adult rat sciatic 
nerve resection. Journal of Neuroscience Methods, 164, 120-130. 
DHALIWAL, G. K. & GREWAL, R. P. 2000. Mitochondrial DNA deletion mutation levels are 
elevated in ALS brains. Neuroreport, 11, 2507-2509. 
DIAPER, D. C., ADACHI, Y., SUTCLIFFE, B., HUMPHREY, D. M., ELLIOTT, C. J. H., STEPTO, A., 
LUDLOW, Z. N., VANDEN BROECK, L., CALLAERTS, P., DERMAUT, B., AL-CHALABI, A., 
SHAW, C. E., ROBINSON, I. M. & HIRTH, F. 2013. Loss and gain of Drosophila TDP-43 
 223 
impair synaptic efficacy and motor control leading to age-related neurodegeneration by 
loss-of-function phenotypes. Human Molecular Genetics, 22, 1539-1557. 
DOBROWOLNY, G., AUCELLO, M., RIZZUTO, E., BECCAFICO, S., MAMMUCARI, C., 
BONCONPAGNI, S., BELIA, S., WANNENES, F., NICOLETTI, C., DEL PRETE, Z., ROSENTHAL, 
N., MOLINARO, M., PROTASI, F., FANO, G., SANDRI, M. & MUSARO, A. 2008. Skeletal 
muscle is a primary target of SOD1(G93A)-mediated toxicity. Cell Metabolism, 8, 425-
436. 
DORMANN, D., CAPELL, A., CARLSON, A. M., SHANKARAN, S. S., RODDE, R., NEUMANN, M., 
KREMMER, E., MATSUWAKI, T., YAMANOUCHI, K., NISHIHARA, M. & HAASS, C. 2009. 
Proteolytic processing of TAR DNA binding protein-43 by caspases produces C-terminal 
fragments with disease defining properties independent of progranulin. Journal of 
Neurochemistry, 110, 1082-1094. 
DUCHEN, L. W. & STRICH, S. J. 1968. An hereditary motor neurone disease with progressive 
denervation of muscle in mouse - mutant wobbler. Journal of Neurology Neurosurgery 
and Psychiatry, 31.6, 535-542. 
DUPUIS, L., OUDART, H., RENE, F., DE AGUILAR, J. L. G. & LOEFFLER, J. P. 2004. Evidence for 
defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a high-energy 
diet in a transgenic mouse. Proceedings of the National Academy of Sciences of the 
United States of America, 101, 11159-11164. 
DUPUIS, L., PRADAT, P.-F., LUDOLPH, A. C. & LOEFFLER, J.-P. 2011. Energy metabolism in 
amyotrophic lateral sclerosis. Lancet Neurology, 10, 75-82. 
EGASHIRA, N., OKUNO, R., HARADA, S., MATSUSHITA, M., MISHIMA, K., IWASAKI, K., 
NISHIMURA, R., OISHI, R. & FUJIWARA, M. 2008. Effects of glutamate-related drugs on 
marble-burying behavior in mice: Implications for obsessive-compulsive disorder. 
European Journal of Pharmacology, 586, 164-170. 
EL-KADI, A. M., SOURA, V. & HAFEZPARAST, M. 2007. Defective axonal transport in motor neuron 
disease. Journal of Neuroscience Research, 85, 2557-2566. 
ELDEN, A. C., KIM, H.-J., HART, M. P., CHEN-PLOTKIN, A. S., JOHNSON, B. S., FANG, X., 
ARMAKOLA, M., GESER, F., GREENE, R., LU, M. M., PADMANABHAN, A., CLAY-FALCONE, 
D., MCCLUSKEY, L., ELMAN, L., JUHR, D., GRUBER, P. J., RUEB, U., AUBURGER, G., 
TROJANOWSKI, J. Q., LEE, V. M. Y., VAN DEERLIN, V. M., BONINI, N. M. & GITLER, A. D. 
2010. Ataxin-2 intermediate-length polyglutamine expansions are associated with 
increased risk for ALS. Nature, 466, 1069-U77. 
ENG, L. F. & GHIRNIKAR, R. S. 1994. GFAP and astrogliosis. Brain Pathology, 4, 229-237. 
FALCK, B. & ALARANTA, H. 1983. Fibrillation potentials, positive sharp waves and fasciculation 
in intrinsic muscles of the foot in healthy subjects. Journal of Neurology Neurosurgery 
and Psychiatry, 46, 681-683. 
FAUL, F., ERDFELDER, E., BUCHNER, A. & LANG, A. G. 2009. Statistical power analyses using 
G*Power 3.1: Tests for correlation and regression analyses. Behavior Research Methods, 
41, 1149-1160. 
FAUSTINO, E. V. S. & DONNELLY, D. F. 2006. An important functional role of persistent Na+ 
current in carotid body hypoxia transduction. Journal of Applied Physiology, 101, 1076-
1084. 
FECTO, F., YAN, J., VEMULA, S. P., LIU, E., YANG, Y., CHEN, W., ZHENG, J. G., SHI, Y., SIDDIQUE, 
N., ARRAT, H., DONKERVOORT, S., AJROUD-DRISS, S., SUFIT, R. L., HELLER, S. L., DENG, 
H.-X. & SIDDIQUE, T. 2011. SQSTM1 mutations in familial and sporadic amyotrophic 
lateral sclerosis. Archives of Neurology, 68, 1440-1446. 
FEILER, M. S., STROBEL, B., FREISCHMIDT, A., HELFERICH, A. M., KAPPEL, J., BREWER, B. M., LI, 
D., THAL, D. R., WALTHER, P., LUDOLPH, A. C., DANZER, K. M. & WEISHAUPT, J. H. 2015. 
TDP-43 is intercellularly transmitted across axon terminals. Journal of Cell Biology, 211, 
897-911. 
FELICE, K. J. & NORTH, W. A. 1998. Creatine kinase values in amyotrophic lateral sclerosis. 
Journal of the Neurological Sciences, 160, S30-S32. 
 224 
FERRAIUOLO, L., HIGGINBOTTOM, A., HEATH, P. R., BARBER, S., GREENALD, D., KIRBY, J. & SHAW, 
P. J. 2011. Dysregulation of astrocyte-motoneuron cross-talk in mutant superoxide 
dismutase 1-related amyotrophic lateral sclerosis. Brain, 134, 2627-2641. 
FISCHER, L. R., CULVER, D. G., TENNANT, P., DAVIS, A. A., WANG, M. S., CASTELLANO-SANCHEZ, 
A., KHAN, J., POLAK, M. A. & GLASS, J. D. 2004. Amyotrophic lateral sclerosis is a distal 
axonopathy: evidence in mice and man. Experimental Neurology, 185, 232-240. 
FLANAGAN, R. J., YUSUFI, B. & BARNES, T. R. E. 2003. Comparability of whole-blood and plasma 
clozapine and norclozapine concentrations. British Journal of Clinical Pharmacology, 56, 
135-138. 
FREISCHMIDT, A., WIELAND, T., RICHTER, B., RUF, W., SCHAEFFER, V., MUELLER, K., 
MARROQUIN, N., NORDIN, F., HUEBERS, A., WEYDT, P., PINTO, S., PRESS, R., 
MILLECAMPS, S., MOLKO, N., BERNARD, E., DESNUELLE, C., SORIANI, M.-H., DORST, J., 
GRAF, E., NORDSTROM, U., FEILER, M. S., PUTZ, S., BOECKERS, T. M., MEYER, T., 
WINKLER, A. S., WINKELMAN, J., DE CARVALHO, M., THAL, D. R., OTTO, M., 
BRANNSTROM, T., VOLK, A. E., KURSULA, P., DANZER, K. M., LICHTNER, P., DIKIC, I., 
MEITINGER, T., LUDOLPH, A. C., STROM, T. M., ANDERSEN, P. M. & WEISHAUPT, J. H. 
2015. Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. 
Nature Neuroscience, 18.5, 631-636. 
FUJII, R., OKABE, S., URUSHIDO, T., INOUE, K., YOSHIMURA, A., TACHIBANA, T., NISHIKAWA, T., 
HICKS, G. G. & TAKUMI, T. 2005. The RNA binding protein TLS is translocated to dendritic 
spines by mGluR5 activation and regulates spine morphology. Current Biology, 15, 587-
593. 
FUNALOT, B., DESPORT, J.-C., STURTZ, F., CAMU, W. & COURATIER, P. 2009. High metabolic level 
in patients with familial amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis, 10, 
113-117. 
GASCON, E., LYNCH, K., RUAN, H., ALMEIDA, S., VERHEYDEN, J. M., SEELEY, W. W., DICKSON, D. 
W., PETRUCELLI, L., SUN, D., JIAO, J., ZHOU, H., JAKOVCEVSKI, M., AKBARIAN, S., YAO, 
W.-D. & GAO, F.-B. 2014. Alterations in microRNA-124 and AMPA receptors contribute 
to social behavioral deficits in frontotemp oral dementia. Nature Medicine, 20, 1444-
1451. 
GAUTIER, G., VERSCHUEREN, A., MONNIER, A., ATTARIAN, S., SALORT-CAMPANA, E. & POUGET, 
J. 2010. ALS with respiratory onset: Clinical features and effects of non-invasive 
ventilation on the prognosis. Amyotrophic Lateral Sclerosis, 11, 379-382. 
GEEVASINGA, N., MENON, P., NG, K., VAN DEN BOS, M., BYTH, K., KIERNAN, M. C. & VUCIC, S. 
2016. Riluzole exerts transient modulating effects on cortical and axonal 
hyperexcitability in ALS. Amyotrophic Lateral Sclerosis Frontotemporal Degeneration, 1, 
1-9. 
GEORGOULOPOULOU, E., FINI, N., VINCETI, M., MONELLI, M., VACONDIO, P., BIANCONI, G., 
SOLA, P., NICHELLI, P. & MANDRIOLI, J. 2013. The impact of clinical factors, riluzole and 
therapeutic interventions on ALS survival: A population based study in Modena, Italy. 
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 14, 338-345. 
GILLI, F., ROYCE, D. B. & PACHNER, A. R. 2016. Measuring progressive neurological disability in a 
mouse model of multiple sclerosis. J Vis Exp., (117). 10.3791/54616. 
GITCHO, M. A., BALOH, R. H., CHAKRAVERTY, S., MAYO, K., NORTON, J. B., LEVITCH, D., 
HATANPAA, K. J., WHITE, C. L., III, BIGIO, E. H., CASELLI, R., BAKER, M., AL-LOZI, M. T., 
MORRIS, J. C., PESTRONK, A., RADEMAKERS, R., GOATE, A. M. & CAIRNS, N. J. 2008. TDP-
43 A315T mutation in familial motor neuron disease. Annals of Neurology, 63, 535-538. 
GONG, Y. H., PARSADANIAN, A. S., ANDREEVA, A., SNIDER, W. D. & ELLIOTT, J. L. 2000. Restricted 
expression of G86R Cu/Zn superoxide dismutase in astrocytes results in astrocytosis but 
does not cause motoneuron degeneration. Journal of Neuroscience, 20.2, 660-665. 
GORDON, P. H. 2013. Amyotrophic lateral sclerosis: An update for 2013 clinical features, 
pathophysiology, management and therapeutic trials. Aging and Disease, 4, 295-310. 
GORDON, P. H., MOORE, D. H., MILLER, R. G., FLORENCE, J. M., VERHEIJDE, J. L., DOORISH, C., 
HILTON, J. F., SPITALNY, G. M., MACARTHUR, R. B., MITSUMOTO, H., NEVILLE, H. E., 
 225 
BOYLAN, K., MOZAFFAR, T., BELSH, J. M., RAVITS, J., BEDLACK, R. S., GRAVES, M. C., 
MCCLUSKEY, L. F., BAROHN, R. J., TANDAN, R. & WESTERN, A. L. S. S. G. 2007. Efficacy of 
minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. 
Lancet Neurology, 6, 1045-1053. 
GOULD, T. W., BUSS, R. R., VINSANT, S., PREVETTE, D., SUN, W., KNUDSON, C. M., MILLIGAN, C. 
E. & OPPENHEIM, R. W. 2006. Complete dissociation of motor neuron death from motor 
dysfunction by Bax deletion in a mouse model of ALS. Journal of Neuroscience, 26, 8774-
8786. 
GRAF, M., ECKER, D., HOROWSKI, R., KRAMER, B., RIEDERER, P., GERLACH, M., HAGER, C., 
LUDOLPH, A. C. & GERMAN VITAMIN, E. A. L. S. S. G. 2005. High dose vitamin E therapy 
in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-
controlled double-blind study. Journal of Neural Transmission, 112, 649-660. 
GREENWAY, M. J., ANDERSEN, P. M., RUSS, C., ENNIS, S., CASHMAN, S., DONAGHY, C., 
PATTERSON, V., SWINGLER, R., KIERAN, D., PREHN, J., MORRISON, K. E., GREEN, A., 
ACHARYA, K. R., BROWN, R. H. & HARDIMAN, O. 2006. ANG mutations segregate with 
familial and 'sporadic' amyotrophic lateral sclerosis. Nature Genetics, 38, 411-413. 
GREHL, T., FISCHER, S., MUELLER, K., MALIN, J.-P. & ZANGE, J. 2007. A prospective study to 
evaluate the impact of P-31-MRS to determinate mitochondrial dysfunction in skeletal 
muscle of ALS patients. Amyotrophic Lateral Sclerosis, 8, 4-8. 
GROENEVELD, G. J., VAN KAN, H., LIE-A-HUEN, L., GUCHELAAR, H. J. & VAN DEN BERG, L. H. 2008. 
An association study of riluzole serum concentration and survival and disease 
progression in patients with ALS. Clinical Pharmacology & Therapeutics, 83, 718-722. 
GROENEVELD, G. J., VAN KAN, H. J. M., TORANO, J. S., VELDINK, J. H., GUCHELAAR, H. J., WOKKE, 
J. H. J. & VAN DEN BERG, L. H. 2001. Inter- and intraindividual variability of riluzole serum 
concentrations in patients with ALS. Journal of the Neurological Sciences, 191, 121-125. 
GROENEVELD, G. J., VELDINK, J. H., VAN DER TWEEL, I., KALMIJN, S., BEIJER, C., DE VISSER, M., 
WOKKE, J. H. J., FRANSSEN, H. & VAN DEN BERG, L. H. 2003. A randomized sequential 
trial of creatine in amyotrophic lateral sclerosis. Annals of Neurology, 53, 437-445. 
GRUNTMAN, E., BENJAMINI, Y. & GOLANI, I. 2007. Coordination of steering in a free-trotting 
quadruped. Journal of Comparative Physiology a-Neuroethology Sensory Neural and 
Behavioral Physiology, 193, 331-345. 
GUILLOT, T. S., ASRESS, S. A., RICHARDSON, J. R., GLASS, J. D. & MILLER, G. W. 2008. Treadmill 
gait analysis does not detect motor deficits in animal models of Parkinson's disease or 
amyotrophic lateral sclerosis. Journal of Motor Behavior, 40, 568-577. 
GUNNARSSON, L. G., BODIN, L., SODERFELDT, B. & AXELSON, O. 1992. A case-control study of 
motor neuron disease - its relation to heritability, and occupational exposures, 
particularly to solvents. British Journal of Industrial Medicine, 49, 791-798. 
GURNEY, M. E., CUTTING, F. B., ZHAI, P., DOBLE, A., TAYLOR, C. P., ANDRUS, P. K. & HALL, E. D. 
1996. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familiar 
amyotrophic lateral sclerosis. Annals of Neurology, 39, 147-157. 
GURNEY, M. E., FLECK, T. J., HIMES, C. S. & HALL, E. D. 1998. Riluzole preserves motor function 
in a transgenic model of familial amyotrophic lateral sclerosis. Neurology, 50, 62-66. 
GURNEY, M. E., PU, H. F., CHIU, A. Y., DALCANTO, M. C., POLCHOW, C. Y., ALEXANDER, D. D., 
CALIENDO, J., HENTATI, A., KWON, Y. W., DENG, H. X., CHEN, W. J., ZHAI, P., SUFIT, R. L. 
& SIDDIQUE, T. 1994. Motor-neuron degeneration in mice that express a human Cu,Zn 
superoxide-dismutase mutation. Science, 264, 1772-1775. 
GYERTYAN, I. 1995. Analysis of the marble burying response - marbles serve to measure digging 
rather than evoke burying. Behavioural Pharmacology, 6, 24-31. 
HAEUSLER, A. R., DONNELLY, C. J. & ROTHSTEIN, J. D. 2016. The expanding biology of the C9orf72 
nucleotide repeat expansion in neurodegenerative disease. Nature Reviews 
Neuroscience, 17, 383-U79. 
HALEY, R. W. 2003. Excess incidence of ALS in young Gulf War veterans. Neurology, 61, 750-756. 
 226 
HAMADEH, M. J., RODRIGUEZ, M. C., KACZOR, J. J. & TARNOPOLSKY, M. A. 2005. Caloric 
restriction transiently improves motor performance but hastens clinical onset of disease 
in the Cu/Zn-superoxide dismutase mutant G93A mouse. Muscle & Nerve, 31, 214-220. 
HAMADEH, M. J. & TARNOPOLSKY, M. A. 2006. Transient caloric restriction in early adulthood 
hastens disease endpoint in male, but not female, Cu/Zn-sod mutant G93A mice. Muscle 
& Nerve, 34, 709-719. 
HAMM, R. J., PIKE, B. R., ODELL, D. M., LYETH, B. G. & JENKINS, L. W. 1994. The rotarod test - an 
evaluation of its effectiveness in assessing motor deficits following traumatic brain 
injury. Journal of Neurotrauma, 11, 187-196. 
HARWOOD, C. A., MCDERMOTT, C. J. & SHAW, P. J. 2009. Physical activity as an exogenous risk 
factor in motor neuron disease (MND): A review of the evidence. Amyotrophic Lateral 
Sclerosis, 10, 191-204. 
HARWOOD, C. A., WESTGATE, K., GUNSTONE, S., BRAGE, S., WAREHAM, N. J., MCDERMOTT, C. 
J. & SHAW, P. J. 2016. Long-term physical activity: an exogenous risk factor for sporadic 
amyotrophic lateral sclerosis? Amyotrophic Lateral Sclerosis and Frontotemporal 
Degeneration, 17.5-6, 377-384. 
HATZIPETROS, T., BOGDANIK, L. P., TASSINARI, V. R., KIDD, J. D., MORENO, A. J., DAVIS, C., 
OSBORNE, M., AUSTIN, A., VIEIRA, F. G., LUTZ, C. & PERRIN, S. 2014. C57BL/6J congenic 
Prp-TDP43A315T mice develop progressive neurodegeneration in the myenteric plexus 
of the colon without exhibiting key features of ALS. Brain Research, 1584, 59-72. 
HAYES, L. R. & ROTHSTEIN, J. D. 2016. C9ORF72-ALS/FTD: Transgenic mice make a come-BAC. 
Neuron, 90, 427-431. 
HEIMAN-PATTERSON, T. D., DEITCH, J. S., BLANKENHORN, E. P., ERWIN, K. L., PERREAULT, M. J., 
ALEXANDER, B. K., BYERS, N., TOMAN, I. & ALEXANDER, G. M. 2005. Background and 
gender effects on survival in the TgN(SOD1-G93A) 1 Gur mouse model of ALS. Journal of 
the Neurological Sciences, 236, 1-7. 
HIGGINS, C. M. J., JUNG, C. W. & XU, Z. S. 2003. ALS-associated mutant SOD1G93A causes 
mitochondrial vacuolation by expansion of the intermembrane space and by 
involvement of SOD1 aggregation and peroxisomes. Bmc Neuroscience, 4.1, 16-16. 
HIGHLEY, J. R., KIRBY, J., JANSWEIJER, J. A., WEBB, P. S., HEWAMADDUMA, C. A., HEATH, P. R., 
HIGGINBOTTOM, A., RAMAN, R., FERRAIUOLO, L., COOPER-KNOCK, J., MCDERMOTT, C. 
J., WHARTON, S. B., SHAW, P. J. & INCE, P. G. 2014. Loss of nuclear TDP-43 in 
amyotrophic lateral sclerosis (ALS) causes altered expression of splicing machinery and 
widespread dysregulation of RNA splicing in motor neurones. Neuropathology and 
Applied Neurobiology, 40, 670-685. 
HOOTEN, K. G., BEERS, D. R., ZHAO, W. & APPEL, S. H. 2015. Protective and toxic 
neuroinflammation in amyotrophic lateral sclerosis. Neurotherapeutics, 12, 364-375. 
HOPPITT, T., PALL, H., CALVERT, M., GILL, P., YAO, G. Q., RAMSAY, J., JAMES, G., CONDUIT, J. & 
SACKLEY, C. 2011. A systematic review of the incidence and prevalence of long-term 
neurological conditions in the UK. Neuroepidemiology, 36, 19-28. 
HOWE, K., CLARK, M. D., TORROJA, C. F., TORRANCE, J., BERTHELOT, C., MUFFATO, M., COLLINS, 
J. E., HUMPHRAY, S., MCLAREN, K., MATTHEWS, L., MCLAREN, S., SEALY, I., CACCAMO, 
M., CHURCHER, C., SCOTT, C., BARRETT, J. C., KOCH, R., RAUCH, G.-J., WHITE, S., CHOW, 
W., KILIAN, B., QUINTAIS, L. T., GUERRA-ASSUNCAO, J. A., ZHOU, Y., GU, Y., YEN, J., 
VOGEL, J.-H., EYRE, T., REDMOND, S., BANERJEE, R., CHI, J., FU, B., LANGLEY, E., 
MAGUIRE, S. F., LAIRD, G. K., LLOYD, D., KENYON, E., DONALDSON, S., SEHRA, H., 
ALMEIDA-KING, J., LOVELAND, J., TREVANION, S., JONES, M., QUAIL, M., WILLEY, D., 
HUNT, A., BURTON, J., SIMS, S., MCLAY, K., PLUMB, B., DAVIS, J., CLEE, C., OLIVER, K., 
CLARK, R., RIDDLE, C., ELIOTT, D., THREADGOLD, G., HARDEN, G., WARE, D., MORTIMER, 
B., KERRY, G., HEATH, P., PHILLIMORE, B., TRACEY, A., CORBY, N., DUNN, M., JOHNSON, 
C., WOOD, J., CLARK, S., PELAN, S., GRIFFITHS, G., SMITH, M., GLITHERO, R., HOWDEN, 
P., BARKER, N., STEVENS, C., HARLEY, J., HOLT, K., PANAGIOTIDIS, G., LOVELL, J., 
BEASLEY, H., HENDERSON, C., GORDON, D., AUGER, K., WRIGHT, D., COLLINS, J., RAISEN, 
C., DYER, L., LEUNG, K., ROBERTSON, L., AMBRIDGE, K., LEONGAMORNLERT, D., 
 227 
MCGUIRE, S., GILDERTHORP, R., GRIFFITHS, C., MANTHRAVADI, D., NICHOL, S., BARKER, 
G., WHITEHEAD, S., KAY, M., et al. 2013. The zebrafish reference genome sequence and 
its relationship to the human genome. Nature, 496, 498-503. 
HUANG, C., ZHOU, H., TONG, J., CHEN, H., LIU, Y.-J., WANG, D., WEI, X. & XIA, X.-G. 2011. FUS 
transgenic rats develop the phenotypes of amyotrophic lateral sclerosis and 
frontotemporal lobar degeneration. Plos Genetics, 7.3, e1002011. 
HUKEMA, R. K., RIEMSLAGH, F. W., MELHEM, S., VAN DER LINDE, H. C., SEVERIJNEN, L.-A. W., 
EDBAUER, D., MAAS, A., CHARLET-BERGUERAND, N., WILLEMSEN, R. & VAN SWIETEN, J. 
C. 2014. A new inducible transgenic mouse model for C9orf72-associated GGGGCC 
repeat expansion supports a gain-of-function mechanism in C9orf72-associated ALS and 
FTD. Acta neuropathologica communications, 2, 166-166. 
ICHIMARU, Y., EGAWA, T. & SAWA, A. 1995. 5-HT1A-receptor subtype mediates the effect of 
fluvoxamine, a selective serotonin reuptake inhibitor, on marble-burying behaviour in 
mice. Japanese Journal of Pharmacology, 68, 65-70. 
IGAZ, L. M., KWONG, L. K., LEE, E. B., CHEN-PLOTKIN, A., SWANSON, E., UNGER, T., MALUNDA, 
J., XU, Y., WINTON, M. J., TROJANOWSKI, J. Q. & LEE, V. M. Y. 2011. Dysregulation of the 
ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice. Journal 
of Clinical Investigation, 121, 726-738. 
IGUCHI, Y., KATSUNO, M., NIWA, J.-I., TAKAGI, S., ISHIGAKI, S., IKENAKA, K., KAWAI, K., 
WATANABE, H., YAMANAKA, K., TAKAHASHI, R., MISAWA, H., SASAKI, S., TANAKA, F. & 
SOBUE, G. 2013. Loss of TDP-43 causes age-dependent progressive motor neuron 
degeneration. Brain, 136, 1371-1382. 
IKEDA, K., IWASAKI, Y. & KINOSHITA, M. 2000. Oral administration of creatine monohydrate 
retards progression of motor neuron disease in the wobbler mouse. Amyotrophic 
Lateral Sclerosis and Other Motor Neuron Disorders, 1, 207-212. 
ITTNER, L. M., HALLIDAY, G. M., KRIL, J. J., GOETZ, J., HODGES, J. R. & KIERNAN, M. C. 2015. 
OPINION FTD and ALS-translating mouse studies into clinical trials. Nature Reviews 
Neurology, 11, 360-366. 
IWANAMI, T., SONOO, M., HATANAKA, Y., HOKKOKU, K., OISHI, C. & SHIMIZU, T. 2011. 
Decremental responses to repetitive nerve stimulation (RNS) in motor neuron disease. 
Clinical Neurophysiology, 122, 2530-2536. 
JAARSMA, D., HAASDIJK, E. D., GRASHORN, J. A. C., HAWKINS, R., VAN DUIJN, W., VERSPAGET, 
H. W., LONDON, J. & HOLSTEGE, J. C. 2000. Human Cu/Zn superoxide dismutase (SOD1) 
overexpression in mice causes mitochondrial vacuolization, axonal degeneration, and 
premature motoneuron death and accelerates motoneuron disease in mice expressing 
a familial amyotrophic lateral sclerosis mutant SOD1. Neurobiology of Disease, 7, 623-
643. 
JAARSMA, D., ROGNONI, F., VAN DUIJN, W., VERSPAGET, H. W., HAASDIJK, E. D. & HOLSTEGE, J. 
C. 2001. CuZn superoxide dismutase (SOD1) accumulates in vacuolated mitochondria in 
transgenic mice expressing amyotrophic lateral sclerosis-linked SOD1 mutations. Acta 
Neuropathologica, 102, 293-305. 
JANSSENS, J., WILS, H., KLEINBERGER, G., JORIS, G., CUIJT, I., CEUTERICK-DE GROOTE, C., VAN 
BROECKHOVEN, C. & KUMAR-SINGH, S. 2013. Overexpression of ALS-associated 
p.M337V human TDP-43 in mice worsens disease features compared to wild-type 
human TDP-43 mice. Molecular Neurobiology, 48, 22-35. 
JIANG, J., ZHU, Q., GENDRON, T. F., SABERI, S., MCALONIS-DOWNES, M., SEELMAN, A., 
STAUFFER, J. E., JAFAR-NEJAD, P., DRENNER, K., SCHULTE, D., CHUN, S., SUN, S., LING, 
S.-C., MYERS, B., ENGELHARDT, J., KATZ, M., BAUGHN, M., PLATOSHYN, O., MARSALA, 
M., WATT, A., HEYSER, C. J., ARD, M. C., DE MUYNCK, L., DAUGHRITY, L. M., SWING, D. 
A., TESSAROLLO, L., JUNG, C. J., DELPOUX, A., UTZSCHNEIDER, D. T., HEDRICK, S. M., DE 
JONG, P. J., EDBAUER, D., VAN DAMME, P., PETRUCELLI, L., SHAW, C. E., BENNETT, C. F., 
DA CRUZ, S., RAVITS, J., RIGO, F., CLEVELAND, D. W. & LAGIER-TOURENNE, C. 2016. Gain 
of toxicity from ALS/FTD-linked repeat expansions in C9ORF72 is alleviated by antisense 
oligonucleotides targeting GGGGCC-containing RNAs. Neuron, 90, 535-550. 
 228 
JOHNSON, J. O., MANDRIOLI, J., BENATAR, M., ABRAMZON, Y., VAN DEERLIN, V. M., 
TROJANOWSKI, J. Q., GIBBS, J. R., BRUNETTI, M., GRONKA, S., WUU, J., DING, J., 
MCCLUSKEY, L., MARTINEZ-LAGE, M., FALCONE, D., HERNANDEZ, D. G., AREPALLI, S., 
CHONG, S., SCHYMICK, J. C., ROTHSTEIN, J., LANDI, F., WANG, Y.-D., CALVO, A., MORA, 
G., SABATELLI, M., MONSURRO, M. R., BATTISTINI, S., SALVI, F., SPATARO, R., SOLA, P., 
BORGHERO, G., GALASSI, G., SCHOLZ, S. W., TAYLOR, J. P., RESTAGNO, G., CHIO, A., 
TRAYNOR, B. J. & CONSORTIUM, I. 2010. Exome sequencing reveals VCP mutations as a 
cause of familial ALS. Neuron, 68, 857-864. 
JOHNSON, J. O., PIORO, E. P., BOEHRINGER, A., CHIA, R., FEIT, H., RENTON, A. E., PLINER, H. A., 
ABRAMZON, Y., MARANGI, G., WINBORN, B. J., GIBBS, J. R., NALLS, M. A., MORGAN, S., 
SHOAI, M., HARDY, J., PITTMAN, A., ORRELL, R. W., MALASPINA, A., SIDLE, K. C., FRATTA, 
P., HARMS, M. B., BALOH, R. H., PESTRONK, A., WEIHL, C. C., ROGAEVA, E., ZINMAN, L., 
DRORY, V. E., BORGHERO, G., MORA, G., CALVO, A., ROTHSTEIN, J. D., DREPPER, C., 
SENDTNER, M., SINGLETON, A. B., TAYLOR, J. P., COOKSON, M. R., RESTAGNO, G., 
SABATELLI, M., BOWSER, R., CHIO, A., TRAYNOR, B. J. & ITALSGEN 2014. Mutations in 
the Matrin 3 gene cause familial amyotrophic lateral sclerosis. Nature Neuroscience, 
17.5, 664-666. 
JOYCE, P. I., MCGOLDRICK, P., SACCON, R. A., WEBER, W., FRATTA, P., WEST, S. J., ZHU, N., 
CARTER, S., PHATAK, V., STEWART, M., SIMON, M., KUMAR, S., HEISE, I., BROS-FACER, 
V., DICK, J., CORROCHANO, S., STANFORD, M. J., TU VINH, L., NOLAN, P. M., MEYER, T., 
BRANDNER, S., BENNETT, D. L. H., OZDINLER, P. H., GREENSMITH, L., FISHER, E. M. C. & 
ACEVEDO-AROZENA, A. 2015. A novel SOD1-ALS mutation separates central and 
peripheral effects of mutant SOD1 toxicity. Human Molecular Genetics, 24, 1883-1897. 
KABASHI, E., LIN, L., TRADEWELL, M. L., DION, P. A., BERCIER, V., BOURGOUIN, P., ROCHEFORT, 
D., HADJ, S. B., DURHAM, H. D., VELDE, C. V., ROULEAU, G. A. & DRAPEAU, P. 2010. Gain 
and loss of function of ALS-related mutations of TARDBP (TDP-43) cause motor deficits 
in vivo. Human Molecular Genetics, 19, 671-683. 
KABASHI, E., VALDMANIS, P. N., DION, P., SPIEGELMAN, D., MCCONKEY, B. J., VELDE, C. V., 
BOUCHARD, J.-P., LACOMBLEZ, L., POCHIGAEVA, K., SALACHAS, F., PRADAT, P.-F., CAMU, 
W., MEININGER, V., DUPRE, N. & ROULEAU, G. A. 2008. TARDBP mutations in individuals 
with sporadic and familial amyotrophic lateral sclerosis. Nature Genetics, 40, 572-574. 
KARAM, C., SCELSA, S. N. & MACGOWAN, D. J. L. 2010. The clinical course of progressive bulbar 
palsy. Amyotrophic Lateral Sclerosis, 11, 364-368. 
KASARSKIS, E. J., BERRYMAN, S., VANDERLEEST, J. G., SCHNEIDER, A. R. & MCCLAIN, C. J. 1996. 
Nutritional status of patients with amyotrophic lateral sclerosis: Relation to the 
proximity of death. American Journal of Clinical Nutrition, 63, 130-137. 
KASARSKIS, E. J. & WINSLOW, M. 1989. When did Lou Gehrig's personal illness begin. Neurology, 
39, 1243-1245. 
KELLER, A. F., GRAVEL, M. & KRIZ, J. 2011. Treatment with minocycline after disease onset alters 
astrocyte reactivity and increases microgliosis in SOD1 mutant mice. Experimental 
Neurology, 228, 69-79. 
KILKENNY, C., BROWNE, W. J., CUTHILL, I. C., EMERSON, M. & ALTMAN, D. G. 2010. Improving 
bioscience research reporting: The ARRIVE guidelines for reporting animal research. Plos 
Biology, 8.6, e1000412. 
KILLIAN, J. M., WILFONG, A. A., BURNETT, L., APPEL, S. H. & BOLAND, D. 1994. Decremental 
motor-responses to repetitive nerve-stimulation in ALS. Muscle & Nerve, 17, 747-754. 
KIM, H. J., KIM, N. C., WANG, Y.-D., SCARBOROUGH, E. A., MOORE, J., DIAZ, Z., MACLEA, K. S., 
FREIBAUM, B., LI, S., MOLLIEX, A., KANAGARAJ, A. P., CARTER, R., BOYLAN, K. B., 
WOJTAS, A. M., RADEMAKERS, R., PINKUS, J. L., GREENBERG, S. A., TROJANOWSKI, J. Q., 
TRAYNOR, B. J., SMITH, B. N., TOPP, S., GKAZI, A.-S., MILLER, J., SHAW, C. E., KOTTLORS, 
M., KIRSCHNER, J., PESTRONK, A., LI, Y. R., FORD, A. F., GITLER, A. D., BENATAR, M., KING, 
O. D., KIMONIS, V. E., ROSS, E. D., WEIHL, C. C., SHORTER, J. & TAYLOR, J. P. 2013. 
Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem 
proteinopathy and ALS. Nature, 495.7442, 467-473. 
 229 
KLIVENYI, P., FERRANTE, R. J., MATTHEWS, R. T., BOGDANOV, M. B., KLEIN, A. M., ANDREASSEN, 
O. A., MUELLER, G., WERMER, M., KADDURAH-DAOUK, R. & BEAL, M. F. 1999. 
Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral 
sclerosis. Nature Medicine, 5, 347-350. 
KOERNER, S., HENDRICKS, M., KOLLEWE, K., ZAPF, A., DENGLER, R., SILANI, V. & PETRI, S. 2013. 
Weight loss, dysphagia and supplement intake in patients with amyotrophic lateral 
sclerosis (ALS): impact on quality of life and therapeutic options. Bmc Neurology, 13.1, 
84-84. 
KONG, J. M. & XU, Z. S. 1998. Massive mitochondrial degeneration in motor neurons triggers the 
onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. Journal of 
Neuroscience, 18, 3241-3250. 
KOPPERS, M., BLOKHUIS, A. M., WESTENENG, H.-J., TERPSTRA, M. L., ZUNDEL, C. A. C., DE SA, R. 
V., SCHELLEVIS, R. D., WAITE, A. J., BLAKE, D. J., VELDINK, J. H., VAN DEN BERG, L. H. & 
PASTERKAMP, R. J. 2015. C9orf72 ablation in mice does not cause motor neuron 
degeneration or motor deficits. Annals of Neurology, 78, 426-438. 
KOYAMA, A., SUGAI, A., KATO, T., ISHIHARA, T., SHIGA, A., TOYOSHIMA, Y., KOYAMA, M., 
KONNO, T., HIROKAWA, S., YOKOSEKI, A., NISHIZAWA, M., KAKITA, A., TAKAHASHI, H. & 
ONODERA, O. 2016. Increased cytoplasmic TARDBP mRNA in affected spinal motor 
neurons in ALS caused by abnormal autoregulation of TDP-43. Nucleic Acids Research, 
44, 5820-5836. 
KRAEMER, B. C., SCHUCK, T., WHEELER, J. M., ROBINSON, L. C., TROJANOWSKI, J. Q., LEE, V. M. 
Y. & SCHELLENBERG, G. D. 2010. Loss of murine TDP-43 disrupts motor function and 
plays an essential role in embryogenesis. Acta Neuropathologica, 119, 409-419. 
KRECIC, A. M. & SWANSON, M. S. 1999. hnRNP complexes: composition, structure, and function. 
Current Opinion in Cell Biology, 11, 363-371. 
KRIZ, J., NGUYEN, M. D. & JULIEN, J. P. 2002. Minocycline slows disease progression in a mouse 
model of arnyotrophic lateral sclerosis. Neurobiology of Disease, 10, 268-278. 
KUO, J. J., LEE, R. H., ZHANG, L. & HECKMAN, C. J. 2006. Essential role of the persistent sodium 
current in spike initiation during slowly rising inputs in mouse spinal neurones. Journal 
of Physiology-London, 574, 819-834. 
KWIATKOWSKI, T. J., JR., BOSCO, D. A., LECLERC, A. L., TAMRAZIAN, E., VANDERBURG, C. R., 
RUSS, C., DAVIS, A., GILCHRIST, J., KASARSKIS, E. J., MUNSAT, T., VALDMANIS, P., 
ROULEAU, G. A., HOSLER, B. A., CORTELLI, P., DE JONG, P. J., YOSHINAGA, Y., HAINES, J. 
L., PERICAK-VANCE, M. A., YAN, J., TICOZZI, N., SIDDIQUE, T., MCKENNA-YASEK, D., SAPP, 
P. C., HORVITZ, H. R., LANDERS, J. E. & BROWN, R. H., JR. 2009. Mutations in the FUS/TLS 
gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science, 323, 1205-
1208. 
LAGIER-TOURENNE, C., BAUGHN, M., RIGO, F., SUN, S., LIU, P., LI, H.-R., JIANG, J., WATT, A. T., 
CHUN, S., KATZ, M., QIU, J., SUN, Y., LING, S.-C., ZHU, Q., POLYMENIDOU, M., DRENNER, 
K., ARTATES, J. W., MCALONIS-DOWNES, M., MARKMILLER, S., HUTT, K. R., PIZZO, D. P., 
CADY, J., HARMS, M. B., BALOH, R. H., VANDENBERG, S. R., YEO, G. W., FU, X.-D., 
BENNETT, C. F., CLEVELAND, D. W. & RAVITS, J. 2013. Targeted degradation of sense and 
antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. 
Proceedings of the National Academy of Sciences of the United States of America, 110, 
E4530-E4539. 
LAPVETELAINEN, T., TIIHONEN, A., KOSKELA, P., NEVALAINEN, T., LINDBLOM, J., KIRALY, K., 
HALONEN, P. & HELMINEN, H. J. 1997. Training a large number of laboratory mice using 
running wheels and analyzing running behavior by use of a computer-assisted system. 
Laboratory Animal Science, 47, 172-179. 
LE LIBOUX, A., CACHIA, J. P., KIRKESSELI, S., GAUTIER, J. Y., GUIMART, C., MONTAY, G., PEETERS, 
P. A. M., GROEN, E., JONKMAN, J. H. G. & WEMER, J. 1999. A comparison of the 
pharmacokinetics and tolerability of riluzole after repeat dose administration in healthy 
elderly and young volunteers. Journal of Clinical Pharmacology, 39, 480-486. 
 230 
LECLERC, N., RIBERA, F., ZOLL, J., WARTER, J. M., POINDRON, P., LAMPERT, E. & BORG, J. 2001. 
Selective changes in mitochondria respiratory properties in oxidative or glycolytic 
muscle fibers isolated from G93AhumanSOD1 transgenic mice. Neuromuscular 
Disorders, 11, 722-727. 
LEE, J. K., SHIN, J. H., HWANG, S. G., GWAG, B. J., MCKEE, A. C., LEE, J., KOWALL, N. W., RYU, H., 
LIM, D.-S. & CHOI, E.-J. 2013. MST1 functions as a key modulator of neurodegeneration 
in a mouse model of ALS. Proceedings of the National Academy of Sciences of the United 
States of America, 110, 12066-12071. 
LEMMENS, R., VAN HOECKE, A., HERSMUS, N., GEELEN, V., D'HOLLANDER, I., THIJS, V., VAN DEN 
BOSCH, L. & CARMELIET, P. 2007. Overexpression of mutant superoxide dismutase 1 
causes a motor axonopathy in the zebrafish. Human Molecular Genetics, 16, 2359-2365. 
LI, J., SUNG, M. & RUTKOVE, S. B. 2013. Electrophysiologic biomarkers for assessing disease 
progression and the effect of riluzole in SOD1 G93A ALS mice. Plos One, 8.6, e65976. 
LING, J. P., PLETNIKOVA, O., TRONCOSO, J. C. & WONG, P. C. 2015. TDP-43 repression of 
nonconserved cryptic exons is compromised in ALS-FTD. Science, 349, 650-655. 
LING, S.-C., POLYMENIDOU, M. & CLEVELAND, D. W. 2013. Converging mechanisms in ALS and 
FTD: disrupted RNA and protein homeostasis. Neuron, 79, 416-438. 
LINO, M. M., SCHNEIDER, C. & CARONI, P. 2002. Accumulation of SOD1 mutants in postnatal 
motoneurons does not cause motoneuron pathology or motoneuron disease. Journal of 
Neuroscience, 22, 4825-4832. 
LIU, Q., SHU, S., WANG, R. R., LIU, F., CUI, B., GUO, X. N., LU, C. X., LI, X. G., LIU, M. S., PENG, B., 
CUI, L.-Y. & ZHANG, X. 2016a. Whole-exome sequencing identifies a missense mutation 
in hnRNPA1 in a family with flail arm ALS. Neurology, 87, 1763-1769. 
LIU, Y., PATTAMATTA, A., ZU, T., REID, T., BARDHI, O., BORCHELT, D. R., YACHNIS, A. T. & RANUM, 
L. P. W. 2016b. C9orf72 BAC mouse model with motor deficits and neurodegenerative 
features of ALS/FTD. Neuron, 90, 521-534. 
LLADO, J., HAENGGELI, C., PARDO, A., WONG, V., BENSON, L., COCCIA, C., ROTHSTEIN, J. D., 
SHEFNER, J. M. & MARAGAKIS, N. J. 2006. Degeneration of respiratory motor neurons 
in the SOD1 G93A transgenic rat model of ALS. Neurobiology of Disease, 21, 110-118. 
LONDEI, T., VALENTINI, A. M. V. & LEONE, V. G. 1998. Investigative burying by laboratory mice 
may involve non-functional, compulsive, behaviour. Behavioural Brain Research, 94, 
249-254. 
LONGSTRETH, W. T., MCGUIRE, V., KOEPSELL, T. D., WANG, Y. & VAN BELLE, G. 1998. Risk of 
amyotrophic lateral sclerosis and history of physical activity - A population-based case-
control study. Archives of Neurology, 55, 201-206. 
LUDOLPH, A. C., BENDOTTI, C., BLAUGRUND, E., CHIO, A., GREENSMITH, L., LOEFFLER, J.-P., 
MEAD, R., NIESSEN, H. G., PETRI, S., PRADAT, P.-F., ROBBERECHT, W., RUEGG, M., 
SCHWALENSTOECKER, B., STILLER, D., VAN DEN BERG, L., VIEIRA, F. & VON HORSTEN, S. 
2010. Guidelines for preclinical animal research in ALS/MND: A consensus meeting. 
Amyotrophic Lateral Sclerosis, 11, 38-45. 
LUDOLPH, A. C., BENDOTTI, C., BLAUGRUND, E., HENGERER, B., LOFFLER, J.-P., MARTIN, J., 
MEININGER, V., MEYER, T., MOUSSAOUI, S., ROBBERECHT, W., SCOTT, S., SILANI, V., VAN 
DEN BERG, L. H., OF, E. G. F. T. E. O. G. F. T. C. & PRECLINICAL AND PROOF OF CONCEPT 
STUDIES IN, A. L. S. M. N. D. M. 2007. Guidelines for the preclinical in vivo evaluation of 
pharmacological active drugs for ALS/MND: report on the 142nd ENMC international 
workshop. Amyotrophic lateral sclerosis : official publication of the World Federation of 
Neurology Research Group on Motor Neuron Diseases, 8, 217-23. 
MACKENZIE, I. R. A., BIGIO, E. H., INCE, P. G., GESER, F., NEUMANN, M., CAIRNS, N. J., KWONG, 
L. K., FORMAN, M. S., RAVITS, J., STEWART, H., EISEN, A., MCCLUSKY, L., KRETZSCHMAR, 
H. A., MONORANU, C. M., HIGHLEY, J. R., KIRBY, J., SIDDIQUE, T., SHAW, P. J., LEE, V. M. 
Y. & TROJANOWSKI, J. Q. 2007. Pathological TDP-43 distinguishes sporadic amyotrophic 
lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Annals of 
Neurology, 61, 427-434. 
 231 
MAJOUNIE, E., RENTON, A. E., MOK, K., DOPPER, E. G. P., WAITE, A., ROLLINSON, S., CHIO, A., 
RESTAGNO, G., NICOLAOU, N., SIMON-SANCHEZ, J., VAN SWIETEN, J. C., ABRAMZON, Y., 
JOHNSON, J. O., SENDTNER, M., PAMPHLETT, R., ORRELL, R. W., MEAD, S., SIDLE, K. C., 
HOULDEN, H., ROHRER, J. D., MORRISON, K. E., PALL, H., TALBOT, K., ANSORGE, O., 
HERNANDEZ, D. G., AREPALLI, S., SABATELLI, M., MORA, G., CORBO, M., GIANNINI, F., 
CALVO, A., ENGLUND, E., BORGHERO, G., FORIS, G. L., REMES, A. M., LAAKSOVIRTA, H., 
MCCLUSKEY, L., TROJANOWSKI, J. Q., VAN DEERLIN, V. M., SCHELLENBERG, G. D., NALLS, 
M. A., DRORY, V. E., LU, C.-S., YEH, T.-H., ISHIURA, H., TAKAHASHI, Y., TSUJI, S., LE BER, 
I., BRICE, A., DREPPER, C., WILLIAMS, N., KIRBY, J., SHAW, P., HARDY, J., TIENARI, P. J., 
HEUTINK, P., MORRIS, H. R., PICKERING-BROWN, S., TRAYNOR, B. J., CHROMOSOME, A. 
L. S. F. T. D. C., FRENCH RES NETWORK, F. F. A. & CONSORTIUM, I. 2012. Frequency of 
the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral 
sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurology, 11, 
323-330. 
MANCUSO, R., OLIVAN, S., OSTA, R. & NAVARRO, X. 2011a. Evolution of gait abnormalities in 
SOD1(G93A) transgenic mice. Brain Research, 1406, 65-73. 
MANCUSO, R., OSTA, R. & NAVARRO, X. 2014. Presymptomatic electrophysiological tests predict 
clinical onset and survival in SOD1(G93A) ALS mice. Muscle & Nerve, 50, 943-949. 
MANCUSO, R., SANTOS-NOGUEIRA, E., OSTA, R. & NAVARRO, X. 2011b. Electrophysiological 
analysis of a murine model of motoneuron disease. Clinical Neurophysiology, 122, 1660-
1670. 
MANUEL VIDAL-TABOADA, J., LOPEZ-LOPEZ, A., SALVADO, M., LORENZO, L., GARCIA, C., MAHY, 
N., RODRIGUEZ, M. J. & GAMEZ, J. 2015. UNC13A confers risk for sporadic ALS and 
influences survival in a Spanish cohort. Journal of Neurology, 262, 2285-2292. 
MARUYAMA, H., MORINO, H., ITO, H., IZUMI, Y., KATO, H., WATANABE, Y., KINOSHITA, Y., 
KAMADA, M., NODERA, H., SUZUKI, H., KOMURE, O., MATSUURA, S., KOBATAKE, K., 
MORIMOTO, N., ABE, K., SUZUKI, N., AOKI, M., KAWATA, A., HIRAI, T., KATO, T., 
OGASAWARA, K., HIRANO, A., TAKUMI, T., KUSAKA, H., HAGIWARA, K., KAJI, R. & 
KAWAKAMI, H. 2010. Mutations of optineurin in amyotrophic lateral sclerosis. Nature, 
465, 223-U109. 
MASSETT, M. P. & BERK, B. C. 2005. Strain-dependent differences in responses to exercise 
training in inbred and hybrid mice. American Journal of Physiology-Regulatory 
Integrative and Comparative Physiology, 288, R1006-R1013. 
MATTIAZZI, M., D'AURELIO, M., GAJEWSKI, C. D., MARTUSHOVA, K., KIAEI, M., BEAL, M. F. & 
MANFREDI, G. 2002. Mutated human SOD1 causes dysfunction of oxidative 
phosphorylation in mitochondria of transgenic mice. Journal of Biological Chemistry, 
277, 29626-29633. 
MCCOMAS, A. J., FAWCETT, P. R. W., CAMPBELL, M. J. & SICA, R. E. P. 1971. Electrophysiological 
estimation of number of motor units within a human muscle. Journal of Neurology 
Neurosurgery and Psychiatry, 34, 121-131. 
MCDERMOTT, C. J., SHAW, P. J., COOPER, C. L., DIXON, S., BAIRD, W. O., BRADBURN, M. J., 
FITZGERALD, P., MAGUIRE, C., WILLIAMS, T., BAUDOUIN, S. V., KARAT, D., TALBOT, K., 
STRADLING, J., MAYNARD, N., TURNER, M., BIANCHI, S., ACKROYD, R., BOURKE, S. C., 
EALING, J., HAMDALLA, H., BENTLEY, A., GALLOWAY, S., ORRELL, R. W., WEDZICHA, W., 
ELLIOT, M., HUGHES, P., HANEMANN, C. O. & DI, P. S. G. C. 2015a. Safety and efficacy of 
diaphragm pacing in patients with respiratory insufficiency due to amyotrophic lateral 
sclerosis (DiPALS): a multicentre, open-label, randomised controlled trial. Lancet 
Neurology, 14, 883-892. 
MCDERMOTT, C. J., SHAW, P. J., STAVROULAKIS, T., WALTERS, S. J., AL-CHALABI, A., CHANDRAN, 
S., CRAWLEY, F., DICK, D., DONAGHY, C., EAMES, P., FISH, M., GENT, C., GORRIE, G., 
HAMDALLA, H., HANEMANN, C. O., JOHNSON, M., MAJEED, T., MALASPINA, A., 
MORRISON, K., ORRELL, R., PINTO, A., RADUNOVIC, A., ROBERTS, M., TALBOT, K., 
TURNER, M. R., WILLIAMS, T., YOUNG, C. & PROGAS STUDY, G. 2015b. Gastrostomy in 
 232 
patients with amyotrophic lateral sclerosis (ProGas): a prospective cohort study. Lancet 
Neurology, 14, 702-709. 
MEAD, R. J., BENNETT, E. J., KENNERLEY, A. J., SHARP, P., SUNYACH, C., KASHER, P., BERWICK, J., 
PETTMANN, B., BATTAGLIA, G., AZZOUZ, M., GRIERSON, A. & SHAW, P. J. 2011. 
Optimised and rapid pre-clinical screening in the SOD1(G93A) transgenic mouse model 
of amyotrophic lateral sclerosis (ALS). Plos One, 6.8, e23244. 
MENON, P., GEEVASINGA, N., YIANNIKAS, C., HOWELL, J., KIERNAN, M. C. & VUCIC, S. 2015. 
Sensitivity and specificity of threshold tracking transcranial magnetic stimulation for 
diagnosis of amyotrophic lateral sclerosis: a prospective study. Lancet Neurology, 14, 
478-484. 
MIANA-MENA, F. J., MUNOS, M. J., YAGUE, G., MENDEZ, M., MORENO, M., CIRIZA, J., 
ZARAGOZA, P. & OSTA, R. 2005. Optimal methods to characterize the G93A mouse 
model of ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 6, 55-
62. 
MILLECAMPS, S., SALACHAS, F., CAZENEUVE, C., GORDON, P., BRICKA, B., CAMUZAT, A., 
GUILLOT-NOEL, L., RUSSAOUEN, O., BRUNETEAU, G., PRADAT, P.-F., LE FORESTIER, N., 
VANDENBERGHE, N., DANEL-BRUNAUD, V., GUY, N., THAUVIN-ROBINET, C., 
LACOMBLEZ, L., COURATIER, P., HANNEQUIN, D., SEILHEAN, D., LE BER, I., CORCIA, P., 
CAMU, W., BRICE, A., ROULEAU, G., LEGUERN, E. & MEININGER, V. 2010. SOD1, ANG, 
VAPB, TARDBP, and FUS mutations in familial amyotrophic lateral sclerosis: genotyp-
phenotype correlations. Journal of Medical Genetics, 47, 554-560. 
MILLER, R. G., MITCHELL, J. D., LYON, M. & MOORE, D. H. 2003. Riluzole for amyotrophic lateral 
sclerosis (ALS)/motor neuron disease (MND). Amyotrophic Lateral Sclerosis and Other 
Motor Neuron Disorders, 4, 191-206. 
MILLER, R. G., MITCHELL, J. D. & MOORE, D. H. 2012. Riluzole for amyotrophic lateral sclerosis 
(ALS)/motor neuron disease (MND). Cochrane Database Syst Rev., CD001447. doi: 
10.1002/14651858.CD001447.pub3. 
MILLER, R. G., MOORE, D. H., GELINAS, D. F., DRONSKY, V., MENDOZA, M., BAROHN, R. J., BRYAN, 
W., RAVITS, J., YUEN, E., NEVILLE, H., RINGEL, S., BROMBERG, M., PETAJAN, J., AMATO, 
A. A., JACKSON, C., JOHNSON, W., MANDLER, R., BOSCH, P., SMITH, B., GRAVES, M., 
ROSS, M., SORENSON, E. J., KELKAR, P., PARRY, G., OLNEY, R. & GRP, W. S. 2001. Phase 
III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. 
Neurology, 56, 843-848. 
MITCHELL, J. C., CONSTABLE, R., SO, E., VANCE, C., SCOTTER, E., GLOVER, L., HORTOBAGYI, T., 
ARNOLD, E. S., LING, S.-C., MCALONIS, M., DA CRUZ, S., POLYMENIDOU, M., TESSAROLO, 
L., CLEVELAND, D. W. & SHAW, C. E. 2015. Wild type human TDP-43 potentiates ALS-
linked mutant TDP-43 driven progressive motor and cortical neuron degeneration with 
pathological features of ALS. Acta Neuropathologica Communications, 3.1, 36. 
MITCHELL, J. C., MCGOLDRICK, P., VANCE, C., HORTOBAGYI, T., SREEDHARAN, J., ROGELJ, B., 
TUDOR, E. L., SMITH, B. N., KLASEN, C., MILLER, C. C. J., COOPER, J. D., GREENSMITH, L. 
& SHAW, C. E. 2013. Overexpression of human wild-type FUS causes progressive motor 
neuron degeneration in an age- and dose-dependent fashion. Acta Neuropathologica, 
125, 273-288. 
MITCHELL, J. D. & BORASIO, G. D. 2007. Amyotrophic lateral sclerosis. Lancet, 369, 2031-2041. 
MITCHELL, J. D., CALLAGHER, P., GARDHAM, J., MITCHELL, C., DIXON, M., ADDISON-JONES, R., 
BENNETT, W. & O'BRIEN, M. R. 2010. Timelines in the diagnostic evaluation of people 
with suspected amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) - a 20-
year review: Can we do better? Amyotrophic Lateral Sclerosis, 11, 537-541. 
MIZIELINSKA, S., GROENKE, S., NICCOLI, T., RIDLER, C. E., CLAYTON, E. L., DEVOY, A., MOENS, T., 
NORONA, F. E., WOOLLACOTT, I. O. C., PIETRZYK, J., CLEVERLEY, K., NICOLL, A. J., 
PICKERING-BROWN, S., DOLS, J., CABECINHA, M., HENDRICH, O., FRATTA, P., FISHER, E. 
M. C., PARTRIDGE, L. & ISAACS, A. M. 2014. C9orf72 repeat expansions cause 
neurodegeneration in Drosophila through arginine-rich proteins. Science, 345, 1192-
1194. 
 233 
MOSER, J. M., BIGINI, P. & SCHMITT-JOHN, T. 2013. The wobbler mouse, an ALS animal model. 
Molecular Genetics and Genomics, 288, 207-229. 
MURAKAMI, T., YANG, S.-P., XIE, L., KAWANO, T., FU, D., MUKAI, A., BOHM, C., CHEN, F., 
ROBERTSON, J., SUZUKI, H., TARTAGLIA, G. G., VENDRUSCOLO, M., SCHIERLE, G. S. K., 
CHAN, F. T. S., MOLONEY, A., CROWTHER, D., KAMINSKI, C. F., ZHEN, M. & ST GEORGE-
HYSLOP, P. 2012. ALS mutations in FUS cause neuronal dysfunction and death in 
Caenorhabditis elegans by a dominant gain-of-function mechanism. Human Molecular 
Genetics, 21, 1-9. 
NAGAI, M., RE, D. B., NAGATA, T., CHALAZONITIS, A., JESSELL, T. M., WICHTERLE, H. & 
PRZEDBORSKI, S. 2007. Astrocytes expressing ALS-linked mutated SOD1 release factors 
selectively toxic to motor neurons. Nature Neuroscience, 10, 615-622. 
NANDEDKAR, S. D., BARKHAUS, P. E. & STALBERG, E. V. 2010. Motor unit number index (MUNIX): 
principle, method, and findings in healthy subjects and in patients with motor neuron 
disease. Muscle & Nerve, 42, 798-807. 
NEUMANN, M., SAMPATHU, D. M., KWONG, L. K., TRUAX, A. C., MICSENYI, M. C., CHOU, T. T., 
BRUCE, J., SCHUCK, T., GROSSMAN, M., CLARK, C. M., MCCLUSKEY, L. F., MILLER, B. L., 
MASLIAH, E., MACKENZIE, I. R., FELDMAN, H., FEIDEN, W., KRETZSCHMAR, H. A., 
TROJANOWSKI, J. Q. & LEE, V. M. Y. 2006. Ubiquitinated TDP-43 in frontotemporal lobar 
degeneration and amyotrophic lateral sclerosis. Science, 314, 130-133. 
NEUWIRTH, C., BARKHAUS, P. E., BURKHARDT, C., CASTRO, J., CZELL, D., DE CARVALHO, M., 
NANDEDKAR, S., STALBERG, E. & WEBER, M. 2015. Tracking motor neuron loss in a set 
of six muscles in amyotrophic lateral sclerosis using the Motor Unit Number Index 
(MUNIX): a 15-month longitudinal multicentre trial. Journal of Neurology Neurosurgery 
and Psychiatry, 86, 1172-1179. 
NICOLAS, L. B., KOLB, Y. & PRINSSEN, E. P. M. 2006. A combined marble burying-locomotor 
activity test in mice: A practical screening test with sensitivity to different classes of 
anxiolytics and antidepressants. European Journal of Pharmacology, 547, 106-115. 
NJUNGE, K. & HANDLEY, S. L. 1991. Evaluation of marble-burying behaviour as a model of 
anxiety. Pharmacology Biochemistry and Behavior, 38, 63-67. 
O'ROURKE, J. G., BOGDANIK, L., MUHAMMAD, A. K. M. G., GENDRON, T. F., KIM, K. J., AUSTIN, 
A., CADY, J., LIU, E. Y., ZARROW, J., GRANT, S., HO, R., BELL, S., CARMONA, S., 
SIMPKINSON, M., LALL, D., WU, K., DAUGHRITY, L., DICKSON, D. W., HARMS, M. B., 
PETRUCELLI, L., LEE, E. B., LUTZ, C. M. & BALOH, R. H. 2015. C9orf72 BAC Transgenic mice 
display typical pathologic features of ALS/FTD. Neuron, 88, 892-901. 
O'ROURKE, J. G., BOGDANIK, L., YANEZ, A., LALL, D., WOLF, A. J., MUHAMMAD, A. K. M. G., HO, 
R., CARMONA, S., VIT, J. P., ZARROW, J., KIM, K. J., BELL, S., HARMS, M. B., MILLER, T. 
M., DANGLER, C. A., UNDERHILL, D. M., GOODRIDGE, H. S., LUTZ, C. M. & BALOH, R. H. 
2016. C9orf72 is required for proper macrophage and microglial function in mice. 
Science, 351, 1324-1329. 
OU, S. H. I., WU, F., HARRICH, D., GARCIA-MARTINEZ, L. F. & GAYNOR, R. G. 1995. Cloning and 
characterization of a novel cellular protein, TDP-43, that binds to human 
immunodeficiency virus type 1 TAR DNA sequence motifs. Journal of Virology, 69, 3584-
3596. 
PALAMIUC, L., SCHLAGOWSKI, A., NGO, S. T., VERNAY, A., DIRRIG-GROSCH, S., HENRIQUES, A., 
BOUTILLIER, A. L., ZOLL, J., ECHANIZ-LAGUNA, A., LOEFFLER, J. P. & RENE, F. 2015. A 
metabolic switch toward lipid use in glycolytic muscle is an early pathologic event in a 
mouse model of amyotrophic lateral sclerosis. Embo Molecular Medicine, 7, 526-546. 
PELEDKAMAR, M., LOTEM, J., WIRGUIN, I., WEINER, L., HERMALIN, A. & GRONER, Y. 1997. 
Oxidative stress mediates impairment of muscle function in transgenic mice with 
elevated level of wild-type Cu/Zn superoxide dismutase. Proceedings of the National 
Academy of Sciences of the United States of America, 94, 3883-3887. 
PENSATO, V., TILOCA, C., CORRADO, L., BERTOLIN, C., SARDONE, V., DEL BO, R., CALINI, D., 
MANDRIOLI, J., LAURIA, G., MAZZINI, L., QUERIN, G., CERONI, M., CANTELLO, R., CORTI, 
S., CASTELLOTTI, B., SOLDA, G., DUGA, S., COMI, G. P., CEREDA, C., SORARU, G., 
 234 
D'ALFONSO, S., TARONI, F., SHAW, C. E., LANDERS, J. E., TICOZZI, N., RATTI, A., GELLERA, 
C., SILANI, V. & CONSORTIUM, S. 2015. TUBA4A gene analysis in sporadic amyotrophic 
lateral sclerosis: identification of novel mutations. Journal of Neurology, 262, 1376-
1378. 
PETERS, O. M., CABRERA, G. T., TRAN, H., GENDRON, T. F., MCKEON, J. E., METTERVILLE, J., 
WEISS, A., WIGHTMAN, N., SALAMEH, J., KIM, J., SUN, H., BOYLAN, K. B., DICKSON, D., 
KENNEDY, Z., LIN, Z., ZHANG, Y. J., DAUGHRITY, L., JUNG, C., GAO, F. B., SAPP, P. C., 
HORVITZ, H. R., BOSCO, D. A., BROWN, S. P., DE JONG, P., PETRUCELLI, L., MUELLER, C. 
& BROWN, R. H., JR. 2015. Human C9ORF72 hexanucleotide expansion reproduces RNA 
foci and dipeptide repeat proteins but not neurodegeneration in BAC transgenic mice. 
Neuron., 88, 902-9. doi: 10.1016/j.neuron.2015.11.018. 
PETROFF, O. A. C., PRICHARD, J. W., BEHAR, K. L., ALGER, J. R., DENHOLLANDER, J. A. & 
SHULMAN, R. G. 1985. Cerebral intracellular pH by P-31 nuclear magnetic-resonance 
spectroscopy. Neurology, 35, 781-788. 
PLATT, R. J., CHEN, S., ZHOU, Y., YIM, M. J., SWIECH, L., KEMPTON, H. R., DAHLMAN, J. E., 
PARNAS, O., EISENHAURE, T. M., JOVANOVIC, M., GRAHAM, D. B., JHUNJHUNWALA, S., 
HEIDENREICH, M., XAVIER, R. J., LANGER, R., ANDERSON, D. G., HACOHEN, N., REGEV, 
A., FENG, G., SHARP, P. A. & ZHANG, F. 2014. CRISPR-Cas9 knockin mice for genome 
editing and cancer modeling. Cell, 159, 440-455. 
POLYMENIDOU, M., LAGIER-TOURENNE, C., HUTT, K. R., BENNETT, C. F., CLEVELAND, D. W. & 
YEO, G. W. 2012. Misregulated RNA processing in amyotrophic lateral sclerosis. Brain 
Research, 1462, 3-15. 
POLYMENIDOU, M., LAGIER-TOURENNE, C., HUTT, K. R., HUELGA, S. C., MORAN, J., LIANG, T. Y., 
LING, S.-C., SUN, E., WANCEWICZ, E., MAZUR, C., KORDASIEWICZ, H., SEDAGHAT, Y., 
DONOHUE, J. P., SHIUE, L., BENNETT, C. F., YEO, G. W. & CLEVELAND, D. W. 2011. Long 
pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss 
of TDP-43. Nature Neuroscience, 14, 459-U92. 
PRUDLO, J., KONIG, J., SCHUSTER, C., KASPER, E., BUTTNER, A., TEIPEL, S. & NEUMANN, M. 2016. 
TDP-43 pathology and cognition in ALS: A prospective clinicopathologic correlation 
study. Neurology, 87.10, 1019-1023. 
PULS, I., JONNAKUTY, C., LAMONTE, B. H., HOLZBAUR, E. L. F., TOKITO, M., MANN, E., FLOETER, 
M. K., BIDUS, K., DRAYNA, D., OH, S. J., BROWN, R. H., LUDLOW, C. L. & FISCHBECK, K. H. 
2003. Mutant dynactin in motor neuron disease. Nature Genetics, 33, 455-456. 
RAFIQ, M. K., LEE, E., BRADBURN, M., MCDERMOTT, C. J. & SHAW, P. J. 2016. Creatine kinase 
enzyme level correlates positively with serum creatinine and lean body mass, and is a 
prognostic factor for survival in amyotrophic lateral sclerosis. European Journal of 
Neurology, 23, 1071-1078. 
RAMAN, R., ALLEN, S. P., GOODALL, E. F., KRAMER, S., PONGER, L. L., HEATH, P. R., MILO, M., 
HOLLINGER, H. C., WALSH, T., HIGHLEY, J. R., OLPIN, S., MCDERMOTT, C. J., SHAW, P. J. 
& KIRBY, J. 2015. Gene expression signatures in motor neurone disease fibroblasts 
reveal dysregulation of metabolism, hypoxia-response and RNA processing functions. 
Neuropathology and Applied Neurobiology, 41, 201-226. 
RAMESH, T., LYON, A. N., PINEDA, R. H., WANG, C., JANSSEN, P. M. L., CANAN, B. D., BURGHES, 
A. H. M. & BEATTIE, C. E. 2010. A genetic model of amyotrophic lateral sclerosis in 
zebrafish displays phenotypic hallmarks of motoneuron disease. Disease Models & 
Mechanisms, 3, 652-662. 
REN, J., SHERRY, A. D. & MALLOY, C. R. 2015. P-31-MRS of healthy human brain: ATP synthesis, 
metabolite concentrations, pH, and T-1 relaxation times. Nmr in Biomedicine, 28, 1455-
1462. 
RENEMA, W. K. J., SCHMIDT, A., VAN ASTEN, J. J. A., OERLEMANS, F., ULLRICH, K., WIERINGA, B., 
ISBRANDT, D. & HEERSCHAP, A. 2003. MR spectroscopy of muscle and brain in 
guanidinoacetate methyltransferase (GAMT)-deficient mice: Validation of an animal 
model to study creatine deficiency. Magnetic Resonance in Medicine, 50, 936-943. 
 235 
RENTON, A. E., CHIO, A. & TRAYNOR, B. J. 2014. State of play in amyotrophic lateral sclerosis 
genetics. Nature Neuroscience, 17, 17-23. 
RENTON, A. E., MAJOUNIE, E., WAITE, A., SIMON-SANCHEZ, J., ROLLINSON, S., GIBBS, J. R., 
SCHYMICK, J. C., LAAKSOVIRTA, H., VAN SWIETEN, J. C., MYLLYKANGAS, L., KALIMO, H., 
PAETAU, A., ABRAMZON, Y., REMES, A. M., KAGANOVICH, A., SCHOLZ, S. W., 
DUCKWORTH, J., DING, J., HARMER, D. W., HERNANDEZ, D. G., JOHNSON, J. O., MOK, K., 
RYTEN, M., TRABZUNI, D., GUERREIRO, R. J., ORRELL, R. W., NEAL, J., MURRAY, A., 
PEARSON, J., JANSEN, I. E., SONDERVAN, D., SEELAAR, H., BLAKE, D., YOUNG, K., 
HALLIWELL, N., CALLISTER, J. B., TOULSON, G., RICHARDSON, A., GERHARD, A., 
SNOWDEN, J., MANN, D., NEARY, D., NALLS, M. A., PEURALINNA, T., JANSSON, L., 
ISOVIITA, V.-M., KAIVORINNE, A.-L., HOLTTA-VUORI, M., IKONEN, E., SULKAVA, R., 
BENATAR, M., WUU, J., CHIO, A., RESTAGNO, G., BORGHERO, G., SABATELLI, M., 
HECKERMAN, D., ROGAEVA, E., ZINMAN, L., ROTHSTEIN, J. D., SENDTNER, M., DREPPER, 
C., EICHLER, E. E., ALKAN, C., ABDULLAEV, Z., PACK, S. D., DUTRA, A., PAK, E., HARDY, J., 
SINGLETON, A., WILLIAMS, N. M., HEUTINK, P., PICKERING-BROWN, S., MORRIS, H. R., 
TIENARI, P. J., TRAYNOR, B. J. & CONSORTIUM, I. 2011. A hexanucleotide repeat 
expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron, 72, 
257-268. 
RICKETTS, T., MCGOLDRICK, P., FRATTA, P., DE OLIVEIRA, H. M., KENT, R., PHATAK, V., 
BRANDNER, S., BLANCO, G., GREENSMITH, L., ACEVEDO-AROZENA, A. & FISHER, E. M. C. 
2014. A nonsense mutation in mouse Tardbp affects TDP43 alternative splicing activity 
and causes limb-clasping and body tone defects. Plos One, 9.1, e85962. 
RINGHOLZ, G. M., APPEL, S. H., BRADSHAW, M., COOKE, N. A., MOSNIK, D. M. & SCHULZ, P. E. 
2005. Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology, 65, 
586-590. 
RIPPS, M. E., HUNTLEY, G. W., HOF, P. R., MORRISON, J. H. & GORDON, J. W. 1995. Transgenic 
mice expressing an altered murine superoxide-dismutase gene provide an animal-model 
of amyotrophic lateral sclerosis. Proceedings of the National Academy of Sciences of the 
United States of America, 92, 689-693. 
ROSEN, D. R., SIDDIQUE, T., PATTERSON, D., FIGLEWICZ, D. A., SAPP, P., HENTATI, A., 
DONALDSON, D., GOTO, J., OREGAN, J. P., DENG, H. X., RAHMANI, Z., KRIZUS, A., 
MCKENNAYASEK, D., CAYABYAB, A., GASTON, S. M., BERGER, R., TANZI, R. E., HALPERIN, 
J. J., HERZFELDT, B., VANDENBERGH, R., HUNG, W. Y., BIRD, T., DENG, G., MULDER, D. 
W., SMYTH, C., LAING, N. G., SORIANO, E., PERICAKVANCE, M. A., HAINES, J., ROULEAU, 
G. A., GUSELLA, J. S., HORVITZ, H. R. & BROWN, R. H. 1993. Mutations in Cu/Zn 
superoxide-dismutase gene are associated with familial amyotrophic-lateral-sclerosis. 
Nature, 362, 59-62. 
ROSENFELD, J. & STRONG, M. J. 2015. Challenges in the Understanding and Treatment of 
Amyotrophic Lateral Sclerosis/Motor Neuron Disease. Neurotherapeutics, 12, 317-325. 
ROWLAND, L. P. & SHNEIDER, N. A. 2001. Medical progress: Amyotrophic lateral sclerosis. New 
England Journal of Medicine, 344, 1688-1700. 
RUTHERFORD, N. J., ZHANG, Y.-J., BAKER, M., GASS, J. M., FINCH, N. A., XU, Y.-F., STEWART, H., 
KELLEY, B. J., KUNTZ, K., CROOK, R. J. P., SREEDHARAN, J., VANCE, C., SORENSON, E., 
LIPPA, C., BIGIO, E. H., GESCHWIND, D. H., KNOPMAN, D. S., MITSUMOTO, H., PETERSEN, 
R. C., CASHMAN, N. R., HUTTON, M., SHAW, C. E., BOYLAN, K. B., BOEVE, B., GRAFF-
RADFORD, N. R., WSZOLEK, Z. K., CASELLI, R. J., DICKSON, D. W., MACKENZIE, I. R., 
PETRUCELLI, L. & RADEMAKERS, R. 2008. Novel mutations in TARDBP (TDP-43) in 
patients with familial amyotrophic lateral sclerosis. Plos Genetics, 4.9, e1000193. 
RYAN, T. E., ERICKSON, M. L., VERMA, A., CHAVEZ, J., RIVNER, M. H. & MCCULLY, K. K. 2014. 
Skeletal muscle oxidative capacity in amyotrophic lateral sclerosis. Muscle & nerve, 50.5, 
767-774. 
SAKAMOTO, K. & HOLMAN, G. D. 2008. Emerging role for AS160/TBC1D4 and TBC1D1 in the 
regulation of GLUT4 traffic. American Journal of Physiology-Endocrinology and 
Metabolism, 295, E29-E37. 
 236 
SASAGURI, H., CHEW, J., XU, Y. F., GENDRON, T. F., GARRETT, A., LEE, C. W., JANSEN-WEST, K., 
BAUER, P. O., PERKERSON, E. A., TONG, J., STETLER, C. & ZHANG, Y. J. 2016. The extreme 
N-terminus of TDP-43 mediates the cytoplasmic aggregation of TDP-43 and associated 
toxicity in vivo. Brain Res, 4, 30318-3. 
SASAKI, S. & IWATA, M. 1996. Dendritic synapses of anterior horn neurons in amyotrophic lateral 
sclerosis: An ultrastructural study. Acta Neuropathologica, 91, 278-283. 
SCHMITT-JOHN, T., DREPPER, C., MUSSMANN, A., HAHN, P., KUHLMANN, M., THIEL, C., HAFNER, 
M., LENGELING, A., HEIMANN, P., JONES, J. M., MEISLER, M. H. & JOCKUSCH, H. 2005. 
Mutation of Vps54 causes motor neuron disease and defective spermiogenesis in the 
wobbler mouse. Nature Genetics, 37, 1213-1215. 
SCOTT, S., KRANZ, J. E., COLE, J., LINCECUM, J. M., THOMPSON, K., KELLY, N., BOSTROM, A., 
THEODOSS, J., AL-NAKHALA, B. M., VIEIRA, F. G., RAMASUBBU, J. & HEYWOOD, J. A. 
2008. Design, power, and interpretation of studies in the standard murine model of ALS. 
Amyotrophic Lateral Sclerosis, 9, 4-15. 
SCOTTER, E. L., VANCE, C., NISHIMURA, A. L., LEE, Y.-B., CHEN, H.-J., URWIN, H., SARDONE, V., 
MITCHELL, J. C., ROGELJ, B., RUBINSZTEIN, D. C. & SHAW, C. E. 2014. Differential roles of 
the ubiquitin proteasome system and autophagy in the clearance of soluble and 
aggregated TDP-43 species. Journal of Cell Science, 127, 1263-1278. 
SEPHTON, C. F., GOOD, S. K., ATKIN, S., DEWEY, C. M., MAYER, P., III, HERZ, J. & YU, G. 2010. TDP-
43 Is a developmentally regulated protein essential for early embryonic development. 
Journal of Biological Chemistry, 285, 6826-6834. 
SHAN, X., CHIANG, P.-M., PRICE, D. L. & WONG, P. C. 2010. Altered distributions of Gemini of 
coiled bodies and mitochondria in motor neurons of TDP-43 transgenic mice. 
Proceedings of the National Academy of Sciences of the United States of America, 107, 
16325-16330. 
SHARMA, K. R., KENTBRAUN, J. A., MAJUMDAR, S., HUANG, Y., MYNHIER, M., WEINER, M. W. & 
MILLER, R. G. 1995. Physiology of fatigue in amyotrophic-lateral-sclerosis. Neurology, 
45, 733-740. 
SHAW, P. J. 1994. Excitotoxicity and motor-neuron disease - a review of the evidence. Journal of 
the Neurological Sciences, 124, 6-13. 
SHAW, P. J. 2005. Molecular and cellular pathways of neurodegeneration in motor neurone 
disease. Journal of Neurology Neurosurgery and Psychiatry, 76, 1046-1057. 
SHEFNER, J. M., CUDKOWICZ, M. E. & BROWN, R. H. 2002. Comparison of incremental with 
multipoint mune methods in transgenic ALS mice. Muscle & Nerve, 25, 39-42. 
SHEFNER, J. M., CUDKOWICZ, M. E., SCHOENFELD, D., CONRAD, T., TAFT, J., CHILTON, M., 
URBINELLI, L., QURESHI, M., ZHANG, H., PESTRONK, A., CARESS, J., DONOFRIO, P., 
SORENSON, E., BRADLEY, W., LOMEN-HOERTH, C., PIORO, E., REZANIA, K., ROSS, M., 
PASCUZZI, R., HEIMAN-PATTERSON, T., TANDAN, R., MITSUMOTO, H., ROTHSTEIN, J., 
SMITH-PALMER, T., MACDONALD, D., BURKE, D. & CONSORTIUM, N. 2004. A clinical trial 
of creatine in ALS. Neurology, 63, 1656-1661. 
SHERWIN, C. M. 1998. Voluntary wheel running: a review and novel interpretation. Animal 
Behaviour, 56, 11-27. 
SHI, Y., IVANNIKOV, M. V., WALSH, M. E., LIU, Y., ZHANG, Y., JARAMILLO, C. A., MACLEOD, G. T. 
& VAN REMMEN, H. 2014. The lack of CuZnSOD leads to impaired neurotransmitter 
release, neuromuscular junction destabilization and reduced muscle strength in mice. 
Plos One, 9.6, e100834. 
SHIIHASHI, G., ITO, D., YAGI, T., NIHEI, Y., EBINE, T. & SUZUKI, N. 2016. Mislocated FUS is 
sufficient for gain-of-toxic-function amyotrophic lateral sclerosis phenotypes in mice. 
Brain, 139.9, 2380-2394. 
SIKLOS, L., ENGELHARDT, J., HARATI, Y., SMITH, R. G., JOO, F. & APPEL, S. H. 1996. Ultrastructural 
evidence for altered calcium in motor nerve terminals in amyotrophic lateral sclerosis. 
Annals of Neurology, 39, 203-216. 
 237 
SLOWIE, L. A., PAIGE, M. S. & ANTEL, J. P. 1983. Nutritional considerations in the management 
of patients with amyotrophic lateral sclerosis (ALS). Journal of the American Dietetic 
Association, 83, 44-47. 
SMITH, B. N., TICOZZI, N., FALLINI, C., GKAZI, A. S., TOPP, S., KENNA, K. P., SCOTTER, E. L., KOST, 
J., KEAGLE, P., MILLER, J. W., CALINI, D., VANCE, C., DANIELSON, E. W., TROAKES, C., 
TILOCA, C., AL-SARRAJ, S., LEWIS, E. A., KING, A., COLOMBRITA, C., PENSATO, V., 
CASTELLOTTI, B., DE BELLEROCHE, J., BAAS, F., TEN ASBROEK, A. L. M. A., SAPP, P. C., 
MCKENNA-YASEK, D., MCLAUGHLIN, R. L., POLAK, M., ASRESS, S., ESTEBAN-PEREZ, J., 
MUNOZ-BLANCO, J. L., SIMPSON, M., VAN RHEENEN, W., DIEKSTRA, F. P., LAURIA, G., 
DUGA, S., CORTI, S., CEREDA, C., CORRADO, L., SORARU, G., MORRISON, K. E., WILLIAMS, 
K. L., NICHOLSON, G. A., BLAIR, I. P., DION, P. A., LEBLOND, C. S., ROULEAU, G. A., 
HARDIMAN, O., VELDINK, J. H., VAN DEN BERG, L. H., AL-CHALABI, A., PALL, H., SHAW, 
P. J., TURNER, M. R., TALBOT, K., TARONI, F., GARCIA-REDONDO, A., WU, Z., GLASS, J. D., 
GELLERA, C., RATTI, A., BROWN, R. H., JR., SILANI, V., SHAW, C. E., LANDERS, J. E. & 
CONSORTIUM, S. 2014. Exome-wide rare variant analysis identifies TUBA4A mutations 
associated with familial ALS. Neuron, 84, 324-331. 
SNOW, R. J., TURNBULL, J., DA SILVA, S., JIANG, F. & TARNOPOLSKY, M. A. 2003. Creatine 
supplementation and riluzole treatment provide similar beneficial effects in copper, zinc 
superoxide dismutase (G93A) transgenic mice. Neuroscience, 119, 661-667. 
SREEDHARAN, J., BLAIR, I. P., TRIPATHI, V. B., HU, X., VANCE, C., ROGELJ, B., ACKERLEY, S., 
DURNALL, J. C., WILLIAMS, K. L., BURATTI, E., BARALLE, F., DE BELLEROCHE, J., MITCHELL, 
J. D., LEIGH, P. N., AL-CHALABI, A., MILLER, C. C., NICHOLSON, G. & SHAW, C. E. 2008. 
TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science, 319, 
1668-1672. 
STALLINGS, N. R., PUTTAPARTHI, K., DOWLING, K. J., LUTHER, C. M., BURNS, D. K., DAVIS, K. & 
ELLIOTT, J. L. 2013. TDP-43, an ALS linked protein, regulates fat deposition and glucose 
homeostasis. Plos One, 8.8, e71793. 
STALLINGS, N. R., PUTTAPARTHI, K., LUTHER, C. M., BURNS, D. K. & ELLIOTT, J. L. 2010. 
Progressive motor weakness in transgenic mice expressing human TDP-43. 
Neurobiology of Disease, 40, 404-414. 
STEWART, A., SANDERCOCK, J., BRYAN, S., HYDE, C., BARTON, P. M., FRY-SMITH, A. & BURLS, A. 
2001. The clinical effectiveness and cost-effectiveness of riluzole for motor neurone 
disease: a rapid and systematic review. Health technology assessment (Winchester, 
England), 5, 1-97. 
STONE, S., ABKEVICH, V., RUSSELL, D. L., RILEY, R., TIMMS, K., TRAN, T., TREM, D., FRANK, D., 
JAMMULAPATI, S., NEFF, C. D., ILIEV, D., GRESS, R., HE, G., FRECH, G. C., ADAMS, T. D., 
SKOLNICK, M. H., LANCHBURY, J. S., GUTIN, A., HUNT, S. C. & SHATTUCK, D. 2006. 
TBC1D1 is a candidate for a severe obesity gene and evidence for a gene/gene 
interaction in obesity predisposition. Human Molecular Genetics, 15, 2709-2720. 
STOVER, C., ENDO, Y., TAKAHASHI, M., LYNCH, N. J., CONSTANTINESCU, C., VORUP-JENSEN, T., 
THIEL, S., FRIEDL, H., HANKELN, T., HALL, R., GREGORY, S., FUJITA, T. & SCHWAEBLE, W. 
2001. The human gene for mannan-binding lectin-associated serine protease-2 (MASP-
2), the effector component of the lectin route of complement activation, is part of a 
tightly linked gene cluster on chromosome 1p36.2-3. Genes and Immunity, 2, 119-127. 
STOVER, K. R., CAMPBELL, M. A., VAN WINSSEN, C. M. & BROWN, R. E. 2015. Analysis of motor 
function in 6-month-old male and female 3xTg-AD mice. Behavioural Brain Research, 
281, 16-23. 
STYS, P. K., WAXMAN, S. G. & RANSOM, B. R. 1992. Ionic mechanisms of axonic injury in 
mammalian CNS white matter - role of Na+ channels and Na+-Ca2+ exchanger. Journal 
of Neuroscience, 12, 430-439. 
SUN, H., HOU, Z., YANG, H., MENG, M., LI, P., ZOU, Q., YANG, L., CHEN, Y., CHAI, H., ZHONG, H., 
YANG, Z. Z., ZHAO, J., LAI, L., JIANG, X. & XIAO, Z. 2014. Multiple systemic 
transplantations of human amniotic mesenchymal stem cells exert therapeutic effects 
in an ALS mouse model. Cell and Tissue Research, 357, 571-582. 
 238 
SUTEDJA, N. A., FISCHER, K., VELDINK, J. H., VAN DER HEIJDEN, G. J. M. G., KROMHOUT, H., 
HEEDERIK, D., HUISMAN, M. H. B., WOKKE, J. J. H. & VAN DEN BERG, L. H. 2009. What 
we truly know about occupation as a risk factor for ALS: A critical and systematic review. 
Amyotrophic Lateral Sclerosis, 10, 295-U70. 
SWARUP, V., PHANEUF, D., BAREIL, C., ROBERTSON, J., ROULEAU, G. A., KRIZ, J. & JULIEN, J.-P. 
2011. Pathological hallmarks of amyotrophic lateral sclerosis/frontotemporal lobar 
degeneration in transgenic mice produced with TDP-43 genomic fragments. Brain, 134, 
2610-2626. 
TAYLOR, E. B., AN, D., KRAMER, H. F., YU, H., FUJII, N. L., ROECKL, K. S. C., BOWLES, N., 
HIRSHMAN, M. F., XIE, J., FEENER, E. P. & GOODYEAR, L. J. 2008. Discovery of TBC1D1 as 
an insulin-, AICAR-, and contraction-stimulated signaling nexus in mouse skeletal 
muscle. Journal of Biological Chemistry, 283, 9787-9796. 
TAYLOR, J. P., BROWN, R. H., JR. & CLEVELAND, D. W. 2016. Decoding ALS: from genes to 
mechanism. Nature, 539, 197-206. 
TEYSSOU, E., TAKEDA, T., LEBON, V., BOILLEE, S., DOUKOURE, B., BATAILLON, G., SAZDOVITCH, 
V., CAZENEUVE, C., MEININGER, V., LEGUERN, E., SALACHAS, F., SEILHEAN, D. & 
MILLECAMPS, S. 2013. Mutations in SQSTM1 encoding p62 in amyotrophic lateral 
sclerosis: genetics and neuropathology. Acta Neuropathologica, 125, 511-522. 
THOMAS, A., BURANT, A., BUI, N., GRAHAM, D., YUVA-PAYLOR, L. A. & PAYLOR, R. 2009. Marble 
burying reflects a repetitive and perseverative behavior more than novelty-induced 
anxiety. Psychopharmacology, 204, 361-373. 
TOLLERVEY, J. R., CURK, T., ROGELJ, B., BRIESE, M., CEREDA, M., KAYIKCI, M., KOENIG, J., 
HORTOBAGYI, T., NISHIMURA, A. L., ZUPUNSKI, V., PATANI, R., CHANDRAN, S., ROT, G., 
ZUPAN, B., SHAW, C. E. & ULE, J. 2011. Characterizing the RNA targets and position-
dependent splicing regulation by TDP-43. Nature Neuroscience, 14, 452-U180. 
TRACEY, I., DUNN, J. F. & RADDA, G. K. 1996. Brain metabolism is abnormal in the mdx model of 
Duchenne muscular dystrophy. Brain, 119, 1039-1044. 
TSAI, K.-J., YANG, C.-H., FANG, Y.-H., CHO, K.-H., CHIEN, W.-L., WANG, W.-T., WU, T.-W., LIN, C.-
P., FU, W.-M. & SHEN, C.-K. J. 2010. Elevated expression of TDP-43 in the forebrain of 
mice is sufficient to cause neurological and pathological phenotypes mimicking FTLD-U. 
Journal of Experimental Medicine, 207, 1661-1673. 
TURNER, M. J., KLEEBERGER, S. R. & LIGHTFOOT, J. T. 2005. Influence of genetic background on 
daily running-wheel activity differs with aging. Physiological Genomics, 22, 76-85. 
TURNER, M. R., BOWSER, R., BRUIJN, L., DUPUIS, L., LUDOLPH, A., MCGRATH, M., MANFREDI, G., 
MARAGAKIS, N., MILLER, R. G., PULLMAN, S. L., RUTKOVE, S. B., SHAW, P. J., SHEFNER, 
J. & FISCHBECK, K. H. 2013. Mechanisms, models and biomarkers in amyotrophic lateral 
sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 14, 19-32. 
TURNER, M. R., CAGNIN, A., TURKHEIMER, F. E., MILLER, C. C. J. & SHAW, C. E. 2004. Evidence of 
widespread cerebral microglial activation in amyotrophic lateral sclerosis: an C-11 (R)-
PK11195 positron emission tomography study. Neurobiology of Disease, 15, 601-609. 
TURNER, M. R., KIERNAN, M. C., LEIGH, P. N. & TALBOT, K. 2009. Biomarkers in amyotrophic 
lateral sclerosis. Lancet Neurology, 8, 94-109. 
TURNER, M. R. & TALBOT, K. 2013. Mimics and chameleons in motor neurone disease. Practical 
neurology, 13, 153-64. 
UCHIDA, A., SASAGURI, H., KIMURA, N., TAJIRI, M., OHKUBO, T., ONO, F., SAKAUE, F., KANAI, K., 
HIRAI, T., SANO, T., SHIBUYA, K., KOBAYASHI, M., YAMAMOTO, M., YOKOTA, S., 
KUBODERA, T., TOMORI, M., SAKAKI, K., ENOMOTO, M., HIRAI, Y., KUMAGAI, J., 
YASUTOMI, Y., MOCHIZUKI, H., KUWABARA, S., UCHIHARA, T., MIZUSAWA, H. & 
YOKOTA, T. 2012. Non-human primate model of amyotrophic lateral sclerosis with 
cytoplasmic mislocalization of TDP-43. Brain, 135, 833-846. 
VAN RHEENEN, W., SHATUNOV, A., DEKKER, A. M., MCLAUGHLIN, R. L., DIEKSTRA, F. P., PULIT, 
S. L., VAN DER SPEK, R. A. A., VOSA, U., DE JONG, S., ROBINSON, M. R., YANG, J., FOGH, 
I., VAN DOORMAAL, P. T. C., TAZELAAR, G. H. P., KOPPERS, M., BLOKHUIS, A. M., 
SPROVIERO, W., JONES, A. R., KENNA, K. P., VAN EIJK, K. R., HARSCHNITZ, O., SCHELLEVIS, 
 239 
R. D., BRANDS, W. J., MEDIC, J., MENELAOU, A., VAJDA, A., TICOZZI, N., LIN, K., ROGELJ, 
B., VRABEC, K., RAVNIK-GLAVAC, M., KORITNIK, B., ZIDAR, J., LEONARDIS, L., GROSELJ, L. 
D., MILLECAMPS, S., SALACHAS, F., MEININGER, V., DE CARVALHO, M., PINTO, S., MORA, 
J. S., ROJAS-GARCIA, R., POLAK, M., CHANDRAN, S., COLVILLE, S., SWINGLER, R., 
MORRISON, K. E., SHAW, P. J., HARDY, J., ORRELL, R. W., PITTMAN, A., SIDLE, K., FRATTA, 
P., MALASPINA, A., TOPP, S., PETRI, S., ABDULLA, S., DREPPER, C., SENDTNER, M., 
MEYER, T., OPHOFF, R. A., STAATS, K. A., WIEDAU-PAZOS, M., LOMEN-HOERTH, C., VAN 
DEERLIN, V. M., TROJANOWSKI, J. Q., ELMAN, L., MCCLUSKEY, L., BASAK, A. N., TUNCA, 
C., HAMZEIY, H., PARMAN, Y., MEITINGER, T., LICHTNER, P., RADIVOJKOV-BLAGOJEVIC, 
M., ANDRES, C. R., MAUREL, C., BENSIMON, G., LANDWEHRMEYER, B., BRICE, A., PAYAN, 
C. A. M., SAKER-DELYE, S., DUERR, A., WOOD, N. W., TITTMANN, L., LIEB, W., FRANKE, 
A., RIETSCHEL, M., CICHON, S., NOETHEN, M. M., AMOUYEL, P., TZOURIO, C., 
DARTIGUES, J.-F., UITTERLINDEN, A. G., RIVADENEIRA, F., ESTRADA, K., HOFMAN, A., 
CURTIS, C., BLAUW, H. M., VAN DER KOOI, A. J., et al. 2016. Genome-wide association 
analyses identify new risk variants and the genetic architecture of amyotrophic lateral 
sclerosis. Nature Genetics, 48.9, 1043-1048. 
VANCE, C., ROGELJ, B., HORTOBAGYI, T., DE VOS, K. J., NISHIMURA, A. L., SREEDHARAN, J., HU, 
X., SMITH, B., RUDDY, D., WRIGHT, P., GANESALINGAM, J., WILLIAMS, K. L., TRIPATHI, 
V., AL-SARAJ, S., AL-CHALABI, A., LEIGH, P. N., BLAIR, I. P., NICHOLSON, G., DE 
BELLEROCHE, J., GALLO, J.-M., MILLER, C. C. & SHAW, C. E. 2009. Mutations in FUS, an 
RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science, 323, 
1208-1211. 
VERHAMME, C., KING, R. H. M., TEN ASBROEK, A., MUDDLE, J. R., NOURALLAH, M., 
WOLTERMAN, R., BAAS, F. & VAN SCHAIK, I. N. 2011. Myelin and axon pathology in a 
long-term study of PMP22-overexpressing mice. Journal of Neuropathology and 
Experimental Neurology, 70, 386-398. 
VUCIC, S. & KIERNAN, M. C. 2006. Novel threshold tracking techniques suggest that cortical 
hyperexcitability is an early feature of motor neuron disease. Brain, 129, 2436-2446. 
WAIBEL, S., REUTER, A., MALESSA, S., BLAUGRUND, E. & LUDOLPH, A. C. 2004. Rasagiline alone 
and in combination with riluzole prolongs survival in an ALS mouse model. Journal of 
Neurology, 251, 1080-1084. 
WALKER, A. K., SPILLER, K. J., GE, G., ZHENG, A., XU, Y., ZHOU, M., TRIPATHY, K., KWONG, L. K., 
TROJANOWSKI, J. Q. & LEE, V. M. Y. 2015. Functional recovery in new mouse models of 
ALS/FTLD after clearance of pathological cytoplasmic TDP-43. Acta Neuropathologica, 
130, 643-660. 
WANG, F. C., DE PASQUA, V., GERARD, P. & DELWAIDE, P. J. 2001. Prognostic value of 
decremental responses to repetitive nerve stimulation in ALS patients. Neurology, 57, 
897-899. 
WANG, H. Y., WANG, I. F., BOSE, J. & SHEN, C. K. J. 2004. Structural diversity and functional 
implications of the eukaryotic TDP gene family. Genomics, 83, 130-139. 
WANG, J., FARR, G. W., HALL, D. H., LI, F., FURTAK, K., DREIER, L. & HORWICH, A. L. 2009. An ALS-
linked mutant SOD1 produces a locomotor defect associated with aggregation and 
synaptic dysfunction when expressed in neurons of Caenorhabditis elegans. Plos 
Genetics, 5.1, e1000350. 
WANG, J., XU, G. L., GONZALES, V., COONFIELD, M., FROMHOLT, D., COPELAND, N. G., JENKINS, 
N. A. & BORCHELT, D. R. 2002. Fibrillar inclusions and motor neuron degeneration in 
transgenic mice expressing superoxide dismutase 1 with a disrupted copper-binding 
site. Neurobiology of Disease, 10, 128-138. 
WANG, J., XU, G. L., SLUNT, H. H., GONZALES, V., COONFIELD, M., FROMHOLT, D., COPELAND, N. 
G., JENKINS, N. A. & BORCHELT, D. R. 2005. Coincident thresholds of mutant protein for 
paralytic disease and protein aggregation caused by restrictively expressed superoxide 
dismutase cDNA. Neurobiology of Disease, 20, 943-952. 
WANG, W., WANG, L., LU, J., SIEDLAK, S. L., FUJIOKA, H., LIANG, J., JIANG, S., MA, X., JIANG, Z., 
DA ROCHA, E. L., SHENG, M., CHOI, H., LEROU, P. H., LI, H. & WANG, X. 2016. The 
 240 
inhibition of TDP-43 mitochondrial localization blocks its neuronal toxicity. Nat Med, 
22.8, 869-878. 
WANG, X., FAN, H., YING, Z., LI, B., WANG, H. & WANG, G. 2010. Degradation of TDP-43 and its 
pathogenic form by autophagy and the ubiquitin-proteasome system. Neuroscience 
Letters, 469, 112-116. 
WANG, Y.-T., KUO, P.-H., CHIANG, C.-H., LIANG, J.-R., CHEN, Y.-R., WANG, S., SHEN, J. C. K. & 
YUAN, H. S. 2013. The truncated C-terminal RNA recognition motif of TDP-43 protein 
plays a key role in forming proteinaceous aggregates. Journal of Biological Chemistry, 
288, 9049-9057. 
WATSON, M. R., LAGOW, R. D., XU, K., ZHANG, B. & BONINI, N. M. 2008. A Drosophila model for 
amyotrophic lateral sclerosis reveals motor neuron damage by human SOD1. Journal of 
Biological Chemistry, 283, 24972-24981. 
WEGORZEWSKA, I., BELL, S., CAIRNS, N. J., MILLER, T. M. & BALOH, R. H. 2009. TDP-43 mutant 
transgenic mice develop features of ALS and frontotemporal lobar degeneration. 
Proceedings of the National Academy of Sciences of the United States of America, 106, 
18809-18814. 
WEISSKOPF, M. G., MCCULLOUGH, M. L., CALLE, E. E., THUN, M. J., CUDKOWICZ, M. & ASCHERIO, 
A. 2004. Prospective study of cigarette smoking and amyotrophic lateral sclerosis. 
American Journal of Epidemiology, 160, 26-33. 
WEISSKOPF, M. G., O'REILLY, E. J., MCCULLOUGH, M. L., CALLE, E. E., THUN, M. J., CUDKOWICZ, 
M. & ASCHERIO, A. 2005. Prospective study of military service and mortality from ALS. 
Neurology, 64, 32-37. 
WENDT, S., DEDEOGLU, A., SPEER, O., WALLIMANN, T., BEAL, M. F. & ANDREASSEN, O. A. 2002. 
Reduced creatine kinase activity in transgenic amyotrophic lateral sclerosis mice. Free 
Radical Biology and Medicine, 32, 920-926. 
WEYDT, P., HONG, S. Y., KLIOT, M. & MOLLER, T. 2003. Assessing disease onset and progression 
in the SODI mouse model of ALS. Neuroreport, 14, 1051-1054. 
WHALE, A. S., HUGGETT, J. F., COWEN, S., SPEIRS, V., SHAW, J., ELLISON, S., FOY, C. A. & SCOTT, 
D. J. 2012. Comparison of microfluidic digital PCR and conventional quantitative PCR for 
measuring copy number variation. Nucleic Acids Research, 40. 
WHITTAKER, R. G. 2012. The fundamentals of electromyography. Practical neurology, 12, 187-
94. 
WIEDEMANN, F. R., MANFREDI, G., MAWRIN, C., BEAL, F. & SCHON, E. A. 2002. Mitochondrial 
DNA and respiratory chain function in spinal cords of ALS patients. Journal of 
Neurochemistry, 80, 616-625. 
WILLIAMS, E. R. & BRUFORD, A. 1970. Creatine phosphokinase in motor neurone disease. Clinica 
Chimica Acta, 27.1, 53-56. 
WILS, H., KLEINBERGER, G., JANSSENS, J., PERESON, S., JORIS, G., CUIJT, I., SMITS, V., CEUTERICK-
DE GROOTE, C., VAN BROECKHOVEN, C. & KUMAR-SINGH, S. 2010. TDP-43 transgenic 
mice develop spastic paralysis and neuronal inclusions characteristic of ALS and 
frontotemporal lobar degeneration. Proceedings of the National Academy of Sciences of 
the United States of America, 107, 3858-3863. 
WINTON, M. J., IGAZ, L. M., WONG, M. M., KWONG, L. K., TROJANOWSKI, J. Q. & LEE, V. M. Y. 
2008. Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43) 
induces disease-like redistribution, sequestration, and aggregate formation. Journal of 
Biological Chemistry, 283, 13302-13309. 
WONG, P. C., PARDO, C. A., BORCHELT, D. R., LEE, M. K., COPELAND, N. G., JENKINS, N. A., 
SISODIA, S. S., CLEVELAND, D. W. & PRICE, D. L. 1995. An adverse property of a familial 
ALS-linked SOD1 mutation causes motor-neuron disease characterized by vacuolar 
degeneration of mitochondria. Neuron, 14, 1105-1116. 
WOOD, J. D., BEAUJEUX, T. P. & SHAW, P. J. 2003. Protein aggregation in motor neurone 
disorders. Neuropathology and Applied Neurobiology, 29, 529-545. 
WOOD, S. J. & SLATER, C. R. 2001. Safety factor at the neuromuscular junction. Progress in 
Neurobiology, 64, 393-429. 
 241 
WOOLEY, C. M., SHER, R. B., KALE, A., FRANKEL, W. N., COX, G. A. & SEBURN, K. L. 2005. Gait 
analysis detects early changes in transgenic SOD1(G93A) mice. Muscle & Nerve, 32, 43-
50. 
WU, C.-H., FALLINI, C., TICOZZI, N., KEAGLE, P. J., SAPP, P. C., PIOTROWSKA, K., LOWE, P., 
KOPPERS, M., MCKENNA-YASEK, D., BARON, D. M., KOST, J. E., GONZALEZ-PEREZ, P., 
FOX, A. D., ADAMS, J., TARONI, F., TILOCA, C., LECLERC, A. L., CHAFE, S. C., MANGROO, 
D., MOORE, M. J., ZITZEWITZ, J. A., XU, Z.-S., VAN DEN BERG, L. H., GLASS, J. D., 
SICILIANO, G., CIRULLI, E. T., GOLDSTEIN, D. B., SALACHAS, F., MEININGER, V., ROSSOLL, 
W., RATTI, A., GELLERA, C., BOSCO, D. A., BASSELL, G. J., SILANI, V., DRORY, V. E., 
BROWN, R. H., JR. & LANDERS, J. E. 2012a. Mutations in the profilin 1 gene cause familial 
amyotrophic lateral sclerosis. Nature, 488.7412, 499-503. 
WU, L.-S., CHENG, W.-C. & SHEN, C. K. J. 2012b. Targeted depletion of TDP-43 expression in the 
spinal cord motor neurons leads to the development of amyotrophic lateral sclerosis-
like phenotypes in mice. Journal of Biological Chemistry, 287, 27335-27344. 
WU, Y., LIANG, D., WANG, Y., BAI, M., TANG, W., BAO, S., YAN, Z., LI, D. & LI, J. 2013. Correction 
of a genetic disease in mouse via use of CRISPR-Cas9. Cell Stem Cell, 13, 659-662. 
XU, Y.-F., GENDRON, T. F., ZHANG, Y.-J., LIN, W.-L., D'ALTON, S., SHENG, H., CASEY, M. C., TONG, 
J., KNIGHT, J., YU, X., RADEMAKERS, R., BOYLAN, K., HUTTON, M., MCGOWAN, E., 
DICKSON, D. W., LEWIS, J. & PETRUCELLI, L. 2010. Wild-type human TDP-43 expression 
causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early 
mortality in transgenic mice. Journal of Neuroscience, 30, 10851-10859. 
XU, Y.-F., ZHANG, Y.-J., LIN, W.-L., CAO, X., STETLER, C., DICKSON, D. W., LEWIS, J. & PETRUCELLI, 
L. 2011. Expression of mutant TDP-43 induces neuronal dysfunction in transgenic mice. 
Molecular Neurodegeneration, 6.1, 73. 
YAMANAKA, K., CHUN, S. J., BOILLEE, S., FUJIMORI-TONOU, N., YAMASHITA, H., GUTMANN, D. 
H., TAKAHASHI, R., MISAWA, H. & CLEVELAND, D. W. 2008a. Astrocytes as determinants 
of disease progression in inherited amyotrophic lateral sclerosis. Nature Neuroscience, 
11, 251-253. 
YAMANAKA, K., YAMASHITA, H., FUJIMORI-TONOU, N., TAKAHASHI, R., MISAWA, H. & 
CLEVELAND, D. W. 2008b. Astrocytes as determinants of disease progression in 
inherited ALS. Neuroscience Research, 61, S45-S45. 
YANG, C., WANG, H., QIAO, T., YANG, B., ALIAGA, L., QIU, L., TAN, W., SALAMEH, J., MCKENNA-
YASEK, D. M., SMITH, T., PENG, L., MOORE, M. J., BROWN, R. H., JR., CAI, H. & XU, Z. 
2014. Partial loss of TDP-43 function causes phenotypes of amyotrophic lateral sclerosis. 
Proceedings of the National Academy of Sciences of the United States of America, 111, 
E1121-E1129. 
YIN, F., DUMONT, M., BANERJEE, R., MA, Y., LI, H., LIN, M. T., BEAL, M. F., NATHAN, C., THOMAS, 
B. & DING, A. 2010. Behavioral deficits and progressive neuropathology in progranulin-
deficient mice: a mouse model of frontotemporal dementia. Faseb Journal, 24, 4639-
4647. 
YOKOSEKI, A., SHIGA, A., TAN, C.-F., TAGAWA, A., KANEKO, H., KOYAMA, A., EGUCHI, H., 
TSUJINO, A., IKEUCHI, T., KAKITA, A., OKAMOTO, K., NISHIZAVA, M., TAKAHASHI, H. & 
ONODERA, O. 2008. TDP-43 mutation in familial amyotrophic lateral sclerosis. Annals of 
Neurology, 63, 538-542. 
ZHANG, Y.-J., CAULFIELD, T., XU, Y.-F., GENDRON, T. F., HUBBARD, J., STETLER, C., SASAGURI, H., 
WHITELAW, E. C., CAI, S., LEE, W. C. & PETRUCELLI, L. 2013. The dual functions of the 
extreme N-terminus of TDP-43 in regulating its biological activity and inclusion 
formation. Human Molecular Genetics, 22, 3112-3122. 
ZHOU, H., HUANG, C., CHEN, H., WANG, D., LANDEL, C. P., XIA, P. Y., BOWSER, R., LIU, Y.-J. & XIA, 
X. G. 2010. Transgenic rat model of neurodegeneration caused by mutation in the TDP 
gene. Plos Genetics, 6.3, e1000887. 
ZHU, L., XU, M., YANG, M., YANG, Y., LI, Y., DENG, J., RUAN, L., LIU, J., DU, S., LIU, X., FENG, W., 
FUSHIMI, K., BIGIO, E. H., MESULAM, M., WANG, C. & WU, J. Y. 2014. An ALS-mutant 
 242 
TDP-43 neurotoxic peptide adopts an anti-parallel beta-structure and induces TDP-43 
redistribution. Human Molecular Genetics, 23, 6863-6877. 
ZOCCOLELLA, S., BEGHI, E., PALAGANO, G., FRADDOSIO, A., SAMARELLI, V., LAMBERTI, P., 
LEPORE, V., SERLENGA, L., LOGROSCINO, G. & REGISTRY, S. 2006. Predictors of delay in 
the diagnosis and clinical trial entry of amyotrophic lateral sclerosis patients: A 
population-based study. Journal of the Neurological Sciences, 250, 45-49. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 243 
8. Project Outputs and Achievements 
 Publication in revision: Stephenson, J. et al. (2017) Detailed Phenotypic 
Characterisation of Human TDP-43Q331K Transgenic Mice Demonstrates Potential 
as a Preclinical Model for Testing Therapeutic Agents. Disease Models and 
Mechanisms   
 Poster presentation at the MNDA 27th International Symposium on ALS/MND 
(Dublin, Ireland, 11-13th Dec 2016) https://f1000research.com/posters/5-2872 
 Oral presentation at the European Network for the Cure of ALS (ENCALS) meeting 
2016 (Milan, Italy, 19th-21st May 2016) entitled ‘Evaluation of a TDP-43Q331K 
mouse model: is it useful for therapeutic trials in ALS?’ 
 Lay presentation to the Manchester MND Association’s AGM (April 2016) 
 Lay presentation to the South Yorkshire MND Association’s AGM (Feb 2016) 
 Poster presentation at the MNDA 26th International Symposium on ALS/MND 
(Orlando, Florida, USA, 11-13th Dec 2015) http://f1000research.com/posters/4-
1501  
 
